NITROGEN CONTAINING HETEROAROMATICS WITH ORTHO-SUBSTITUTED P1'S AS FACTOR XA INHIBITORS

Abstract: The present application describes nitrogen containing heteroaromatics with ortho-substituted P1's and derivatives thereof of Formula (I) or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is N or NH and D is substituted ortho to G on E and may be CH2NH2, which are useful as inhibitors of factor Xa.

Description: TITLE Nitrogen Containing Heteroaromatics with Ortho-Substituted Pi's as Factor Xa Inhibitors FIELD OF THE INVENTION This invention relates generally to nitrogen containing heteroaromatics, with ortho-substituted PI groups, which are inhibitors of trypsin-like serine protease enzymes, especially factor Xa, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders . BACKGROUND OF THE INVENTION WO 95/18111 addresses fibrinogen receptor antagonists, containing basic and acidic termini, of the formula: wherein R 1 represents the basic termini, U is an alkylene or heteroatom linker, V may be a heterocycle, and the right hand portion of the molecule represents the acidic termini . The presently claimed compounds do not contain the acidic termini of WO 95/18111. In U.S. Patent No. 5,463,071, Hi melsbach et al depict cell aggregation inhibitors which are 5-membered heterocycles of the formula: wherein the heterocycle may be aromatic and groups A-B-C- and F-E-D- are attached to the ring system. A-B-C- can be a wide variety of substituents including a basic group attached to an aromatic ring. The F-E-D- group, however, would appear to be an acidic functionality which differs from the present invention. Furthermore, use of these compounds as inhibitors of factor Xa is not discussed. Baker et al, in U.S. Patent No. 5,317,103, discuss 5-HTι agonists which are indole substituted five-membered heteroaromatic compounds of the formula: wherein R 1 may be pyrrolidine or piperidine and A may be a basic group including amino and amidino . Baker et al, however, do not indicate that A can be a substituted ring system like that contained in the presently claimed heteroaromatics . Baker et al, in WO 94/02477, discuss 5-HTι agonists which are imidazoles, triazoles, or tetrazoles of the formula: wherein R 1 represents a nitrogen containing ring system or a nitrogen substituted cyclobutane, and A may be a basic group including amino and amidino. Baker et al, however, do not indicate that A can be a substituted ring system like that contained in the presently claimed heteroaromatics . Illig et al, in WO 97/47299, illustrate amidino and guanidino heterocycle protease inhibitors of the formula: R i -Z-X-Y-W wherein R 1 can be a substituted aryl group, Z is a two carbon linker containing at least one heteroatome, X is a heterocycle, Y is an optional linker and W is an amidino or guanidino containing group. Compounds of this sort are not considered part of the present invention. Jackson et al, in WO 97/32583, describe cytokine inhibitors useful for inhibiting angiogenesis . These inhibitors include imidazoles of the formula: wherein Ri is a variety of heteroaryl groups, R 4 is phenyl, naphthyl, or a heteroaryl group, and R 2 can be a wide variety of groups . Jackson et al do not teach inhibition of factor Xa. Furthermore, the imidazoles of Jackson et al are not considered part of the present invention. Activated factor Xa, whose major practical role is the generation of thrombin by the limited proteolysis of prothrombin, holds a central position that links the intrinsic and extrinsic activation mechanisms in the final common pathway of blood coagulation. The generation of thrombin, the final serine protease in the pathway to generate a fibrin clot, from its precursor is amplified by formation of prothrombinase complex (factor Xa, factor V, Ca 2+ and phospholipid) . Since it is calculated that one molecule of factor Xa can generate 138 molecules of thrombin (Elodi, S., Varadi, K. : Optimization of conditions for the catalytic effect of the factor IXa-factor VIII Complex: Probable role of the complex in the amplification of blood coagulation. Thro b. Res . 1979, 15, 617-629), inhibition of factor Xa may be more efficient than inactivation of thrombin in interrupting the blood coagulation system. Therefore, efficacious and specific inhibitors of factor Xa are needed as potentially valuable therapeutic agents for the treatment of thromboembolic disorders. It is thus desirable to discover new factor Xa inhibitors . SUMMARY OF THE INVENTION Accordingly, one object of the present invention is to provide novel nitrogen containing aromatic heterocycles, with ortho-substituted PI groups, which are useful as factor Xa inhibitors or pharmaceutically acceptable salts or prodrugs thereof . It is another object of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof. It is another object of the present invention to provide a method for treating thromboembolic disorders comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof. These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery that compounds of formula (I): I or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, D, E, G, J, M, R la , R lb , and s are defined below, are effective factor Xa inhibitors . DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS [1] Thus, in a first embodiment, the present invention provides novel compounds of formula I : I or a stereoisomer or pharmaceutically acceptable salt thereof, wherein; ring M contains, in addition to J, 0-3 N atoms, provided that if M contains 2 N atoms then R lb is not present and if M contains 3 N atoms then R la and R lb are not present; J is N or NH; D is selected from CN, C (=NR 8 )NR 7 R 9 , NHC (=NR 8 ) NR 7 R 9 , NR 8 CH(=NR 7 ), C(0)NR 7 R 8 , and (CR 8 R 9 ) t NR 7 R 8 , provided that D is substituted ortho to G on E; E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, and piperidinyl substituted with 1-2 R; R is selected from H, Cl, F, Br, I, (CH 2 ) t OR 3 , C 1 - 4 alkyl, OCF 3 , CF 3 , C(0)NR 7 R 8 , and (CR 8 R 9 ) t NR 7 R 8 ; G is absent or is selected from NHCH 2 , OCH 2 , and SCH2, provided that when s is 0, then G is attached to a carbon atom on ring M; Z is selected from a Cχ_ 4 alkylene, (CH 2 ) r O (CH 2 ) r > (CH 2 ) r NR 3 (CH 2 ) r , (CH 2 ) r C (O) (CH 2 ) r , (CH 2 ) r C (0) 0 (CH 2 ) r , (CH 2 ) r OC(0) (CH 2 ) r , (CH 2 ) r C(0)NR 3 (CH 2 ) r , (CH 2 ) r NR 3 C(0) (CH 2 ) r , (CH 2 ) r 0C(0)0(CH 2 ) r , (CH 2 ) r OC(0)NR 3 (CH 2 ) r , (CH 2 ) r NR 3 C (0) O (CH 2 ) r , (CH 2 ) r NR 3 C(0)NR 3 (CH 2 ) r , (CH 2 ) r S (0) p (CH 2 ) r , (CH 2 ) r S0 2 NR 3 (CH 2 ) r , (CH 2 ) r NR 3 S0 2 (CH 2 ) r , and (CH 2 ) r NR 3 S0NR 3 (CH 2 ) r , provided that Z does not form a N- N, N-0, N-S, NCH 2 N, NCH 2 0, or NCH 2 S bond with ring M or group A; R la and R lb are independently absent or selected from -(CH 2 ) r -R 1' -CH^H-R 1 ', NCH2R 1 ", OCH2R 1" , SCH2R 1" , NH(CH 2 ) 2 (CH 2 ) t R 1 ', 0(CH 2 ) 2 (CH 2 ) t R 1 ', and S (CH 2 ) 2 ( CH 2 ) tR 1 ' ; alternatively, R la and R lb , when attached to adjacent carbon atoms, together with the atoms to which they are attached form a 5-8 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R 4 and which contains from 0-2 heteroatoms selected from the group consisting of N, O, and S; R 1 ' is selected from H, C 1 - 3 alkyl, -F, Cl, Br, I, -CN, -CHO, (CF 2 ) r CF 3 , (CH 2 ) r OR 2 , NR 2 R 2a , C(0)R 2c , OC(0)R 2 , (CF 2 ) r C0 2 R 2c , S(0) p R 2b , NR 2 (CH 2 ) r OR 2 , CH (=NR 2c ) NR 2 R 2a , NR 2 C(0)R 2b , NR 2 C(0)NHR 2b , NR 2 C(0) 2 R 2a , OC (0) NR 2a R 2b , C(0)NR 2 R 2a , C(0)NR 2 (CH 2 ) r OR 2 , S0 2 NR 2 R 2a , NR 2 S0 2 R 2b , C 3 - 6 carbocyclic residue substituted with 0-2 R 4 , and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4 ; R 1 " is selected from H, CH(CH 2 OR 2 ) 2 , C(0)R 2c , C(0)NR 2 R 2a , S(0)R 2b , S(0) 2 R 2b , and S0 2 NR 2 R 2a ; R 2 , at each occurrence, is selected from H, CF 3 , C 1 - 5 alkyl, benzyl, C 3 - 6 carbocyclic residue substituted with 0-2 R b , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4b ; R 2a , at each occurrence, is selected from H, CF 3 , -e alkyl, benzyl, C 3 - 6 carbocyclic residue substituted with 0-2 R b , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4b ; R 2b , at each occurrence, is selected from CF 3 , Cχ_ 4 alkoxy, C 1 - 6 alkyl, benzyl, C 3 .-6 carbocyclic residue substituted with 0-2 R b , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4b ; R 2c , at each occurrence, is selected from CF 3 , OH, C 1 - 4 alkoxy, Cι_6 alkyl, benzyl, C 3 _ 6 carbocyclic residue substituted with 0-2 R b , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4b ; alternatively, R 2 and R 2a combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R 4b which contains from 0-1 additional heteroatoms selected from the group consisting of N, O, and S; alternatively, R 2 and R 2a , together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R 4b and containing from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S; R 3 , at each occurrence, is selected from H, C 1 - 4 alkyl, and phenyl ; R 3a , at each occurrence, is selected from H, C 1 - 4 alkyl, and phenyl ; R 3b , at each occurrence, is selected from H, C 1 - 4 alkyl, and phenyl ; R 3c , at each occurrence, is selected from Cχ_ 4 alkyl, and phenyl ; A is selected from: C 3 - 10 carbocyclic residue substituted with 0-2 R 4 , and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R ; B is selected from: X-Y, NR 2 R 2a , C(=NR 2 )NR 2 R 2a , NR 2 C (=NR 2 ) NR 2 R 2a , C3-.10 carbocyclic residue substituted with 0-2 R 4a , and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4a ; X is selected from Cι_ alkylene, -CR 2 (CR 2 R 2b ) (CH 2 ) t - , -C(0)-, -C(=NR 1 ")-, -CR 2 (NR 1 "R 2 )-, -CR 2 (OR 2 )-, -CR 2 (SR 2 )-, -C(0)CR 2 R 2a -, -CR 2 R 2a C(0), -S(0) p -, -S (0) p CR 2 R 2a -, -CR 2 R 2a S(0) p -, -S(0) 2 NR 2 -, -NR 2 S(0) 2 -, -NR 2 S (0) 2 CR 2 R 2a - , -CR 2 R 2a S(0) 2 NR 2 -, -NR 2 S(0) 2 NR 2 -, -C(0)NR 2 -, -NR 2 C(0)-, -C(0)NR 2 CR 2 R 2a -, -NR 2 C(0)CR 2 R 2 -, -CR 2 R 2a C (O) NR 2 - , -CR 2 R 2a NR 2 C(0)-, -NR 2 C(0)0-, -OC(0)NR 2 -, -NR 2 C (O)NR 2 - , -NR 2 -, -NR 2 CR 2 R 2a -, -CR 2 R 2a NR 2 -, O, -CR 2 R 2a O-, and -OCR 2 R 2a - ; Y is selected from: (CH 2 ) r NR 2 R 2a , provided that X-Y do not form a N-N, O-N, or S-N bond, C 3 - 10 carbocyclic residue substituted with 0-2 R a , and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R a ; R 4 , at each occurrence, is selected from H, =0, (CH 2 ) r OR 2 , F, Cl, Br, I, C 1 - 4 alkyl, -CN, N0 2 , (CH 2 ) r NR 2 R 2a , (CH 2 ) r C(0)R 2c , NR 2 C(0)R 2b , C(0)NR 2 R 2a , NR 2 C (0)NR 2 R 2a , CH(=NR 2 )NR 2 R 2a , CH(=NS(0) 2 R 5 )NR 2 R 2a , NHC (=NR 2 )NR 2 R 2a , C(0)NHC(=NR 2 )NR 2 R 2a , S0 2 NR 2 R 2a , NR 2 S0 2 NR 2 R 2a , NR 2 S0 2 -Cι_ alkyl, NR 2 S0 2 R 5 , S(0) p R 5 , (CF 2 ) r CF 3 , NO^R 1 ", OCH2R 1 ", SCH 2 R 1Λ , N(CH 2 ) 2 (CH 2 ) t R l ', O (CH 2 ) 2 (CH 2 ) t R x ' , and S(CH 2 ) 2 (CH 2 ) t R 1' , alternatively, one R 4 is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S; R 4a , at each occurrence, is selected from H, =0, (CH 2 ) r 0R 2 , (CH 2 ) r -F, (CH 2 ) r -Br, (CH 2 ) r -Cl, Cl, Br, F, I, C1-4 alkyl, -CN, N0 2 , (CH 2 ) r NRR 2a , (CH 2 ) r C (0) R 2c , NR 2 C(0)R 2b , C(0)NR 2 R 2a , C(0)NH(CH 2 ) 2 NR 2 R 2a , NR 2 C (0) NR 2 R 2a , CH(=NR 2 )NR 2 R 2a , NHC(=NR 2 )NR 2 R 2a , S0 2 NR 2 R 2a , NR 2 S0 2 NR 2 R 2a , NR 2 S0 2 -Cι_ 4 alkyl, C (0)NHSO 2 -Cι_ alkyl, NR 2 S0 2 R 5 , S(0) p R 5 , and (CF 2 ) r CF ; alternatively, one R 4a is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-1 R 5 ; R 4b , at each occurrence, is selected from H, =0, (CH 2 ) r OR 3 , F, Cl, Br, I, Cι_ 4 alkyl, -CN, N0 2 , (CH 2 ) r NR 3 R 3a , (CH 2 ) r C(0)R 3 , (CH 2 ) r C(0)OR 3c , NR 3 C(0)R 3a , C(0)NR 3 R 3a , NR 3 C(0)NR 3 R 3a , CH(=NR 3 )NR 3 R 3a , NR 3 C (=NR 3 ) NR 3 R 3 , S0 2 NR 3 R 3a , NR 3 S0 2 NR 3 R 3a , NR 3 S0 2 -Cι_ 4 alkyl, NR 3 S0 2 CF 3 , NR 3 S0 2 -phenyl, S(0) p CF 3 , S(0) p -Cι_ 4 alkyl, S (0) p -phenyl, and (CF 2 )rCF 3 ; R 5 , at each occurrence, is selected from CF 3 , Cι_ 6 alkyl, phenyl substituted with 0-2 R 6 , and benzyl substituted with 0-2 R 6 ; R 6 , at each occurrence, is selected from H, OH, (CH2) r OR 2 , halo, C 1 - 4 alkyl, CN, N0 2 , (CH 2 ) r NR 2 R 2a , (CH 2 ) r C (0) R 2b , NR 2 C(0)R 2b , NR 2 C(0)NR 2 R 2a , CH(=NH)NH 2 , NHC(=NH)NH 2 , S0 2 NR 2 R 2a , NR 2 S0 2 NR 2 R 2a , and NR 2 S0 2 Cι_ 4 alkyl; R 7 , at each occurrence, is selected from H, OH, Cχ_ 6 alkyl, C 1 - 6 alkylcarbonyl , C -β alkoxy, Cι_ 4 alkoxycarbonyl , (CH 2 ) n -phenyl, C 6 _ιo aryloxy, C 6 -ιo aryloxycarbonyl , C 6 -ιo arylmethylcarbonyl , C 1 - 4 alkylcarbonyloxy C 1 - 4 alkoxycarbonyl, C δ -io arylcarbonyloxy C 1 - 4 alkoxycarbonyl, Cι_6 alkylaminocarbonyl, phenylaminocarbonyl , and phenyl C 1 - 4 alkoxycarbonyl; R 8 , at each occurrence, is selected from H, C 1 - 6 alkyl and (CH 2 ) n -phenyl; alternatively, R 7 and R 8 combine to form a 5 or 6 membered saturated, ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S; R 9 , at each occurrence, is selected from H, Cι_ 6 alkyl and (CH 2 )n-phenyl; n, at each occurrence, is selected from 0, 1, 2, and 3 ; m, at each occurrence, is selected from 0, 1, and 2 ; p, at each occurrence, is selected from 0, 1, and 2; r, at each occurrence, is selected from 0, 1, 2, and 3; s, at each occurrence, is selected from 0, 1, and 2; and, t, at each occurrence, is selected from 0, 1, 2, and 3; provided that D-E-G- (CH 2 ) s - and -Z-A-B are not both benzamidines . [2] In a preferred embodiment, the present invention provides novel compounds of formulae Ia-Ih: Id le If wherein, groups D-E- and -Z-A-B are attached to adjacent atoms on the ring; R is selected from H, Cl, F, Br, I, (CH 2 ) t OR 3 , C 1 - 4 alkyl, OCF 3 , CF 3 , C(0)NR 7 R 8 , and (CR 8 R 9 ) t NR 7 R 8 ; Z is selected from a CH 2 0, 0CH 2 , CH 2 NH, NHCH 2 , C(0), CH 2 C(0), C(0)CH 2 , NHC(O), C(0)NH, CH 2 S(0) 2 , S(0) 2 (CH 2 ), S0 2 NH, and NHS0 2 , provided that Z does not form a N-N, N-0, NCH 2 N, or NCH 2 O bond with ring M or group A; A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4 ; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl , pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2 , 3 -oxadiazolyl, 1, 2, 4-oxadiazolyl, 1, 2 , 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2, 3-thiadiazolyl, 1, 2 , 4-thiadiazolyl, 1,2, 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2 , 3 -triazolyl, 1,2, 4-triazolyl, 1, 2 , 5-triazolyl, 1, 3 , 4-triazolyl, benzofuranyl, benzothiof ranyl , indolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl; B is selected from: Y, X-Y, NR 2 R 2a , C (=NR 2 )NR 2 R 2a , and NR 2 C(=NR 2 )NR 2 R 2a ; X is selected from Cι_ 4 alkylene, -C(O)-, -C(=NR)-, -CR 2 (NR 2 R 2a )-, -C(0)CR 2 R 2a -, -CR 2 R 2a C(0), -C(0)NR 2 -, -NR 2 C(0)-, -C(0)NR 2 CR 2 R 2a -, -NR 2 C (0) CR 2 R 2a -, -CR 2 R 2a C(0)NR 2 -, -CR 2 R 2 NR 2 C(0)-, -NR 2 C (O)NR 2 - , -NR 2 -, -NR 2 CR 2 R 2a -, -CR 2 R 2a NR 2 -, 0, -CR 2 R 2a O-, and -OCR 2 R 2a -; Y is NR 2 R 2a , provided that X-Y do not form a N-N or O-N bond; alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4a ; cylcopropyl, cyclopentyl, cyclohexyl, phenyl, piperidinyl, piperazinyl, pyridyl , pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2, 3-oxadiazolyl, 1, 2, 4-oxadiazolyl, 1, 2 , 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2, 3 -thiadiazolyl , 1,2, 4-thiadiazolyl , 1, 2, 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl , 1, 2 , 3 -triazolyl, 1,2, 4-triazolyl, 1, 2 , 5-triazolyl, 1, 3 , 4-triazolyl, benzofuranyl, benzothiofuranyl, indolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl; alternatively, Y is selected from the following bicyclic heteroaryl ring systems: K is selected from O, S, NH, and N. [3] In a more preferred embodiment, the present invention provides novel compounds of formulae Ila-IIf: wherein ; Z is selected from a C(0), CH 2 C(0), C(0)CH 2 , NHC(O), C(0)NH, C(0)N(CH 3 ), CH 2 S(0) 2 , S(0) 2 (CH 2 ), S0 2 NH, and NHS0 2 , provided that Z does not form a N-N or NCH 2 N bond with ring M or group A. [4] In an even more preferred embodiment, the present invention provides novel compounds of formulae Ila-IIf, wherein; E is phenyl substituted with R or 2-pyridyl substituted with R; D is selected from NH 2 , NHCH 3 , CH 2 NH 2 , CH 2 NHCH 3 , CH(CH 3 )NH 2 , and C(CH 3 ) 2 H 2 , provided that D is substituted ortho to ring M on E; and, R is selected from H, OCH 3 , Cl, and F. [5] In a further preferred embodiment, the present invention provides novel compounds of formulae Ila-IIf, wherein; D-E is selected from 2-aminophenyl, 2-methylaminophenyl, 2- aminomethylphenyl , 4-methoxy-2-aminophenyl, 4-methoxy-2- (methylamino) phenyl, 4-methoxy-2-aminomethylphenyl , 4- methoxy-2- (methylaminomethyl ) phenyl , 4-methoxy-2- (1- aminoethyl) phenyl, 4-methoxy-2- (2-amino-2-propyl) phenyl, 4-Cl-2-aminophenyl, 4-Cl-2- (methylamino) phenyl, 4-C1-2- aminomethylphenyl, 4-C1-2- (methylaminomethyl) phenyl, 4- Cl-2- (1-aminoethyl) phenyl, 4-C1-2- (2-amino-2- propyl) phenyl , 4-F-2-aminophenyl, 4-F-2- (methylamino) phenyl, 4-F-2-aminomethylphenyl, 4-F-2- (methylaminomethyl) henyl, 4-F-2- (1-aminoethyl) phenyl, and 4-F-2- (2-amino-2-propyl) phenyl . [6] In another even more preferred embodiment, the present invention provides novel compounds of formulae Ila-IIf, wherein; Z is C(0)CH 2 and CONH, provided that Z does not form a N-N bond with group A; A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R 4 ; and, B is selected from X-Y, phenyl, pyrrolidino, morpholino, 1,2, 3 -triazolyl, and imidazolyl, and is substituted with 0-1 R a ; R 4 , at each occurrence, is selected from OH, (CH 2 ) r OR 2 , halo, Cι- 4 alkyl, (CH 2 ) r NR 2 R 2a , and (CF 2 ) r CF 3 ; R 4a is selected from Cι_ alkyl, CF 3 , S(0) p R 5 , S0 2 NR 2 R 2a , and l-CF 3 -tetrazol-2-yl; R 5 , at each occurrence, is selected from CF 3 , -e alkyl, phenyl, and benzyl; X is CH 2 or C(O); and, Y is selected from pyrrolidino and morpholino, [7] In another further preferred embodiment, the present invention provides novel compounds of formulae Ila-IIf, wherein; A is selected from the group: phenyl, 2-pyridyl, 3 -pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F- phenyl, 2-methylphenyl, 2-aminophenyl, and 2- methoxyphenyl ; and, B is selected from the group: 2-CF3 -phenyl, 2- (aminosulfonyl) phenyl, 2- (methylaminosulfonyl) phenyl, 2- (dimethylaminosulfonyl) phenyl, 1-pyrrolidinocarbonyl, 2- (methylsulfonyl) phenyl, 4-morpholino, 2- (1 ' -CF3~tetrazol- 2-yl) henyl, 4-morpholinocarbonyl, 2-methyl-1-imidazolyl, 5-methyl-l-imidazolyl, 2-methylsulfonyl-l-imidazolyl and, 5-methyl-l,2, 3-triazolyl. [8] In another even more preferred embodiment, the present invention provides novel compounds of formulae Ila-IIf, wherein; E is phenyl substituted with R or 2-pyridyl substituted with R; D is selected from NH 2 , NHCH 3 , CH 2 NH 2 , CH 2 NHCH 3 , CH(CH 3 )NH 2 , and C(CH 3 ) 2 NH 2 , provided that D is substituted ortho to ring M on E; and, R is selected from H, OCH 3 , Cl, and F; Z is C(0)CH 2 and CONH, provided that Z does not form a N-N bond with group A; A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R 4 ; and, B is selected from X-Y, phenyl, pyrrolidino, morpholino, 1, 2, 3-triazolyl, and imidazolyl, and is substituted with 0-1 R 4a ; R 4 , at each occurrence, is selected from OH, (CH 2 ) r OR 2 , halo, Cι- 4 alkyl, (CH 2 ) r NR 2 R 2a , and (CF 2 )rCF 3 ; R 4 a i s selected from Cι_ 4 alkyl, CF 3 , S(0) P R 5 , S0 2 NR 2 R 2a , and l-CF 3 -tetrazol-2-yl; R 5 , at each occurrence, is selected from CF 3 , Cι_ 6 alkyl, phenyl, and benzyl; X is CH 2 or C(O); and, Y is selected from pyrrolidino and morpholino. [9] In another further preferred embodiment, the present invention provides novel compounds of formulae Ila-IIf, wherein; D-E is selected from 2-aminophenyl, 2-methylaminophenyl, 2- aminomethylphenyl, 4-methoxy-2-aminophenyl, 4-methoxy-2- (methylamino) phenyl, 4-methoxy-2-aminomethylphenyl, 4- methoxy-2- (methylaminomethyl) phenyl, 4-methoxy-2- (1- aminoethyl) phenyl , 4-methoxy-2- (2-amino-2-propyl) phenyl, 4-Cl-2-aminophenyl, 4-C1-2- (methylamino) phenyl, 4-C1-2- aminomethylphenyl , 4-Cl-2- (methylaminomethyl) phenyl , 4- Cl-2- (1-aminoethyl) phenyl, 4-C1-2- (2-amino-2- propyl) phenyl , 4-F-2-aminophenyl, 4-F-2- (methylamino)phenyl, 4-F-2-aminomethylphenyl, 4-F-2- (methylaminomethyl) phenyl, 4-F-2- (1-aminoethyl) henyl, and 4-F-2- (2-amino-2-propyl) phenyl; A is selected from the group: phenyl, 2-pyridyl, 3 -pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F- phenyl, 2-methylphenyl, 2-aminophenyl, and 2- ethoxyphenyl ; and, B is selected from the group: 2-CF3 -phenyl, 2- (aminosulfonyl) phenyl, 2- (methylaminosulfonyl) phenyl, 2- (dimethylaminosulfonyl) phenyl, 1-pyrrolidinocarbonyl, 2- (methylsulfonyl) phenyl, 4-morpholino, 2- (1' -CF3~tetrazol- 2-yl)phenyl, 4-morpholinocarbonyl , 2-methyl-l-imidazolyl, 5-methyl-l-imidazolyl, 2-methylsulfonyl-1-imidazolyl and, 5-methyl-l, 2 , 3 -triazolyl . [10] In a still further preferred embodiment, the present invention provides a novel compound of formula Ha. [11] In another still further preferred embodiment, the present invention provides a novel compound of formula lib. [12] In another still further preferred embodiment, the present invention provides a novel compound of formula lie [13] In another still further preferred embodiment, the present invention provides a novel compound of formula lid. [14] In another still further preferred embodiment, the present invention provides a novel compound of formula lie [15] In another still further preferred embodiment, the present invention provides a novel compound of formula Ilf [16] In another even more preferred embodiment, the present invention provides novel compounds of formulae Ila-IIf, wherein; D is selected from -CN, C ( =NR 8 ) NR 7 R 9 , C(0)NR 7 R 8 , NR 7 R 8 , and CH 2 NR 7 R 8 , provided that D is substituted ortho to ring M on E; E is phenyl substituted with R or pyridyl substituted with R; R is selected from H, Cl, F, OR 3 , CH 3 , CH 2 CH 3 , OCF 3 , CF 3 , NR 7 R 8 , and CH 2 NR 7 R 8 ; Z is selected from C(O), CH 2 C(0), C(0)CH 2 , NHC(O), and C(0)NH, provided that Z does not form a N-N bond with ring M or group A; R la and R lb are independently absent or selected from -(CH^r-R 1 ', NCH 2 R!", OC^R 1 ", SO^R 1 ", N(CH 2 ) 2 (CH 2 ) tR 1 ' , 0(CH ) 2 (CH 2 ) t R 1 ' , and S (CH 2 ) 2 (CH 2 ) t 1 ' - or combined to form a 5-8 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R 4 and which contains from 0-2 heteroatoms selected from the group consisting of N, 0, and S; R 1 ', at each occurrence, is selected from H, C 1 - 3 alkyl, halo, (CF 2 ) r CF 3 , OR 2 , NR 2 R a , C(0)R 2c , (CF 2 ) r C0 2 R 2c , S(0) p R 2b , NR 2 (CH 2 ) r OR 2 , NR 2 C(0)R 2b , NR 2 C(0) 2 R 2b , C(0)NR 2 R 2a , S0 2 NR 2 R 2 , and NR 2 S0 2 R 2b ; A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4 ,- phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, and imidazolyl; B is selected from: Y, X-Y, NR 2 R 2a , C (=NR 2 )NR 2 R 2a , and NR 2 C(=NR 2 )NR 2 R 2a ; X is selected from CH 2 , -CR 2 (CR 2 R 2b ) (CH 2 ) t ~ . -C(0)-, -C(=NR)-, -CH(NR 2 R 2a )-, -C(0)NR 2 -, -NR 2 CtO)-, -NR 2 C (O)NR 2 - , -NR 2 -, and 0; Y is NR 2 R 2a , provided that X-Y do not form a N-N or 0-N bond; alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4a ; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl , thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2, 3-oxadiazolyl, 1,2, 4-oxadiazolyl, 1, 2, 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2, 3-thiadiazolyl, 1, 2 , 4-thiadiazolyl, 1,2,5-thiadiazolyl, 1, 3 , 4-thiadiazolyl , 1, 2 , 3-triazolyl, 1,2,4-triazolyl, 1, 2, 5-triazolyl, and 1, 3 , 4-triazolyl; R 4 , at each occurrence, is selected from =0, OH, Cl, F, C1-4 alkyl, (CH 2 ) r NR 2 R 2a , (CH 2 ) r C (0) R 2b , NR 2 C(0)R 2b , C(0)NR 2 R 2a , CH(=NH)NH 2 , NHC(=NH)NH 2 , S0 2 NR 2 R 2a , NR 2 S0 2 -Cι-4 alkyl, NR 2 S0 2 R 5 , S(0) p R 5 , and (CF 2 ) r CF 3 ; R 4a , at each occurrence, is selected from =0, OH, Cl, F, C1- 4 alkyl, (CH 2 ) r NR 2 R 2a , (CH 2 ) r C (0) R 2b , NR 2 C(0)R 2b , C(0)NR 2 R 2a , CH(=NH)NH 2 , NHC(=NH)NH 2 , Sθ 2 NR 2 R 2 , NR 2 S0 2 "Cι_4 alkyl, NR 2 S02R 5 , S(0) p R 5 , (CF 2 ) r CF 3 , and l-CF 3 -tetrazol-2-yl; R 5 , at each occurrence, is selected from CF 3 , C 1 - 6 alkyl, phenyl substituted with 0-2 R 6 , and benzyl substituted with 0-2 R 6 ; R 6 , at each occurrence, is selected from H, =0, OH, OR 2 , Cl, F, CH 3 , CN, N0 2 , (CH 2 ) r NR 2 R 2a , (CH 2 ) r C (O) R 2b , NR 2 C(0)R 2b , CH(=NH)NH 2 , NHC(=NH)NH 2 , and S0 2 NR 2 R 2a ; R 7 , at each occurrence, is selected from H, OH, C s alkyl, Cι_ 6 alkylcarbonyl , Cι_ 6 alkoxy, C 1 - 4 alkoxycarbonyl, benzyl, C6-10 aryloxy, Cβ-io aryloxycarbonyl, Ce-io arylmethylcarbonyl , C 1 - 4 alkylcarbonyloxy C 1 - 4 alkoxycarbonyl, Cβ-io arylcarbonyloxy C _ 4 alkoxycarbonyl, C 1 - 6 alkylaminocarbonyl , phenylaminocarbonyl , and phenyl C 1 - 4 alkoxycarbonyl; R 8 , at each occurrence, is selected from H, C_ . - alkyl and benzyl ; and alternatively, R 7 and R 8 combine to form a morpholino group; and, R 9 , at each occurrence, is selected from H, Cis alkyl and benzyl . [17] In a another further preferred embodiment, the present invention provides novel compounds of formulae Ila-IIf, wherein; E is phenyl substituted with R or 2-pyridyl substituted with R; R is selected from H, Cl, F, OCH 3 , CH 3 , OCF 3 , CF 3 , NH , and CH 2 NH 2 ; Z is selected from a C(0)CH 2 and C(0)NH, provided that Z does not form a N-N bond with group A; R la is selected from H, CH 3 , CH 2 CH 3 , Cl , F, CF3 , OCH3 , NR 2 R 2a , S(0) p R b , CH 2 S(0) p R 2b , CH 2 NR 2 S(0) p R 2b , C(0)R 2c , CH 2 C(0)R 2c , C(0)NR 2 R 2a , and S0 2 NR 2 R 2a ; R lb ig selected from H, CH , CH 2 CH 3 , Cl, F, CF 3 , OCH 3 , NR 2 R 2 , S(0) p R 2b , CH 2 S(0) p R 2b , CH 2 NR 2 S(0) p R 2b , C(0)R 2c , CH 2 C(0)R 2 , C(0)NR 2 R 2a , and S0 2 NR 2 R 2a ; A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4 ; phenyl, pyridyl, pyrimidyl, furanyl, thiophenyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, and imidazolyl; B is selected from: Y and X-Y; X is selected from CH 2 , -CR 2 (CR 2 R 2b ) - , -C(O)-, -C(=NR)-, -CH(NR 2 R 2 )-, -C(0)NR 2 -, -NR 2 C(0)-, -NR 2 C (0) NR 2 - , -NR 2 -, and O; Y is NR 2 R 2 , provided that X-Y do not form a N-N or O-N bond; alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4a ; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2 , 3-oxadiazolyl, 1, 2, 4-oxadiazolyl, 1, 2 , 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2, 3-thiadiazolyl, 1,2, 4-thiadiazolyl, 1,2,5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2, 3-triazolyl, 1,2, 4-triazolyl, 1, 2, 5-triazolyl, and 1, 3 , 4-triazolyl; R 2 , at each occurrence, is selected from H, CF 3 , CH 3 , benzyl, and phenyl; R 2a , at each occurrence, is selected from H, CF 3 , CH 3 , benzyl, and phenyl; R 2b , at each occurrence, is selected from CF 3 , OCH3 , CH3 , benzyl, and phenyl; R 2c , at each occurrence, is selected from CF 3 , OH, OCH3 , CH 3 , benzyl, and phenyl; alternatively, R 2 and R 2a combine to form a 5 or 6 membered saturated, partially unsaturated, or unsaturated ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S; R 3 , at each occurrence, is selected from H, CH 3 , CH 2 CH 3 , and phenyl ; R 3a , at each occurrence, is selected from H, CH 3 , CH 2 CH3 , and phenyl ; R 4 , at each occurrence, is selected from OH, Cl, F, CH3 , CH 2 CH , NR 2 R 2a , CH 2 NR 2 R 2a , C(0)R 2b , NR 2 C(0)R 2b , C(0)NR 2 R 2a , and CF 3 ; R 4a , at each occurrence, is selected from OH, Cl, F, CH3, CH 2 CH 3 , NR 2 R 2a , CH 2 NR 2 R 2a , C(0)R 2b , C(0)NR 2 R 2a , S0 2 NR 2 R 2a , S(0) p R 5 , CF 3 , and l-CF 3 -tetrazol-2-yl; R 5 , at each occurrence, is selected from CF 3 , Cis alkyl, phenyl substituted with 0-2 R 6 , and benzyl substituted with 1 R 6 ; R 6 , at each occurrence, is selected from H, OH, OCH 3 , Cl, F, CH 3 CN, N0 2 , NR 2 R 2a , CH 2 NR 2 R 2a , and S0 2 NR 2 R 2a ; R 7 , at each occurrence, is selected from H and C 1 - 3 alkyl; R 8 , at each occurrence, is selected from H, CH 3 , and benzyl; R 9 , at each occurrence, is selected from H, CH 3 , and benzyl; and, t, at each occurrence, is selected from 0 and 1. [18] In a another still further preferred embodiment, the present invention provides novel compounds of formulae Ila-IIf, wherein; D is selected from NR 7 R 8 , and CHNR 7 R 8 , provided that D is substituted ortho to ring M on E; R la is absent or is selected from H, CH 3 , CH 2 CH 3 , Cl, F, CF 3 , OCH 3 , NR 2 R 2a , S(0) p R 2b , C(0)NR 2 R 2a , CH 2 S(0) p R 2b , CH 2 NR 2 S(0) p R 2b , C(0)R 2c , CH 2 C(0)R 2c , and S0 2 NR 2 R 2a ; R lb is absent or is selected from H, CH 3 , CH 2 CH 3 , Cl , F, CF 3 , OCH 3 , NR 2 R 2a , S(0) p R 2b , C(0)NR 2 R 2a , CH 2 S(0) p R 2b , CH 2 NR 2 S(0) p R 2b , C(0)R 2b , CH 2 C(0)R 2b , and S0NR 2 R 2a ; A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4 ; phenyl, pyridyl, and pyrimidyl; B is selected from: Y and X-Y; X is selected from -C(O)- and 0; Y is NR 2 R 2a , provided that X-Y do not form a O-N bond; alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R a ; phenyl, piperazinyl, pyridyl, pyrimidyl, morpholinyl, pyrrolidinyl, imidazolyl, and 1,2,3- triazolyl; R 2 , at each occurrence, is selected from H, CF 3 , CH 3 , benzyl, and phenyl; R 2a , at each occurrence, is selected from H, CF 3 , CH 3 , benzyl, and phenyl; R 2b , at each occurrence, is selected from CF 3 , OCH 3 , CH 3 , benzyl, and phenyl; R 2c , at each occurrence, is selected from CF 3 , OH, OCH 3 , CH 3 , benzyl, and phenyl; alternatively, R 2 and R 2a combine to form a ring system selected from pyrrolidinyl , piperazinyl and morpholino; R 4 , at each occurrence, is selected from Cl, F, CH 3 , NR 2 R 2a , and CF 3 ; R 4a , at each occurrence, is selected from Cl, F, CH 3 , S0 2 NR 2 R 2a , S(0) p R 5 , and CF 3 ; R 5 , at each occurrence, is selected from CF 3 and CH 3 ; R 7 , at each occurrence, is selected from H, CH 3 , and CH 2 CH 3 ; and, R 8 , at each occurrence, is selected from H and CH 3 . [19] Specifically preferred compounds of the present invention are selected from the group: 3-Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2 ' -sulfamido- [1,1'] -biphen-4-yl) ) carboxyamide; 3-Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2 ' -sulfamido- [1,1'] -biphen-4-yl) ) carboxyamide ; 3-Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2 ' -sulfamido- [1, 1 ' ] -biphen-4- yl) ) carboxyamide; -Methyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5-(N- (2 '-sulfamido- [1,1' ] -biphen-4- yl) ) carboxyamide; -Ethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (2 ' -sulfamido- [1,1'] -biphen-4-yl) ) carboxyamide ; -Trifluoromethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (2 ' -sulfamido- [1,1'] -biphen-4- yl ) ) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2 ' -methylsulfonyl- [1,1' ] -biphen-4-yl) ) carboxyamide; -Ethyl-1- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2 ' -methylsulfonyl- [1, 1 ' ] -biphen-4-yl) ) carboxyamide ; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2 ' -methylsulfonyl- [1,1'] -biphen-4- yl ) ) carboxyamide; -Methyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2 ' -methylsulfonyl- [1,1'] -biphen-4- yl ) ) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -iH-pyrazole- 5- (N- (2 ' -methylsulfonyl- [1, 1 ' ] -biphen-4-yl) ) carboxyamide; -Trifluoro ethy1-1- (2-N-methylaminomethy1-4-methoxypheny1) lH-pyrazole-5- (N- (2 ' -methylsulfonyl- [1, 1 ' ] -biphen-4- yl) ) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (3-fluoro-2 '-sulfamido- [1,1'] -biphen-4-yl) ) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (3- fluoro-2 ' -sulfamido- [1,1' ] -biphen-4-yl) ) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5-(N-(3-fluoro-2 ' -sulfamido- [1, 1 ' ]-biphen-4- yl) ) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1,1'] -biphen-4- yl ) ) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (3-fluoro-2 ' -sulfamido- [1 , 1 ' ]-biphen-4- yl) ) carboxyamide; -Trifluoromethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1, 1 ' ] -biphen-4- yl ) ) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (3-fluoro-2 '-methylsulfonyl- [1,1' ]-biphen-4- yl ) ) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (3- fluoro-2 ' -methylsulfonyl- [1,1'] -biphen-4- yl ) ) carboxyamide; -Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl ) ) carboxyamide ; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) ) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -IH-pyrazole- 5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) ) carboxyamide; -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1']- biphen-4-yl) ) carboxyamide ; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- ( 1-pyrrolidinocarbonyl) phenyl) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- ( 1-pyrrolidinocarbonyl) phenyl ) carboxyamide; -Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5-(N- (4- (1- pyrrolidinocarbonyl) phenyl) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (4- (1- pyrrolidinocarbonyl) phenyl) carboxyamide ; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (4- (1-pyrrolidinocarbonyl) phenyl) carboxyamide; -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (4- (1- pyrrolidinocarbonyl) phenyl) carboxyamide ; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2-fluoro-4- ( 1-pyrrolidinocarbonyl) phenyl) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2- fluoro-4- ( 1-pyrrolidinocarbonyl) phenyl) carboxyamide; -Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2-fluoro-4- (1- pyrrolidinocarbonyl) phenyl) carboxyamide ; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2-fluoro-4- (1- pyrrolidinocarbonyl ) phenyl) carboxyamide ; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N-(2-fluoro-4- ( 1-pyrrolidinocarbonyl) carboxyamide ; -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (2-fluoro-4- (1- pyrrolidinocarbonyl ) phenyl) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- ( (2-sulfamido) phenyl)pyridin-2-yl) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- ( (2-sulfamido)phenyl)pyridin-2-yl) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-sulfamido) phenyl)pyridin-2- yl ) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-sulfamido) phenyl)pyridin-2- yl) carboxyamide; -Ethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (5- ( (2-sulfamido) phenyl)pyridin-2-yl) carboxyamide; -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (5- ( (2-sulfamido) phenyl)pyridin-2- y1 ) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- ( (2-methylsulphonyl) phenyl )pyridin-2-yl) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- (2-methylsulphonyl) phenyl) pyridin-2-yl ) carboxyamide; -Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-methylsulphonyl) phenyl)pyridin-2- yl) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-methylsulphonyl) phenyl)pyridin-2- yl) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (5- ( (2-methylsulphonyl) phenyl-) pyridin-2- yl) carboxyamide; -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (5- ( (2-methylsulphonyl) phenyl )pyridin-2 yl) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- ( (2-sulfamido) phenyl) pyrimidin-2-yl ) carboxyamide ; -Ethyl-1- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- ( (2-sulfamido) phenyl ) pyrimidin-2-yl ) carboxyamide ; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-sulfamido) phenyl)pyrimidin-2- yl) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-sulfamido) phenyl) pyrimidin-2- yl ) carboxyamide; -Ethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (5- ( (2-sulfamido) phenyl) pyrimidin-2-yl) carboxyamide; -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (5- ( (2-sulfamido)phenyl)pyrimidin-2- yl ) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- ( (2-methylsulphonyl) phenyl)pyrimidin-2- yl ) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- (2-methylsulphonyl) phenyl ) pyrimidin-2-yl) carboxyamide; -Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-methylsulphonyl) phenyl) pyrimidin-2- yl) carboxyamide; -Methyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5-JN- (5- ( (2-methylsulphonyl) phenyl) pyrimidin-2- yl) carboxyamide; -Ethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (5- ( (2-methylsulphonyl) phenyl )pyrimidin-2- yl) carboxyamide; -Trifluoromethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (5- ( (2-methylsulphonyl) phenyl)pyrimidin- 2-yl) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- ( (2-methyl) imidazo-1-yl) phenyl) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- ( (2-methyl) imidazo-1-yl)phenyl) carboxyamide ; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (4- ( (2-methyl) imidazo-1- yl) phenyl) carboxyamide; -Methyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (4- ( (2-methyl) imidazo-1- y1) phenyl) carboxyamide; -Ethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (4- ( (2-methyl) imidazo-1-yl) phenyl) carboxyamide ; -Trifluoromethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (4- ( (2-methyl) imidazo-1- yl ) phenyl) carboxyamide; -Methyl-1- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- ( (5-methyl) imidazo-1-yl) phenyl) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- ( (5-methyl) imidazo-1-yl) phenyl) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (4- ( (5-methyl) imidazo-1- yl) phenyl) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (4- ( (5-methyl) imidazo-1- yl) phenyl) carboxyamide; -Ethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (4- ( (5-methyl) imidazo-1-yl) phenyl) carboxyamide; -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (4- ( (5-methyl) imidazo-1- yl) phenyl) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2-fluoro-4- ( (2-methyl) imidazo-1-yl) phenyl) carboxyamide; -Ethyl-1- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2- fluoro-4- ( (2-methyl) imidazo-1-yl) phenyl) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2-fluoro-4- ( (2-methyl) imidazo-1- yl) phenyl) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2-fluoro-4- ( (2-methyl) imidazo-1- yl) phenyl) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (2-fluoro-4- ( (2-methyl) imidazo-1- yl) phenyl ) carboxyamide; -Trifluoromethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (2-fluoro-4- ( (2-methyl) imidazo-1- yl) phenyl) carboxyamide; -Methyl-1- (2-aminomethyl-4-methoxyphenyl) -IH-pyrazole-5- (N- (2-fluoro-4- ( (5-methyl) imidazo-1-yl) phenyl) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (M- (2- fluoro-4- ( (5-methyl) imidazo-1-yl) phenyl) carboxyamide; 3-Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2-fluoro-4- ( (5-methyl) imidazo-1- yl ) phenyl ) carboxyamide; 3-Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2-fluoro-4- ( (5-methyl) imidazo-1- yl ) phenyl) carboxyamide; 3-Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5-(N-(2-fluoro-4-( (5-methyl) imidazo-1- yl ) phenyl) carboxyamide; and, 3-Trifluoromethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (2-fluoro-4- ( (5-methyl) imidazo-1- yl) phenyl) carboxyamide; and pharmaceutically acceptable salts thereof. [20] More specifically preferred compounds of the present invention are selected from the group: 3-Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2 ' -sulfamido- [1,1'] -biphen-4-yl) ) carboxyamide ; 5-Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-3- (N- (2 ' -sulfamido- [1,1'] -biphen-4-yl) ) carboxyamide; 3-Methyl-l- (2-N,N-dimethylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5-(N- (2 ' -N-methylsulfamido- [1, 1 ' ] -biphen-4- yl ) ) carboxyamide ; 3-Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1,1] -biphen-4- yl ) ) carboxyamide; 3-Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1] -biphen-4- yl) ) carboxyamide; 3-Trifluoromethyl-l- (2-aminomethyl-4-methoxyρhenyl) -1H- pyrazole-5-(N- (2' -methylsulfonyl- [1, 1] -biphen-4- yl ) ) carboxyamide; 3-Trifluoromethyl-1- (2-aminomethyl-4-methoxyρhenyl) -1H- pyrazole-5- (N- (2 ' -sulfamido- [1, 1] -biphen-4- yl ) ) carboxyamide; 3 -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5-(N-(4-N- pyrrolidinocarbonyl ) phenyl) carboxyamide; N-Benzylsulfonyl-4- (3-trifluoromethyl-1- (2-aminomethyl-4- methoxyphenyl) -lH-pyrazole-5-carboxyamido) piperidine, • 3-Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- (2 ' -sulfonair do) phenyl)pyrid-2- yl ) carboxyamide; 3-Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- (pyrid-2-yl) ) pyrid-2-yl) carboxyamide; N-Benzyl-4- (3-trifluoromethyl-1- (2-aminomethyl-4- methoxyphenyl) -lH-pyrazole-5-carboxyamido) piperidine; N-Phenylsulfonyl-4- (3-trifluoromethyl-1- (2-aminomethyl-4- methoxyphenyl) -lH-pyrazole-5-carboxyamido)piperidine; 3-Trifluoromethyl-1- (2-aminomethyl-4-chlorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) ) carboxyamide; 3-Trifluoromethyl-1- (2-aminomethyl-4-chlorophenyl) -1H- pyrazole-5-(N- (3-fluoro-2 ' -sulfamido- [1, 1 ' ]-biphen-4- yl) ) carboxyamide; 3-Trifluoromethyl-l- (2-aminomethyl-5-chlorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl ) ) carboxyamide ; 3-Trifluoromethyl-1- (2-aminomethyl-4-chlorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1, 1 ' ] -biphen-4- yl ) ) carboxyamide; 3-Trifluoromethyl-1- (2-aminomethyl-4-fluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl ) ) carboxyamide; 3-Trifluoromethyl-1- (2-aminomethyl-4-fluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1,1'] -biphen-4- yl ) ) carboxyamide; 3-Trifluoromethyl-1- (2-aminomethyl-5-fluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) ) carboxyamide; 3-Trifluoromethyl-1- (2-aminomethyl-5-fluorophenyl) -1H- pyrazole-5-(N- (3-fluoro-2 ' -sulfamido- [1, 1 ' ]-biphen-4- yl ) ) carboxyamide; 3-Trifluoromethyl-l- (2-aminomethyl-4, 5-difluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) ) carboxyamide; 3-Trifluoromethyl-1- (2-aminomethyl-4, 5-difluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1, 1 ' ] -biρhen-4- yl ) ) carboxyamide,- -Trifluoromethyl-1- (2-aminomethyl-3 -fluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) ) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-3 -fluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1,1' ] -biphen-4- yl ) ) carboxyamide; -Trifluoromethyl-l- (2-aminomethyl-4-fluorophenyl) -1H- pyrazole-5-(N- (4- (2-methylsulfonyl- [1, 1' ] -biphen-4- yl ) ) carboxyamide ; -Trifluoromethyl-l- (2-aminomethyl-4-fluorophenyl) -1H- pyrazole-5- (N- (4- (2-sulfamido- [1,1'] -biphen-4- yl ) ) carboxyamide ; -Trifluoromethyl-1- (2-aminomethyl-4-fluorophenyl) -1H- pyrazole-5-(N-(4-(N-( (N'~ methylsulfonyl) iminoly) pyrrolidino) ) phenyl) carboxyamide; -Trifluoromethyl-l- (2- (N-glycyl) aminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1']- biphen-4-yl ) ) carboxyamide ; -Trifluoromethyl-l- (2- (N-phenylacetyl) aminomethyl-4- methoxyphenyl ) -lH-pyrazole-5- (N- (3-fluoro-2 ' - methylsulfonyl- [1,1'] -biphen-4-yl) ) carboxyamide; - (Trifluoromethyl) -1- (2- (aminomethyl) phenyl) -lH-pyrazole-5- (N- (2 ' -methylsulfonyl- [1, 1 ' ] -biphen-4-yl) ) carboxyamide; -Trifluoromethyl-1- (2- (aminomethyl)phenyl ) -lH-pyrazole-5- (N- (2 ' -aminosulfonyl- [1,1' ] -biphen-4-yl) ) carboxyamide; -Trifluoromethyl-l- (2- (aminomethyl ) phenyl ) -lH-pyrazole-5- (N- (3-fluoro-2 ' -aminosulfonyl- [1,1'] -biphen-4- yl) ) carboxyamide; -Trifluoromethyl-1- (2- (aminomethyl ) phenyl) -lH-pyrazole-5- (N- (3-fluoro-2" -methylsulfonyl- [1,1' ]-biphen-4- yl) ) carboxyamide; -Trifluoromethyl-1- (2- (N- (glycyl) aminomethyl) phenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) ) carboxyamide; -Trifluoromethyl-1- (2- ( (N- (N- methylglycyl) aminomethyl) phenyl) -lH-pyrazole-5- (N- (3- fluoro-2 ' -methylsulfonyl- [1, 1 ' ] -biphen-4- yl ) ) carboxyamide; -Trifluoromethyl-l- (2-carboxamidophenyl) -lH-pyrazole-5- (N- (3- fluoro-2 ' -methylsulfonyl- [1,1' ] -biphen-4- yl ) ) carboxyamide; 3-Trifluoromethyl-1- (2-cyanophenyl) -lH-pyrazole-5- (N- (3- fluoro-2 ' -methylsulfonyl- [1,1' ] -biphen-4- yl) ) carboxyamide; 1- (2 ' -Aminomethylphenyl) -5- [ [ (2 ' -methylsulfonyl) -3-fluoro- [1,1'] -biphen-4-yl]aminocarbonyl] -tetrazole; 1- (2 ' -Aminomethylphenyl) -5- [ (2 ' -aminosulfonyl- [1,1'] -biphen-4- yl ) aminocarbonyl] -tetrazole; 1- [2- (Aminomethyl) phenyl] -3-thiomethoxy-5- [ (2-fluoro) - (2 ' - methylsulfonyl- [1,1'] -biphen-4-yl) aminocarbonyl]pyrazole; 1- [2- (Aminomethyl) phenyl] -3-methysulfonyl-5- [ (2-fluoro) - (2 ' - methylsulfonyl- [1,1'] -biphen-4-yl) aminocarbonylJpyrazole; 1- [2- (Aminomethyl) phenyl] -5- [ (2-fluoro) - (2 ' -methylsulfonyl- [1,1'] -biphen-4-yl) aminocarbonyl] triazole; 1- [2-(Aminomethyl) phenyl] -5- [ (2-fluoro) - (2 ' -methylsulfonyl- [1,1'] -biphen-4-yl) aminocarbonyl]pyrazole; 1- [2- (Aminomethyl) phenyl] -3-trifluoromethy1-5- [ ( (2-fluoro)- (2 ' -pyrrolidinomethyl) -[1,1'] -biphen-4- yl) aminocarbonyl]pyrazole; and, 1- [2- (Aminomethyl) phenyl] -3-trifluoromethyl-5- [ ( (2-fluoro) - ( 2 ' -hydroxymethyl) - [1 , 1 ' ] -biphen-4- yl) aminocarbonyl] pyrazole; and pharmaceutically acceptable salts thereof. In a second embodiment, the present invention provides novel pharmaceutical compositions, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt form thereof. In a third embodiment, the present invention provides a novel method for treating or preventing a thromboembolic disorder, comprising: administering to_ a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt form thereof . DEFINITIONS The compounds herein described may have asymmetric centers . Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms . It is welJ known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. Many geometric isomers of olefins, C=N double bonds , and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. All processes used to prepare compounds of the present invention and intermediates made therein are considered to be part of the present invention. The term "substituted, " as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substitent is keto (i.e., =0), then 2 hydrogens on the atom are replaced. Keto substituents are not present on aromatic moieties . The present invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium. Isotopes of carbon include C-13 and C-14. When any variable (e.g., R " ) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R 6 , then said group may optionally be substituted with up to two R 6 groups and R 6 at each occurrence is selected independently from the definition of R 6 . Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds . As used herein, "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, and s-pentyl. "Haloalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogen (for example -C V F W where v = 1 to 3 .and w = 1 to (2v+l) ) . Examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl , pentafluoroethyl , and pentachloroethyl . "Alkoxy" represents an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, n-pentoxy, and s-pentoxy. "Cycloalkyl" is intended to include saturated ring groups, such as cyclopropyl, cyclobutyl, or cyclopentyl. Alkenyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl and propenyl . "Alkynyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more triple carbon-carbon bonds which may occur in any stable point along the chain, such as ethynyl and propynyl . "Halo" or "halogen" as used herein refers to fluoro, chloro, bromo, and iodo; and "counterion" is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, and sulfate. As used herein, "carbocycle" or "carbocyclic residue" is intended to mean any stable 3- to 7-membered monocyclic or bicyclic or 7-to 13 -membered bicyclic or tricyclic, any of which may be saturated, partially unsaturated, or aromatic. Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4. O]bicyclodecane, [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, and tetrahydronaphthyl . As used herein, the term "heterocycle" or "heterocyclic system" is intended to mean a stable 5-to 7-membered monocyclic or bicyclic or 7-to 10-membered bicyclic heterocyclic ring which is saturated partially unsaturated or unsaturated (aromatic) , and which consists of carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, O and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. A nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and 0 atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and 0 atoms in the heterocycle is not more than 1. As used herein, the term "aromatic heterocyclic system" or "heteroaryl" is intended to mean a stable 5-to 7-membered monocyclic or bicyclic or 7-to 10-membered bicyclic heterocyclic aromatic ring which consists of carbon atoms and from 1 to 4 heterotams independently selected from the group consisting of N, 0 and S. It is preferred that the total number of S and 0 atoms in the aromatic heterocycle is not more than 1. Examples of heterocycles include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H, 6H-1 , 5 , 2-dithiazinyl, dihydrofuro [2,3 -b] tetrahydrofuran, furanyl , furazanyl , imidazolidinyl, imidazolinyl, imidazolyl, lff-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl , octahydroisoquinolinyl, oxadiazolyl, 1, 2, 3-oxadiazolyl, 1, 2 , 4-oxadiazolyl, 1,2,5- oxadiazolyl, 1, 3 , 4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl , phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl , pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl , tetrahydroisoquinolinyl , tetrahydroquinolinyl, 6H-1, 2, 5-thiadiazinyl, 1,2,3- thiadiazolyl, 1,2, 4-thiadiazolyl, 1, 2, 5-thiadiazolyl, 1,3,4- thiadiazolyl , thianthrenyl , thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2, 3-triazolyl, 1, 2, 4-triazolyl, 1, 2 , 5-triazolyl, 1,3, 4-triazolyl, and xanthenyl . Preferred heterocycles include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, imidazolyl, indolyl, benzimidazolyl, lH-indazolyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, and isatinoyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles. The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without- excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods . Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed. , Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference. "Prodrugs" are intended to include any covalently bonded carriers which release the active parent drug according to formula (I) in vivo when such prodrug is administered to a mammalian subject. Prodrugs of a compound of formula (I) are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound. Prodrugs include compounds of formula (I) wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when the prodrug or compound of formula (I) is administered to a mammalian subject, cleaves to form a free hydroxyl, free amino, or free sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of formula (I) , and the like. Preferred prodrugs are amidine prodrugs wherein D is C(=NR 7 )NH 2 or its tautomer C(=NH)NHR 7 and R 7 is selected from OH, Cι_ 4 alkoxy, Cs- o aryloxy, C 1 -- 4 alkoxycarbonyl, C 6 _ιo aryloxycarbonyl , C δ -io arylmethylcarbonyl , C 1 - 4 alkylcarbonyloxy Cι_ 4 alkoxycarbonyl, and Cβ-io arylcarbonyloxy Cι_ 4 alkoxycarbonyl . More preferred prodrugs are where R 7 is OH, methoxy, ethoxy, benzyloxycarbonyl, methoxycarbonyl, and methylcarbonyloxymethoxycarbonyl . "Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent . "Substituted" is intended to indicate that one or more hydrogens on the atom indicated in the expression using "substituted" is replaced with a selection from the indicated group (s) , provided that the indicated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substituent is keto (i.e., =0) group, then 2 hydrogens on the atom are replaced. "Therapeutically effective amount" is intended to include an amount of a compound of the present invention or an amount of the combination of compounds claimed effective to inhibit HIV infection or treat the symptoms of HIV infection in a host. The combination of compounds- is preferably a synergistic combination. Synergy, as described for example by Chou and Talalay, Adv. Enzyme Regul . 22:27-55 (1984), occurs when the effect (in this case, inhibition of HIV replication) of the compounds when administered in combination is greater than the additive effect of the compounds when administered alone as a single agent. In general, a synergistic effect is most clearly demonstrated at suboptimal concentrations of the compounds. Synergy can be in terms of lower cytotoxicity, increased antiviral effect, or some other beneficial effect of the combination compared with the individual components . SYNTHESIS The compounds of the present invention can be prepared in a number of ways known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or by variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. The reactions are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformations being effected. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule should be consistent with the transformations proposed. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention. It will also be recognized that another major consideration in the planning of any synthetic route in this field is the judicious choice of the protecting group used for protection of the reactive functional groups present in the compounds described in this invention. An authoritative account describing the many alternatives to the trained practitioner is Greene and Wuts (Protective Groups In Organic Synthesis, Wiley and Sons, 1991) . All references cited herein are hereby incorporated in their entirety herein by reference. The compounds of Formula I in which ring M is pyrrole can be prepared by the procedures described in Schemes 1-9. In Scheme 1 is shown how to prepare pyrroles in which the group Q-E is attached to the pyrrole nitrogen, wherein Q is a functionality that can be converted into D of Formula I, R e is functionality that can be converted into Z-A-B of Formula I and R f is or can be converted into R la of Formula I . Oxidation of a furan with bromine in acetic acid can afford a 2,5- diacetoxydihydrofuran which can react with amine Q-E-NH2 to afford a pyrrole. Vilsmeier-Haack formylation with phosphorous oxychloride and DMF preferentially can acylate the pyrrole ring at C-2. Oxidation of the resulting aldehyde can give a carboxylic acid. The carboxylic acid can then be converted into amine derivatives using either the Hofmann degradation of the derived primary amide (Huisgen et. al . Chem . Ber. 1960, 93 , 65) or the Curtius rearrangement of the derived acyl azi ' de (J. Prakt . Chem . 1909, 42, 477) . Derivatives which contain a sulfur atom attached to the pyrrole ring can be obtained by direct sulfonation with pyridine sulfur trioxide complex to give the sulfonic acids or treatment with copper (II) thiocyanate (J. Het . Chem . 1988, 25, 431) followed by the reduction of the intermediate thiocyanate with sodium borohydride to give a mercaptan. Scheme 1 3) heat; then I§0 In Scheme 2 is shown how to prepare pyrroles in which Q-E is attached to the 2-position, wherein R f and R9 collectively are hydrogen or a group that can be converted into R la and R lb of Formula I. The Hantzsch pyrrole synthesis is a versatile reaction involving the cyclization of an appropriate β- ketoester with an α-halo ketone or aldehyde in the presence of a primary amine {Ber. Dtsch . Chem. Ges . 1890, 23 , 1474) . The β-ketoesters can be prepared from acid chlorides (X = Cl) by the addition of the magnesium anion of potassium alkylmalonate followed by decarboxylation (Synthesis 1993, 290) . Alternatively, β-ketoesters can be prepared from an appropriate aldehyde (R = H) by Reformatsky reaction with an α- bromoacetate followed by oxidation. Cyclization with an α- halo ketone or aldehyde in the presence" of a primary amine can afford pyrroles. Acidic hydrolysis of the 3-carboalkoxy pyrrole can afford the carboxylic acids. Pyrroles which contain a 3-amino substituent can be prepared from the acids by treatment with phosphoryl azide and triethylamine to effect a Curtius rearrangement to afford the isocyanates (J. Med. Chem. 1981, 24 , 33) which upon hydrolysis can yield 3- aminopyrroles . Pyrroles which contain a sulfur atom at C-3 can be prepared from the acids by employing the Hunsdiecker procedure to give the 3-bromo derivatives. Halogen-metal exchange at low temperature with an alkyllithium reagent can afford the 3-lithio derivative which can be quenched with a variety of electrophiles, such as Ss to afford thiols directly or Cu(SCN) 2 to afford a thiocyanate which can be reduced with sodium borohydride. The thiols can further be oxidized to the sulfonic acid derivatives by an oxidant such as KMnθ 4 • Scheme 2 K + -0 2 CCH 2 C0 2 R h (R = Cl, H) 2 ) oxidation (R = H ) then NaBH 4 In Scheme 3 is shown how to prepare pyrroles in which Q-E is attached to the 3-position. This scheme relies upon the extremely versatile Knorr pyrrole synthesis, which involves condensation of α-aminoketones with β-ketoesters . The α- aminoketones can be prepared from β-ketoesters (Scheme 2) by nitrosation followed by reduction with zinc/acetic acid. Condensation of α-aminoketones with appropriate β-ketoesters can afford good yields of pyrroles.- These intermediates are very versatile and can be converted into pyrroles with a wide variety of substituents with varying substitution patterns. For cases wherein R e (Z-A-B precursor) is at the 2-position, acidic hydrolysis can selectively hydrolyze the C-3 ester. Heating should then effect decarboxylation. Hydrolysis of the 2-carboxylic acid can be achieved under basic conditions. Curtius rearrangement of the acid as described previously can afford the amino derivatives. To prepare compounds with a sulfur atom attached to C-2, basic hydrolysis and decarboxylation can afford the C-2 unsubstituted pyrroles. These pyrroles can undergo electrophilic substitution to afford thiols (Cu(SCN) 2 , then NaBH 4 ) and sulfonic acids (pyridine SO 3 complex or chlorosulfonic acid) . The R la group contained in Formula I can be derived either from the remaining ester or from R f . Alternatively, the thiol and sulfonic acid derivatives can also be derived form the C-2 acids by manipulation of the carboxylic acid group as described previously. Scheme 3 In Scheme 4 is shown how to prepare pyrroles in which Q-E is attached to the 3-position. Cyclization of α-aminoketones as described previously with β-ketoesters can afford pyrroles. Hydrolysis under basic conditions can selectively hydrolyze the C-2 ester which upon heating should undergo decarboxylation to afford 2-unsubstituted pyrroles. The C-3 ester can then be hydrolyzed under acidic conditions to afford the 3-carboxypyrroles . Curtius rearrangement under conditions described previously can afford the 3-aminopyrroles . The carboxylic acids can be used to prepare the 3-mercapto and 3- sulfonic acid derivatives. The Hunsdiecker procedure can be used to prepare the 3-bromopyrroles. Halogen metal exchange with t-BuLi at low temperature followed by quenching with copper isocyanate should introduce -an isocyanate group at C-3. This intermediate can be reduced with sodium borohydride to afford the 3-mercaptopyrroles . Alternatively, the carboxylic acids can be decarboxylated to afford pyrroles which can be N- protected with a bulky protecting group such as triisopropylsilyl (TIPS) . This bulky group directs electrophilic substitution to C-3 of the pyrrole ring. Thus, reaction with copper isocyanate followed by sodium borohydride reduction and then fluoride induced TIPS deprotection can afford 3-mercaptopyrroles. Sulfonation of N-protected pyrrole with pyridine sulfur trioxide complex can again be directed to C-3 of the pyrrole to afford, after TIPS deprotection, the 3- sulfonic acids . Scheme 4 LiOH or NaOH , heat ( -C0 2 ) Another general method of pyrrole synthesis that can be used to prepare compounds of the present invention is shown in Scheme 5. This approach (Cushman et. al. J. Org. Chem . 1996, 61, 4999) uses N-protected α-aminoketones and N-protected α- aminoaldehydes which are readily available from α-amino acids by initial preparation of the N-methoxy-N-methylamides followed by addition of an alkyl Grignard reagent (to produce ketones) or by reduction with a hydride reducing agent such as lithium aluminum hydride or diisobutylaluminum hydride. These aldehydes and ketones can be allowed to react with the enolates of additional ketones to afford intermediate aldol addition products which under acidic conditions cyclize to form pyrroles. The reacting partners in this approach can be of wide scope and can be chosen so -that one skilled in the art will be able to prepare varied pyrroles . Scheme 5 PG ( PG = protecting group) Another very general method of pyrrole synthesis useful for preparing compounds of the present invention is the Paal- Knorr reaction shown in Scheme 6. This reaction involves the reacting 1, 4-diketones or 1, 4-ketoaldehydes with primary amines to afford pyrroles. The starting 1, 4-diketones and 1, 4-ketoaldehydes can be prepared using standard enolate chemistry or by other procedures which are familiar to those skilled in the art of organic synthesis. The reaction is of wide scope and the starting materials can be chosen so that a variety of pyrroles can be prepared. Scheme 6 N-E-Q, N S) In Scheme 7 is shown how the compounds of Schemes 1-6 wherein R e is a carboxylic ester group can be converted into compounds containing the Z-A-B residue. For the amide linker (Formula I, Z = -CONH-), when R e = carboalkoxy, it can be hydrolyzed to the acid under either basic or acidic conditions depending on the substitution pattern, as described previously. Formation of the acid chloride with thionyl chloride followed by the addition of an appropriate amine H 2 - A-B can afford the amide-linked compounds. Alternatively, the acid can be combined with amine H 2 N-A-B in the presence of a suitable peptide coupling agent, such as BOP-C1, HBTU or DCC. In another method the ester can be directly coupled with an aluminum reagent, prepared by the addition of trimethylalu inum to the amine H 2 N-A-B. To form ether- or thioether-linked compounds of Formula I (Z = -CH 2 O-, -CH 2 S-) the acid can be reduced to the alcohol. Preferred procedures for this transformation are reduction with borane THF complex, or a procedure involving the reduction of the mixed anhydride with sodium borohydride (IBCF=isobutyl chloroformate and NMM=N-methylmorpholine) . Completion of the ether and thioether linked compounds of Formula I can readily be accomplished by the Mitsonobu protocol with an appropriate phenol, thiophenol or hydroxy- or mercaptoheterocycle HX-A-B (X = 0,S) (Formula I, A = aryl or heteroaryl). Other ethers or thioethers (X = 0,S) can be prepared following initial conversion of the alcohol to a suitable leaving group, such as tosylate. Where X = S, thioethers can be further oxidized to prepare the sulfones (Formula I, Z = -CH 2 S0 2 -) . To prepare the amine-linked compounds of Formula I (Z = -CH 2 NH-) the alcohol can be oxidized to the aldehyde by a number of procedures, two preferred methods of which are the Swern oxidation and oxidation with pyridinium chlorochromate (PCC) . Alternatively, the aldehyde may be directly prepared by direct formylation of the pyrrole ring by the Vilsmeier-Haack procedure in certain cases , as described in previous schemes. Reductive amination of the aldehyde with an appropriate amine H 2 N-A-B and sodium cyanoborohydride can then afford the amine linked compounds. The aldehyde also can be used to prepare the ketone- linked compounds of Formula I (Z = -COCH 2 -) • Treatment with an organometallic species can afford the alcohol. The organometallic species (wherein M = magnesium or zinc) can preferably be prepared from the corresponding halide by treatment with metallic magnesium or zinc. These reagents should readily react with aldehydes to afford alcohols . Oxidation of the alcohol by any of a number of procedures, such as the Swern oxidation or PCC oxidation, can afford the ketones-linked compounds. Scheme 7 BH 3 , or IBCF , NMM ; then NaBH 4 TsCl, base; then HX-A-B, base (X = 0,S) oxidation H 2 N-A-B, NaCNBH 3 L n -M-CH 2 A-B (M = Mg, Zn) oxidation Additional compounds of Formula I in which the linking group m/z contains a nitrogen atom attached to ring M can be prepared by the procedures described in Scheme 8. The amines can be converted to sulfonamides (Formula I, m/z-NHS02-) by treatment with an appropriate sulfonyl chloride B-A-SO2CI in the presence of a base such as triethylamine. The amines can be converted into amides (Formula I, Z = -NHCO-) by treatment with an appropriate acid chloride Cl-CO-A-B in the presence of a base or by treatment with an appropriate carboxylic acid HO- CO-A-B in the presence of a suitable peptide coupling agent, such as DCC, HBTU or BOP. The amines can also be converted into amine-linked compounds (Formula I, Z = -NHCH 2 -) by reductive amination with an appropriate aldehyde OHC-A-B. Scheme 8 OHC-A-B , NaCNBH 3 Additional compounds of Formula I in which the linking group Z contains a sulfur atom attached to ring M can be prepared by the procedures described in Scheme 9. Treatment of sulfonic acids with phosphorous pentachloride followed by treatment with an appropriate amine H 2 N-A-B can afford sulfonamide-linked compounds (Formula I, Z = -SO 2 NH-) . The thiols can be alkylated with a suitable alkylating reagent in the presence of a base to afford thioethers (Formula I, Z = -SCH 2 -) . These compounds can be further oxidized by a variety of reagents to afford the sulfone-linked compounds (Formula I, Z = -S0 2 CH 2 -) . Scheme 9 Q- Compounds of Formula I wherein ring M is an imidazole can be formed using procedures described in Schemes 10-16. N- Substituted imidazole derivatives can be made by the general procedure shown in Scheme 10, wherein V is either V or a precusor of (CH 2 ) n V, V is nitro, amino, thio, hydroxy, sulfonic acid, sulfonic ester, sulfonyl chloride, ester, acid, or halide, n is 0 and 1, and PG is either a hydrogen or a protecting group. Substitution can be achieved by coupling an imidazole with a halogen containing fragment Q-E-G-Hal in the presence of a catalyst, such as base, Cu/CuBr/base, or Pd/base, followed by conversion of V to (CH 2 ) n V. Then, Q can be converted to D, and finally V can be converted to -Z-A-B following the procedures outlined in Schemes 7-9. Alternatively, V can be converted to Z-A-B followed by deprotection of N. This product can then be coupled as before to obtain the desired imidazole. Scheme 10 One way to make amidino-phenyl-imidazole derivatives is shown in Scheme 11. 4-Imidazole carboxylic acid can be treated with thionyl chloride and then coupled with H 2 N-A-B in the presence of a base and then be heated with 3- fluorobenzonitrile in the presence of a base. The Pinner reaction using standard procedures known to those of skill in the art can be used to form the amidino group. Scheme 11 Pinner 1, 2-Disubstituted .and 1, 5-disubstituted imidazole derivatives can be made by the general procedures described in Scheme 12 , wherein R lb is either a hydrogen or an alkyl group and U is aldehyde, ester, acid, amide, amino, thiol, hydroxy, sulfonic acid, sulfonic ester, sulfonyl chloride, or methylene halide. Step a involves coupling in the presence of a catalyst, such as base, Cu/CuBr/base, or Pd/base. When R lb is a hydrogen, it can be deprotonated with a lithium base and trapped by formate, formamide, carbon dioxide, sulfonyl chloride (sulfur dioxide and then chlorine) , or isocyanate to give 1, 2-disubstituted imidazoles (Route bl) . Also, in Route bl when R lb is CH 3 , it can be oxidized with Seθ 2 , Mnθ 2 , NaI0 4 /cat. RI1CI 3 , or NBS to form U. When R lb is hydrogen, sequential deprotonation and quenching with a lithium base and trimethysilyl chloride, followed by a second deprotonation with a lithium base and quenching with formate, formamide, carbon dioxide, sulfonyl chloride (sulfur dioxide and then chlorine), or isocyanate can afford 1, 5-disubstituted imidazoles (Route b2 ) . When R lb is not hydrogen, the procedure of Route b2 can again be used to form 1, 5-disubstituted imidazoles (Route b3 ) . Scheme 12 A preferred way of making 1, 2-disubstituted and 1,5- disubstituted imidazole derivatives is shown in Scheme 13. Imidazole can be heated with 3-fluorobenzonitrile in the presence of a base. The coupled product can then be treated with an alkyl lithium base and quenched with ClCθ 2 Me to give the 1, 2-disubstituted compound. Further treatment with a solution prepared of H 2 N-A-B in trimethylaluminum can give the amide, which can be further modified via the Pinner reaction to form the desired compound. The 1, 5-disubstituted compounds can be made using the same procedure, except that the initial anion is protected and a second anion is formed which is then quenched as noted above. Further modifications can follow the same procedures as the 1, 2-disubstituted compounds. Scheme 13 Another way of making 1, 2-disubstituted imidazole derivatives is described in Scheme 14. By reacting an N- substituted imidazole with a cyanate, the amide can be obtained. This amide can then be coupled with group B as will be described later. Scheme 14 Another means of making 1, 5-disubstituted imidazole derivatives is described in Scheme 15. Alkylation with 2- bromoethylacetate and subsequent reaction with Gold's reagent in the presence of a base, such as NaOMe, or LDA, can form ester substituted imidazoles which can be further modified as previously discribed. Scheme 15 A general procedure to make 2 , 4, 5-trisubstituted or 4,5- disubstituted imidazole derivatives is shown in Scheme 16. After metal halogen exchange of the Q-E-G fragment, it can be reacted with the amide shown, brominated with NBS and cyclized with excess NH 3 and R la C0 2 H to afford an imidazole. This can then be modified as before. Scheme 16 A general procedure to make 4, 5-disubstituted triazole derivatives is described in Scheme 17. Ethyl propiolate can be substituted in the presence of Cul/Pd and then reacted with NaN 3 to form a triazole. The triazole can be converted as described previously. Scheme 17 The tetrazole compounds of the present invention where Z is -CONH- can be prepared as exemplified in Scheme 18. An appropiately substituted amine can be acylated with ethyl oxalyl chloride. The resulting amide can be converted to the tetrazole either by the methods described by Duncia {J. Org. Chem . 1991, 2395-2400) or Thomas (Synthesis 1993, 767-768). The amide can be converted to the iminoyl chloride first and the reacted with NaN 3 to form the 5-carboethoxytetrazole (J " . Org. Chem. 1993, 58, 32-35 and Bioorg. & Med. Chem . Lett . 1996, 6, 1015-1020) . The 5-carboethoxytetrazole can then be further modified as described in Scheme 7. The tetrazole compounds of the present invention where Z is -CO- can also be prepared via iminoyl chloride ( Chem. Ber. 1961, 94 , 1116 and J. Org. Chem . 1976, 41 , 1073) using an appropriately substituted acyl chloride as starting material . The ketone-linker can be reduced to compounds wherein Z is alkyl . Scheme 18 Cl cι-^ U- co 2 Et u HN lτ J 0 ' U Ph 3 P C0 2 Et cCl 4 QE — NH 2 I N C0 2 Et CH,Cl, /Et,N E Q EQ The methods described in Scheme 18 can also be used to synthesize compounds where the E-Q is linked to the carbon atom of the tetrazole as shown in Scheme 19. The 5- substituted tetrazole can then be alkylated or acylated to give the desired products. Scheme 19 The tetrazole compounds of the present invention wherein Z is -SO 2 NH-, -S-, -S(O)-, SO 2 - can be prepared from the thiol prepared as shown in Scheme 20. Appropiately substituted thioisocyanate can be reacted with sodium azide to give the 5- thiotetrazole (J. Org. Chem. 1967, 32, 3580-3592) . The thio- compound can be modified as described in Scheme 9. The tetrazole compounds of the present invention wherein Z is -O- can be prepared via the same method described in Scheme 20 by using appropiately substituted isocyanate as the starting material. The hydroxy compound can be modified similarily to the thiols described in Scheme 9. Scheme 20 N— N NCS NaN 3 Nχ N^ SH I EO - CHC1 3 /H 2 0 EQ The tetrazole compounds of the present invention wherein Z is -NH-, -NHCO-, -NHS0 2 - can be prepared from 5- aminotetrazole, which can be prepared by Smiles Rearrangement as shown in Scheme 21. The thio-compound prepared as described in Scheme 20 can be alkylated with 2- chloroacetamide . The resulting compound can then be refluxed in ethanolic sodium hydroxide to give the corresponding 5- amino-tetrazole { Chem . Pharm . Bull . 1991, 39, 3331-3334). The resulting 5-amino-tetrazole can then be alkylated or acylated to form the desired products. Scheme 21 Pyrazoles of Formula I (such as those described in Scheme 22) can be prepared by the condensation of an appropriately substituted hydrazine with a variety of diketo esters. Condensations of this type typically afford a mixture of pyrazole regioisomers which can be effectively separated via silica gel column chromatography. The esters can be converted to Z-A-B as previously described. Alternatively, if in Scheme 22, the starting diketone contains CH 3 in place of Cθ 2 Et, then the resulting methyl pyrazole can be separated and oxidized as in Route bl in Scheme 12 to form the pyrazole carboxylic acid. Scheme 22 When ketoimidates are used for condensations with hydrazines the corresponding pyrazole amino esters are obtained (Scheme 23). Conversion of these intermediates to the final compounds of formula I can then be accomplished by the protection of the amino functionality with a suitable protecting group or by derivatization (e.g. sulfonamide) and then modifying the ester as previously noted. Scheme 23 Me 2 Sθ 2 Cl pyridine ,, As shown in Scheme 24, pyrazoles wherein the 4-position is substituted can be prepared by bromination (bromine or NBS in either dichloromethane or acetic acid) of the initial pyrazole. Conversion of 4-bromo-pyrazojLe to 4-carboxylic acid pyrazole can be accomplished by a number of methods commonly known to those in the art of organic synthesis . Further manipulations as previously described can afford pyrazoles of the present invention. Scheme 24 Pyrazoles can also be prepared according to method described in Scheme 25. The bromo-pyrazoles are formed as in Scheme 24. QE can then be coupled using palladium catalysed Suzuki cross-coupling methodology. Further modification is achieved as previously described. Scheme 25 B (OH) 2 Pd ( PPh 3 ) 4 , 2N Na 2 C0 3 EQ 5-substituted phenylpyrazoles can be prepared by the method shown in Scheme 26. Conversion of the 5-hydroxy pyrazole to its triflate (triflic anhydride, lutidine in dichloromethane) or bromide (POBr3) followed by palladium Suzuki cross-coupling with an apppropriately substituted phenylboronic acid should then afford 5-substituted pyrazoles Conversion of this intermediate to the 4-bromo derivative followed by its carbonylation as described in Scheme 24 should then afford the appropriate ester which can be further afford the compounds of formula I . Scheme 26 1) P0Br 3 or Tf 2 θ, lutidine 2) QE-B(OH) 2 , Pd(PPh 3 ) 4 , 2N Na 2 C0 3 1-Substituted-l, 2 , 3-triazoles of the present invention can be prepared by the treatment of an appropriately substituted azide with a variety of dipolarophiles {Tetrahedron 1971, 27, 845 and J. Amer. Chem. Soc. 1951, 73, 1207) as shown in Scheme 27. Typically a mixture of regioisomers are obtained which can be easily separated and elaborated to the triazole carboxylic acids . Further transformations as previously described can then afford the compounds of the present invention. Scheme 27 hydrolysis Ag 2 0 1, 2, 4-Triazoles of the present invention can be obtained by the methodology of Huisgen et al (Liebigs Ann . Chem . 1962, 653 , 105) by the cycloaddition of nitriliminium species (derived from the treatment of triethylamine and chloro 5 hydrazone) and an appropriate nitriJe dipolarophile (Scheme 28) . This methodology provides a wide variety of 1,2,4 triazoles with a varied substitution pattern at the 1, 3, and 5 positions . 0 Scheme 28 1,2,4 Triazoles can also be prepared by the methodology 5 of Zecchi et al { Synthesis 1986, 9, 772) by an aza Wittig condensation (Scheme 29) . Scheme 29 1, 2, 4-Triazoles wherein the -E-D(Q) substituent is at the 5-position of the triazole can be obtained as shown in Scheme 30. 5 Scheme 30 1, 3 , 4-Triazoles of the present invention can be obtained via the methodology of Moderhack et al ( J. Prakt . Chem . 1996, 338, 169) . As shown in Scheme 31, this reaction involves the condensation of a carbazide with an appropriately substituted commercially available thioisocyanate to form the cyclic thiourea derivative. Alkylation or nucleophilic displacement reactions on the thiono-urea intermediate can then afford a thio-alkyl or aryl intermediate which can be hydrolysed, oxidized and decarboxylated to the 5-H 2-thio-triazole intermediate which can be converted to the compounds of the present invention. Alternatively the thiono-urea intermediate can be oxidized directly to the 2-H triazole which can then be converted to the ester and modified as previously described. The thiono-urea intermediate can also be oxidized to the sulfonyl chloride by methods shown previously. Scheme 31 < 0EC)2 Hydrolyze The imidazole core shown in Scheme 32 can be prepared by the condensation of 3-cyanoaniline with n-butylglyoxylate to afford the imine which can then be treated with TosylMIC in basic methanol to afford the desired imidazole compound. Coupling of the ester under standard conitions then affords a variety of analogs which then can be further manipulated to afford e.g. the benzylamine or the benzamidines . Scheme 32 Compounds of the present invention wherein AB is a biphenylamine or similar amine may be prepared as shown in Scheme 33. 4-Bromoaniline can be protected as Boc-derivative and coupled to a phenylboronic acid under Suzuki conditions (Bioorg. Med. Chem . Lett . 1994, 189) . Deprotection with TFA provides the aminobiphenyl compound. Other similar amines wherein A and/or B are heterocycles can be prepared by the same method using appropiately substituted boronic acids and arylbromide. The bromoaniline can also be linked to the core ring structures first as described above, and then undergo a Suzuki reaction to give the desired product. Scheme 33 Compounds of the present invention wherein A-B is A-X-Y can be prepared like the piperazine derivative shown in Scheme 34. Scheme 34 Scheme 35 shows how one can couple cyclic groups wherein X=NH, 0, or S. Scheme 35 Halo X = NH, 0, S When B is defined as X-Y, the following description applies . Groups A and B are available either through commercial sources, known in the literature or readily synthesized by the adaptation of standard procedures known to practioners skilled in the art of organic synthesis . The required reactive functional groups appended to analogs of A and B are also available either through commercial sources, known in the literature or readily synthesized by the adaptation of standard procedures known to practioners skilled in the art of organic synthesis . In the tables that follow the chemistry required to effect the coupling of A to B is outlined. Table A: Preparation of Amide, Ester, Urea, Sulfonamide and Sulfamide linka es between A and B, The chemistry of Table A can be carried out in aprotic solvents such as a chlorocarbon, pyridine, benzene or toluene, at temperatures ranging from -20 * C to the reflux point of the solvent and with or without a trialkylamine base. Table B: Preparation of ketone linkages between A and B. then the reactive to give the Rxn. substituent of following product No. if A contains Y is : A-X-Y : A-C(0)C1 BrMg-Y A-C(Q)-Y A-CR 2 R 2a C(Q)Cl BrMg-Y A-CR 2 R 2a 2C(0)-Y A-C(0)C1 BrMgCR 2 R 2 -Y A-C(Q)CR 2 R 2a -Y A-CR 2 R 2a C(0)Cl BrMgCR 2 R 2a -Y A-CR 2 R 2a C (0) CR 2 R 2a - Y The coupling chemistry of Table B can be carried out by a variety of methods . The Grignard reagent required for Y is prepared from a halogen analog of Y in dry ether, dimethoxyethane or tetrahydrofuran at 0 C to the reflux point of the solvent. This Grignard reagent can be reacted directly under very controlled conditions, that is low temeprature (- 20 C or lower) and with a large excess of acid chloride or with catalytic or stoichiometric copper bromide'dimethyl sulfide complex in dimethyl sulfide as a solvent or with a variant thereof . Other methods available include transforming the Grignard reagent to the cadmium reagent and coupling according to the procedure of Carson and Prout (Org. Syn. Col. Vol. 3 (1955) 601) or a coupling mediated by Fe(acac)3 according to Fiandanese et al. (Tetrahedron Lett., (1984) 4805) , or a coupling mediated by manganese (II) catalysis (Cahiez and Laboue, Tetrahedron Lett . , 33(31), (1992) 4437). Table C: Preparation of ether and thioether linkages between A and B The ether and thioether linkages of Table C can be prepared by reacting the two components in a polar aprotic solvent such as acetone, dimethylformamide or dimethylsulfoxide in the presence of a base such as potassium carbonate, sodium hydride or potassium t-butoxide at temperature ranging from ambient temperature to the reflux point of the solvent used. Table D: Preparation of -SO- and -S02- linkages from The thioethers of Table C serve as a convenient starting material for the preparation of the sulfoxide and sulfone analogs of Table D. A combination of wet alumina and oxone can provide a reliable reagent for the oxidation of the thioether to the sulfoxide while m-chloroperbenzoic acid oxidation will give the sulfone. Table E: Methods of Preparing Group E Rxn D is to be then a transformation that may be used is -CN -C ( =NH) NH2 NH i) HCI MeOH / ■ N ii) NH 3 OAc, MeOH NH -CN -CH2NH2 UAIH 4 -CH 2 NH 2 Et,O -C02H -CH2NH2 i) iBuOC(O)Cl -C02H -NH2 i) iBuOC(O)Cl In Table E several methods of transforming a functional group Q into group D of Formula 1 are shown. While not all possible functional groups for Q and D are listed and the synthetic methods suggested are not comprehensive, Table E is meant to illustrate strategies and transformations available to a practitioner skilled in the art of organic synthesis for preparing compounds of Formula 1. In reaction 1 of Table E the transformation of a nitrile into an amidine by the Pinner methodology is shown; in reaction 2 the " direct reduction of a nitrile by a hydride reducing agent to a methylene amine is illustrated. In reaction 3, the utility of a carboxylic acid, which may be readily derived from its ester or a nitrile if necessary, in the preparation of a methylene amine is shown. This synthetic route is exceptionally flexible because of the several stable intermediates prepared en route to the final product. As outlined, formation of an activated analog, such as the mixed anhydride, allows for the mild reduction of the acid to the methylene alcohol, this may in turn be transformed into a leaving group by sulfonylation or halogenation or protected with a suitable protecting group to be transformed later in the synthesis as the chemistry demands. Once the methylene alcohol is so activated, displacement by an efficient nitrogen nucleophile, such as azide anion, can again provide another suitably stable analog, -the methylene azide- which may be used as a protected form of the methylene amine or transformed directly into the methylene amine group by reduction. Reaction 4 addresses the problem of appending the amine functionality directly through a bond to group E of Formula 1. Once again, the carboxylic acid provides a convenient entre into this selection for group D. The well- know Curtius rearrangement is illustrated here; an activated acid analog can be used to form an acyl azide which upon thermal decomposition is rearranged to the corresponding isocyanate. The isocyanate intermediate may then be captured as a stable carbamate by the addition of a suitable alcohol and further heating. This carbamate can be used as a stable protecting group for the amine or cleaved directly to the desired D. Alternatively, it may be convenient to quench the isocyanate intermediate with water to give the amine directly. Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof. EXAMPLES Example 1 3-Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazolβ- 5- (N- (2 '-sulfamido- [1,1'] -biphen-4-yl) ) carboxyamide, trifluoroacetic acid salt Part A: 2-Carboxy-4-methoxyphenylhydrazine: 2-Nitro-5- methoxybenzoic acid (5.0 g) in methanol (150 mL) was shaken under an atmosphere of hydrogen (50 psi) in the presence of 10% palladium on carbon catalyst (0.5 g) until hydrogen uptake ceased (ca. 3 h) . The methanol solution was purge with nitrogen, filtered through a pad of Celite® and evaporated. There was obtained 4.2 g (25.1 mmoJ) of the aniline; ESI mass spectrum analysis m/z (relative intensity) 168 (M+H, 100) . The aniline prepared above (4.2 g, 25.1 mmol) in concentrated hydrochloric acid (50 mL) was cooled to 0°C and sodium nitrite (2.08 g, 30.2 mmol) in cold water (20 mL) was added dropwise. This mixture was stirred at 0°C for 30 min - 1 h then tin (II) chloride dihydrate (17.0 g, 75.4 mmol) in cold concentrated hydrochloric acid (25 mL) was added dropwise. This mixture was allowed to thaw to ambient temperature over 3-5 h then filtered and air dried for several more. The filter cake was broken up and dried further in a vacuum oven at 60°C overnight. There was obtained 8.76 g of 2-carboxy-4- methoxyphenylhydrazine tin salt. Part B: Ethyl 2-N- (methoxy) imino-4-oxopentanoate: A mixture of ethyl pentanoate-2 , 4-dione (24.5 g, 154.9 mmol) and methoxyamine hydrogen chloride (13.58 g, 162.6 mmol) in ethanol (100 mL) was allowed to stand over activated 3 A molecular sieves (75 g) at ambient temperature for 18h. Following removal of the molecular sieves by filtration, dichloromethane (100 mL) was added and the reaction filtered. The resulting solution was evaporated and the residue applied to a silica gel column. The title compound was isolated in a homogenous form by elution with 5:1 hexane: ethyl acetate to give 9.09 g of product. Part C: Ethyl 3-methyl-1- (2-carboxy-4-methoxyphenyl) -IH- pyrazole-5-carboxylate and ethyl 5-methyl-l- (2-carboxy-4- methoxyphenyl)-lH-pyrazole-3-carboxylate: Ethyl 2-N- (methoxy) imino-4-oxopentanoate (1.0 g, 5.35 mmol) and crude 2- carboxy-4-methoxyphenylhydrazine (5.83 g) in acetonitrile (40 mL) and acetic acid (5 mL) was stirred at ambient temperature for 3 h then heated at reflux for an additional 3 h. The reaction was cooled to ambient temperature, diluted with methylene chloride (150 mL) and filtered. The filtrate was evaporated and the product isolated by flash chromatography by elution with 10% methanol in chloroform. This material (1.28 g) co-eluted as a mixture of regiosiomers as evident by proton NMR. ESI mass spectrum analysis m/z" (relative intensity) 306 (M+H, 100) . Part D: Ethyl 3-methyl-1- (2-hydroxymethyl-4-me hoxyphenyl) -1H- pyrazole-5-carboxylate and ethyl 5-methyl-l- (2-hydroxymethyl- 4-methoxyphenyl ) -lH-pyrazole-3-carboxylate: The mixture of regioisomers prepared in part C (1.28 g, 4.2 mmol) was dissolved in tetrahydrofuran (60 mL) and cooled to 0°C. To the cold solution was added N-methylmorpholine (0.42 g, 4.2 mmol) and isobutylchloroformate (0.57 g, 4.2 mmol). The reaction was stirred for 30 min at 0°C, the precipitate removed by filtration and the cold solution poured immediately into a cold (5°C) solution of sodium borohydride (0.48 g, 12.6 mmol) in water (20 mL) and tetrahydrofuran (20 mL) . The reaction was allowed to thaw to room temperature over 18 h. The reaction mixture was evaporated, partitioned between ethyl acetate (100 mL) and IN hydrochloric acid (50 mL) , then washed with 5% sodium bicarbonate (50 mL) and brine (50 mL) . The organic layer was dried and evaporated; three products were isolated by elution of the crude mixture from a silica gel column with 2:1 hexane: ethyl acetate. The first product to elute was a ring closed lactone (0.14 g) ; ESI mass spectrum analysis m/z (relative intensity) 245 (M+H, 100) . The second product isolated was ethyl 3-methyl-1- (2-hydroxymethyl-4- methoxyphenyl) -lH-pyrazole-5-carboxylate (0.18 g) as determined by proton NMR nOe experiments; ESI mass spectrum analysis m/z (relative intensity) 291 (M+H, 100). The third product to elute was the regioisomer ethyl 5-methyl-l- (2- hydroxymethyl-4-methoxyphenyl) -lH-pyrazole-3-carboxylate ( 0.14 g) ; ESI mass spectrum analysis m/z (relative intensity) 291 (M+H, 100) . Part E: Ethyl 3-methyl-1- (2-azidomethy1-4-methoxyphenyl ) -1H- pyrazole-5-carboxylate: Ethyl 3-methyl-l- (2-hydroxymethyl-4- methoxyphenyl) -lH-pyrazole-5-carboxylate (0.18 g, 0.62 mmol) was dissolved in chloroform (20 mL) then methanesulfonyl chloride (0.3 g, 2.6 mmol) and triethylamine (0.26 g, 2.6 mmol) added. The reaction was complete in 6 h; it was evaporated, dissolved in ethyl acetate (100 mL) , washed with IN hydrochloric acid (50 mL) and brine (50 mL) , dried and evaporated to give 0.22 g of product. The mesylate prepared above (0.22 g, 0.6 mmol) .and sodium azide (0.12 g, 1.79 mmol) were dissolved in dimethylformamide (15 mL) and heated for 1.5 h at 60°C, then diluted with brine (50 mL) , extracted with ethyl acetate (100 mL) , dried and evaporated. There was obtained 0.11 g of ethyl 3-methyl-1- (2- azidomethyl-4-methoxyphenyl) -lH-pyrazole-5-carboxylate; ESI mass spectrum -analysis m/z (relative intensity) 316 (M+H, 100). Part F: 3-Methyl-1- (2-azidomethyl-4-methoxyphenyl) -1H- pyrazole-5-carboxylic acid: Ethyl 3-methyl-l- (2-azidomethyl- 4-methoxyphenyl) -lH-pyrazole-5-carboxylate (0.11 g, 0.35 mmol) in ethanol (2 mL) and water (2 mL) was stirred with 50% sodium hydroxide (3 drops) at 45°C and followed by TLC (1:1 hexane: ethyl acetate) . When all of the ester was consumed the reaction was cooled, diluted with brine and washed with ethyl ether (25 mL) . The aqueous layer was acidified with IN hydrochloric acid (pH = 1) , extracted with ethyl acetate (2x 30 mL) , dried and evaporated. There was obtained 3-methyl-1- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole-5-carboxylic acid (0.06 g) ; ESI mass spectrum analysis m/z (relative intensity) 285 (M+H, 100) . Part G: 3-Methyl-l- (2-azidomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (4- (2-N-t- butylsulfamido) phenyl) phenyl) carboxyamide: 3-Methyl-l- (2- azidomethyl-4-methoxyphenyl) -lH-pyrazole-5-carboxylic acid (0.60 g, 0.21 mmol) in dichloromethane (5 mL) was cooled to 0°C and oxalyl chloride (0.21 mL of a 2M solution in dichloromethane) and dimethyl formamide (1 drop) were added. The reaction was complete inside of 1 h; it was evaporated and pumped on to remove residual HCI. There was obtained 0.17 g of the acid chloride. To the acid chloride prepared above (0.17 g, 0.50 mmol) in dichloromethane (3 mL) was added dropwise to an ice-cold solution of 4- (2-N-tertbutylsulfonamido) phenyl aniline (0.15 g, 0.51 mmol), pyridine (0.39 g, 4.4 mmol) and 4,4- dimethylaminopyridine (0.09 g, 0.7 mmol) in dichloromethane (15 mL) . The reaction was allowed to warm to ambient temperature over 18 h, then evaporated, dissolved in ethyl acetate (30 mL) , washed with IN hydrochloric acid (20 mL) and dried. Silica gel flash chromatography, eluting with a gradient of 2:1 to 1:1 hexane: ethyl acetate, gave 0.09 g of 3- methyl-1- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- (2-N-t-butylsulfamido)phenyl)phenyl) carboxyamide; ESI mass spectrum analysis m/z (relative intensity) 572 (M+H, 100) . Part H: 3-Methyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2' -sulfamido- [1, 1 ' ] -biphen-4- yl) ) carboxyamide*TFA: 3-Methyl-l- (2-azidomethyl-4- methoxyphenyl) -lH-pyrazole-5- (N- (2 ' -N-t-butylsulfamido- [1, 1 ' ] - biphen-4-yl) ) carboxyamide (0.09 g, 0.16 mmol) was stirred with tin (II) chloride dihydrate (0.11 g, 0.47 mmol) in methanol (10 mL) . When the reaction was complete by TLC (1:1 hexane: ethyl acetate) it was evaporated to give a crude mixture of the aminomethyl product and tin salts weighing 0.39 g. The material was heated at reflux in trifluoroacetic acid (10 mL) for 45 min then evaporated. The residue was partitioned between IN sodium hydroxide (30 mL) and ethyl acetate (30 mL) . The ethyl acetate solution was dried and evaporated to give 0.04 g of crude product. This material was purified further by hplc utilizing gradient elution with a mixture of water: acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column to give 0.010 g of the title compound; mp 184.3°C; HRMS (M+H) + calc . m/z: 492.170551, obs m/z: 492.171712. Example 2 5 -Methyl- 1- ( 2 -aminomethyl-4 -methoxyphenyl ) - lH-pyrazole- 3- (N- (2 ' -sulfamido- [1, 1' ] -biphen-4-yl) ) carboxyamide, trifluoroacetic acid salt The regioisomeric acid prepared in Example 1, ethyl 5- methyl-1- (2-hydroxymethyl-4-methoxyphenyl) -lH-pyrazole-3- carboxylate (0.14 g, 0.48 mmol), was transformed into the azidomethyl analog, coupled with 4-(2-N- tertbutylsulfonamido) phenyl aniline and transformed into 5- methyl-1- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-3- (N- (4- (2-sulfamido) phenyl) phenyl) carboxyamide by the same procedures described in Example 1. The final product was purified further by hplc utilizing gradient elution with a mixture of water : acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column; HRMS (M+H) + calc . m/z: 492.170551, obs m/z: 492.169327. Example 3 3-methyl-l- ( 2 -N,N-dimethylaminomethyl-4 -methoxyphenyl) - IH-pyrazole- 5- (N- (2' -N-methylsulfamido- [1,1' ] -biphen-4- yl) ) carboxyamide, trifluoroacetic acid salt 3-Methyl-l- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2 ' -N-t-butylsulfamido- [1,1'] -biphen-4-yl) ) carboxyamide (0.09 g, 0.16 mmol), prepared in Example 1, was stirred with tin (II) chloride dihydrate (0.11 g, 0.47 mmol) in methanol (10 mL) . When the reaction was complete by TLC (1:1 hexane: ethyl acetate) it was evaporated to give a crude mixture of the aminomethyl product and tin salts weighing 0.39 g. A portion of the crude reduction product (0.1 g, 0.20 mmol) prepared above was stirred at ambient temperature with methyl iodide (0.2 mL) , and potassium hydrogen carbonate (solid, 0.2 g) in methanol (4 mL) at ambient temperature. After 18 h the reaction was evaporated and stirred with chloroform (30 mL) , filtered and evaporated again to give 0.28 g of crude product. The material from above was heated at reflux in trifluoroacetic acid (10 mL) for 45 min then evaporated. The residue was partitioned between IN sodium hydroxide (30 mL) and ethyl acetate ( 30 mL) . The ethyl acetate solution was dried and evaporated to give crude product . This material was purified further by hplc utilizing gradient elution with a mixture of water : acetonitrile with 0 . 05% trifluoroacetic acid on a reverse phase C18 ( 60 A) column to give the title compound; mp 114 . 5°C ; HRMS (M+H) + calc . m/ z : 534 .217502 , obs m/z : 534 .218000 . Example 4 3 -Trif luoromethyl - 1 - ( 2 -aminomethyl - 4 -methoxyphenyl ) - IH- pyrazole - 5 - ( N- ( 3 - f luoro -2 ' - sulf amido- [ 1 , 1 ] -biphen-4 - yl ) ) carboxyamide , trifluoroacetic acid salt Part A: 3 -Trifluoromethyl-l- (2 -carboxy -4 -methoxyphenyl ) -5- ( furan-2-yl ) -IH-pyrazole : Crude 2-carboxy-4- methoxyphenylhydrazine (8.88 g) , prepared in Example 1, and 4,4,4-trifluoro-l-(2-furyl)-l,3-butanedione (7.4 g, 135.9 mmol) in acetic acid (150 mL) was heated at 100°C for 4 h. The hot reaction mixture was evaporated and the residue stirred in a biphasic mixture of water (150 mL) and chloroform (150 mL) . The layers were filtered and separated, the solid percipitate washed several times with additional chloroform (3x 50 mL) and the chloroform layer and washings combined, dried and evaporated. There was obtained 3.55 g of 3- trifluoromethyl-1- (2-carboxy-4-methoxyphenyl) -5- (furan-2-yl) - IH-pyrazole; ESI (-ve) mass spectrum analysis m/z (relative intensity) 351 (M-H, 100) . Part B: 3-Trifluoromethyl-1- (2-hydroxymethyl-4-methoxyphenyl) - 5- (furan-2-yl) -IH-pyrazole: 3-Trifluoromethyl-l- (2-carboxy-4- methoxyphenyl) -5- (furan-2-yl) -IH-pyrazole (3.55 g, 10.1 mmol) in tetrahydrofuran (100 mL) was cooled to 0°C then N- methylmorpholine (1.02 g, 10.1 mmol) and isobutyl chloroformate (1.38 g, 10.1 mmol) were added. The reaction mixture was stirred for 30 min at 0°C, filtered and added immediately to a cold solution of sodium borohydride (1.15 g, 30.2 mmol) in water (50 mL) and tetrahydrofuran (50 mL) . The reaction mixture was evaporated, partitioned between ethyl acetate (100 mL) and IN hydrochloric acid (50 mL) , then washed with 5% sodium bicarbonate (50 mL) and brine (50 mL) . The organic layer was dried and evaporated then purified further by flash chromatography using 4:1 hexane: ethyl acetate as the eluent. There was obtained 1.5 g of 3-trifluoromethyl-1- (2- hydroxymethyl-4-methoxyphenyl) -5- (furan-2-yl) -IH-pyrazole; ESI mass spectrum analysis m/z (relative intensity) 339 (M+H, 100) . Part C: 3-Trifluoromethyl-l- (2-azidomethyl-4-methoxyphenyl) -5- (furan-2-yl) -IH-pyrazole: To a cooled chloroform (50 mL) solution of 3-trifluoromethyl-1- (2-hydroxymethyl-4- methoxyphenyl ) -5- (furan-2-yl) -IH-pyrazole (1.5 g, 4.44 mmol) and triethylamine (1.79 g, 17.7 mmol) was added a chloroform solution (10 mL) of methanesulfonyl chloride (2.03 g, 17.7 mmol) . The reaction was complete in 4 h. It was evaporated, dissolved in ethyl acetate (100 mL) and the ethyl acetate solution washed with cold 5% NaHSθ4 (50 mL) and cold saturated NaHC03 (50 mL) . The organic layer was dried and evaporated to give 2.1 g of the mesylate which was used immediately in the next reaction; ESI mass spectrum analysis m/z (relative intensity) 417 (M+H, 100). A mixture of the mesylate prepared above (2.1 g, 5.05 mmol) and sodium azide (0.98 g, 15.1 mmol) in dimethylformamide (40 mL) was heated at 60°C for 2 h. The reaction mixture was cooled, diluted with brine (100 mL) and extracted with ethyl acetate (100 mL) . The ethyl acetate extract was washed with water (5x 50 mL) then dried and evaporated. There was obtained 1.43 g of 3-trifluoromethyl-l- (2-azidomethyl-4-methoxyphenyl) -5- (furan-2-yl) -IH-pyrazole; ESI mass spectrum analysis m/z (relative intensity) 364 (M+H, 100) . Part D: 3-Trifluoromethyl-l- (2-azidomethyl-4-methoxyphenyl) - IH-pyrazole-5-carboxylic acid: To 1.43 g of 3- trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -5- (furan-2- yl) -IH-pyrazole (3.9 mmol) in acetone (60 mL) was added potassium permaganate (5.0 g, 27.5 m mol) in water (60 mL) . The reaction was heated at 60°C for 3 h, then cooled to ambient temperature and isopropyl alcohol (60 mL) added. This mixture was stirred for 18 h then filtered through a Celite® pad and washed with copious amounts of isopropyl alcohol . The combined filtrates were evaporated/ the residue dissolved in IN NaOH (50 mL) and washed with ethyl ether (2x 50 mL) . The basic layer was acidified with IN HCI (75 mL) and solid NaCl added. The suspension was extracted with EtOAc (3x 100 mL) ; the extracts were dried and evaporated. There was obtained 0.91 g of 3-trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) - lH-pyrazole-5-carboxylic acid; ESI (-ve) mass spectrum analysis m/z (relative intensity) 340 (M-H, 100) . Part E: 3-Trifluoromethyl-l- (2-azidomethyl-4-methoxyphenyl) - lH-pyrazole-5-carboxylic acid chloride: 3-Trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole-5-carboxylic acid (1.09 g, 3.2 mmol) in dichloromethane (50 mL) was stirred at 0°C with oxalyl chloride from 3.2 mL of a 2M dichloromethane solution of the reagent and a catalytic amount of DMF (3 drops) . The reaction was complete in 3 h, then evaporated and pumped on to remove residual reagent. There was obtained 1.04 g (2.9 mmol) of 3-trifluoromethyl-l- (2-azidomethyl-4- methoxyphenyl) -lH-pyrazole-5-carboxylic acid chloride. Part F: 3-Trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (2-fluoro-4- (2-N-tertbutylsulfamido- [1, 1] - biphen-4-yl) ) carboxyamide: 3-Trifluoromethyl-1- (2- azidomethyl-4-methoxyphenyl) -lH-pyrazole-5-carboxylic acid chloride prepared above (0.52 g, 1.45 mmol) in dichloromethane (10 mL) was added dropwise to an ice-cold solution of 2- fluoro-4-(2-N-tertbutylsulfonamido) phenyl aniline (0.56 g, 1.74 mmol), pyridine (1.14 g, 14.5 mmol . ) and 4,4- dimethylaminopyridine (0.21 g, 1.74 mmol) in dichloromethane (30 mL) . The reaction was allowed to warm to ambient temperature over 18 h, then evaporated, dissolved in ethyl acetate (100 mL) , washed with IN hydrochloric acid (50 mL) and dried. Silica gel flash chromatography, eluting with 4:1 hexane:ethyl acetate, gave 0.28 g of 3-trifluoromethyl-l- (2- azidomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2-fluoro-4- (2- N-tertbutylsulfamidophenyl) phenyl) carboxyamide; ESI (-ve) mass spectrum analysis m/z (relative intensity) 644 (M-H, 100) . Part G: 3-Trifluoromethyl-1- (2-aminomethyl-4-methoxyphen-1- yl) -lH-pyrazole-5- (N- (2-fluoro-4- (2-sulfamido- [1,1] -biphen-4- yl) ) carboxyamide*TFA: 3-Trifluoromethyl-1- (2-azidomethyl-4- methoxyphenyl) -lH-pyrazole-5- (N- (2-fluoro-4- (2-N- tertbutylsulfamidophenyl) phenyl) carboxyamide (0.28 g, 0.43 mmol) and tin (II) chloride dihydrate (0.29 g, 1.3 mmol) was stirred in methanol (30 mL) for 18 h. The reaction was evaporated and the reduction product (0.60 g) was carried on to the next step without further processing. The product prepared above was refluxed in trifluoroacetic acid (20 mL) for 30 min, then evaporated. The residue was suspened in IN NaOH (30 mL) , extracted with EtOAc (3x 50 mL) , dried and evaporated. This material was purified further by hplc utilizing gradient elution with a mixture of water : acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column to give the title compound; mp 103.2 °C; ESI ESI mass spectrum analysis m/z (relative intensity) 564.2 (M+H, 100). Example 5 3-Trifluoromethyl-1- ( 2 -aminomethyl-4 -methoxyphenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1, 1] -biphen- 4-yl )) carboxyamide, trifluoroacetic acid salt Part A: 3-Trifluoromethyl-l- (2-azidomethyl-4-methoxyphenyl) - IH-pyrazole-5- (N- (2-fluoro-4- (2- methylsulfonylphenyl) phenyl) carboxyamide : 3-Trifluoromethyl- 1- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole-5-carboxylic acid chloride prepared in Example 4 (0.52 g, 1.45 mmol) in dichloromethane (10 mL) was added dropwise to an ice-cold solution of 2-fluoro-4- (2-methylsulfonylphenyl) aniline (0.52 g, 1.74 mmol), pyridine (1.14 g, 14.5 mmol) and 4,4- dimethyla inopyridine (0.21 g, 1.74 mmol) in dichloromethane (30 mL) . The reaction was allowed to warm to ambient temperature over 18 h, then evaporated, dissolved in ethyl acetate (100 mL) , washed with IN hydrochloric acid (50 mL) and dried. Silica gel flash chromatography, eluting with a gradient of 5:1 to 1:1 hexane: ethyl acetate, gave 0.46 g of 3- trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (2-fluoro-4- (2-methylsulfonylphenyl) phenyl) carboxyamide; ESI mass spectrum analysis m/z (relative intensity) 587 (M+H, 100) . Part B: 3-Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1] -biphen-4- yl) ) carboxyamide*TFA: 3-Trifluoromethyl-1- (2-azidomethyl-4- methoxyphenyl) -lH-pyrazole-5- (N- (3-fluoro-2 ' -methy1sulfonyl- [1, 1] -biphen-4-yl) ) carboxyamide (0.46 g, 0.78 mmol) and tin (II) chloride dihydrate (0.53 g, 2.35 mmol) was stirred in methanol (25 mL) for 18 h. The reaction was evaporated and the residue was suspended in IN NaOH (50 mL) , extracted with EtOAc (3x 100 mL) , dried and evaporated to give 0.29 g of crude product. This material was purified further by hplc utilizing gradient elution with a mixture of water: acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column to give the title compound; mp 101.5 °C; ESI mass spectrum analysis m/z (relative intensity) 563 (M+H, 100). Example 6 3-Trifluoromethyl-1- (2 -aminomethyl-4-methoxyphenyl) -IH- pyrazole-5- (N- (2 ' -methylsulfonyl- [1, 1] -biphen-4- yl) ) carboxyamide, trifluoroacetic acid salt Part A: 3-Trifluoromethyl-l-(2-azidomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (2 ' -methylsulfonyl- [1,1] -biphen-4- yl) ) carboxyamide: 3-Trifluoromethyl-1- (2-azidomethyl-4- methoxyphenyl)-lH-pyrazole-5-carboxylic acid chloride and 4- (2-methylsulfonylphenyl) aniline were treated in the manner described for Example 5, Part A to give 3-trifluoromethyl-l- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- (2- methylsulfonylphenyl) phenyl ) carboxyamide . Part B: 3-Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (2 ' -methylsulfonyl- [1 , 1] -biphen-4- yl) ) carboxyamide*TFA: 3-Trifluoromethyl-1- (2-azidomethyl-4- methoxyphenyl) -lH-pyrazole-5- (N- (4- (2- methylsulfonylphenyl)phenyl) carboxyamide was treated in the same manner as Example 5, Part B to give the title compound; HRMS (M+H) + calc. m/z: 545.147037, obs m/z: 545.145700. Example 7 3-Trif luoromethyl-1- (2 -aminomethyl -4 -methoxyphenyl ) -1H- pyrazole-5- (N- (2 ' -sulfamido- [1,1] -biphen-4- yl) ) carboxyamide, trifluoroacetic acid salt Part A: 3-Trif luoromethyl-1- (2-azidomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (2 ' -N-tertbutyl sulfamido- [1,1] -biphen-4- yl) ) carboxy-amide : 3-Trifluoromethyl-l- (2-azidomethyl-4- me thoxyphenyl ) -lH-pyrazole-5-carboxylic acid chloride and 4- (2-N-tertbutylsulfonamido) phenyl aniline were treated as described in Example 4, Part F to give 3-trif luoromethyl-1- (2- azidomethyl-4-me thoxyphenyl) -lH-pyrazole-5- (N- (4- (2-N- tertbutylsulf amidophenyl ) phenyl ) carboxyamide . Part B: 3-Trifluoromethyl-l- (2-aminomethyl-4-methoxyphen-l- yl) -lH-pyrazole-5- (N- (2 ' -sulfamido- [1,1] -biphen-4- yl) ) carboxyamide* TFA: 3 -Trifluoromethyl- 1- (2 -azidomethyl-4- methoxyphenyl ) -lH-pyrazole-5- (N- (4- (2-N- tertbutyl sulf amidophenyl) phenyl) carboxyamide was treated as described in Example 4, Part G to give the title compound; LRMS (M+H) + : m/z 546.2. Example 8 3 -Trif luorome thy 1 - 1 - ( 2 - aminome hyl - 4 -methoxyphenyl ) - 1H- pyrazole-5- (N- (4-N- pyrrolidinocarbonyl) phenyl) carboxyamide* TFA Part A: 5- (Furan-2-yl) -3-trif luoromethyl-1- ( 2 -carboxyl -4- me thoxyphenyl ) -IH-pyrazole: 3-Methoxy-6-aminobenzoic acid (23 g, 138 mmol) in cone. HCI (300 mL) was cooled to 0 °C and NaNθ 2 (11.4 g, 165 mmol) in H 2 O (50 mL) was added dropwise while the temperature of the reaction was maintained below 10 °C. The reaction was stirred at or below 10 °C for 1 h, then SnCl 2 *H 2 θ (92.3 g, 413 mmol) in cone. HCI (125 mL) was added dropwise. The reaction was allowed to thaw to ambient temperature and stirred for 3 h. The precipitate was filtered and air-dried then heated in a vacuum oven for 18 h. There was obtained 71.4 g of 3-methoxy-6-hydrazinobenzoic acid entrained with tin (II) salts. The hydrazine prepared above (71.4 g) in acetic acid (800 mL) was heated at 45 °C until dissolved, then 4,4,4- trifluoromethyl-l-(2-furyl)-l,3-butanedione (28.42 g, 138 mmol) was added and the mixture heated at reflux for 2.5 h. The reaction was cooled and evaporated to dryness . The residue was partitioned between H 2 O (400 mL) and CHCI 3 (400 mL) and stirred for 30 min. The biphasic mixture was filtered, the layers separated and the organic layer dried (Na 2 Sθ 4 ) and evaporated to give 49.4 g of 5- (furan-2-yl) -3-trifluoromethyl- l-(2-carboxyl-4-methoxyphenyl) -IH-pyrazole; LRMS (ES -) M ~ : 351 m/z. Part B: 3-Trifluoromethyl-l- (2-azidomethyl-4-methoxyphenyl) - lH-pyrazole-5-carboxylic acid: To a solution of 5-(furan-2- yl) -3-trifluoromethyl-1- (2-carboxyl-4-methoxyphenyl) -1H- pyrazole (49.4 g, 140.3 mmol) in THF (600 mL) at 0 °C was added N-methylmorpholine (14.9 g, 147 mmol) and isobutylchloroformate (20.1 g, 147.3 mmol). After 3 h at 0 °C, the reaction mixture was filtered into a H 2 θ:THF (200 mL: 200 mL) solution of NaBH (10.6 g, 280 mmol) at 0 °C. After 18 h, the reaction was quenched with IN HCl (500 mL) then the THF was removed in vaccuo . The remaining aqueous suspension was saturated with solid NaCl and extracted with EtOAc, dried (Na 2 Sθ 4 ) and evaporated. The crude product was recrystallized from 1-chlorobutane to give 16.8 g of benzyl alcohol product. The mother liquors were applied to a column of flash Siθ 2 (500 g) and eluted with 2:1 hexane: EtOAc to give 8.7 g of benzyl alcohol product; LRMS ES + (M+H) + : 339 m/z. The benzyl alcohol product (8.7 g, 25.1 mmol) prepared above and Et 3 N (3.1 g, 30.9 mmol) in CH 2 C1 (200 mL) was cooled to 0 °C. Methanesulfonyl chloride (3.5 g, 30.9 mmol) in CH 2 C1 2 (10 mL) was added dropwise. The cooling bath was removed and the reaction stirred for 3 h. A 5% solution of NaHS0 4 (200 mL) was added, the organic layer was separated, dried and evaporated to give 10.25 g of mesylate. The mesylate (10.25 g, 24.6 mmol) from above and NaN 3 (4.8 g, 73.8 mmol) in DMF (100 mL) was stirred at ambient temperature for 18 h. The reaction was diluted with brine (500 mL) , extracted with EtOAc and the extracts washed with H 2 O (5 x 150 mL) . The EtOAc layer was dried (Na 2 S0 4 ) and evaporated to give 8.16 of the azidomethyl compound; LRMS ES + (M+H) + : 364 m/z. The azidomethyl coumpound (23 g, 63.4 mmol) in acetone (400 mL) was heated at 60 °C, then KMn0 (50 g, 317 mmol) in H 2 O (300 mL) was added. After addition was complete, the reaction was heated for 1.5 h. The cooled reaction was filtered through a pad of Celite® and evaporated. The water layer was made basic with IN NaOH (200 mL) and washed with Et 2 θ (3x) , then acidified with cone. HCI, saturated with solid NaCl and extracted with EtOAc (3x) . The EtOAc layer was dried and evaporated to give 15.1 g of 3-trifluoromethyl-1- (2- azidomethyl-4-methoxyphenyl) -IH-pyrazole-5-carboxylic acid; LRMS ES " (M-H) " : 340 m/z. Part C: 3-Trifluoromethyl-l- (2-azidomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (4-N-carboxylpyrrolidino) phenyl ) carboxyamide : To 3-trifluoromethyl-l- (2-azidomethyl-4-methoxyphenyl) -1H- pyrazole-5-carboxylic acid (0.44 g, 1.29 mmol) prepared above in CH 2 CI2 at 0 °C was added a 2M solution of oxalyl chloride in CH 2 CI 2 (2 equivilents, 1.29 mL) followed by a drop of DMF. The ice bath was removed and the reaction stirred for 3 h then evaporated. The resulting acid chloride was combined with N- (4-aminobenzoyl)pyrrolidine (0.32 g, 1.68 mmol) and DMAP (0.47 g, 3.87 mmol) and dissolved in CH 2 CI 2 (20 mL) . The reaction was stirred for 18 h, then evaporated and dissolved in EtOAc. The EtOAc layer was washed with IN HCI and brine, dried (Na 2 Sθ 4 ) and evaporated. The product was purified further by a column of flash Siθ 2 (50 g) eluting with 5-10 % MeOH in CHCI 3 to give 0.24 g of 3-trifluoromethyl-l- (2-azidomethyl-4- methoxyphenyl ) -lH-pyrazole-5- (N- (4-N- carboxylpyrrolidino) phenyl) carboxyamide; LRMS ES+ (M+H)+: 514 m/z. Part D: 3-Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (4-N- carboxylpyrrolidino) phenyl) carboxyamide*TFA: A mixture of 3- trifluoromethyl-l- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (4-N-carboxylpyrrolidino) phenyl) carboxyamide (0.24 g, 0.27 mmol) and SnCl »2H 2 0 (0.24 g, 0.95 mmol) in MeOH (20 mL) was stirred for 18 h. The reaction was evaporated and dissolved in IN NaOH. The basic layer was extracted with EtOAc dried and evaporated. The crude product was purified further by HPLC utilizing gradient elution with a mixture of water : acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column to give 31.2 mg of title compound; mp 117.5 °C; HRMS (M+H) + calc . m/z: 488.190950, obs: 488.191005. Example 9 N-Benzylsulfonyl-4- (3-trifluoromethyl-l- ( 2 -aminomethyl- 4 -methoxyphenyl) -IH-pyrazole-5- carboxyamido)piperidine*TFA 3-Trifluoromethyl-l- (2-azidomethyl-4-methoxyphenyl) -1H- pyrazole-5-carboxylic acid prepared in Part B of Example 8 was coupled with N-Benzylsulfonyl-4-aminopiperidine according to the procedure in Part C of Example 8. The title compound was prepared and purified by the method outlined in Part D of Example 8; mp 98.3 °C; HRMS (M+H) + calc. m/z: 552.189236 obs: 552.188800. Example 10 3-Trif luoromethyl-l- ( 2 -aminomethyl -4 -methoxyphenyl ) -IH- pyrazole- 5- (N- (5- (2 ' -sulf onamido) phenyl) pyr id- 2- yl) carboxyamide * TFA 3 -Trif luoromethyl-l- (2-azidomethyl-4-methoxyphenyl) -1H- pyrazole-5-carboxylic acid prepared in Part B of Example 8 was coupled with 2-amino-5- ( (2-N-t- butyl sulf onamido) phenyl) pyridine according to the procedure in Part C of Example 8. The azidomethyl group was reduced to the aminomethyl group with SnCl 2 *2H 2 θ by the method outlined in Part D of Example 8. The crude reduction product was then refluxed in trifluoroacetic acid (10 mL) for 1 h to remove the t-butyl protecting group. The title compound was isolated by HPLC utilizing gradient elution with a mixture of water: acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column; mp 86.6 °C; HRMS (M+H) + calc. m/z: 547.137535, obs: 547.138200. Example 11 3 - Tr i f luorome t hy 1 - 1 - ( 2 - aminomethyl - 4 -methoxyphenyl ) - IH- pyrazole-5- (N- (5- (pyrid-2-yl) )pyrid-2- y 1 ) carboxyamide • FA 3 -Trif luoromethyl-l- (2-azidomethyl-4-methoxyphenyl) -1H- pyrazole- 5 -carboxylic acid prepared in Part B of Example 8 was coupled with 2-amino-5- (pyrid-2-yl) yridine according to the procedure in Part C of Example 8. The title compound was prepared and purified by the method outlined in Part D of Example 8; mp 48.2 °C; HRMS (M+H) + : 469.1602 m/z. Example 12 N-Benzyl-4- (3-trif luoromethyl-l- (2-aminomethyl-4- methoxyphenyl) -lH-pyrazole-5- carboxyamido ) piper idine • TFA 3 -Trifluoromethyl-l- (2-azidomethyl-4-methoxyphenyl) -1H- pyrazole-5-carboxylic acid prepared in Part B of Example 8 was coupled with N-Benzyl-4-aminopiperidine according to the procedure in Part C of Example 8. The title compound was prepared and purified by the method outlined in Part D of Example 8; mp 116.1 °C; HRMS (M+H) + : 488.2266 m/z. Example 13 N-Phenylsulfonyl-4- ( 3-trifluoromethyl-l- (2 -aminomethyl - 4 -methoxyphenyl) -IH-pyrazole- 5- carboxyamido ) piperidine •TFA 3-Trifluoromethyl-l- (2-azidomethyl-4-methoxyphenyl) -1H- pyrazole-5-carboxylic acid prepared in Part B of Example 8 was coupled with N-phenylsulfonyl-4-aminopiperidine according to the procedure in Part C of Example 8. The title compound was prepared and purified by the method outlined in Part D of Example 8; mp 103 °C; HRMS (M+H) + : 538.1729 m/z. Example 14 3 -Trif luoromethyl-l- ( 2 -aminomethyl-4-chlorophenyl ) - 1H- pyrazole-5- (N- ( 3 - f luoro-2 ' -methylsulfonyl- [ 1 , 1 • ] - biphen-4 -yl ) ) carboxyamide * TFA 3 -Trif luoromethyl-l- (2-azidomethyl-4-chlorophenyl) -1H- pyrazole-5-carboxylic acid was prepared from 3-chloro-6- aminobenzoic acid by essentially the same method used for 3- trif luoromethyl-l- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 2-fluoro-4- ( (2- methansulfonyl) phenyl) aniline according to the procedure in Part C of Example 8. The title compound was prepared and purified by the method outlined in Part D of Example 8 ; mp 97.5 °C; HRMS (M+H) + : 567 .0891 m/z . Example 15 3-Trifluoromethyl-l- (2-aminomethyl-4-chlorophenyl ) -1H- pyrazole-5- (N- (3-fluoro-2 ■ -sulfamido- [1, 1 ' ] -biphen-4- yl) ) carboxyamide*TFA 3-Trifluoromethyl-l- (2-azidomethyl-4-chlorophenyl) -1H- pyrazole-5-carboxylic acid was prepared from 3-chloro-6- a inobenzoic acid by essentially the same method used for 3- trifluoromethyl-l- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 2-fluoro-4- ( (2-N-t- butylsulfonamido) phenyl) aniline according to the procedure in Part C of Example 8. The azidomethyl group was reduced to the aminomethyl group with SnCl 2 »2H 2 θ by the method outlined in Part D of Example 8. The crude reduction product was then refluxed in trifluoroacetic acid (10 mL) for 1 h to remove the t-butyl protecting group. The title compound was isolated by HPLC utilizing gradient elution with a mixture of water: acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column; mp 128 °C; HRMS (M+H) + : 568.0832 m/z. Example 16 3 -Trif luoromethyl- l- ( 2 -aminomethyl - 5 -chlorophenyl ) - 1H- pyrazole- 5 - (N- ( 3 - f luoro-2 ■ -methylsulfonyl - [ 1 , 1 • ] - biphen-4 -yl ) ) carboxyamide *TFA 3 -Trif luoromethyl-l- (2-azidomethyl-5-chlorophenyl ) -1H- pyrazole- 5 -carboxylic acid was prepared from 4-chloro-6- aminobenzoic acid by essentially the same method used for 3- trif luoromethyl-l- ( 2 -azidomethyl -4 -methoxyphenyl ) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8 . This compound was coupled with 2-fluoro-4- ( ( 2- methansulfonyl ) phenyl ) aniline according to the procedure in Part C of Example 8 . The title compound was prepared and purified by the method outlined in Part D of Example 8 ; mp 99 .7 °C ; HRMS (M+H) + : 567 . 0859 m/z . Example 17 3-Trif luoromethyl-l- (2-aminomethyl-4-chlorophenyl ) -1H- pyrazole-5- (N- (3-f luoro-2 ' -sulfamido- [1,1'] -biphen-4- yl ) ) carboxyamide • TFA 3 -Trifluoromethyl-l- (2-azidomethyl-5-chlorophenyl) -1H- pyrazole-5-carboxylic acid was prepared from 4-chloro-6- aminobenzoic acid by essentially the same method used for 3- trifluoromethyl-l- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 2-fluoro-4- ( (2-N-t- butylsulfonamido) phenyl) aniline according to the procedure in Part C of Example 8. The azidomethyl group was reduced to the aminomethyl group with SnCl 2 *2H 2 θ by the method outlined in Part D of Example 8. The crude reduction product was then refluxed in trifluoroacetic acid (10 mL) for 1 h to remove the t-butyl protecting group. The title compound was isolated by HPLC utilizing gradient elution with a mixture of water: acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column; mp 127.4 °C; HRMS (M+H) + : 568.0837 m/z. Example 18 3-Trif luoromethyl-l- (2-aminomethyl-4-f luorophenyl) -1H- pyrazole-5- (N- (3-f luoro-2 ' -methylsulfonyl- [1,1*]- biphen-4-yl) ) carboxyamide* TFA 3 -Trif luoromethyl-l- (2-azidomethyl-4-f luorophenyl) -1H- pyrazole-5 -carboxylic acid was prepared from 3-fluoro-6- aminobenzoic acid by essentially the same method used for 3- trif luoromethyl-l- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 2-fluoro-4- ( (2- methansulfonyl) phenyl) aniline according to the procedure in Part C of Example 8. The title compound was prepared and purified by the method outlined in Part D of Example 8; mp 125 °C; HRMS (M+H) + : 551.1177 m/z. Example 19 3 -Trif luoromethyl- l- ( 2 -aminomethyl -4 - f luorophenyl ) - 1H- pyrazole- 5 - ( N- ( 3 - f luoro-2 ■ - sulf amido- [ 1 , 1 ■ ] -biphen-4 - yl ) ) carboxyamide •TFA 3-Trifluoromethyl-l- (2-azidomethyl-4-fluorophenyl) -IH- pyrazole-5-carboxylic acid was prepared from 3-fluoro-6- aminobenzoic acid by essentially the same method used for 3- trifluoromethyl-l- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 2-fluoro-4- ( (2-N-t- butylsulfonamido) phenyl) aniline according to the procedure in Part C of Example 8. The azidomethyl group was reduced to the aminomethyl group with SnCl 2 »2H 2 θ by the method outlined in Part D of Example 8. The crude reduction product was then refluxed in trifluoroacetic acid (10 mL) for 1 h to remove the t-butyl protecting group. The title compound was isolated by HPLC utilizing gradient elution with a mixture of water:acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column; mp 113.1 °C; HRMS (M+H) + : 552.1112 m/z. Example 20 3-Trifluoromethyl-l- (2-aminomethyl-5-fluorophenyl) -IH- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1']- biphen-4-yl) ) carboxyamide*TFA 3-Trifluoromethyl-1- (2-azidomethyl-5-fluorophenyl) -1H- pyrazole-5-carboxylic acid was prepared from 4-fluoro-6- aminobenzoic acid by essentially the same method used for 3- trifluoromethyl-l- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 2-fluoro-4- ( (2- methansulfonyl)phenyl) aniline according to the procedure in Part C of Example 8. The title compound was prepared and purified by the method outlined in Part D of Example 8; mp 97.2 °C; HRMS (M+H) + : 551.1179 m/z. Example 21 3 -Trif luoromethyl- l- ( 2 -aminomethyl - 5 - f luorophenyl ) - 1H- pyrazole- 5 - (N- ( 3 - f luoro-2 ' - sulfamido- [ 1 , 1 ' ] -biphen-4 - yl) ) carboxyamide* TFA 3 -Trifluoromethyl-l- (2-azidomethyl-5-fluorophenyl) -IH- pyrazole-5-carboxylic acid was prepared from 4-fluoro-6- aminobenzoic acid by essentially the same method used for 3- trifluoromethyl-l- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 2-fluoro-4- ( (2-N-t- butylsulfonamido) phenyl) aniline according to the procedure in Part C of Example 8. The azidomethyl group was reduced to the aminomethyl group with SnCl 2 »2H 2 θ by the method outlined in Part D of Example 8. The crude reduction product was then refluxed in trifluoroacetic acid (10 mL) for 1 h to remove the t-butyl protecting group. The title compound was isolated by HPLC utilizing gradient elution with a mixture of water: acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column; mp 101 °C; HRMS (M+H) + : 552.1120 m/z. Example 22 3 -Trifluoromethyl-l- ( 2 -aminomethyl-4 , 5-difluorophenyl) - lH-pyrazole-5- (N- (3-fluoro-2 * -methylsulfonyl- [1,1*]- biphen-4-yl) ) carboxyamide *TFA 3-Trifluoromethyl-l- (2-azidomethyl-4, 5-difluorophenyl) -1H- pyrazole-5-carboxylic acid was prepared from 3 , 4-difluoro-6- aminobenzoic acid by essentially the same method used for 3- trifluoromethyl-l- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 2-fluoro-4- ( (2- methansulfonyl) phenyl) aniline according to the procedure in Part C of Example 8. The title compound was prepared and purified by the method outlined in Part D of Example 8; HRMS (M+H) + : 569.1082 m/z. Example 21 3 -Trifluoromethyl-l- (2 -aminomethyl-4 , 5-difluorophenyl ) - lH-pyrazole-5- (N- (3-fluoro-2 • -sulfamido- [1,1'] -biphen- 4-yl) ) carboxyamide* TFA 3-Trifluoromethyl-l- (2-azidomethyl-4, 5-difluorophenyl) -1H- pyrazole-5-carboxylic acid was prepared from 3 , 4-difluoro-6- aminobenzoic acid by essentially the same method used for 3- trifluoromethyl-l- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 2-fluoro-4- ( (2-N-t- butylsulfonamido) phenyl) aniline according to the procedure in Part C of Example 8. The azidomethyl group was reduced to the aminomethyl group with SnCl 2 *2H 2 θ by the method outlined in Part D of Example 8. The crude reduction product was then refluxed in trifluoroacetic acid (10 mL) for 1 h to remove the t-butyl protecting group. The title compound was isolated by HPLC utilizing gradient elution with a mixture of water : acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column; mp 118.7 °C; HRMS (M+H) + : 570.1038 m/z. Example 24 3 -Trifluoromethyl-l- ( 2 -aminomethyl-3- fluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1, 1 • ] - biphen-4-yl) ) carboxyamide* TFA 3-Trifluoromethyl-l- (2-azidomethyl-3-fluorophenyl) -1H- pyrazole-5-carboxylic acid was prepared from 2-fluoro-6- aminobenzoic acid by essentially the same method used for 3- trifluoromethyl-l- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 2-fluoro-4- ( (2- methansulfonyl) phenyl) aniline according to the procedure in Part C of Example 8. The title compound was prepared and purified by the method outlined in Part D of Example 8; mp 105.1 °C; HRMS (M+H) + : 551.1180 m/z. Example 25 3-Trifluoromethyl-l- (2 -aminomethyl-3 -fluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1, 1 ' ] -biphen-4- yl) ) carboxyamide*TFA 3-Trifluoromethyl-l- ( 2-azidomethyl-J -fluorophenyl) -IH- pyrazole-5-carboxylic acid was prepared from 2-fluoro-6- aminobenzoic acid by essentially the same method used for 3- trifluoromethyl-l- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 2-fluoro-4- ( (2-N-t- butylsulfonamido) phenyl) aniline according to the procedure in Part C of Example 8. The azidomethyl group was reduced to the aminomethyl group with SnCl 2 *2H 2 θ by the method outlined in Part D of Example 8. The crude reduction product was then refluxed in trifluoroacetic acid (10 mL) for 1 h to remove the t-butyl protecting group. The title compound was isolated by HPLC utilizing gradient elution with a mixture of water : acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column; mp 115.8 °C; HRMS (M+H) + : 552.1111 m/z. Example 26 3-Trifluoromethyl-l- ( 2 -aminomethyl-4-fluorophenyl) -1H- pyrazole-5- (N- (4- ( 2 -methylsulfonyl- [1,1'] -biphen-4- yl) ) carboxyamide * TFA 3-Trifluoromethyl-l- (2-azidomethyl-4-fluorophenyl) -1H- pyrazole-5-carboxylic acid was prepared from 3-fluoro-6- aminobenzoic acid by essentially the same method used for 3- trifluoromethyl-l- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 4- ( (2-methansulfonyl) phenyl) aniline according to the procedure in Part C of Example 8. The title compound was prepared and purified by the method outlined in Part D of Example 8; mp 110.3 °C; HRMS (M+H) + : 533.1265 m/z. Example 27 3-Trifluoromethyl-l- (2-aminomethyl-4-fluorophenyl) -IH- pyrazole- 5- (N- (4- (2 -sulfamido- [1,1*] -biphen-4- yl) ) carboxyamide*TFA 3 -Trifluoromethyl-l- (2-azidomethyl-4-fluorophenyl) -IH- pyrazole-5-carboxylic acid was prepared from 3-fluoro-6- aminobenzoic acid by essentially the same method used for 3- trifluoromethyl-l- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 4-((2-N-t- butylsulfonamido) phenyl) aniline according to the procedure in Part C of Example 8. The azidomethyl group was reduced to the aminomethyl group with SnCl 2 »2H 2 θ by the method outlined in Part D of Example 8. The crude reduction product was then refluxed in trifluoroacetic acid (10 mL) for 1 h to remove the t-butyl protecting group. The title compound was isolated by HPLC utilizing gradient elution with a mixture of water : acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column; mp 136.8 °C; HRMS (M+H) + : 534.1227 m/z. Example 28 3-Trifluoromethyl-l- ( 2 -aminomethyl-4- fluorophenyl) -1H- pyrazole-5-(N-(4- (N-( (N 1 - methylsulfonyl) iminoly) pyrrolidino) ) henyl) carboxyamide* TFA Part A: 4-Amino-N- ( (N 1 -methylsulfonyl) iminoyl)pyrrolidine : 4-Nitrobenzonitrile (5.4 g, 36.5 mmol) in anhydrous methyl acetate (200 mL) and MeOH (20 mL) was cooled to 0 °C and treated with a stream of dry HCI gas for 1 h. The reaction was securely stoppered and left to stand at 5 °C in a refrigerator for 24 h. The solvent was removed and the reaction was evaporated repeatedly (5 x) with Et2θ to remove the last traces of free HCI. There was obtained 28.6 g of the imidate as an HCI salt. This material was dissolved in anhydrous MeOH (100 mL) and pyrrolidine (40.1 mmol, 2.85 g) added. The reaction was stirred for 18 h, then evaporated and stirred in IN HCI (150 mL) ; the insoluable material was removed by filtration then the HCI solution evaporated. The residue was dried by the azeotropic removal of H 2 O with EtOH and there was obtained 7.44 g of the amidine product; LRMS ES + (M+H) + : 220.1 m/z. The free base of the amidine prepared above was formed by suspending the product in IN NaOH (250 mL) and extracting this suspension with CHCI 3 (3 x) . The material was dried and evaporated to give 4.49 g of product. To 3.1 g of the free base of the amidine prepared above (14.2 mmol) in CH 2 C1 2 (100 mL) at 0 °C was added DMAP (2.1 g, 17 mmol) followed by methanesulfonyl chloride (1.95 g, 17 mmol) in CH 2 CI 2 (25 mL) . After 18 h at ambient temperature, the reaction was washed with IN HCI (2 x) , IN NaOH and brine, dried and evaporated. There was obtained 3.6 g of the mesylation product; LRMS ES + (M+H) + : 298.1. The mesyltion product (3.6 g, 12 mmol) and SnC12*2H20 (8.12 g, 36 mmol) in EtOH (100 mL) was heated at reflux for 2 h. The solvent was removed and the residue partioned between IN NaOH (150 mL) and CH2C12 (100 mL) . The aqueous layer was extracted with CH2C12 (2 x 100 mL) , dried (Na2S04) and evaporated to give 2.7 g of 4-amino-N- ( (N' - methylsulfonyl) iminoyl)pyrrolidine; LRMS ES + (M+H) + : 268.1 m/z . Part B: 3-Trifluoromethyl-l- (2-aminomethyl-4-fluorophenyl) - lH-pyrazole-5- (N- (4- (N- ( (N' - methylsulfonyl ) iminoly) pyrrolidino) ) phenyl) carboxyamide*TFA: 3-Trifluoromethyl-l- (2-azidomethyl-4- fluorophenyl) -lH-pyrazole-5-carboxylic acid was prepared from 3-fluoro-6-aminobenzoic acid by essentially the same method used for 3-trifluoromethyl-l- (2-azidomethyl-4-methoxyphenyl) - lH-pyrazole-5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 4-amino-N- ( (N' - methylsulfonyl) iminoyl)pyrrolidine, prepared in Part A of Example 28, according to the procedure in Part C of Example 8. The title compound was prepared and purified by the method outlined in Part D of Example 8; mp 138.4 °C; HRMS (M+H) + : 553.1640 m/z. Example 29 3-Trifluoromethyl-l- (2- (N-glycyl) aminomethyl-4- methoxyphenyl) -lH-pyrazole-5- (N- (3-fluoro-2 ■ - methylsulfonyl- [1,1'] -biphen-4-yl) ) carboxyamide* TFA 3 -Trifluoromethyl-l- (2- (N-glycyl) aminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1, 1 ' ] -biphen-4- yl) ) carboxyamide*TFA: A mixture of 3-Trifluoromethyl-l- (2- aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (3-fluoro-2 ' - methylsulfonyl- [1,1'] -biphen-4-yl) ) carboxyamide•TFA (prepared in Example 5, 0.15 g, 0.22 mmol) ,N-Boc glycine (0.039 g, 0.22 mmol) and HBTU (0.084 g, 0.22 mmol) in DMF (3 mL) were cooled to 0 °C and NMM (0.075 g, 0.75 mmol) added. After 6 h, the reaction was diluted with brine and extracted with EtOAc . The EtOAc layer was washed with 5% NaHSθ 4 and brine (5 x) then dried (MgS0 4 ) and evaporated to give 0.14 g of product; LRMS ES + (M+H) + : 720.4 m/z. The product from above was stirred in 5% TFA in CH 2 CI 2 (20 mL) for 18 h. The reaction was evaporated and the product purified by HPLC utilizing gradient elution with a mixture of water : acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column to give 0.087 g of the title compound; mp 92.5 °C; HRMS (M+H) + : 620.160000 m/z. Example 30 3 -Trif luoromethyl- l- ( 2 - (N-phenylacetyl ) aminomethyl-4 - methoxyphenyl ) -lH-pyrazole- 5 - (N- ( 3 -f luoro-2 ' - methylsulfonyl- [ 1 , 1 ■ ] -biphen-4 -yl ) ) carboxyamide 3 -Trif luoromethyl-l- (2- (N-phenylacetyl ) aminomethyl-4- methoxyphenyl ) -lH-pyrazole-5- (N- (3-f luoro-2 ' -methylsulf onyl - [1 , 1 ' ] -biphen-4-yl) ) carboxyamide : A mixture of 3- Trif luoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) ) carboxyamide*TFA (prepared in Example 5, 0.15 g, 0.22 mmol) and Et 3 N (0.068 g, 0.66 mmol) in CH 2 C1 (10 mL) was cooled to 0 °C and phenylacetyl chloride (0.22 mol in 1 mL of CH 2 CI 2 ) was added dropwise. The reaction was complete in 3 h. It was diluted with more CH 2 CI 2 then washed with IN HCI, dried and evaporated. The residue was purified further by MPLC on a 200g column of flash Siθ 2 by elution with 1:1 Hexane :EtOAc . Fractions (25 mL) were collected and the product isolated in tubes 44-75. There was obtained 0.086 g of the desired product; mp 179-181 °C; HRMS (M+H)+: 681.1786 m/z. Example 31 3- (Trifluoromethyl) -1- (2- (aminomethyl ) phenyl) -1H- pyrazole-5- (N- (2 • -methylsulfonyl- [1,1'] -biphen-4- yl ) ) carboxyamide•TFA 2- [5- (2-Furyl) -3- (trifluoromethyl) -lH-pyrazol-1-yl] benzoic acid: 4,4,4-Trifluoro-l- (2-furyl) -1, 3-butanedione (2.4 mL, 16 mmol) was added to 2-hydrazinobenzoic acid (3.01 g, 16 mmol) in acetic acid (20 mL) and heated at reflux for 25 h. The reaction was cooled, diluted with EtOAc, and extracted twice with water. The organic layer was dried over Na 2 S0 4 , filtered, and evaporated to yield a thick red paste (5.71 g, >100%) . ^E NMR (CDCI 3 ) δ 8.18 (dd, IH, J = 7.7, J 1 = 1.8), 7.74 (td, IH, J = 7.7, J 1 = 1.4), 7.65 (td, IH, J = 7.7, J' = 1.5), 7.50 (dd, IH, J = 7.3, J' = 1.1), 7.35 (m, IH) , 6.89 (s, IH) , 6.28 (m, IH) , 5.76 (d, IH, J = 3.3) . 2- [5- (2-Furyl) -3- (trifluoromethyl) -lH-pyrazol-l-yl]benzamide: 2- [5- (2-Furyl) -3- (trifluoromethyl) -lH-pyrazol-1-yl]benzoic acid (5.13 g, 16 mmol) was dissolved in thionyl chloride (25 mL) and heated at reflux for 2 h. The excess thionyl chloride was evaporated, and the resulting acid chloride was placed under high vacuum. The acid chloride was then redissolved in CH 2 CI 2 (25 mL) and cooled to 0 * C. Cone, aqueous NH 3 (6 mL)was added portionwise over 30 min. The resulting mixture was stirred at 0'C for 30 min, then at room temperature for 1 h. The reaction was diluted with water and extracted with CH2CI2 (3x) . The organic layers were combined and extracted with 2M Na 2 Cθ 3 - The organic layer was dried over MgS0 4 , filtered, and evaporated to yield the desired product (4.76 g, 93%). ^H NMR (CDCI 3 ) δ 7.98 (dd, IH, J = 7.3, J'- = 2.2), 7.67 (m, 2H) , 7.41 (m, 2H) , 6.96 (s, IH) , 6.28 (m, IH) , 5.89 (bs, IH) , 5.67 (d, IH, J = 2.9) . 2- [5- (2-Furyl) -3- ( trifluoromethyl) -lH-pyrazol-1- yl]benzonitrile: 2- [5- (2-Furyl) -3- (trifluoromethyl) -1H- pyrazol-l-yl]benzamide (6.73 g, 21 mmol) and triethylamine (5.8 mL, 42 mmol) were combined in dry CH 2 CI 2 (55 mL) under argon and cooled to O'C. Trichloroacetyl chloride (2.7 mL, 24 mmol) in CH 2 CI2 (15 mL) was added dropwise over 30 min. The resulting solution was stirred at O'C for 20 min, then at room temperature for 65 min. The reaction was quenched with a small amount of water, then partitioned between 1M HCI and CH 2 CI 2 • The organic layer was removed and extracted with sat . NaHCθ 3 , then dried over Na 2 Sθ 4 , filtered, and evaporated to yield crude product (6.66 g) . The crude product was chromatographed on silica gel (30-40% EtOAc/hexanes) to yield a yellow solid (6.51 g, >100%) . ^ NMR (CDCI 3 ) δ 7.79 (m, 2H) , 7.64 (m, 2H) , 7.39 (d, IH, J = 1.8), 6.96 (s, IH) , 6.37 ( , IH) , 6.04 (d, IH, J = 3.7) . 2- [5- (2-Furyl) -3- (trifluoromethyl) -lH-pyrazol-1- yl]benzylamine : Cobalt chloride (1.76 g, 13.6 mmol) was added to 2- [5- (2-furyl) -3- (trifluoromethyl) -lH-pyrazol-1- yljbenzonitrile (4.12 g, 13.6 mmol) and sodium borohydride (1.03 g, 27.2 mmol) in DMF (40 mL) . The reaction turned black and became warm. An ice bath was added and the reaction was stirred at O'C for 45 min, then at room temperature for 23 h. Additional sodium borohydride (0.25 g, 6.6 mmol) was added and the resulting mixture was stirred at room temperature for 6 h. A room temperature water bath was added, and the reaction was quenched with water (10 mL) over 10 min, then MeOH (20 mL) , then 6M HCI (20 mL) over 15 min. The quenched reaction was stirred at room temperature for 16 h, diluted with EtOAc, and extracted with water and 0.1M HCI. The resulting emulsion was filtered through celite, and the organic layer was removed, dried over Na 2 S0 4 , filtered, and evaporated to yield crude product (857 mg) . The aqueous layers were combined and neutralized (pH 8) with solid Na 2 C0 3 (6.9 g) . Addition of EtOAc yielded another emulsion, which was filtered through celite. The organic layer was removed, and the aqueous layer was extracted again with EtOAc. The organic layers were combined, dried over Na 2 Sθ 4 , filtered, and evaporated to yield a second batch of crude product (3.55 g) . The two batches of crude product were combined and chromatographed on silica gel (0-10% MeOH/CHCl 3 ) to yield the desired product (3.77 g, 90%). X H NMR (CDC1 3 ) δ 7.59 (m, 2H) , 7.38 (m, 2H) , 7.33 (d, IH, J = 7.3), 6.96 (s, IH) , 6.27 (m, IH) , 5.59 (d, IH, J = 3.6), 3.51 (s, 2H) . t-Butyl 2- [5- (2-furyl) -3- (trifluoromethyl) -lH-pyrazol-1- yl]benzylcarbamate: Triethylamine (2.6 mL, 18.7 mmol) and di- t-butyl dicarbonate (4.0 g, 18.4 mmol) were added to 2- [5- (2- furyl) -3- (trifluoromethyl) -lH-pyrazol-l-yl]benzylamine (3.77 g, 12.3 mmol) in THF (60 mL) and stirred at room temperature for 17 h. The reaction was concentrated, diluted with Et 2 θ, and extracted with water (2x) . The aqueous layers were combined and extracted with Et 2 θ. The organic layers were combined, dried over MgS0 4 , filtered, and evaporated to yield crude product (5.58 g) . The crude product was chromatographed on silica gel (10-20% EtOAc/hexanes) to yield a waxy solid (3.82 g, 76%). !H NMR (CDCI 3 ) δ 7.57 (m, 2H) , 7.43 (m, 2H) , 7.32 (d, IH, J = 7.7), 6.95 (s, IH) , 6.28 (m, IH) , 5.66 (d, IH, J = 3.3), 4.82 (bs, IH) , 4.01 (bd, 2H, J = 6.2), 1.39 (s, 9H) . 1- (2- ( [ (t-Butoxycarbonyl) amino] methyl) phenyl) -3- (trifluoromethyl) -lH-pyrazol-1-yl-5-carboxylic acid: t-Butyl 2- [5- (2-furyl) -3- (trifluoromethyl) -lH-pyrazol-1- yl]benzylcarbamate (3.77 g, 9.2 mmol) was dissolved in t-BuOH (60 mL) . A 5% aqueous solution of NaH 2 P0 4 (40 mL) was added, followed by portionwise addition of solid KMnθ 4 (5.86 g, 37 mmol) over 25 min. The resulting mixture was heated at 65 * C for 40 min. Additional Mnθ 4 (1.39 g, 8.8 mmol) was added, and the reaction continued heating at 65 'C for 35 min. The reaction mixture was cooled and filtered through celite, using EtOH and acetone to rinse the celite. The filtrate was concentrated to approx. half its original volume and treated with aq. sodium bisulfite to remove residual KMnθ 4 . The resulting mixture was extracted with EtOAc, and the organic layer was removed, dried over Na 2 S0 4 , filtered, and evaporated to yield crude product (1.50 g) . The aqueous layer was cooled in ice, acidified with 1M HCI (6 mL) and extracted with EtOAc (containing a small amount of EtOH) . Before separating, both layers were filtered through celite and treated with sat NaHC0 3 (1.5 mL) . The aqueous layer was removed and extracted twice with EtOAc/EtOH. Solid NaCl was added both times to aid separation of the emulsion. The aqueous layer was extracted with CHCI 3 , adjusted to pH 5 with 1M HCI, and extracted twice with CHCl 3 /EtOH. The final 6 organic layers were combined, dried over Na 2 S0 4 , filtered, and evaporated to yield a second batch of product (2.43 g, 68%). The first batch of product was chromatographed on silica gel (0-30% MeOH/CHCl 3 ) to yield clean product (0.95 g, 27%). 1H NMR (DMSO) δ 7.34 (m, 4H) , 7.16 (d, IH) , 6.81 (bs, IH) , 3.79 (bd, 2H) , 1.32 (s, 9H) . 1- [2- ( ( [ ( t-Butoxycarbony1) amino] methyl) phenyl) -5- (2 ' - methylsufonyl- [1,1'] -biphen-4-yl) ) aminocarbonyl] -3- (trifluoromethyl) pyrazole: Oxalyl chloride (90 μl, 1.0 mmol) and DMF (2 drops) were added to l-(2-([(t- butoxycarbonyl ) amino]methyl)phenyl) -3- (trifluoromethyl) -1H- pyrazol-l-yl-5-carboxylic acid (200 mg, 0.52 mmol) in CH2CI2 (5 mL) and the resulting solution was stirred for 90 min at room temperature. The solvents were evaporated and the resulting compound was placed briefly under high vacuum before redissolving in CH 2 CI 2 (5 mL) . Triethylamine (220 μl, 1.6 mmol) , 4-amino-2 ' -methylsulfonyl- [1,1'] -biphenyl hydrochloride (177 mg, 0.62 mmol), and 4-dimethylaminopyridine (20 mg, 0.16 mmol) were added, and the resulting solution was stirred for 23 h at room temperature. The reaction was extracted with ice-cooled 1M HCI, then sat. NaHCθ 3 . The organic layer was dried over MgS0 4 , filtered, and evaporated to yield crude product (241 mg) . The crude product was chromatographed on silica gel (30-40% EtOAc/hexanes) to yield the desired product (64 mg, 20%). X H NMR (CDC1 3 ) δ 8.21 (d, IH, J = 8.1), 7.58 (m, 5H) , 7.35 ( , 8H) , 7.18 (s, IH) , 4.16 (d, 2H, J = 5.8), 2.59 (s, 3H) , 1.33 (s, 9H) . 3- (Trifluoromethyl) -1- (2- (aminomethyl) phenyl) -lH-pyrazole-5- (N- (2 ' -methylsulfonyl- [1,1'] -biphen-4-yl) ) carboxyamide trifluoroacetic acid salt: TFA (1 mL) was added to l-[2- ( ( [ (t-butoxycarbonyl) amino] methyl) phenyl) -5- (2 ' -methylsufonyl- [1,1'] -biphen-4-yl) ) aminocarbonyl] -3- ( trifluoromethyl ) pyrazole (64 mg, 0.10 mmol) in CH 2 CI 2 (1 mL) .and stirred at room temperature for 21 h. The reaction was evaporated and purified by reverse phase prep. HPLC (15-70% MeCN/H 2 O/0.5% TFA) to yield the desired product (30 mg, 46%) . ^H NMR (DMSO) d 10.79 (s, IH) , 8.16 (bs, 2H) , 8.04 (d, IH, J = 7.7), 7.77 (s, IH) , 7.71 (td, IH, J = 5.8), 7.64 (m, 6H) , 7.51 (m, IH) , 7.45 (d, IH, J = 7.6), 7.34 (m, 3H) , 3.79 (bm, 2H) , 2.78 (s, 3H) . 19 F NMR (DMSO) d -61.22, -73.97. HRMS calc. C 25 H 22 N4O 3 F 3 S: 515.1365; found, 515.1359. Example 32 3 -Trifluoromethyl-l- (2- (aminomethyl) phenyl) -1H- pyrazole-5- (N- (2 ' -aminosulfonyl- [1,1* ] -biphen-4- yl) ) carboxyamide*TFA l-[2-( ( [ (t-Butoxycarbonyl) amino]methyl)phenyl) -5- (2 '-(t- butylamino) sulfonyl- [1,1'] -biphen-4-yl) ) aminocarbonyl] -3- (trifluoromethyl)pyrazole: Oxalyl chloride (90 μl, 1.0 mmol) and DMF (2 drops) were added to l-(2-([_(t- butoxycarbonyl) amino]methyl) phenyl) -3- (trifluoromethyl) -1H- pyrazol-l-yl-5-carboxylic acid (Example 31 Part A, 200 mg, 0.52 mmol) in CH 2 CI2 (5 mL) and the resulting solution was stirred for 95 min at room temperature. The solvents were evaporated and the resulting compound was placed briefly under high vacuum before redissolving in CH2CI2 (5 mL) . Triethylamine (150 μl, 1.1 mmol), 4-amino-2 ' ( t- butylamino) sulfonyl- [1, 1 '] -biphenyl (190 mg, 0.62 mmol), and 4-dimethylaminopyridine (20 mg, 0.16 mmol) were added, and the resulting solution was stirred for 23 h at room temperature. The reaction was extracted with dilute brine solution, ice- cooled 1M HCI, and sat. NaHC0 3 . The organic layer was dried over MgSθ 4 , filtered, and evaporated to yield crude product (371 mg) . The crude product was chromatographed on silica gel (30% EtOAc/hexanes) to yield the desired product (74 mg, 21%) . 1H NMR (CDC1 3 ) δ 8.64 (bs, IH) , 8.15 (dd, IH, J = 7.7, J' = 1.5), 7.45 (m, 10H) , 7.25 (d, IH, J = 6.9), 7.20 (s, IH) , 5.33 (bs, IH) , 4.15 (d, 2H, J = 5.8), 3.49 (bs, IH) , 1.34 (s, 9H) , 0.97 (s, 9H) . 3 -Trifluoromethyl-l- (2- (aminomethyl ) phenyl) -lH-pyrazole-5- (N- (2 ' -aminosulfonyl- [1,1' ] -biphen-4-yl) ) carboxyamide trifluoroacetic acid salt: TFA (2 mL) was added to l-[2- ( ( [ (t-butoxycarbonyl) amino]methyl) phenyl) -5- (2 ' - (t- butylamino) sulfonyl- [1,1'] -biphen-4-yl) ) aminocarbonyl] -3- (trifluoromethyl) pyrazole (74 mg, 0.11 mmol) in CH 2 C1 2 (1 mL) and stirred at room temperature for 19 h. Additional TFA (2 mL) was added, and the reaction continued stirring for 3 h. The reaction was evaporated and purified by reverse phase prep. HPLC (15-70% MeCN/H 2 O/0.5% TFA) to yield the desired product (41 mg, 59%). -T-H NMR (DMSO) δ 10.75 (s, IH) , 8.17 (bs, 3H) , 7.98 (dd, IH, J = 7.3), 7.76 (s, IH) , 7.57 (m, 7H) , 7.44 (d, IH, J = 6.7), 7.32 (d, 2H, J = 8.8), 7.25 (m, 3H) 3.79 (bd, 2H, J = 5.1). 19 F NMR (DMSO) δ -61.22, -73.99. HRMS calc. C 24 H 21 N 5 O 3 F 3 S: 516.1317; found, 516.1319. Example 33 3 -Trif luoromethyl-l- (2- (aminomethyl) phenyl) -1H- pyrazolβ-5- (N- (3-f luoro-2 • -aminosulfonyl- [1, 1 ' ] -biphen- 4-yl) ) carboxyamide* TFA 1- [2- ( ( [ (t-Butoxycarbonyl) amino] methyl) phenyl) -5- (3-fluoro-2 ' - (t-butylamino) sulfonyl- [1, 1 ' ] -biphen-4-yl) ) aminocarbonyl ] -3- ( trifluoromethyl) pyrazole: Oxalyl chloride (300 μl, 3.4 mmol) and DMF (3 drops) were added to l-(2-[(t- butoxycarbonyl ) amino]methylphenyl ) -3 - ( trifluoromethyl ) -1H- pyrazol-l-yl-5-carboxylic acid (Example 31 Part A, 888 mg, 2.3 mmol) in CH 2 CI 2 (30 mL) and the resulting solution was stirred for 65 min at room temperature. The solvents were evaporated and the resulting compound was placed briefly under high vacuum before redissolving in CH 2 CI 2 (30 mL) . 4-Amino-3- fluoro-2'-(t-butylamino) sulfonyl- [ 1, 1' ] -biphenyl (890 mg, 2.8 mmol), and 4-dimethylaminopyridine (420 mg, 3.4 mmol) were added, and the resulting solution was stirred for 22 h at room temperature. The reaction was concentrated and chromatographed on silica gel (20-30% EtOAc/hexanes) . The fractions containing product were combined and concentrated to half the original volume, then extracted 3x with ice-cooled IM HCI, 2x with room temperature IM HCI, sat. NaHC0 3 , 2M HCI, and sat. NaHCθ 3 . The organic layer was dried over Na 2 Sθ 4 , filtered, and evaporated to yield the desired product (600 mg, 38%) . 3 -Trifluoromethyl-l- (2- (aminomethyl) phenyl) -lH-pyrazole-5- (N- (3-fluoro-2 ' -aminosulfonyl- [1,1'] -biphen-4-yl) ) carboxyamide trifluoroacetic acid salt: TFA (9 mL) was added to l-[2- ( ( [ (t-butoxycarbonyl) amino] methyl) phenyl) -5- (3-fluoro-2 ' - (t- butylamino) sulfonyl- [1,1'] -biphen-4-yl) ) aminocarbonyl] -3- (trifluoromethyl) pyrazole (600 mg, 0.87 mmol) in CH 2 CI2 (3 mL) and stirred at room temperature for 18 h. The reaction was evaporated and purified by reverse phase prep. HPLC (10-70% MeCN/H 2 O/0.5% TFA) to yield impure product (349 mg) . This material was again purified by reverse phase HPLC (5-70% MeCN/H 2 O/0.5% TFA) to yield clean product (162 mg, 35%). Any impure fractions containing product were combined and purified by reverse phase HPLC (20-60% MeCN/H 2 O/0.5% TFA) to yield additional product (119 mg, 26%) X H NMR (DMSO) δ 10.62 (s, IH) , 8.16 (bs, 2H) , 7.98 (dd, IH, J = 7.0, J' = 2.2), 7.79 (s, IH) , 7.54 (m, 7H) , 7.39 (s, 2H) , 7.28 (m, 2H) , 7.15 (d, IH, J = 8.4), 3.78 (bm, 2H) . l^F NMR (DMSO) δ -61.26, -74.29, -122 . 79 . HRMS calc . C 24 H 20 N 5 O 3 F4S : 534. 1223 ; found, 534 . 1216 . Example 34 3-Trifluoromethyl-l- (2- (aminomethyl ) phenyl ) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1, 1 ' ] - biphen-4-yl) ) carboxyamide*TFA 1- [2- ( ( [ (t-Butoxycarbonyl) amino] methyl) phenyl) -5- (3-fluoro-2 ' - methylsulfonyl- [1,1'] -biphen-4-yl) ) aminocarbonyl] -3- ( trifluoromethyl) pyrazole: Oxalyl chloride (320 μl, 3.7 mmol) and DMF (4 drops) were added to 1- (2- ( [ (t-butoxy carbonyl) amino]methyl) phenyl) -3- (trifluoromethyl) -lH-pyrazol- 1-yl-5-carboxylic acid (Example 31 Part A, 940 mg, 2.4 mmol) in CH 2 CI 2 (35 mL) and the resulting solution was stirred for 55 min at room temperature. The solvents were evaporated and the resulting compound was placed briefly under high vacuum before redissolving in CH 2 CI 2 (20 mL) . 4-Amino-3-fluoro-2 ' - methylsulfonyl-[1, 1" ] -biphenyl (750 mg, 2.8 mmol) in CH 2 CI 2 (15 mL) , and 4-dimethylaminopyridine (447 mg, 3.7 mmol) were added, and the resulting solution was stirred for 20 h at room temperature. The reaction was concentrated and chromatographed on silica gel (30-40% EtOAc/hexanes) to yield impure product (802 mg) , which was purified on reverse phase prep. HPLC (10-70% MeCN/H2O/0.5% TFA) to yield clean product (645 mg, 42%) . 3-Trifluoromethyl-l- (2- (aminomethyl)phenyl) -lH-pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1' ] -biphen-4-yl) ) carboxyamide trifluoroacetic acid salt: TFA (2 mL) was added to l-[2- ( ( [ (t-butoxycarbonyl) amino]methyl)phenyl) -5- (3-fluoro-2 ' - methylsulfonyl- [1,1'] -biphen-4-yl ) ) aminocarbonyl] -3 - (trifluoromethyl) pyrazole (132 mg, 0.21 mmol) in CH 2 CI 2 (2 mL) and stirred at room temperature for 5 h. The reaction was evaporated and purified by reverse phase prep. HPLC (10-70% MeCN/H 2 O/0.5% TFA) to yield the desired product (80 mg, 59%). X H NMR (DMSO) δ 10.65, (s, IH) , 8.16 (bs, 3H) , 8.05 (d, IH, J = 6.6), 7.79 (s, IH) , 7.73 (td, IH, J = 6.2, J' = 1.5), 7.67 (dd, IH, J = 7.7, J' = 1.5), 7.54 (m, 5H) , 7.35 (m, 2H) , 7.19 (d, IH, J = 8.0), 3.78 (bd, 2H, J = 5.5), 2.88 (s, 3H) . 19 F NMR (DMSO) δ -61.26, -74.11, -122.19. HRMS calc. C25H21N4O3F4Ξ : 533.1217; found, 533.1258. Example 35 3-Trif luoromethyl-l- (2- (N- (glyσyl) aminomethyl) phenyl) - lH-pyrazole-5- (N- (3-f luoro-2 • -methylsulfonyl- [1, 1 • ] - biphen-4-yl) ) carboxyamide* TFA The title compound was prepared from l-[2- ( (aminomethyl) phenyl) -5- (3-fluoro-2 ' -methylsulfonyl- [1,1']- biphen-4-yl) ) aminocarbonyl] -3- (trif luoromethyl) pyrazole trifluoroacetic acid salt (prepared in Example 34) and N-Boc glycine according to the procedure in Example 29; HRMS (M+H) + : 590.1495 m/z. Example 36 3-Trif luoromethyl-l- (2- ( (N- (N- methylglycyl) aminomethyl) phenyl ) -lH-pyrazole-5- (N- (3- f luoro-2 * -methylsulfonyl- [1,1'] -biphen-4- yl) ) carboxyamide * TFA The title compound was prepared from l-[2- ( (aminomethyl) phenyl) -5- (3-fluoro-2 ' -methylsulfonyl- [1,1']- biphen-4-yl) ) aminocarbonyl] -3- (trif luoromethyl) pyrazole trifluoroacetic acid salt (prepared in Example 34) and N-Boc - N-methyl glycine according to the procedure in Example 29; HRMS (M+H) + : 604.1655 m/z. Example 37 3-Trif luoromethyl-l- (2-carboxamidophenyl) -lH-pyrazole- 5-(N-(3-fluoro-2 ■ -methylsulfonyl- [1,1* ] -biphen-4- yl) ) carboxyamide Methyl 2- [5- (2-furyl) -3- (trif luoromethyl) -lH-pyrazol-1- yl]benzoate: 2- [5- (2-furyl) -3- (trifluoromethyl) -lH-pyrazol-1- yl] benzoic acid (Example 31 Part A, 26.5 g, 82 mmol) was dissolved in SOCI 2 (130 mL) and heated at reflux for 2.5 h. Excess SOCI 2 was evaporated, and the residual acid chloride was placed under high vacuum. The acid chloride was cooled to 0°C, and dry MeOH (130 mL) was added. The resulting solution was allowed to warm slowly to room temperature, then stirred at room temperature for 22 h. The solvent was evaporated, and the crude product was chromatographed on silica gel (0-30% EtOAc/hexanes) to yield the desired product (22.6 g, 82%). ^-H NMR (CDC1 3 ) δ 8.10 (dd, IH, J = 7.3, J' = 1.9), 7.67 (m, 2H) , 7.50 (dd, IH, J = 7.7, J' = 1.4), 7.37 (s, IH) , 6.92 (s, IH) , 6.29 (m, IH) , 5.77 (d, IH, J = 3.3), 3.62 (s, 3H) . 1- (2-Carbomethoxyphenyl) -3- (trifluoromethyl) -lH-pyrazol-1-yl] - 5-carboxylic acid: A 5% aq. solution of NaH 2 P0 4 (320 mL) and water (200 mL) were added to methyl 2- [5- (2-furyl) -3- (trifluoromethyl) -lH-pyrazol-l-yl]benzoate (23.7 g, 71 mmol) in t-BuOH (470 mL) . The reaction was immersed in a room temperature water bath, and solid KMnθ 4 (55.8 g, 353 mmol) was added portionwise over 1 h. The reaction was heated at 70°C for 90 min, cooled, and filtered through celite. The celite was rinsed with acetone and EtOAc . The filtrate was concentrated to remove most of the organics, then extracted with EtOAc. The organic layer was extracted with sat. Na 2 S0 3 , dried over Na 2 S0 4 , filtered, evaporated, and set aside. The aqueous layers were combined and neutralized to pH 6.5 with 2M HCI (100 mL) , and then extracted with EtOAc (3x) . The organic layers were combined, dried over Na 2 S0 4 , filtered, and evaporated to yield clean product (14.8 g, 67%) . ^H NMR (CDCI 3 ) δ 8.10 (dd, IH, J = 7.3, J' = 1.5), 7.64 (m, 2H) , 7.42 (dd, IH, J = 7.3, J' = 1.1), 7.31 (s, IH) , 3.69 (s, 3H) . 1- [2-Carbomethoxyphenyl-5- (3-fluoro-2 ' -methylsulfonyl- [1,1']- biphen-4-yl) ) aminocarbonyl] -3- (trifluoromethyl) pyrazole: Oxalyl chloride (2.9 mL, 33 mmol) and DMF (10 drops) were added to 1- (2-carbomethoxyphenyl ) -3- (trifluoromethyl) -1H- pyrazol-1-yl] -5-carboxylic acid (7.0 g, 22 mmol) in dry CH 2 CI 2 (240 mL) , and the resulting solution was stirred at room temperature for 80 min. The solvents were evaporated, and the resulting compound was placed briefly under high vacuum before redissolving in CH 2 CI 2 (240 mL) . 4-Amino-3-fluoro-2 ' - methylsulfonyl- [1, 1 '] -biphenyl hydrochloride (7.4 g, 25 mmol) and 4-dimethylaminopyridine (7.1 g, 58 mmol) were added, and the resulting solution was stirred at room temperature for 67 h. The reaction was extracted with IM HCI (2x) , then sat. NaHC0 3 . The organic layer was dried over MgSθ 4 , filtered, and evaporated to yield crude product. The crude product was chromatographed on silica gel (30-50% EtOAc/hexanes) to yield the desired product (12.4 g, 99%). E NMR (CDC1 3 ) δ 8.29 (t, IH, J = 8.1), 8.21 (m, 2H) , 8.11 (dd, IH, J = 7.7, J' = 1.5), 7.62 (m, 5H) , 7.30 (m, 2H) , 7.14 (m, 2H) , 3.77 (s, 3H) , 2.69 (s, 3H) . 1- [2-Carboxyphenyl-5- (3-fluoro-2 ' -methylsulfonyl- [1,1']- biphen-4-yl) ) aminocarbonyl] -3- (trifluoromethyl) pyrazole: IM LiOH (34 mL)was added to 1- [2-carbomethoxyphenyl-5- (3-fluoro- 2 ' -methylsulfonyl- [1,1'] -biphen-4-yl) ) aminocarbonyl] -3- (trifluoromethyl) pyrazole (12.0 g, 21 mmol) in THF (285 mL) and stirred at room temperature for 26 h. Additional IM LiOH (15 mL) was added, and the reaction continued stirring for 18 h. The resulting solution was heated at 35°C for 2.5 h, then at 50°C for 18 h. The reaction was cooled, concentrated, and partitioned between Et 2 θ and water. The organic layer was extracted again with water (2x) . A small amount of white solid was assumed to be product, and was added to the aqueous layer. The aqueous layers were combined, neutralized to pH 7 with 2M HCI (23 mL) , and extracted with EtOAc. Additional 2M HCI (2 mL) was added to the aqueous, which was extracted twice with EtOAc. The EtOAc layers were combined, dried over Na 2 S0 4 , filtered, and evaporated to yield the desired product (10.3 g, 88%). 1H NMR (CDCI 3 ) δ 8.21 (m, 4H) , 7.75 (m, IH) , 7.60 (m, 4H) , 7.29 (m, 3H) , 7.13 (m, 2H) , 2.70 (s, 3H) . 3-Trifluoromethyl-l- (2-carboxamidophenyl) -lH-pyrazole-5- (N- (3- fluoro-2 ' -methylsulfonyl- [1, 1 ' ] -biphen-4-yl) ) carboxyamide: 1- [2-Carboxyphenyl-5- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) ) aminocarbonyl] -3- (trifluoromethyl)pyrazole (3.0 g, 5.5 mmol) was dissolved in SOCI 2 (10 mL) and heated at reflux for 2 h. Excess SOCI 2 was evaporated, and the residual acid chloride was placed under high vacuum. The acid chloride was dissolved in dry CH 2 CI 2 and cooled to 0°C, and cone. aq. NH 3 (2.0 mL) was added over 20 min. The resulting mixture was stirred at room temperature for 18 h. The reaction was diluted with CH 2 CI 2 and extracted with water. The aqueous layer was extracted with CHCI 3 , MeOH/CH 2 Cl 2 , and CH 2 CI 2 ■ All of the organics were combined and extracted with sat. NaHC0 3 (2x) , IM HCI, and sat. NaCl. The organic layer was dried over MgS0 4 , filtered, evaporated, and chromatographed on silica gel (30- 75% EtOAc/hexanes) to yield the desired product (794 mg, 27%) . NMR (CDCI 3 . 400 MHz) δ 9.53 (bs, IH) , 8.25 (t, IH, J = 8.3), 8.20 (dd, IH, J = 7.8, J' = 1.2), 7.75 (m, IH) , 7.60 (m, 4H) , 7.45 ( , IH) , 7.29 (dd, IH, J = 7.6, J' = 1.2), 7.20 (dd, IH, J = 11.2, J' = 1.9), 7.12 (m, 2H) , 6.13 (bs, IH) , 5.68 (bs, IH) , 2.67 (s, 3H) . Example 38 3 -Trifluoromethyl-l- (2-cyanophenyl ) -IH-pyrazole- 5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) ) carboxyamide 1- [2-Cyanophenyl-5- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) ) aminocarbonyl] -3- (trifluoromethyl) pyrazole: l-[2- Carboxamidophenyl-5- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) ) aminocarbonyl] -3- (trifluoromethyl) pyrazole (Example 36, 715 mg, 1.3 mmol) and triethylamine (360 μL, 2.6 mmol) were combined in dry CH 2 CI 2 (10 mL) and cooled to 0°C. Trichloroacetyl chloride (160 μl, 1.4 mmol) was added over 5 min.. The resulting solution was stirred at 0°C for 30 min, then at room temperature for 2 h. Additional triethylamine (200μL, 1.4 mmol) was added, and the reaction continued stirring at room temperature for 68 h. Additional trichloroacetyl chloride (20 μL, 0.2 mmol) was added. After stirring 2 h, the reaction was quenched with water. The organic layer was removed and extracted with IM HCI and sat. NaHCθ 3 . A small amount of sat. NaCl was added to break up the emulsion. The organic layer was dried over a 2 S0 4 , filtered, evaporated, and chromatographed on silica gel (20-75% EtOAc/hexanes) to yield the desired product (114 mg, 17%) . IH NMR (CDC1 3 ) δ 8.25 (m, 2H) , 8.09 (bs, IH) , 7.82 (m, 2H) , 7.65 (m, 4H) , 7.35 (m, 2H) , 7.20 (m, 2H) , 2.72 (s, 3H) . Example 39 1- (2 ' -Aminomethylphenyl) -5- [ [ (2 ' -methylsulfonyl) -3- fluoro- [1,1'] -biphen-4-yl] aminocarbonyl] -tetrazole TFA salt Ethyl 1- (2-cyanophenyl) -5-tetrazole carboxylate: To a solution of anthranilonitrile (10.00 g) and Et3N (13.21 mL) in CH2CI2 (250 mL) was added ethyloxalyl chloride (9.92 mL) in a dropwise fashion over 30 minutes. The reaction was stirred at RT under N2 for 3 h. The reaction mixture was filtered. The filtrate was washed with water (2 x 150 mL) and brine (1 x 150 mL) , filtered through phase separatory paper and evaporated. The residue was dissolved in 60 mL of CH2CI2 and 300 mL of hexane was added. The solution was allowed to stand at RT for the weekend. The precipitate was filtered, rinsed with hexane, and dried under vacuum to give 17.74 g of l-(2- cyanophenyl ) -oxoacetic acid ethyl ester. A solution of triphenylphosphine (16.83 g) in CCI4 (100 mL) was stirred at 0° C for 30 minutes. 1- (2-Cyanophenyl) - oxoacetic acid ethyl ester (7.00 g) in CCI4 (100 mL) was added and the reaction was stirred at reflux under N2 for 16 h. The reaction was cooled to RT and the precipitate filtered off. The filtrate was evaporated and dissolved in CH3CN (300 mL) . Sodium azide (2.29 g) was added and the reaction stirred at RT under N2 for 16 h. The solvent was evaporated and the residue taken up in EtOAc (100 mL) . The organic solution was washed with water (2 x 100 mL) and brine (1 x 100 mL) , dried over MgS04, and evaporated. The crude material was purified by silica gel chromatography eluting with CH2CI2 to give 3.80 g of the title compound; LRMS (ES + ) M + : 244 m/z 1- (2 ' -Aminomethylphenyl ) -5- [ [ (2 ' -methylsulfonyl) -3-fluoro- [1, 1 '] -biphen-4-yl] aminocarbonyl] -tetrazole: To a solution of [ (2 ' -methylaminosulfonyl) -3-fluoro- [1,1'] -biphen-4-yl] amine (0.32 g) in anhydrous CH2CI2 (10 mL) was added trimethylaluminum (2.12 mL, 2M in heptane) . The reaction was stirred at RT under N2 for 30 minutes. A solution of ethyl 1- (2-cyanophenyl) -5-tetrazole carboxylate (0.28 g) in anhydrous CH2CI2 (10 mL) was added and the reaction was stirred at RT under N2 for 64 h. The reaction was quenched with 5 drops of IN HCI and diluted with CH2CI2 (30 mL) . The organic solution was washed with water (2 x 25 mL) and brine (1 x 25 mL) , filtered through phase separatory paper, and evaporated. The crude material was purified by silica gel chromatography eluting with 10% EtOH/CH2Cl 2 to give 0.35 g of l-(2'- cyanophenyl) -5- [ [ (2 ' -methylsulfonyl) -3-fluoro- [1,1'] -biphen-4- yl] aminocarbonyl] -tetrazole; LMRΞ (ES " ) M ~ : 461 m/z. Cobalt chloride (0.098 g ) was added to 1- (2 ' -cyanophenyl) -5- [ [ (2 '-methylsulfonyl) -3-fluoro- [1,1'] -biphen-4- yl] aminocarbonyl] -tetrazole (0.35 g) and sodium borohydride (0.072 g) in DMF (5 mL) . The reaction was stirred at room temperature for 16 h. The resulting mixture was stirred at room temperature for 16 h. 6M HCI (5 mL) was added over 5 min. The quenched reaction was stirred at room temperature for 3.5 h, diluted with EtOAc and water. The resulting emulsion was filtered through celite, and the organic layer was washed with IN HCI, dried over a2S04, filtered, and evaporated to yield crude product (100 mg) . The aqueous layers were combined and neutralized (pH 7) with saturate NaHCθ3 , extracted with EtOAc . The organic layers were combined, dried over a2S04, filtered, and evaporated to yield a second batch of crude product. The two batches of crude product were combined and purified by reverse phase HPLC (10- 90% MeCN/H 2 O/0.5% TFA) to yield 102 mg of the title compound as its TFA salt. LMRS (ES + ) M + : 467 m/z. Example 40 1- (2 ■ -Aminomethylphenyl) -5- [ (2 • -aminosulfonyl- [1,1']- biphen-4-yl) aminocarbonyl] -tetrazole*TFA The title compound was prepared in an analogous fashion as its TFA salt. LRMS (ES + ) M + : 468 m/z. Example 41 1- [2- (Aminomethyl) phenyl] -3 -thiomethoxy-5- [ (2-fluoro) - (2 • -methylsulfonyl- [1,1'] -biphen-4- yl) aminocarbonyl] pyrazole *TFA Methyl 3- ( thiomethoxy) pyrazole-5-carboxylate: A mixture of methyl 4, 4-bis (thiomethoxy) -2-oxo-3-butenoate (9.9 g, 48 mmol) and hydrazine monohydrate (2.6 mL, 53 mmol) in 200 mL of glacial acetic acid was stirred at 100 °C for 18 h. The reaction was cooled and concentrated. The residue was taken up in ethyl acetate, washed with sat'd aq NaHC0 3 and brine, dried (MgS0 4 ) and concentrated. The solid residue was recrystallized from hexanes/ethyl acetate to afford 6.0 g (73%) of the title compound. X H NMR (CDCI 3 ) δ 11.0 (broad s, IH) , 6.74 (s, IH) , 3.88 (s, 3H) , 2.48 (s, 3H) . Methyl 1- [2-formylphenyl] -3- (thiomethoxy) pyrazole-5- carboxylate: To a solution of methyl 3- (thiomethoxy)pyrazole- 5-carboxylate (0.87 g, 5.05 mmol) in 20 mL of 1,4-dioxane was added 2-formylphenyl boronic acid (1.13 g, 7.58 mmol), pyridine (0.82 mL, 10.1 mmol), crushed 4 A molecular sieves and cupric acetate (1.38 g, 7.58 mmol). The flask was equipped with a drying tube and the mixture was allowed to stir at ambient temperature under an air atmosphere for 18 h. The mixture was filtered through a pad of Celite and concentrated. The residue was purified by flash chromatography to afford 0.22 g (16%) of the title compound. H NMR (CDCI 3 ) 5 9.66 (s, IH) , 8.02 (dd, IH) , 7.69 (td, IH) , 7.63 (t, IH) , 7.42 (d, IH) , 6.96 (s, IH) , 3.75 (s, 3H) , 2.55 (s, 3H) . l-[ (2- (Hydroxymethyl) phenyl] -3-thiomethoxy-5- [ (2-fluoro) - (2 ' - methylsulfonyl- [1,1'] -biphen-4-yl) aminocarbonyl] pyrazole: To a solution of methyl 1- [2-formylphenyl] -3- ( thiomethoxy) pyrazole-5-carboxylate (0.48 g, 1.74 mmol) in 15 mL of methanol at 0°C was added sodium borohydride (33 mg, 0.87 mmol) . The cooling bath was removed and the reaction was stirred for 10 min and then quenched by dilution with water. The reaction mixture was extracted with ethyl acetate and the organics were washed with brine, dried (MgSθ 4 ) and concentrated to afford 0.41 g (85%) of about a 2:1 mixture of a hydroxy ester and a seven-membered ring lactone. This mixture was used without purification. To a solution of (2- fluoro-2 ' -methylsulfonyl- [1,1'] -biphen-4-yl) amine hydrochloride (0.89 g, 2.94 mmol) in methylene chloride was added trimethylaluminum (2.95 mL of a 2.0 M solution in hexanes, 5.89 mmol) dropwise. This solution was stirred until gas evolution ceased (15-20 min) and then there was added the hydroxy ester/lactone mixture from above (0.41 g, 1.47 mmol) in methylene chloride. The resulting solution was allowed to stir at reflux for 4 h and then it was cooled and quenched by dropwise addition of sat'd aq ammonium chloride. The mixture was diluted with ethyl acetate, the layers were separated, the organic layer was washed with water and brine, dried (MgS0 4 ) and concentrated. The solid residue was purified by flash chromatography (elution with 1:1 hexanes/ethyl acetate) to afford 0.68 g (91%) of the title compound. LRMS (ES+) : 534.1 (M+Na) + . l-[ (2- (Bromomethyl) phenyl] -3-thiomethoxy-5-[ (2-fluoro) - (2 '- methylsulfonyl- [1,1'] -biphen-4-yl) aminocarbonyl]pyrazole: To a solution of 1- [ (2- (hydroxymethyl) phenyl] -3-thiomethoxy-5- [ (2-fluoro) -(2' -methylsulfonyl- [1,1' ]-biphen-4- yl) aminocarbonyl]pyrazole (0.68 g, 1.3 mmol) in 20 mL of methylene chloride was added carbon tetrabromide (1.06 g, 3.2 mmol) and triphenylphosphine (0.84 g, 3.2 mmol). The resulting solution was stirred at ambient temperature for 4 h. The reaction was diluted with ethyl acetate, washed with water and brine, dried (MgS0 4 ) and concentrated. The residue was purified by flash chromatography (elution with 3:1 hexanes/ethyl acetate) to afford 0.60 g (81%) of the title compound. l-[ (2- (Azidomethyl) phenyl] -3-thiomethoxy-5- [ (2-fluoro) - (2 '- methylsulfonyl- [1,1'] -biphen-4-yl) aminocarbonyl] pyrazole: To a solution of 1- [ (2- (bromomethyl) phenyl] -3-thiomethoxy-5- [ (2- fluoro) - (2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) aminocarbonyl] pyrazole (0.42 g, O.73 mmol) in 5 mL of N,N- dimethylformamide was added sodium azide (0.38 g, 5.85 mmol). This mixture was stirred at ambient temperature for 1 h and then was diluted with ethyl acetate. The organics were washed with water and brine, dried (MgS0 4 ) and concentrated to afford 0.38 g (97%) of the title compound which was used directly without purification. LRMS (ES + ) : 559.1 (M+Na) + . 1- [2- (Aminomethyl)phenyl] -3-thiomethoxy-5- [ (2-fluoro)- (2 ' - methylsulfonyl- [1,1'] -biphen-4-yl ) aminocarbonyl] pyrazole, trifluoroacetic acid salt: To a solution of l-[(2- (azidomethyl) phenyl] -3-thiomethoxy-5- [ (2-fluoro) - (2 ' - methylsulfonyl- [1, 1 ' ] -biphen-4-yl) aminocarbonyl]pyrazole (0.38 g, 0.71 mmol) in 10 mL of methanol was added tin (II) chloride (0.80 g, 4.24 mmol) . The reaction mixture was stirred at reflux for 1 h and then was cooled to room temperature and diluted with ethyl acetate. The organics were washed with 5% aq sodium hydroxide and brine, dried (MgS0 4 ) and concentrated. The residue was purified by preparative HPLC (C18 reverse phase column, elution with a H 2 O/CH 3 CN gradient with 0.5% TFA) and lyophilized to afford 230 mg (52%) of the title compound as a white powder. LRMS (ES+) : 511.1 (M+H) + . Example 42 1- [2- (aminomethyl) henyl] -3-methysulfonyl-5- [ (2- fluoro) - (2 ■ -methylsulfonyl- [1,1'] -biphen-4- yl ) aminocarbonyl ] pyrazole •TFA 1- [ (2- (Bromomethyl) phenyl ] -3-methylsulfonyl-5- [ (2-fluoro) - (2 ' - methylsulfonyl- [1,1* ] -biphen-4-yl) aminocarbonyl] pyrazole: To a solution of 1- [ (2- (bromomethyl) phenyl] -3-thiomethoxy-5- [ (2- fluoro) - (2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) aminocarbonyl] pyrazole (85 mg, 0.15 mmol) in 10 mL of methylene chloride was added m-chloroperoxybenzoic acid (130 mg of 57-86% pure material, -0.5 mmol). The resulting solution was stirred at ambient temperature for 3 h. The reaction was diluted with ethyl acetate, washed with sat'd aq NaHC0 3 and brine, dried (MgS0 4 ) and concentrated to afford 80 mg (88%) of the title compound which was sufficiently pure to be used without purification. 1- [ (2- (Azidomethyl) phenyl] -3-methylsulfonyl-5- [ (2-fluoro) - (2 ' - methylsulfonyl- [1,1'] -biphen-4-yl) aminocarbonyl] pyrazole: To a solution of 1- [ (2- (bromomethyl)phenyl] -3-methylsulfonyl-5- [ (2-fluoro) - (2 ' -methylsulfonyl- [1, 1 ' ] -biphen-4- yl) aminocarbonyl]pyrazole (55 mg, 0.09 mmol) in 1 mL of dimethylsulfoxide was added sodium azide (30 mg, 0.45 mmol). This mixture was stirred at ambient temperature for 1 h and then was diluted with ethyl acetate. The organics were washed with water and brine, dried (MgSθ 4 ) and concentrated to afford 50 mg (97%) of the title compound which was used directly without purification. LRMS (ES+) : 591.1 (M+Na) + . 1- [2- (Aminomethyl) phenyl] -3-methylsulfonyl-5- [ (2-fluoro) - (2 ' - methylsulfonyl- [1,1'] -biphen-4-yl)aminocarbonyl]pyrazole, trifluoroacetic acid salt: To a solution of l-[(2- ( zidomethyl)phenyl] -3-methylsulfonyl-5- [ (2-fluoro) - (2 ' - methylsulfonyl- [1,1' ] -biphen-4-yl) aminocarbonyl] pyrazole (90 mg, 0.16 mmol) in 4 mL of methanol was added tin (II) chloride (0.30 g, 1.6 mmol) . The reaction mixture was stirred at reflux for 1 h and then was cooled to room temperature and diluted with ethyl acetate. The organics were washed with 5% aq sodium hydroxide and brine, dried (MgS0 4 ) and concentrated. The residue was purified by preparative HPLC (C18 reverse phase column, elution with a H 2 O/CH 3 CN gradient with 0.5% TFA) and lyophilized to afford 18 mg (17%) of the title compound as a white powder. LRMS (ES+) : 543.2 (M+H) + . Example 43 1- [2- (aminomethyl) phenyl] -5- [ (2-fluoro) - (2 • - methylsulfonyl- [1,1'] -biphen-4- yl) aminocarbonyl] triazole*TFA 2-Azidobenzyl alcohol: To a solution of 2-aminobenzyl alcohol (12.0 g, 97.4 mmol) in 50 mL of trifluoroacetic acid at 0°C was added sodium nitrite (7.39 g, 107.2 mmol) . This solution was stirred for 45 min and then there was added sodium azide (6.33 g, 97.4 mmol) dropwise as a solution in water. The resulting mixture was stirred at 0°C for 45 min and then was carefully quenched by slow addition of potassium carbonate. The reaction mixture was diluted with ethyl acetate, washed with brine, dried (MgSθ 4 ) , filtered through a pad of silica gel and concentrated to afford 10.5 g (72%) of the title compound which was used without further purification. H NMR (CDCI 3 ) δ 7.33 (m, 2H) , 7.14 (m, 2H) , 4.59 (s, 2H) , 2.69 (broad s, IH) . (2-Azidophenyl)methyl propiolate: To a solution of 2- azidobenzyl alcohol (15.66 g, 105.1 mmol) in 200 mL of methylene chloride was added propiolic acid (7.1 mL, 115.6 mmol), dicyclohexylcarbodiimide (20.0 g, 110.3 mmol) and 4- dimethylaminopyridine (1.93 g, 15.8 mmol). The resulting mixture was allowed to stir at ambient temperature for 18h. The mixture was filtered, concentrated and the residue was purified by flash chromatography (elution with 1:1 hexanes/ethyl acetate) to afford 10.7 g (51%) of the title compound. X H NMR (CDC1 3 ) δ 7.40 (m, 2H) , 7.17 (m, 2H) , 5.20 (s, 2H) , 2.92 (s, IH) . Triazololactone : A solution of (2-azidophenyl)methyl propiolate (10.7 g, 53.2 mmol) in 100 mL of toluene was stirred at 100°C for 18 h. The reaction was cooled and concentrated and the residue was purified by flash chromatography (elution with 1:1 hexanes/ethyl acetate) to afford 1.4 g (13%) of the title compound. X H NMR (CDCI 3 ) δ 8.38 (s, IH) , 8.04 (d, IH) , 7.63 (m, IH) , 7.54 (m, 2H) , 5.16 (s, 2H) . 1- [ (2- (Hydroxymethyl)phenyl] -5- [ (2-fluoro) - (2 ' -methylsulfonyl- [1, 1' ]-biphen-4-yl) aminocarbonyl] triazole: To a solution of (2-fluoro-2 ' -methylsulfonyl- [1, 1 ' ] -biphen-4-yl) amine hydrochloride (2.10 g, 6.96 mmol) in methylene chloride was added trimethylaluminum (20.8 mL of a 2.0 M solution in hexanes, 41.8 mmol) dropwise. This solution was stirred until gas evolution ceased (about 30 min) and then there was added the triazololactone from above (1.40 g, 6.96 mmol) as a solution in methylene chloride. The resulting solution was allowed to stir at reflux for 18 h and then it was cooled and quenched by dropwise addition of sat'd aq ammonium chloride. The mixture was diluted with ethyl acetate, the layers were separated, the organic layer was washed with water and brine, dried (MgSθ 4 ) and concentrated. The solid residue was purified by flash chromatography (elution with 3:1 ethyl acetate/hexanes) to afford 1.0 g (31%) of the title compound. LRMS (ES+) : 467.2 (M+H) + . 1- [ (2- (Bromomethyl)phenyl] -5- [ (2-fluoro) - (2 ' -methylsulfonyl- [1, 1 '] -biphen-4-yl) aminocarbonyl] triazole: To a solution of 1- [ (2- (hydroxymethyl)phenyl] -5- [ (2-fluoro) - (2 * -methylsulfonyl- [1, 1 '] -biphen-4-yl) aminocarbonyl] triazole (0.80 g, 1.71 mmol) in 20 mL of methylene chloride was added carbon tetrabromide (2.83 g, 8.55 mmol) and triphenylphosphine (2.24 g, 8.55 mmol) . The resulting solution was stirred at ambient temperature for 18 h. The reaction was diluted with ethyl acetate, washed with water and brine, dried (MgS0 4 ) and concentrated. The residue was purified by flash chromatography (elution with 1:1 hexanes/ethyl acetate) to afford 0.80 g (89%) of the title compound. LRMS (ES+) : 529.1/531.1 (M+H) + . 1- [ (2- (Azidomethyl)phenyl] -5- [ (2-fluoro) - (2 ' -methylsulfonyl- [1,1' ] -biphen-4-yl) aminocarbonyl] triazole: To a solution of 1- [ (2- (bromomethyl)phenyl] -5- [ (2-fluoroj - (2 ' -methylsulfonyl- [1, 1 '] -biphen-4-yl) aminocarbonyl] triazole (0.25 g, 0.47 mmol) in 10 mL of N,N-dimethylformamide was added sodium azide (0.37 g, 5.6 mmol) . This mixture was stirred at 65°C for 18 h and then was cooled and diluted with ethyl acetate. The organics were washed with water and brine, dried (MgS0 4 ) and concentrated to afford 0.22 g (96%) of the title compound which was used directly without purification. LRMS (ES+) : 514.2 (M+Na) + . 1- [2- (Aminomethyl) phenyl] -5- [ (2-fluoro) - (2 ' -methylsulfonyl- [1, 1 '] -biphen-4-yl) aminocarbonyl] triazole, trifluoroacetic acid salt: To a solution of 1- [ (2- (azidomethyl) phenyl] -5- [ (2- fluoro) - (2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) aminocarbonyl] triazole (0.22 g, 0.45 mmol) in 10 mL of absolute ethanol was added 10% palladium on carbon catalyst (25 mg) and concentrated HCI (0.04 mL, 0.45 mmol). The reaction mixture was stirred at ambient temperature under 1 at of hydrogen for 2 h and then was filtered through a pad of Celite and concentrated. The residue was purified by preparative HPLC (C18 reverse phase column, elution with a H 2 0/CH 3 CN gradient with 0.5% TFA) and lyophilized to afford 26 mg (10%) of the title compound as a white powder. LRMS (ES+) : 466.2 (M+H) + . Example 44 1- [2- (Aminomethyl) phenyl] -5- [ (2-fluoro) - (2 ■ - methylsulfonyl) -[1,1'] -biphen-4- yl ) aminocarbonyl ] pyrazole •TFA Methyl 1- [2-methylphenyl] pyrazole-5-carboxylate: A neat mixture of methyl pyruvate (11.37 mL, 125.9 mmol) and dimethylformamide dimethylacetal (16.72 mL, 125.9 mmol) was stirred at 80°C for 24 h. The mixture was cooled and concentrated. A portion of the residue (4.00 g, 25.45 mmol) was dissolved in 50 mL of glacial acetic acid and then there was added o-tolylhydrazine hydrochloride (4.44 g, 27.99 mmol). This mixture was stirred at 100°C for 18 h and then was cooled and concentrated. The residue was dissolved in ethyl acetate, washed with sat'd aq sodium carbonate and brine, dried (MgS0 4 ) and concentrated. The residue was purified by flash chromatography (elution with 2:1 hexanes/ethyl acetate) to afford 3.0 g (55%) of the title compound. X H NMR (CDC1 ) δ 7.70 (d, IH), 7.4-7.2 (m, 4H) , 7.00 (d, IH) , 3.71 (s, 3H) , 2.00 (s, 3H) . Methyl 1- [2- (bromomethyl ) phenyl] pyrazole-5-carboxylate: To a solution of methyl 1- [2-methylphenyl]pyrazole-5-carboxylate (1.00 g, 4.62 mmol) in 20 mL of carbon tetrachloride was added N-bromosuccinimide (0.823 g, 4.62 mmol) and AIBN (76 mg, 0.46 mmol) . This mixture was stirred at 80°C for 18 h. The volatiles were removed and the residue was taken up in ether, filtered through a pad of silica gel and concentrated to afford 1.3 g (95%) of the title compound which was used without further purification. LRMS (ES+) : 295.0/297.0 (M+H) + . Methyl 1- [2- (azidomethyl)phenyl]pyrazole-5-carboxylate: To a solution of methyl 1- [2- (bromomethyl) phenyl]pyrazole-5- carboxylate (1.30 g, 4.40 mmol) in 10 mL of N,N- dimethylformamide was added sodium azide (2.86 g, 44.0 mmol) . This mixture was stirred at ambient temperature for 48 h and then was diluted with ethyl acetate. The organics were washed with water and brine, dried (MgS0 4 ) and concentrated to afford 0.80 g (71%) of the title compound which was used directly without purification. LRMS (ES+) : 280.1 (M+Na) + . 1- [ (2- (Azidomethyl) phenyl] -5- [ (2-fluoro) - (2 ' -methylsulfonyl- [1, 1' ]-biphen-4-yl)aminocarbonyl]pyrazole: To a solution of (2-fluoro-2 ' -methylsulfonyl- [1,1 ' ] -biphen-4-yl) amine hydrochloride (0.94 g, 3.11 mmol) in 20 mL of methylene chloride was added trimethylaluminum (4.67 mL of a 2.0 M solution in hexanes, 9.33 mmol) dropwise. This solution was stirred until gas evolution ceased (about 30 min) and then there was methyl 1- [2- (azidomethyl) phenyl]pyrazole-5- carboxylate (0.80 g, 3.11 mmol) as a solution in methylene chloride. The resulting solution was allowed to stir at reflux for 18 h and then it was cooled and quenched by dropwise addition of sat'd aq ammonium chloride. The mixture was diluted with ethyl acetate, the layers were separated, the organic layer was washed with water and brine, dried (MgS0 4 ) , filtered through a pad of silica gel and concentrated to afford 1.0 g (67%) of the title compound. LRMS (ES+) : 513.0 (M+Na) + . 1- [2- (Aminomethyl) phenyl] -5- [ (2-fluoro) - (2 ' -methylsulfonyl- [1,1' ] -biphen-4-yl) aminocarbonyl] pyrazole, trifluoroacetic acid salt: To a solution of 1- [ (2- (azidomethyl) phenyl] -5- [ (2- fluoro) - (2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) aminocarbonyl] pyrazole (0.50 g, 1.0 mmol) in 20 mL of absolute ethanol was added 10% palladium on carbon catalyst (50 mg) and concentrated HCI (0.085 mL, 1.0 mmol). The reaction mixture was stirred at ambient temperature under 1 atm of hydrogen for 2 h and then was filtered through a pad of Celite and concentrated. The residue was purified by preparative HPLC (C18 reverse phase column, elution with a H 2 O/CH 3 CN gradient with 0.5% TFA) and lyophilized to afford 60 mg (10%) of the title compound as a white powder. LRMS (ES+) : 465.2 (M+H) + . Example 45 1- [2- (Aminomethyl) phenyl] -3-trifluoromethyl-5- [ ( (2- fluoro) - (2 ■ -pyrrolidinomethyl) -[1,1'] -biphen-4- yl) aminocarbonyl] pyrazole* TFA Part A: 2-Fluoro-4- ( (2 ' - tert- butyldimethylsilyloxymethyl) phenyl) aniline: A solution of 2- formylphenylboronic acid (5 g, 33.3 mmol) and 4-bromo-2- fluoroaniline (4.2 g, 22.2 mmol) in THF (80 mL) and aqueous Na2C03 solution (2M, 80 mL) was bubbled with nitrogen for 10 minutes. After Pd(PPh3)4 (1.54 g, 1.33 mmol) was added, the resulting mixture was refluxed under nitrogen for 4 hours . The THF layer was separated and filtered through a pad of silica gel. The silica gel was washed with THF. To the combined filtrates containing 2-fluoro-4- (2 ' - formylphenyl) aniline (65 mL) was portion by portion added NaBH4 (2.2 g, 29.1 mmoL) . The resulting mixture was stirred at room temperature for 1 hour, quenched with IN HCI (10 mL) , and washed with IN HCI (100 mL x 3) . The combined HCI layers were neutralized with 50% NaOH to pH 12 and extracted with EtOAc (100 mL x 3) . The EtOAc layers were dried over Na2Sθ4, concentrated, and purified by column chromatography with a graduate solvent (hexane to EtOAc) to give 2-fluoro-4- (2 ' - hydroxymethylphenyl ) aniline (3.83 g, 97.6%). X H NMR (CDCI3) δ 7.53 (dd, J = 6.6 Hz, J = 2.2 Hz, IH) , 7.36-7.33 (m, 2H) , 7.25 (dd, J = 6.6 Hz, J = 2.2 Hz, IH) , 7.06 (dd, J = 12.1 Hz, J = 1.8 Hz, IH) , 6.97 (dd, J = 8.0 Hz, J = 1.8 Hz, IH) , 6.82 (t, J = 8.8 Hz, IH) , 4.63 (s, 2H) , 3.79 (bs, 2H) ; 19 F NMR (CDCI3): δ -135.66 (dd, J= 12.21 Hz, J = 9.2 Hz); CIMS(CI) m/z 218 (M+H, 100%) . To a solution of 2-fluoro-4- (2 ' -hydroxymethyl- phenyl) aniline (5 g, 23 mmol) in THF (150 mL) was added imidazole (2.35 g, 34.5 mmol) and 2'-tert- butyldimethylsilylchloride (5.18 g, 34.5 mmol), and the resulting mixture was stirred at room temperature for 24 hours. The mixture was diluted with hexane (150 mL) and washed with water (150 mL) . The organic layer was washed with brine, dried over MgS04, purified by column chromatography with hexane and methylenechloride (1 to 1) to give 2-fluoro-4- ( (2 ' - ert-butyldimethylsilyloxymethyl) phenyl) aniline (7.1 g, 92.8%) as a colorless oil. NMR (CDCI3) δ 7.55 (dd, J = 7.7 Hz, J = 1.1 Hz, IH) , 7.35 (dd, J = 7.4 Hz, J = 1.9 Hz, IH) , 7.30 (dd, J = 9.1 Hz, J = 1.4 Hz, IH) , 7.20 (dd, J = 7.3 Hz, J = 1.5 Hz, IH) , 7.05 (dd, J = 12.1 Hz, J = 1.8 Hz, IH) , 6.93 (dd, J = 8.0 Hz, J = 1.4 Hz, IH) , 6.80 (dd, J = 9.1 Hz, J = 8.0 Hz, IH) , 4.60 (s 2H) , 3.77 (bs, 2H) , 0.91 (s, 9H) , 0.04 (s, 6H) ; 19 F NMR (CDCI3): δ -136.04; CIMS : 332 (M+H, 100). Part B: 1- (2-cyanophenyl) -5-furyl-3-trifluoromethylpyrazole: To a solution of 4, 4, 4-trifluoro-1- (2-furyl) -1, 3 -butanedione (2.06 g, 10 mmol) in ethanol (mL) was added hydrazine monohydrate (0.46 g, 10 mmol). The resulting mixture was refluxed for 16 hours and dried under vacuum to give 5-furyl- 3-trifluoromethyl-3-hydroxypyrazoline in almost quantitative yield. ^ NMR (CDCI3) δ 7.48 (d, J = 1.9 Hz, IH) , 6.63 (d, J = 3.7 Hz, IH) , 6.47 (dd, J = 3.7 Hz, J = 1.9 Hz, IH) , 6.16 (s, IH) , 3.48 (d, J = 17.9 Hz, IH) , 3.18 (d, J = 17.9 Hz, IH) ; 19 F NMR (CDCI3): δ-81.47; ESMS(+): 221 (M+H, 100). To a solution of 2-fluorobenzonitrile (0.605 g, 5 mmol) and 5-furyl-3-trifluoromethyl-3-hydroxypyrazoline (1.1 g, 5 mmol) in DMF (10 mL) was added CΞ2CO3 (1.63 g, 5 mmol), and the resulting mixture was stirred at 110 'C for 16 hours. The mixture was diluted with EtOAc, washed with brine (x 5) , dried over MgSθ4, and purified by column chromatography with a gradient solvent (hexane to ethyl acetate) to give l-(2- cyanophenyl) -5-furyl-3-trifluoromethylpyrazole and l-(2- cyanophenyl) -3-furyl-5-trifluoromethylpyrazole (1.27 g, 83.8 %) in a ratio of 95 to 5. 1H NMR (CDCI3) δ 7.82 (dd, J = 7.7 Hz, J = 1.5 Hz, IH) , 7.77 (dd, J = 7.7 Hz, J = 1.5 Hz, IH) , 7.66 (td, J = 7.7 Hz, J = 1.1 Hz, IH) , 7.61 (d, J = 7.7 Hz, IH) , 7.39 (d, J = 1.4 Hz, IH) , 6.96 (s, IH) , 6.37 (dd, J = 3.3 Hz, J = 1.4 Hz, IH) , 6.04 (d, J = 3.3 Hz, IH) ; 19 F NMR (CDCI3) : δ- 62.98; ESMS(+): 304 (M+H, 100). Part C: 1- (2- (N-Boc-aminomethyl )phenyl) -3- trifluoromethylpyrazol-5-yl-carboxylic acid: To a solution of 1- (2-cyanophenyl) -5-furyl-3-trifluoromethylpyrazole (1.5 g, 4.67 mmol) in DMF (20 mL) was portion by portion added ΝaBH4 (0.71 g, 18.7 mmol) and then C0CI2 (0.61 g, 4,67 mmol) at O'C. After the resulting mixture was stirred at room temperature for 18 hours, a black suspension was cooled to 0 * C and carefully acidified with 6N HCI (20 mL) . The resulting mixture was stirred at room temperature for 3 hours, and neutralized with IN NaOH to pH 14. The mixture was diluted with EtOAc (100 mL) , and filtered through a pad of sand (top layer) and Celite (bottom layer) . The filtrate was separated and the organic layer was washed with brine (5 x 10 mL) , dried over Na2S04, and concentrated to give l-(2- (aminomethyl)phenyl) -5-furyl-3-trifluoromethylpyrazole (1.4 g, 91.5%). !H NMR (CD3OD) δ 7.69-7.61 (m, 2H) , 7.52 (d, J = 1.5 Hz, IH) , 7 47 (td, J = 7.7 Hz, J = 1.1 Hz, IH) , 7.34 (d, J = 8.0 Hz, IH) , 7.07 (s, IH) , 6.34 (dd, J . = 1.8 Hz, J = 3.6 Hz, IH) , 5.75 (d, J = 3.3 Hz, IH) , 3.40 (s, 2H) ; ESMS(+): 308 (M+H, 100); To a solution of 1- (2- (aminomethyl)phenyl) -5-furyl-3- trifluoromethylpyrazole (1.4 g, 4.27 mmol) in THF (10 mL) was added a solution of (Boc)2θ (1.4 g, 6.4 mmol) in THF (10 mL) , and the resulting mixture was stirred at room temperature for 1 hour. The mixture was diluted with EtOAc (100 mL) , washed with water and brine, dried over Na2Sθ4, and concentrated to provide crude 1- (2- (N-Boc-aminomethyl) henyl ) -5-furyl-3- trifluoromethylpyrazole. 1H ΝMR (CDCI3) δ 7.60-7.55 (m, 2H) , 7.42 (d, J = 6.2 Hz, IH) , 7 40 (s, -IH) , 7.32 (d, J = 7.7 Hz, IH) , 6.95 (s, IH) , 6.28 (dd, J = 1.8 Hz, J = 3.3 Hz, IH) , 5.65 (d, J = 3.3 Hz, IH) , 4.01 (d, J = 6.8 Hz, 2H) , 3.40 (s, 2H) , 1.41 (s, 9H) ; 19 F ΝMR (CDCI3): δ -62.76. To a solution of crude product in acetone (20 mL) and water (20 mL) was portion by portion added KMnθ4 (3.95 g, 25 mmol) , and the resulting mixture was stirred at 60 'C for 20 minutes and then filtered through Celite. The filtrate was concentrated, acidified with IN HCI to pH 4, and extracted with EtOAc (3 x 50 mL) . The organic layer was washed with brine, dried over Νa2Sθ4, concentrated, and purified by column chromatography with 20% MeOH in dichloromethane to provide 1- (2- (N-Boc-aminomethyl)phenyl) -3-trifluoromethylpyrazol-5-yl- carboxylic acid (1.05 g, 56% for the two steps). ESMS(-): 384.2 (M-H, 100) . Part D: l-(2- (N-Boc-aminomethyl) phenyl) -3-trifluoromethy1-5- [ ( (2-fluoro) - (2 ' -hydroxymethylsilyloxymethyl) -[1,1'] -biphen-4- yl) aminocarbonyl] pyrazole: To a solution of l- (2- (N-Boc- aminomethyl)phenyl) -3-trifluoromethylpyrazol-5-yl-carboxylic acid (0.768 g, 2 mmol) in CH2CI2 (50 mL) was added DMF (1 drop) and oxalyl chloride (0.381 g, 3 mmol), and the resulting mixture was stirred at room temperature for 1.5 hours . The mixture was concentrated and the residue was dissolved in THF (10 mL) . To the solution was added a solution of 2-fluoro-4- (2' -( tert-butyldimethylsilyloxymethyl) phenyl) aniline (0.6 g, 1.8 mmoL) in THF (10 mL) and Et3Ν (1.5 mL) , and the resulting mixture was stirred at room temperature for 24 hours. The mixture was diluted with EtOAc (100 mL) , washed with water and brine, dried over MgSθ4, and purified on thin layer chromatography with CH2Cl2/hexane (3:2) to give l- (2 - (N-Boc- aminomethyl) phenyl ) -3-trifluoromethyl-5- [ ( (2-fluoro) - (2 ' -tert- butyldimethylsilyloxymethyl) - [1, 1 ' ] -biphen-4- yl) aminocarbonyl] pyrazole (0.49 g, 80%). To a solution of 1- (2 ' -N-Boc-aminomethylphenyl) -3- trifluoromethyl-5-[ ( (2-fluoro) - (2 ' -tert- butyldimethylsilyloxymethyl] -[1,1'] -biphen-4- yl) aminocarbonyl]pyrazole (0.57 g, 0.93 mmol) in THF (10 mL) was added BU4ΝF (IM in THF, 3 mL) , -and the resulting solution was stirred at room temperature for 2 hours. The mixture was diluted with EtOAc (150 mL) , washed with water (20 mL) , dried over Na2S04, and purified by column chromatography with a gradient solvent (hexane to EtOAc) to give l- ( 2- (N-Boc- aminomethyl) phenyl) -3-trifluoromethyl-5- [ ( (2-fluoro) - (2 ' - hydroxymethyl) -[1,1'] -biphen-4-yl) aminocarbonyl] pyrazole (484 mg, - 100%) . 1H ΝMR (CD3OD) δ 7.69 (t, J = 8.0 Hz, IH) , 7.55- 7.27 ( , 9H) , 7.21 (dd, J = 7.4 Hz, J = 1.8 Hz, IH) , 7.13 (dd, J = 8.4 Hz, J = 1.1 Hz, IH) , 4.46 (s, 2H) , 4.05 (s, 2H) , 1.34 (s, 9H) ; 19 F ΝMR (CD3OD) : δ -64.08, -125.53; ESMS(+ ): 606.3 (M+Νa, 100) . Part E: l-(2- (aminomethyl) phenyl) -3-trifluoromethyl-5- [ ( (2- fluoro) - (2 ' -pyrrolidinomethyl) -[1,1'] -biphen-4- yl) aminocarbonyl] pyrazole, TFA salt: To a solution of l-(2- (N-Boc-aminomethyl)phenyl) -3-trifluoromethyl-5- [ ( (2-fluoro) - (2 ' -hydroxymethyl) -[1,1'] -biphen-4-yl) aminocarbonyl]pyrazole (150 mg, 0.26 mmol) in THF (5 mL) was added CS2CO3 (167 mg, 0.51 mmol) and MsCl (4 mg, 0.39 mmol). After the resulting mixture was stirred at room temperature for 18 hours and concentrated, the residue was dissolved in THF (10 mL) and treated with pyrrolidine (0.5 mL) at room temperature 8 hours. ESMS(+): 638.4 (M+H, 100). The mixture was treated with TFA/CH2CI2 (1 to 1, 10 mL) at room temperature for 5 hours, and concentrated. The residue was purified on HPLC with a gradient solvent (H2O-CH3CΝ-O .05% TFA) on C18 give the title compound (50 mg, 36% for the two steps) !H NMR (CD3OD) δ 7.80 (T, J = 8.1 HZ, IH) , 7.71-7.30 (m. 9H) , 7.27 (dd, J = 11.3 Hz, J = 1.8 Hz, IH) , 7.15 (d, J = 8.4 Hz, IH) , 4.40 (s, 2H) , 3.99 (s, 2H) , 3.42-3.34 (m, 2H) , 2.93-2.87 (m, 2H) , 2.00-1.94 (m, 4H) ; 19 F NMR (CD3OD) : δ -64.22, -77.57 (TFA), -123.82; HRMS: 538.2243 for C29H28O1F4N5. Example 46 1- [2- (Aminomethyl) phenyl] -3-trifluoromethyl-5- [ ( (2- fluoro) - (2 ' -hydroxymethyl) -[1,1'] -biphen-4- yl ) aminocarbonyl ] pyrazole • TFA A solution of 1- (2- ( N-Boc-aminomethyD phenyl) -3- trifluoromethyl-5-[ ( (2-fluoro) - (2 ' - hydroxymethylsilyloxymethyl ) - [ 1 , 1 ' ] -biphen-4- yl) aminocarbonyl]pyrazole (10 mg) was treated with TFA/CH2CI2 (1 to 1, 1 mL) at room temperature for 3 hours and concentrated. The residue was purified by HPLC with a gradient solvent (H2O-CH3CΝ-O .05% TFA) on C18 to give the title compound (2 mg) . NMR (CD3OD) : δ7.66-7.45 (m, 6H) , 7.38-7.21 (m, 4H) , 7.15 (d, J = 9.5 Hz, IH) , 7,10 (d, J = 6.6 Hz, IH) , 4.39 (s, 2H) , 3.91 (s, 2H) ; 19 F NMR (CD3OD) : δ -64.23, -77.38, -125.40; ESMS(-): 483.2 (M-H, 100). Table 1 Pyrazole-d Pyrazole-e Pyrazole-f Triazole Tetrazole Unless otherwise indicated, D is at the 2-position and is The following tables contain representative examples of the present invention. Each entry in each table is intended to be paired with each formulae at the start of the table. For example, in Table 2, example 1 is intended to be paired with each of formulae a-bbbb and in Table 3 , example 1 is intended to be paired with each of formulae a-bbbb. The following groups are intended for group A in the following tables . -"^ H 3 -"^ -6 - » * - B 2-pyridyl 3-pyridyl 2-pyrimidyl 5-pyrimidyl 2-CI-phβnyl 2-F-phenyl 2,6-diF-phenyl Table 2 hh zz aaa bbb rrr sss ttt uuu www zzz aaaa bbbb R la A CH 3 phenyl 2- (aminosulfonyl) phenyl CH 3 phenyl 2- (methylaminosulfonyl) phenyl CH 3 phenyl 1-pyrrolidinocarbonyl CH 3 phenyl 2- (methylsulfonyl) phenyl CH 3 phenyl 4-morpholino CH 3 phenyl 2- ( 1 ' -CF3 -tetrazol-2-yl) phenyl CH 3 phenyl 4-morpholinocarbonyl CH 3 phenyl 2-methyl-1-imidazolyl CH 3 phenyl 5-methyl-1-imidazolyl CH 3 phenyl 2-methylsulfonyl-1-imidazolyl CH 3 2-pyridyl 2- (aminosulfonyl) phenyl CH 3 2-pyridyl 2- (methylaminosulfonyl) phenyl CH 3 2-pyridyl 1-pyrrolidinocarbonyl CH 3 2-pyridyl 2- (methylsulfonyl) phenyl CH 3 2-pyridyl 4-morpholino CH 3 2-pyridyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl CH 3 2-pyridyl 4-morpholinocarbonyl CH 3 2-pyridyl 2-methyl-1-imidazolyl CH 3 2-pyridyl 5-methyl-l-imidazolyl CH 3 2-pyridyl 2-methylsulfonyl-1-imidazolyl CH 3 3-pyridyl 2- (aminosulfonyl)phenyl CH 3 3-pyridyl 2- (methylaminosulfonyl) phenyl CH 3 3-pyridyl 1-pyrrolidinocarbonyl CH 3 3-pyridyl 2- (methylsulfonyl) phenyl CH 3 3 -pyridyl 4-morpholino CH 3 3-pyridyl 2- (l'-CF3-tetrazol-2-yl) phenyl CH 3 3-pyridyl 4-morpholinocarbonyl CH 3 3-pyridyl 2-methyl-1-imidazolyl CH 3 3-pyridyl 5-methyl-1-imidazolyl CH 3 3-pyridyl 2-methylsulfonyl-1-imidazolyl CH 3 2-pyrimidyl 2- (aminosulfonyl) phenyl CH 3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl CH 3 2-pyrimidyl 1-pyrrolidinocarbonyl CH 3 2-pyrimidyl 2- (methylsulfonyl) phenyl CH 3 2-pyrimidyl 4-morpholino CH 2-pyrimidyl 2-(l'-CF3-tetrazol-2-yl)phenyl CH 3 2-pyrimidyl 4-morpholinocarbonyl CH 3 2-pyrimidyl 2-methyl-1-imidazolyl CH 3 2-pyrimidyl 5-methyl-1-imidazolyl CH 3 2-pyrimidyl 2-methylsulfonyl-1-imidazolyl CH 3 5-pyrimidyl 2- (aminosulfonyl) phenyl CH 3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl CH 3 5-pyrimidyl 1-pyrrolidinocarbonyl CH 3 5-pyrimidyl 2- (methylsulfonyl) phenyl CH 3 5-pyrimidyl 4-morpholino CH 3 5-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl CH 5-pyrimidyl 4-morpholinocarbonyl CH 3 5-pyrimidyl 2-methyl-1-imidazolyl CH 3 5-pyrimidyl 5-methyl-1-imidazolyl CH 3 5-pyrimidyl 2-methylsulfonyl-1-imidazolyl CH 3 2-Cl-phenyl 2- (aminosulfonyl)phenyl CH 3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl CH 3 2-Cl-phenyl 1-pyrrolidinocarbonyl CH 3 2-Cl-phenyl 2- (methylsulfonyl)phenyl CH 2-Cl-phenyl 4-morpholino CH 3 2-Cl-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl CH 3 2-Cl-phenyl 4-morpholinocarbonyl CH 3 2-Cl-phenyl 2-methyl-1-imidazolyl CH 3 2-Cl-phenyl 5-methyl-l-imidazolyl CH 3 2-Cl-phenyl 2-methylsulfonyl-1-imidazolyl CH 2-F-phenyl 2- (aminosulfonyl) phenyl CH 3 2-F-phenyl 2- (methylaminosulfonyl) phenyl CH 3 2-F-phenyl 1-pyrrolidinocarbonyl CH 3 2-F-phenyl 2- (methylsulfonyl)phenyl CH 3 2-F-phenyl 4-morpholino CH 3 2-F-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl CH 3 2-F-phenyl 4-morpholinocarbonyl CH 3 2-F-phenyl 2-methyl-1-imidazolyl CH 3 2-F-phenyl 5-methyl-1-imidazolyl CH 3 2-F-phenyl 2-methylsulfonyl-1-imidazolyl CH 3 2,6-diF-phenyl 2- (aminosulfonyl) phenyl CH 3 2 , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl CH 3 2, 6-diF-phenyl 1-pyrrolidinocarbonyl CH 3 2 , 6-diF-phenyl 2- (methylsulfonyl) phenyl CH 3 2 , 6-diF-phenyl 4-morpholino 76 CH 3 2 , 6-diF-phenyl 2- ( 1 ' -CF3-tetrazol-2-yl ) phenyl 77 CH 3 2, 6-diF-phenyl 4-morpholinocarbonyl 78 CH 3 2 , 6-diF-phenyl 2-methyl-1-imidazolyl 79 CH 3 2, 6-diF-phenyl 5-methyl-1-imidazolyl 80 CH 3 2, 6-diF-phenyl 2-methylsulfonyl-1-imidazolyl 81 CH 2 CH 3 phenyl 2- (aminosulfonyl) phenyl 82 CH CH 3 phenyl 2- (methylaminosulfonyl) phenyl 83 CH 2 CH 3 phenyl 1-pyrrolidinocarbonyl 84 CH 2 CH 3 phenyl 2- (methylsulfonyl) phenyl 85 CH 2 CH 3 phenyl 4-morpholino 86 CH 2 CH 3 phenyl 2- ( 1 ' -CF3 -tetrazol-2-yl ) phenyl 87 CH 2 CH 3 phenyl 4-morpholinocarbonyl 88 CH 2 CH 3 phenyl 2-methyl-l-imidazolyl 89 CH 2 CH 3 phenyl 5-methyl-l-imidazolyl 90 CH 2 CH 3 phenyl 2-methylsulfonyl-1-imidazolyl 91 CH 2 CH 3 2-pyridyl 2- (aminosulfonyl)phenyl 92 CH 2 CH 3 2-pyridyl 2- (methylaminosulfonyl) phenyl 93 CH 2 CH 3 2-pyridyl 1-pyrrolidinocarbonyl 94 CH 2 CH 3 2-pyridyl 2- (methylsulfonyl) phenyl 95 CH 2 CH 3 2-pyridyl 4-morpholino 96 CH 2 CH 3 2-pyridyl 2-(l'-CF3-tetrazol-2-yl)phenyl 97 CH 2 CH 3 2-pyridyl 4-morpholinocarbonyl 98 CH 2 CH 3 2-pyridyl 2-methyl-l-imidazolyl 99 CH 2 CH 3 2-pyridyl 5-methyl-1-imidazolyl 100 CH 2 CH 3 2-pyridyl 2-methylsulfonyl-1-imidazolyl 101 CH 2 CH 3 3-pyridyl 2- (aminosulfonyl) phenyl 102 CH 2 CH 3 3-pyridyl 2- (methylaminosulfonyl) phenyl 103 CH 2 CH 3 3-pyridyl 1-pyrrolidinocarbonyl 104 CH 2 CH 3 3-pyridyl 2- (methylsulfonyl) phenyl 105 CH 2 CH 3 3-pyridyl 4-morpholino 106 CH 2 CH 3 3-pyridyl 2-(l'-CF3-tetrazol-2-yl)phenyl 107 CH 2 CH 3 3-pyridyl 4-morpholinocarbonyl 108 CH 2 CH 3 3-pyridyl 2-methyl-1-imidazolyl 109 CH 2 CH 3 3-pyridyl 5-methyl-l-imidazolyl 110 CH 2 CH 3 3-pyridyl 2-methylsulfonyl-1-imidazolyl 111 CH 2 CH 3 2-pyrimidyl 2- (aminosulfonyl) phenyl 112 CH 2 CH 3 2-pyrimidyl 2- (methylaminosulfonyl ) phenyl 113 CH 2 CH 3 2-pyrimidyl 1-pyrrolidinocarbonyl 114 CH 2 CH 3 2-pyrimidyl 2- (methylsulfonyl) phenyl 115 CH 2 CH 3 2-pyrimidyl 4-morpholino 116 CH 2 CH 3 2-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 117 CH 2 CH 3 2-pyrimidyl 4-morpholinocarbonyl 118 CH 2 CH 3 2-pyrimidyl 2-methyl-l-imidazolyl 119 CH 2 CH 3 2-pyrimidyl 5-methyl-1-imidazolyl 120 CH 2 CH 3 2-pyrimidyl 2-methylsulfonyl-1-imidazolyl 121 CH 2 CH 3 5-pyrimidyl 2- (aminosulfonyl) phenyl 122 CH 2 CH 3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 123 CH 2 CH 3 5-pyrimidyl 1-pyrrolidinocarbonyl 124 CH 2 CH 3 5-pyrimidyl 2- (methylsulfonyl) phenyl 125 CH 2 CH 3 5-pyrimidyl 4-morpholino 126 CH 2 CH 3 5-pyrimidyl 2- (1' -CF3-tetrazol-2-yl) phenyl 127 CH 2 CH 3 5-pyrimidyl 4-morpholinocarbonyl 128 CH 2 CH 3 5-pyrimidyl 2-methyl-1-imidazolyl 129 CH 2 CH 3 5-pyrimidyl 5-methyl-1-imidazolyl 130 CH 2 CH 3 5-pyrimidyl 2-methylsulfonyl-1-imidazolyl 131 CH 2 CH 3 2-Cl-phenyl 2- (aminosulfonyl) phenyl 132 CH 2 CH 3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 133 CH 2 CH 3 2-Cl-phenyl 1-pyrrolidinocarbonyl 134 CH 2 CH 3 2-Cl-phenyl 2- (methylsulfonyl) phenyl 135 CH 2 CH 3 2-Cl-phenyl 4-morpholino 136 CH 2 CH 3 2-Cl-phenyl 2- ( 1 ' -CF3 -tetrazol-2-yl ) phenyl 137 CH 2 CH 3 2-Cl-phenyl 4-morpho1inocarbony1 138 CH 2 CH 3 2-Cl-phenyl 2-methyl-l-imidazolyl 139 CH 2 CH 3 2-Cl-phenyl 5-methyl-1-imidazolyl 140 CH 2 CH 3 2-Cl-phenyl 2-methylsulfony1-1-imidazolyl 141 CH 2 CH 3 2-F-phenyl 2- (aminosulfonyl)phenyl 142 CH 2 CH 3 2-F-phenyl 2- (methylaminosulfonyl) phenyl 143 CH 2 CH 3 2-F-phenyl 1-pyrrolidinocarbonyl 144 CH 2 CH 3 2-F-phenyl 2- (methylsulfonyl) phenyl 145 CH 2 CH 3 2-F-phenyl 4-morpholino 146 CH CH 3 2-F-phenyl 2- ( 1 ' -CF3 -tetrazol-2-yl) phenyl 147 CH 2 CH 3 2-F-phenyl 4-morpholinocarbonyl 148 CH 2 CH 3 2-F-phenyl 2-methyl-1-imidazolyl 149 CH 2 CH 3 2-F-phenyl 5-methyl-l-imidazolyl 150 CH 2 CH 3 2-F-phenyl 2-methylsulfonyl-1-imidazolyl 151 CH 2 CH 3 2, 6-diF-phenyl 2- (aminosulfonyl) phenyl 152 CH 2 CH 3 2, 6-diF-phenyl 2- (methylaminosulfonyl) phenyl 153 CH 2 CH 3 2 , 6-diF-phenyl 1-pyrrolidinocarbonyl 154 CH 2 CH 3 2 , 6-diF-phenyl 2- (methylsulfonyl) phenyl 155 CH 2 CH 3 2, 6-diF-phenyl 4-morpholino 156 CH 2 CH 3 2 , 6-diF-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl 157 CH 2 CH 3 2, 6-diF-phenyl 4-morpholinocarbonyl 158 CH 2 CH 3 2 , 6-diF-phenyl 2-methyl-l-imidazolyl 159 CH 2 CH 3 2, 6-diF-phenyl 5-methyl-l-imidazolyl 160 CH 2 CH 3 2 , 6-diF-phenyl 2-methylsulfonyl-1-imidazolyl 161 CF 3 phenyl 2- (aminosulfonyl) phenyl 162 CF 3 phenyl 2- (methylaminosulfonyl) phenyl 163 CF 3 phenyl 1-pyrrolidinocarbonyl 164 CF 3 phenyl 2- (methylsulfonyl) phenyl 165 CF 3 phenyl 4-morpholino 166 CF 3 phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 167 CF 3 phenyl 4-morpholinocarbonyl 168 CF 3 phenyl 2-methyl-l-imidazolyl 169 CF 3 phenyl 5-methyl-l-imidazolyl 170 CF 3 phenyl 2-methylsulfonyl-1-imidazolyl 171 CF 3 2-pyridyl 2- (aminosulfonyl) phenyl 172 CF 3 2-pyridyl 2- (methylaminosulfonyl) phenyl 173 CF 3 2-pyridyl 1-pyrrolidinocarbonyl 174 CF 3 2-pyridyl 2- (methylsulfonyl) phenyl 175 CF 3 2-pyridyl 4-morpholino 176 CF 3 2-pyridyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 177 CF 3 2-pyridyl 4-morpholinocarbonyl 178 CF 3 2.-pyridyl 2-methyl-l-imidazolyl 179 CF 3 2-pyridyl 5-methyl-1-imidazolyl 180 CF 3 2-pyridyl 2-methylsulfonyl-1-imidazolyl 181 CF 3 3 -pyridyl 2- (aminosulfonyl) phenyl 182 CF 3 3-pyridyl 2- (methylaminosulfonyl) phenyl 183 CF 3 3-pyridyl 1-pyrrolidinocarbonyl 184 CF 3 3-pyridyl 2- (methylsulfonyl ) phenyl 185 CF 3 3 -pyridyl 4-morpholino 186 CF 3 3 -pyridyl 2- (1' -CF3-tetrazol-2-yl) phenyl 187 CF 3 3-pyridyl 4-morpholinocarbonyl 188 CF 3 3-pyridyl 2-methyl-l-imidazolyl 189 CF 3 3 -pyridyl 5-methyl-1-imidazolyl 190 CF 3 3 -pyridyl 2-methylsulfonyl-1-imidazolyl 191 CF 3 2-pyrimidyl 2- (aminosulfonyl) phenyl 192 CF 3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 193 CF 3 2-pyrimidyl 1-pyrrolidinocarbonyl 194 CF 3 2-pyrimidyl 2- (methylsulfonyl) phenyl 195 CF 3 2 -pyrimidyl 4-morpholino 196 CF 3 2-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 197 CF 3 2-pyrimidyl 4-morpholinocarbonyl 198 CF 3 2-pyrimidyl 2-methyl-1-imidazolyl 199 CF 3 2-pyrimidyl 5-methyl-1-imidazolyl 200 CF 3 2-pyrimidyl 2-methylsulfonyl-1-imidazolyl 201 CF 3 5-pyrimidyl 2- (aminosulfonyl)phenyl 202 CF 3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 203 CF 3 5-pyrimidyl 1-pyrrolidinocarbonyl 204 CF 3 5-pyrimidyl 2- (methylsulfonyl)phenyl 205 CF 3 5-pyrimidyl 4-morpho1ino 206 CF 3 5-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 207 CF 3 5-pyrimidyl 4-morpholinocarbonyl 208 CF 3 5-pyrimidyl 2-methyl-1-imidazolyl 209 CF 3 5-pyrimidyl 5-methyl-1-imidazolyl 210 CF 3 5-pyrimidyl 2-methylsulfonyl-1-imidazolyl 211 CF 3 2-Cl-phenyl 2- (aminosulfonyl) phenyl 212 CF 3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 213 CF 3 2-Cl-phenyl 1-pyrrolidinocarbonyl 214 CF 3 2-Cl-phenyl 2- (methylsulfonyl ) phenyl 215 CF 3 2-Cl-phenyl 4-morpholino 216 CF 3 2-Cl-phenyl 2- ( 1 ' -CF3 -tetrazol-2-yl) phenyl 217 CF 3 2-Cl-phenyl 4-morpho1inocarbony1 218 CF 3 2-Cl-phenyl 2-methyl-1-imidazolyl 219 CF 3 2-Cl-phenyl 5-methyl-1-imidazolyl 220 CF 3 2-Cl-phenyl 2-methylsulfonyl-1-imidazolyl 221 CF 3 2-F-phenyl 2- (aminosulfonyl)phenyl 222 CF 3 2-F-phenyl 2- (methylaminosulfonyl) phenyl 223 CF 3 2-F-phenyl 1-pyrrolidinocarbonyl 224 CF 3 2-F-phenyl 2- (methylsulfonyl)phenyl 225 CF 3 2-F-phenyl 4-morpholino 226 CF 3 2-F-phenyl 2- (1' -CF3-tetrazol-2-yl) phenyl 227 CF 3 2-F-phenyl 4-morpholinocarbonyl 228 CF 3 2-F-phenyl 2-methyl-1-imidazolyl 229 CF 3 2-F-phenyl 5-methyl-1-imidazolyl 230 CF 3 2-F-phenyl 2-methylsulfonyl-1-imidazolyl 231 CF 3 2, 6-diF-phenyl 2- (aminosulfonyl) phenyl 232 CF 3 2 , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl 233 CF 3 2, 6-diF-phenyl 1-pyrrolidinocarbonyl 234 CF 3 2, 6-diF-phenyl 2- (methylsulfonyl) phenyl 235 CF 3 2, 6-diF-phenyl 4-morpholino 236 CF 3 2 , 6-diF-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl 237 CF 3 2 , 6-diF-phenyl 4-morpholinocarbonyl 238 CF 3 2, 6-diF-phenyl 2-methyl-1-imidazolyl 239 CF 3 2, 6-diF-phenyl 5-methyl-1-imidazolyl 240 CF 3 2, 6-diF-phenyl 2-methylsulfonyl-1-imidazolyl 241 SCH 3 phenyl 2- (aminosulfonyl) phenyl 242 SCH 3 phenyl 2- (methylaminosulfonyl) phenyl 243 SCH 3 phenyl 1-pyrrolidinocarbonyl 244 SCH 3 phenyl 2- (methylsulfonyl ) phenyl 245 SCH 3 phenyl 4-morpholino 246 SCH 3 phenyl 2- ( 1 ' -CF3 -tetrazol-2-yl ) phenyl 247 SCH 3 phenyl 4-morpholinocarbonyl 248 SCH 3 phenyl 2-methyl-1-imidazolyl 249 SCH 3 phenyl 5-methyl-1-imidazolyl 250 SCH 3 phenyl 2-methylsulfonyl-1-imidazolyl 251 SCH 3 2-pyridyl 2- (aminosulfonyl) phenyl 252 SCH 3 2-pyridyl 2- (methylaminosulfonyl) phenyl 253 SCH 3 2-pyridyl 1-pyrro1idinocarbony1 254 SCH 3 2-pyridyl 2- (methylsulfonyl) phenyl 255 SCH 3 2-pyridyl 4-morpholino 256 SCH 3 2-pyridyl 2- (l'-CF3-tetrazol-2-yl) phenyl 257 SCH 3 2-pyridyl 4-morpholinocarbonyl 258 SCH 3 2-pyridyl 2-methyl-l-imidazolyl 259 SCH 3 2-pyridyl 5-methyl-1-imidazolyl 260 SCH 3 2-pyridyl 2-methylsulfonyl-1-imidazolyl 261 SCH 3 3-pyridyl 2- (aminosulfonyl)phenyl 262 SCH 3 3-pyridyl 2- (methylaminosulfonyl) phenyl 263 SCH 3 3-pyridyl 1-pyrrolidinocarbonyl 264 SCH 3 3-pyridyl 2- (methylsulfonyl) phenyl 265 SCH 3 3-pyridyl 4-morpholino 266 SCH 3 3-pyridyl 2- (l'-CF3-tetrazol-2-yl) phenyl 267 SCH 3 3-pyridyl 4-morpholinocarbonyl 268 SCH 3 3-pyridyl 2-me thyl-J-imidazolyl 269 SCH 3 3-pyridyl 5-methyl-l-imidazolyl 270 SCH 3 3-pyridyl 2-methylsulfonyl-1-imidazolyl 271 SCH 3 2-pyrimidyl 2- (aminosulfonyl)phenyl 272 SCH 3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 273 SCH 3 2-pyrimidyl 1-pyrrolidinocarbonyl 274 SCH 3 2-pyrimidyl 2- (methylsulfonyl) phenyl 275 SCH 3 2-pyrimidyl 4-morpholino 276 SCH 3 2-pyrimidyl 2- (l'-CF3-tetrazol-2-yl) phenyl 277 SCH 3 2-pyrimidyl 4-morpholinocarbonyl 278 SCH 3 2-pyrimidyl 2-methyl-l-imidazolyl 279 SCH 3 2-pyrimidyl 5-methyl-l-imidazolyl 280 SCH 3 2-pyrimidyl 2-methylsulfonyl-1-imidazolyl 281 SCH 3 5-pyrimidyl 2- (aminosulfonyl) phenyl 282 SCH 3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 283 SCH 3 5 -pyrimidyl 1-pyrrolidinocarbonyl 284 SCH 3 5-pyrimidyl 2- (methylsulfonyl) phenyl 285 SCH 3 5-pyrimidyl 4-morpholino 286 SCH 3 5-pyrimidyl 2- ( 1 ' -CF3 - etrazol-2-yl ) phenyl 287 SCH 3 5-pyrimidyl 4-morpholinocarbonyl 288 SCH 3 5-pyrimidyl 2-methyl-1-imidazolyl 289 SCH 3 5-pyrimidyl 5-methyl-1-imidazolyl 290 SCH 3 5-pyrimidyl 2-methylsulfonyl-1-imidazolyl 291 SCH 3 2-Cl-phenyl 2- (aminosulfonyl) phenyl 292 SCH 3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 293 SCH 3 2-Cl-phenyl 1-pyrrolidinocarbonyl 294 SCH 3 2-Cl-phenyl 2- (methylsulfonyl) phenyl 295 SCH 3 2-Cl-phenyl 4-morpholino 296 SCH 3 2-Cl-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 297 SCH 3 2-Cl-phenyl 4-morpholinocarbonyl 298 SCH 3 2-Cl-phenyl 2-methyl-1-imidazolyl 299 SCH 3 2-Cl-phenyl 5-methyl-1-imidazolyl 300 SCH 3 2-Cl-phenyl 2-methylsulfonyl-1-imidazolyl 301 SCH 3 2-F-phenyl 2- (aminosulfonyl) phenyl 302 SCH 3 2-F-phenyl 2- (methylaminosulfonyl) phenyl 303 SCH 3 2-F-phenyl 1-pyrrolidinocarbonyl 304 SCH 3 2-F-phenyl 2- (methylsulfonyl) phenyl 305 SCH 3 2-F-phenyl 4-morpholino 306 SCH 3 2-F-phenyl 2- (1 ' -CF3 -tetrazol-2-yl)phenyl 307 SCH 3 2-F-phenyl 4-morpholinocarbonyl 308 SCH 3 2-F-phenyl 2-methyl-1-imidazolyl 309 SCH 3 2-F-phenyl 5-methyl-1-imidazolyl 310 SCH 3 2-F-phenyl 2-methylsulfonyl-1-imidazolyl 311 SCH 3 2 , 6-diF-phenyl 2- (aminosulfonyl) phenyl 312 SCH 3 2 , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl 313 SCH 3 2 , 6-diF-phenyl 1-pyrro1idinocarbony1 314 SCH 3 2 , 6-diF-phenyl 2- (methylsulfonyl) phenyl 315 SCH 3 2, 6-diF-phenyl 4-morpholino 316 SCH 3 2, 6-diF-phenyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl 317 SCH 3 2 , 6-diF-phenyl 4-morpholinocarbonyl 318 SCH 3 2 , 6-diF-phenyl 2-methyl-l-imidazolyl 319 SCH 3 2 , 6-diF-phenyl 5-methyl-1-imidazolyl 320 SCH 3 2 , 6-diF-phenyl 2-methylsulfonyl-1-imidazolyl 321 SOCH 3 phenyl 2- (aminosulfonyl)phenyl 322 SOCH 3 phenyl 2- (methylaminosulfonyl) phenyl 323 SOCH 3 phenyl 1-pyrrolidinocarbonyl 324 SOCH 3 phenyl 2- (methylsulfonyl)phenyl 325 SOCH 3 phenyl 4-morpholino 326 SOCH phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 327 SOCH 3 phenyl 4-morpholinocarbonyl 328 SOCH 3 phenyl 2-methyl-1-imidazolyl 329 SOCH 3 phenyl 5-methyl-1-imidazolyl 330 SOCH 3 phenyl 2-methylsulfonyl-1-imidazolyl 331 SOCH 3 2-pyridyl 2- (aminosulfonyl) phenyl 332 SOCH 3 2-pyridyl 2- (methylaminosulfonyl) phenyl 333 SOCH 3 2-pyridyl 1-pyrrolidinocarbonyl 334 SOCH 3 2-pyridyl 2- (methylsulfonyl) phenyl 335 SOCH 3 2-pyridyl 4-morpholino 336 SOCH 3 2-pyridyl 2 - ( 1 ' -CF3 -tetrazol-2 -yl ) phenyl 337 SOCH 3 2-pyridyl 4-morpho1inocarbony1 338 SOCH 3 2-pyridyl 2-methyl-l-imidazolyl 339 SOCH 3 2-pyridyl 5-methyl-1-imidazolyl 340 SOCH 3 2-pyridyl 2-methylsulfonyl-1-imidazolyl 341 SOCH 3 3-pyridyl 2- (aminosulfonyl) phenyl 342 SOCH 3 3-pyridyl 2- (methylaminosulfonyl) phenyl 343 SOCH 3 3-pyridyl 1-pyrro1idinocarbonyl 344 SOCH 3 3-pyridyl 2- (methylsulfonyl) phenyl 345 SOCH 3 3-pyridyl 4-morpho1ino 346 SOCH 3 3-pyridyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl 347 SOCH 3 3-pyridyl 4-morpholinocarbonyl 348 SOCH 3 3-pyridyl 2-methyl-1-imidazolyl 349 SOCH 3 3-pyridyl 5-methyl-1-imidazolyl 350 SOCH 3 3-pyridyl 2-methylsulfonyl-1-imidazolyl 351 SOCH 3 2-pyrimidyl 2- (aminosulfonyl) phenyl 352 SOCH 3 2-pyrimidyl 2- (methylaminosulfonyl)phenyl 353 SOCH 3 2-pyrimidyl 1-pyrrolidinocarbonyl 354 SOCH 3 2-pyrimidyl 2- (methylsulfonyl) phenyl 355 SOCH 3 2-pyrimidyl 4-morpholino 356 SOCH 3 2-pyrimidyl 2- (l'-CF3-tetrazol-2-yl) phenyl 357 SOCH 2-pyrimidyl 4-morpholinocarbonyl 358 SOCH 3 2-pyrimidyl 2-methyl-1-imidazolyl 359 SOCH 3 2-pyrimidyl 5-methyl-l-imidazolyl 360 SOCH 3 2-pyrimidyl 2-methylsulfonyl-1-imidazolyl 361 SOCH 3 5-pyrimidyl 2- (aminosulfonyl) phenyl 362 SOCH 3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 363 SOCH 3 5-pyrimidyl 1-pyrrolidinocarbonyl 364 SOCH 3 5-pyrimidyl 2- (methylsulfonyl)phenyl 365 SOCH 3 5-pyrimidyl 4-morpholino 366 SOCH 3 5-pyrimidyl 2- (1 ' -CF3 -tetrazol-2-yl) phenyl 367 SOCH 3 5-pyrimidyl 4-morpho1inocarbony1 368 SOCH 5-pyrimidyl 2-methyl-1-imidazolyl 369 SOCH 3 5-pyrimidyl 5-methyl-1-imidazolyl 370 SOCH 3 5-pyrimidyl 2-methylsulfonyl-1-imidazolyl 371 SOCH 3 2-Cl-phenyl 2- (aminosulfonyl) phenyl 372 SOCH 3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 373 SOCH 3 2-Cl-phenyl 1-pyrrolidinocarbonyl 374 SOCH 3 2-Cl-phenyl 2- (methylsulfonyl)phenyl 375 SOCH 3 2-Cl-phenyl 4-morpho1ino 376 SOCH 3 2-Cl-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl 377 SOCH 3 2-Cl-phenyl 4-morpho1inocarbonyl 378 SOCH 3 2-Cl-phenyl 2-methyl-1-imidazolyl 379 SOCH 3 2-Cl-phenyl 5-methyl-l-imidazolyl 380 SOCH 3 2-Cl-phenyl 2-methylsulfonyl-1-imidazolyl 381 SOCH 3 2-F-phenyl 2- (aminosulfonyl ) phenyl 382 SOCH 3 2-F-phenyl 2- (methylaminosulfonyl) phenyl 383 SOCH 3 2-F-phenyl 1-pyrrolidinocarbonyl 384 SOCH 3 2-F-phenyl 2- (methylsulfonyl) phenyl 385 SOCH 3 2-F-phenyl 4-morpholino 386 SOCH 3 2-F-phenyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl 387 SOCH 3 2-F-phenyl 4-morpho1inocarbony1 388 SOCH 3 2-F-phenyl 2-methyl-1-imidazolyl 389 SOCH 3 2-F-phenyl 5-methyl-1-imidazolyl 390 SOCH 3 2-F-phenyl 2-methylsulfonyl-1-imidazolyl 391 SOCH 3 2, 6-diF-phenyl 2- (aminosulfonyl) phenyl 392 SOCH 3 2 , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl 393 SOCH 3 2 , 6-diF-phenyl 1-pyrrolidinocarbonyl 394 SOCH 3 2, 6-diF-phenyl 2- (methylsulfonyl)phenyl 395 SOCH 3 2, 6-diF-phenyl 4-morpholino 396 SOCH 3 2, 6-diF-phenyl 2- (1 ' -CF3 -tetrazol-2-yl) phenyl 397 SOCH 3 2, 6-diF-phenyl 4-morpholinocarbonyl 398 SOCH 3 2, 6-diF-phenyl 2-methyl-1-imidazolyl 399 SOCH 3 2, 6-diF-phenyl 5-methyl-1-imidazolyl 400 SOCH 3 2, 6-diF-phenyl 2-methylsulfonyl-1-imidazolyl 401 S0 2 CH 3 phenyl 2- (aminosulfonyl)phenyl 402 S0 2 CH 3 phenyl 2- (methylaminosulfonyl) phenyl 403 S0 CH 3 phenyl 1-pyrrolidinocarbonyl 404 S0 2 CH 3 phenyl 2- (methylsulfonyl) phenyl 405 S0 2 CH 3 phenyl 4-morpholino 406 S0 2 CH 3 phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 407 S0 2 CH 3 phenyl 4-morpholinocarbonyl 408 S0 2 CH 3 phenyl 2-methyl-1-imidazolyl 409 S0 2 CH 3 phenyl 5-methyl-1-imidazolyl 410 S0 2 CH 3 phenyl 2-methylsulfonyl-1-imidazolyl 411 S0 2 CH 3 2-pyridyl 2- (aminosulfonyl)phenyl 412 S0 2 CH 3 2-pyridyl 2- (methylaminosulfonyl) phenyl 413 S0 2 CH 3 2-pyridyl 1-pyrrolidinocarbonyl 414 S0 2 CH 3 2-pyridyl 2- (methylsulfonyl) phenyl 415 S0 2 CH 3 2-pyridyl 4-morpholino 416 S0 2 CH 3 2-pyridyl 2- ( 1 ' -CF3- etrazol-2-yl) phenyl 417 S0 2 CH 3 2-pyridyl 4-morpholinocarbonyl 418 S0 2 CH 3 2-pyridyl 2-methyl-1-imidazolyl 419 S0 2 CH 3 2-pyridyl 5-methyl-1-imidazolyl 420 S0 2 CH 3 2-pyridyl 2-methylsulfonyl-1-imidazolyl 421 S0 2 CH 3 3-pyridyl 2- (aminosulfonyl) phenyl 422 S0 2 CH 3 3 -pyridyl 2- (methylaminosulfonyl) phenyl 423 S0 2 CH 3 3-pyridyl 1-pyrrolidinocarbonyl 424 S0 2 CH 3 3-pyridyl 2- (methylsulfonyl)phenyl 425 S0 2 CH 3 3-pyridyl 4-morpholino 426 S0 2 CH 3 3-pyridyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 427 S0 2 CH 3 3-pyridyl 4-morpholinocarbonyl 428 S0 2 CH 3 3-pyridyl 2-methyl-1-imidazolyl 429 S0 2 CH 3 3-pyridyl 5-methyl-1-imidazolyl 430 S0 2 CH 3 3-pyridyl 2-methylsulfonyl-1-imidazolyl 431 S0 2 CH 3 2-pyrimidyl 2- (aminosulfonyl) phenyl 432 S0 2 CH 3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 433 S0 2 CH 3 2-pyrimidyl 1-pyrro1idinocarbony1 434 S0 2 CH 3 2-pyrimidyl 2- (methylsulfonyl) phenyl 435 S0 2 CH 3 2-pyrimidyl 4-morpho1ino 436 S0 2 CH 3 2-pyrimidyl 2- (1' -CF3-tetrazol-2-yl) phenyl 437 S0 2 CH 3 2-pyrimidyl 4-morpholinocarbonyl 438 S0 2 CH 3 2-pyrimidyl 2-methyl-1-imidazolyl 439 S0 2 CH 2-pyrimidyl 5-methyl-l-imidazolyl 440 S0 2 CH 3 2-pyrimidyl 2-methylsulfonyl-1-imidazolyl 441 S0 2 CH 3 5-pyrimidyl 2- (aminosulfonyl ) phenyl 442 S0 2 CH 3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 443 S0 2 CH 5-pyrimidyl 1-pyrrolidinocarbonyl 444 S0 2 CH 3 5-pyrimidyl 2- (methylsulfonyl) phenyl 445 S0 2 CH 3 5-pyrimidyl 4-morpholino 446 S0 2 CH 3 5-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl ) phenyl 447 S0 2 CH 3 5-pyrimidyl 4-morpholinocarbonyl 448 S0 2 CH 3 5-pyrimidyl 2-methyl-l-imidazolyl 449 S0 2 CH 3 5-pyrimidyl 5-methyl-1-imidazolyl 450 S0 2 CH 3 5-pyrimidyl 2-methylsulfonyl-1-imidazolyl 451 S0 2 CH 3 2-Cl-phenyl 2- (aminosulfonyl) phenyl 452 S0 2 CH 3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 453 S0 2 CH 3 2-Cl-phenyl 1-pyrrolidinocarbonyl 454 S0 2 CH 3 2-Cl-phenyl 2- (methylsulfonyl) phenyl 455 S0 2 CH 3 2-Cl-phenyl 4-morpholino 456 S0 2 CH 3 2-Cl-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl 457 S0 2 CH 3 2-Cl-phenyl 4-morpholinocarbonyl 458 S0 2 CH 3 2-Cl-phenyl 2-methyl-l-imidazolyl 459 S0 2 CH 3 2-Cl-phenyl 5-methyl-1-imidazolyl 460 S0 2 CH 3 2-Cl-phenyl 2-methylsulfonyl-1-imidazolyl 461 S0 CH 3 2-F-phenyl 2- (aminosulfonyl) phenyl 462 S0 2 CH 3 2-F-phenyl 2- (methylaminosulfonyl) phenyl 463 S0 2 CH 3 2-F-phenyl 1-pyrrolidinocarbonyl 464 S0 2 CH 3 2-F-phenyl 2- (methylsulfonyl) phenyl 465 S0 2 CH 3 2-F-phenyl 4-morpholino 466 S0 2 CH 3 2-F-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 467 S0 2 CH 3 2-F-phenyl 4-morpholinocarbonyl 468 S0 2 CH 3 2-F-phenyl 2-methyl-1-imidazolyl 469 S0 2 CH 3 2-F-phenyl 5-methyl-l-imidazolyl 470 S0 2 CH 3 2-F-phenyl 2-methylsulfonyl-1-imidazolyl 471 S0 2 CH 3 2 , 6-diF-phenyl 2- (aminosulfonyl) phenyl 472 S0 2 CH 3 2 , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl 473 S0 2 CH 3 2 , 6-diF-phenyl 1-pyrrolidinocarbonyl 474 S0 2 CH 3 2 , 6-diF-phenyl 2- (methylsulfonyl) phenyl 475 S0 2 CH 3 2 , 6-diF-phenyl 4-morpholino 476 S0 2 CH 3 2 , 6-diF-phenyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl 477 S0 2 CH 3 2 , 6-diF-phenyl 4-morpholinocarbonyl 478 S0 2 CH 3 2, 6-diF-phenyl 2-methyl-l-imidazolyl 479 S0 2 CH 3 2 , 6-diF-phenyl 5-methyl-1-imidazolyl 480 S0 2 CH 3 2 , 6-diF-phenyl 2-methylsulfonyl-1-imidazolyl 481 CH 2 H phenyl 2- (aminosulfonyl) phenyl -S0 2 CH 3 482 CH 2 H phenyl 2- (methylaminosulfonyl) phenyl -S0 2 CH 3 483 CH 2 NH phenyl 1-pyrrolidinocarbonyl -S0 2 CH 3 484 CH 2 H phenyl 2- (methylsulfonyl) phenyl -S0 2 CH 3 485 CH 2 NH phenyl 4-morpholino -S0 2 CH 3 486 CH 2 H phenyl 2- (1 ' -CF3-tetrazol-2-yl ) phenyl -S0 2 CH 3 487 CH 2 NH phenyl 4-morpholinocarbonyl -S0 2 CH 3 488 CH 2 NH phenyl 2-methyl-1-imidazolyl -S0 2 CH 3 489 CH 2 NH phenyl 5-methyl-1-imidazolyl -S0 2 CH 3 490 CH 2 H phenyl 2-methylsulfonyl-1-imidazolyl -S0 2 CH 3 491 CH 2 NH 2-pyridyl 2- (aminosulfonyl) phenyl -S0 2 CH 3 492 CH 2 H 2-pyridyl 2- (methylaminosulfonyl) phenyl -S0 2 CH 3 493 CH 2 NH 2-pyridyl 1-pyrrolidinocarbonyl -S0 2 CH 3 494 CH 2 H 2-pyridyl 2- (methylsulfonyl) phenyl -S0 2 CH 3 495 CH 2 NH 2-pyridyl 4-morpholino -S0 2 CH 3 496 CH 2 H 2-pyridyl 2- ( 1 ' -CF3 -tetrazol-2-yl) phenyl -S0 2 CH 3 497 CH 2 NH 2-pyridyl 4-morpholinocarbonyl -S0 2 CH 3 498 CH 2 NH 2-pyridyl 2-methyl-1-imidazolyl -S0 2 CH 3 499 CH 2 H 2-pyridyl 5-methyl-1-imidazolyl 500 CH 2 H 2-pyridyl 2-methylsulfonyl-1-imidazolyl -S0 2 CH 3 501 CH 2 NH 3-pyridyl 2- (aminosulfonyl) phenyl -S0 2 CH 3 502 CH 2 H 3-pyridyl 2- (methylaminosulfonyl) phenyl -S0 2 CH 3 503 CH 2 NH 3-pyridyl 1-pyrrolidinocarbonyl -S0 2 CH 3 504 CH 2 NH 3-pyridyl 2- (methylsulfonyl) phenyl -S0 2 CH 3 505 CH 2 NH 3-pyridyl 4-morpholino -S0 2 CH 3 506 CH 2 NH 3-pyridyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl -S0 2 CH 3 507 CH 2 NH 3-pyridyl 4-morpho1inocarbonyl -S0 2 CH 3 508 CH 2 NH 3-pyridyl 2-methyl-l-imidazolyl -S0 2 CH 3 509 CH 2 NH 3-pyridyl 5-methyl-l-imidazolyl -S0 2 CH 3 510 CH 2 NH 3-pyridyl 2-methylsulfonyl-1-imidazolyl -S0 2 CH 3 511 CH 2 NH 2 -pyrimidyl 2- (aminosulfonyl) phenyl -S0 2 CH 3 512 CH 2 NH 2-pyrimidyl 2- (methylaminosulfonyl) phenyl -S0 2 CH 3 513 CH 2 NH 2-pyrimidyl 1-pyrrolidinocarbonyl -S0 2 CH 3 514 CH 2 NH 2-pyrimidyl 2- (methylsulfonyl) phenyl -S0 2 CH 3 515 CH 2 NH 2-pyrimidyl 4-morpholino -S0 2 CH 3 516 CH 2 NH 2-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl -S0 2 CH 3 517 CH 2 H 2-pyrimidyl 4-morpholinocarbonyl -S0 2 CH 3 518 CH 2 H 2-pyrimidyl 2-methyl-1-imidazolyl -S0 2 CH 3 519 CH 2 NH 2-pyrimidyl 5-methyl-1-imidazolyl -S0 2 CH 3 520 CH 2 H 2-pyrimidyl 2-methylsulfonyl-1-imidazolyl -S0 2 CH 3 521 CH 2 H 5-pyrimidyl 2- (aminosulfonyl) phenyl -S0 2 CH 3 522 CH 2 NH 5-pyrimidyl 2- (methylaminosulfonyl) phenyl -S0 2 CH 3 523 CH 2 H 5-pyrimidyl 1-pyrrolidinocarbonyl -S0 2 CH 3 524 CH 2 H 5-pyrimidyl 2- (methylsulfonyl) phenyl -S0 2 CH 3 525 CH H 5-pyrimidyl 4-morpholino -S0 2 CH 3 526 CH 2 H 5-pyrimidyl 2- (l'-CF3-tetrazol-2-yl) phenyl -S0 2 CH 3 527 CH 2 NH 5-pyrimidyl 4-morpholinocarbonyl -S0 2 CH 3 528 CH 2 NH 5-pyrimidyl 2-methyl-1-imidazolyl -S0 2 CH 3 529 CH 2 NH 5-pyrimidyl 5-methyl-1-imidazolyl -S0 2 CH 3 530 CH 2 NH 5-pyrimidyl 2-methylsulfonyl-1-imidazolyl -S0 2 CH 3 531 CH 2 NH 2-Cl-phenyl 2- (aminosulfonyl) phenyl -S0 2 CH 3 532 CH 2 H 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl -S0 2 CH 3 533 CH 2 H 2-Cl-phenyl 1-pyrrolidinocarbonyl -S0 2 CH 3 534 CH 2 NH 2-Cl-phenyl 2- (methylsulfonyl)phenyl -S0 2 CH 3 535 CH 2 H 2-Cl-phenyl 4-morpholino -S0 2 CH 3 536 CH 2 NH 2-Cl-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl -S0 2 CH 3 537 CH 2 NH 2-Cl-phenyl 4-morpholinocarbonyl -S0 2 CH 3 538 CH 2 H 2-Cl-phenyl 2-methyl-1-imidazolyl -S0 2 CH 3 539 CH 2 NH 2-Cl-phenyl 5 -methyl-1-imidazolyl -S0 2 CH 3 540 CH 2 NH 2-Cl-phenyl 2 -methylsulfonyl-1-imidazolyl -S0 2 CH 3 541 CH 2 H 2-F-phenyl 2 - (aminosulfonyl) phenyl -S0 2 CH 3 542 CH 2 NH 2-F-phenyl 2 - (methylaminosulfonyl)phenyl -S0 2 CH 3 543 CH 2 NH 2-F-phenyl 1 -pyrrolidinocarbonyl -S0 2 CH 3 544 CH 2 H 2-F-phenyl 2 - (methylsulfonyl) phenyl -S0 2 CH 3 545 CH 2 NH 2-F-phenyl 4 -morpholino -S0 2 CH 3 546 CH 2 H 2-F-phenyl 2 - (1' -CF3-tetrazol-2-yl) phenyl -S0 2 CH 3 547 CH 2 NH 2-F-phenyl 4 -morpholinocarbonyl -S0 2 CH 3 548 CH 2 NH 2-F-phenyl 2 -methyl-1-imidazolyl -S0 2 CH 549 CH 2 NH 2-F-phenyl 5 -methyl-1-imidazolyl -S0 2 CH 3 550 CH 2 H 2-F-phenyl 2 -methylsulfonyl-1-imidazolyl -S0 2 CH 3 551 CHNH 2, 6-diF-phenyl 2 - (aminosulfonyl) phenyl -S0 2 CH 3 552 CH 2 H 2, 6-diF-phenyl 2 - (methylaminosulfonyl) phenyl -S0CH 3 553 CH 2 NH 2 , 6-diF-phenyl 1 -pyrrolidinocarbonyl -S0 2 CH 3 554 CH 2 NH 2 , 6-diF-phenyl 2 - (methylsulfonyl)phenyl -S0 2 CH 3 555 CH 2 NH 2 , 6-diF-phenyl 4 -morpholino -S0 2 CH 3 556 CH 2 NH 2 , 6-diF-phenyl 2 - ( 1 ' -CF3-tetrazol-2-yl ) phenyl -S0 2 CH 3 557 CH 2 NH 2 , 6-diF-phenyl 4 -morpholinocarbonyl -S0 2 CH 3 558 CH 2 NH 2, 6-diF-phenyl 2 -methyl-1-imidazolyl -S0 2 CH 559 CH 2 H 2 , 6-diF-phenyl 5 -methyl-1-imidazolyl -S0 2 CH 3 560 CHNH 2, 6-diF-phenyl 2 -methylsulfonyl-1-imidazolyl -S0 2 CH 3 561 Cl phenyl 2 - (aminosulfonyl) phenyl 562 Cl phenyl 2 - (methylaminosulfonyl) phenyl 563 Cl phenyl 1 -pyrrolidinocarbonyl 564 Cl phenyl 2 - (methylsulfonyl)phenyl 565 Cl phenyl 4 -morpholino 566 Cl phenyl 2 - (l'-CF3-tetrazol-2-yl) phenyl 567 Cl phenyl 4 -morpholinocarbonyl 568 Cl phenyl 2 -methyl-1-imidazolyl 569 Cl phenyl 5 -methyl-1-imidazolyl 570 Cl phenyl 2-methylsulfonyl-1-imidazolyl 571 Cl 2-pyridyl 2- (aminosulfonyl) phenyl 572 Cl 2-pyridyl 2- (methylaminosulfonyl) phenyl 573 Cl 2-pyridyl 1-pyrrolidinocarbonyl 574 Cl 2-pyridyl 2- (methylsulfonyl) phenyl 575 Cl 2-pyridyl 4-morpholino 576 Cl 2-pyridyl 2- (l'-CF3-tetrazol-2-yl) phenyl 577 Cl 2-pyridyl 4-morpholinocarbonyl 578 Cl 2-pyridyl 2-methyl-l-imidazolyl 579 Cl 2-pyridyl 5-methyl-1-imidazolyl 580 Cl 2-pyridyl 2-methylsulfonyl-1-imidazolyl 581 Cl 3-pyridyl 2- (aminosulfonyl) phenyl 582 Cl 3-pyridyl 2- (methylaminosulfonyl) phenyl 583 Cl 3-pyridyl 1-pyrro1idinocarbonyl 584 Cl 3-pyridyl 2- (methylsulfonyl) henyl 585 Cl 3-pyridyl 4-morpholino 586 Cl 3-pyridyl 2- ( 1 ' -CF3-tetrazol-2-yl ) phenyl 587 Cl 3-pyridyl 4-morpholinocarbonyl 588 Cl 3-pyridyl 2-methyl-l-imidazolyl 589 Cl 3-pyridyl 5-methyl-1-imidazolyl 590 Cl 3-pyridyl 2-methylsulfonyl-1-imidazolyl 591 Cl 2-pyrimidyl 2- (aminosulfonyl) phenyl 592 Cl 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 593 Cl 2-pyrimidyl 1-pyrrolidinocarbonyl 594 Cl 2-pyrimidyl 2- (methylsulfonyl) phenyl 595 Cl 2-pyrimidyl 4-morpholino 596 Cl 2-pyrimidyl 2- (l'-CF3-tetrazol-2-yl) phenyl 597 Cl 2-pyrimidyl 4-morpholinocarbonyl 598 Cl 2 -pyrimidyl 2-methyl-l-imidazolyl 599 Cl 2-pyrimidyl 5-methyl-l-imidazolyl 600 Cl 2-pyrimidyl 2-methylsulfonyl-1-imidazolyl 601 Cl 5-pyrimidyl 2- (aminosulfonyl)phenyl 602 Cl 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 603 Cl 5-pyrimidyl 1-pyrrolidinocarbonyl 604 Cl 5-pyrimidyl 2- (methylsulfonyl) phenyl 605 Cl 5-pyrimidyl 4-morpholino 606 Cl 5-pyrimidyl 2- (l'-CF3-tetrazol-2-yl) phenyl 607 Cl 5-pyrimidyl 4-morpholinocarbonyl 608 Cl 5-pyrimidyl 2-methyl-1-imidazolyl 609 Cl 5-pyrimidyl 5-methyl-1-imidazolyl 610 Cl 5-pyrimidyl 2-methylsulfonyl-1-imidazolyl 611 Cl 2-Cl-phenyl 2- (aminosulfonyl) phenyl 612 Cl 2-Cl-phenyl 2- (methylaminosulfonyl)phenyl 613 Cl 2-Cl-phenyl 1-pyrrolidinocarbonyl 614 Cl 2-Cl-phenyl 2- (methylsulfonyl) phenyl 615 Cl 2-Cl-phenyl 4-morpholino 616 Cl 2-Cl-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl 617 Cl 2-Cl-phenyl 4-morpholinocarbonyl 618 Cl 2-Cl-phenyl 2-methyl-1-imidazolyl 619 Cl 2-Cl-phenyl 5-methyl-1-imidazolyl 620 Cl 2-Cl-phenyl 2-methylsulfonyl-1-imidazolyl 621 Cl 2-F-phenyl 2- (aminosulfonyl) phenyl 622 Cl 2-F-phenyl 2- (methylaminosulfonyl) phenyl 623 Cl 2-F-phenyl 1-pyrrolidinocarbonyl 624 Cl 2-F-phenyl 2- (methylsulfonyl) phenyl 625 Cl 2-F-phenyl 4-morpholino 626 Cl 2-F-phenyl 2 - ( 1 ' -CF3 -tetrazol-2 -yl ) phenyl 627 Cl 2-F-phenyl 4-morpholinocarbonyl 628 Cl 2-F-phenyl 2-methyl-1-imidazolyl 629 Cl 2-F-phenyl 5-methyl-1-imidazolyl 630 Cl 2-F-phenyl 2-methylsulfonyl-1-imidazolyl 631 Cl 2, 6-diF-phenyl 2- (aminosulfonyl) phenyl 632 Cl 2, 6-diF-phenyl 2- (methylaminosulfonyl)phenyl 633 Cl 2, 6-diF-phenyl 1-pyrrolidinocarbonyl 634 Cl 2, 6-diF-phenyl 2- (methylsulfonyl)phenyl 635 Cl 2, 6-diF-phenyl 4-morpholino 636 Cl 2, 6-diF-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 637 Cl 2, 6-diF-phenyl 4-morpholinocarbonyl 638 Cl 2, 6-diF-phenyl 2-methyl-l-imidazolyl 639 Cl 2, 6-diF-phenyl 5-methyl-l-imidazolyl 640 Cl 2 , 6-diF-phenyl 2-methylsulfonyl-1-imidazolyl 641 F phenyl 2- (aminosulfonyl)phenyl 642 F phenyl 2- (methylaminosulfonyl) phenyl 643 F phenyl 1-pyrrolidinocarbonyl 644 F phenyl 2- (methylsulfonyl)phenyl 645 F phenyl 4-morpholino 646 F phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 647 F phenyl 4-morpho1inocarbony1 648 F phenyl 2-methyl-1-imidazolyl 649 F phenyl 5-methyl-l-imidazolyl 650 F phenyl 2-methylsulfonyl-1-imidazolyl 651 F 2-pyridyl 2- (aminosulfonyl) phenyl 652 F 2-pyridyl 2- (methylaminosulfonyl) phenyl 653 F 2-pyridyl 1-pyrrolidinocarbonyl 654 F 2-pyridyl 2- (methylsulfonyl)phenyl 655 F 2-pyridyl 4-morpholino 656 F 2-pyridyl 2- (l'-CF3-tetrazol-2-yl)phenyl 657 F 2-pyridyl 4-morpholinocarbonyl 658 F 2-pyridyl 2-methyl-1-imidazolyl 659 F 2-pyridyl 5-methyl-l-imidazolyl 660 F 2-pyridyl 2-methylsulfonyl-1-imidazolyl 661 F 3-pyridyl 2- (aminosulfonyl) phenyl 662 F 3-pyridyl 2- (methylaminosulfonyl) phenyl 663 F 3-pyridyl 1-pyrrolidinocarbonyl 664 F 3-pyridyl 2- (methylsulfonyl)phenyl 665 F 3-pyridyl 4-morpho1ino 666 F 3-pyridyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 667 F 3-pyridyl 4-morpholinocarbonyl 668 F 3-pyridyl 2-methy1-1-imidazoly1 669 F 3-pyridyl 5-methyl-l-imidazolyl 670 F 3-pyridyl 2-methylsulfonyl-1-imidazolyl 671 F 2-pyrimidyl 2- (aminosulfonyl)phenyl 672 F 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 673 F 2-pyrimidyl 1-pyrrolidinocarbonyl 674 F 2-pyrimidyl 2- (methylsulfonyl)phenyl 675 F 2-pyrimidyl 4-morpholino 676 F 2-pyrimidyl 2-(l'-CF3-tetrazol-2-yl)phenyl 677 F 2-pyrimidyl 4-morpholinocarbonyl 678 F 2-pyrimidyl 2-methyl-l-imidazolyl 679 F 2-pyrimidyl 5-methyl-1-imidazolyl 680 F 2-pyrimidyl 2-methylsulfonyl-1-imidazolyl 681 F 5-pyrimidyl 2- (aminosulfonyl) phenyl 682 F 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 683 F 5-pyrimidyl 1-pyrrolidinocarbonyl 684 F 5-pyrimidyl 2- (methylsulfonyl)phenyl 685 F 5-pyrimidyl 4-morpholino 686 F 5-pyrimidyl 2- (J ' -CF3-tetrazol-2-yl) phenyl 687 F 5-pyrimidyl 4-morpholinocarbonyl 688 F 5-pyrimidyl 2-methyl-1-imidazolyl 689 F 5-pyrimidyl 5-methyl-1-imidazolyl 690 F 5-pyrimidyl 2-methylsulfonyl-1-imidazolyl 691 F 2-Cl-phenyl 2- (aminosulfonyl) phenyl 692 F 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 693 F 2-Cl-phenyl 1-pyrrolidinocarbonyl 694 F 2-Cl-phenyl 2- (methylsulfonyl) phenyl 695 F 2-Cl-phenyl 4-morpholino 696 F 2-Cl-phenyl 2- (1' -CF3-tetrazol-2-yl) phenyl 697 F 2-Cl-phenyl 4-morpholinocarbonyl 698 F 2-Cl-phenyl 2-methyl-1-imidazolyl 699 F 2-Cl-phenyl 5-methyl-1-imidazolyl 700 F 2-Cl-phenyl 2-methylsulfonyl-1-imidazolyl 701 F 2-F-phenyl 2- (aminosulfonyl) phenyl 702 F 2-F-phenyl 2- (methylaminosulfonyl) phenyl 703 F 2-F-phenyl 1-pyrrolidinocarbonyl 704 F 2-F-phenyl 2- (methylsulfonyl ) phenyl 705 F 2-F-phenyl 4-morpho1ino 706 F 2-F-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl 707 F 2-F-phenyl 4-morpholinocarbonyl 708 F 2-F-phenyl 2-methyl-1-imidazolyl 709 F 2-F-phenyl 5-methyl-1-imidazolyl 710 F 2-F-phenyl 2-methylsulfonyl-1-imidazolyl 711 F 2, 6-diF-phenyl 2- (aminosulfonyl) phenyl 712 F 2, 6-diF-phenyl 2- (methylaminosulfonyl) phenyl 713 F 2, 6-diF-phenyl 1-pyrrolidinocarbonyl 714 F 2, 6-diF-phenyl 2- (methylsulfonyl) phenyl 715 F 2, 6-diF-phenyl 4-morpholino 716 F 2, 6-diF-phenyl 2- (1' -CF3-tetrazol-2-yl) phenyl 717 F 2, 6-diF-phenyl 4-morpholinocarbonyl 718 F 2, 6-diF-phenyl 2-methyl-l-imidazolyl 719 F 2, 6-diF-phenyl 5-methyl-1-imidazolyl 720 F 2, 6-diF-phenyl 2-methylsulfonyl-1-imidazolyl 721 C0 2 CH 3 phenyl 2- (aminosulfonyl) phenyl 722 C0 2 CH 3 phenyl 2- (methylaminosulfonyl) phenyl 723 C0 2 CH 3 phenyl 1-pyrrolidinocarbonyl 724 C0 2 CH 3 phenyl 2- (methylsulfonyl) phenyl 725 C0 2 CH 3 phenyl 4-morpholino 726 C0 2 CH 3 phenyl 2- ( 1 ' -CF3 -tetrazol-2-yl) phenyl 727 C0 2 CH 3 phenyl 4-morpholinocarbonyl 728 C0 2 CH 3 phenyl 2-methyl-l-imidazolyl 729 C0 2 CH 3 phenyl 5-methyl-1-imidazolyl 730 C0 2 CH 3 phenyl 2-methylsulfonyl-1-imidazolyl 731 C0 2 CH 3 2-pyridyl 2- (aminosulfonyl)phenyl 732 C0 2 CH 3 2-pyridyl 2- (methylaminosulfonyl)phenyl 733 C0 2 CH 3 2-pyridyl 1-pyrrolidinocarbonyl 734 C0 2 CH 3 2-pyridyl 2- (methylsulfonyl ) phenyl 735 C0 2 CH 3 2-pyridyl 4-morpholino 736 C0 2 CH 3 2-pyridyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 737 C0 2 CH 3 2-pyridyl 4-morpholinocarbonyl 738 C0 2 CH 3 2-pyridyl 2-methyl-1-imidazolyl 739 C0 2 CH 3 2-pyridyl 5-methyl-1-imidazolyl 740 C0 2 CH 3 2-pyridyl 2-methylsulfonyl-1-imidazolyl 741 C0 2 CH 3 3-pyridyl 2- (aminosulfonyl) phenyl 742 C0 2 CH 3 3 -pyridyl 2- (methylaminosulfonyl) phenyl 743 C0 2 CH 3 3-pyridyl 1-pyrrolidinocarbonyl 744 C0 2 CH 3 3-pyridyl 2- (methylsulfonyl) phenyl 745 C0 2 CH 3 3-pyridyl 4-morpholino 746 C0 2 CH 3 3-pyridyl 2- ( 1 ' -CF3-tetrazol-2-yl ) phenyl 747 C0 2 CH 3 3-pyridyl 4-morpholinocarbonyl 748 C0 2 CH 3 3-pyridyl 2-methyl-1-imidazolyl 749 C0 2 CH 3 3-pyridyl 5-methyl-1-imidazolyl 750 C0 2 CH 3 3-pyridyl 2-methylsulfonyl-1-imidazolyl 751 C0 2 CH 3 2-pyrimidyl 2- (aminosulfonyl) phenyl 752 C0 2 CH 3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 753 C0 2 CH 3 2-pyrimidyl 1-pyrrolidinocarbonyl 754 C0 2 CH 3 2-pyrimidyl 2- (methylsulfonyl) phenyl 755 C0 2 CH 3 2-pyrimidyl 4-morpholino 756 C0 2 CH 3 2-pyrimidyl 2- ( 1 ' -CF3 -tetrazol-2-yl) phenyl 757 C0 2 CH 3 2-pyrimidyl 4-morpholinocarbonyl 758 C0 2 CH 3 2-pyrimidyl 2-methyl-1-imidazolyl 759 C0 2 CH 3 2 -pyrimidyl 5-methyl-1-imidazolyl 760 C0 2 CH 3 2-pyrimidyl 2-methylsulfonyl-1-imidazolyl 761 C0 2 CH 3 5-pyrimidyl 2- (aminosulfonyl) phenyl 762 C0 2 CH 3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 763 C0 2 CH 3 5-pyrimidyl 1-pyrrolidinocarbonyl 764 C0 2 CH 3 5-pyrimidyl 2- (methylsulfonyl) phenyl 765 C0 2 CH 3 5-pyrimidyl 4-morpholino 766 C0 2 CH 3 5-pyrimidyl 2- (1 ' -CF3 -tetrazol-2-yl) phenyl 767 C0 2 CH 3 5-pyrimidyl 4-morpholinocarbonyl 768 C0 2 CH 3 5-pyrimidyl 2-methyl-1-imidazolyl 769 C0 2 CH 3 5-pyrimidyl 5-methyl-1-imidazolyl 770 C0 2 CH 3 5-pyrimidyl 2-methylsulfonyl-1-imidazolyl 771 C0 2 CH 3 2-Cl-phenyl 2- (aminosulfonyl) phenyl 772 C0 2 CH 3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 773 C0 2 CH 3 2-Cl-phenyl 1-pyrrolidinocarbonyl 774 C0 2 CH 3 2-Cl-phenyl 2- (methylsulfonyl) phenyl 775 C0 2 CH 3 2-Cl-phenyl 4-morpholino 776 C0 2 CH 3 2-Cl-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl 777 C0 2 CH 3 2-Cl-phenyl 4-morpholinocarbonyl 778 C0 2 CH 3 2-Cl-phenyl 2-methyl-l-imidazolyl 779 C0 2 CH 3 2-Cl-phenyl 5-methyl-1-imidazolyl 780 C0 2 CH 3 2-Cl-phenyl 2-methylsulfonyl-1-imidazolyl 781 C0 2 CH 3 2-F-phenyl 2- (aminosulfonyl)phenyl 782 C0 2 CH 3 2-F-phenyl 2- (methylaminosulfonyl) phenyl 783 C0 2 CH 3 2-F-phenyl 1-pyrrolidinocarbonyl 784 C0 2 CH 3 2-F-phenyl 2- (methylsulfonyl) phenyl 785 C0 2 CH 3 2-F-phenyl 4-morpho1ino 786 C0 2 CH 3 2-F-phenyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl 787 C0 2 CH 3 2-F-phenyl 4-morpholinocarbonyl 788 C0 2 CH 3 2-F-phenyl 2-methyl-1-imidazolyl 789 C0 2 CH 3 2-F-phenyl 5-methyl-1-imidazolyl 790 C0 2 CH 3 2-F-phenyl 2-methylsulfonyl-1-imidazolyl 791 C0 2 CH 3 2 , 6-diF-phenyl 2- (aminosulfonyl ) phenyl 792 C0 2 CH 3 2 , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl 793 C0 2 CH 3 2 , 6-diF-phenyl 1-pyrrolidinocarbonyl 794 C0 2 CH 3 2 , 6-diF-phenyl 2- (methylsulfonyl) phenyl 795 C0 2 CH 3 2 , 6-diF-phenyl 4-morpholino 796 C0 2 CH 3 2 , 6-diF-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 797 C0 2 CH 3 2 , 6-diF-phenyl 4-morpholinocarbonyl 798 C0 2 CH 3 2, 6-diF-phenyl 2-methyl-1-imidazolyl 799 C0 2 CH 3 2, 6-diF-phenyl 5-methyl-1-imidazolyl 800 C0 2 CH 3 2, 6-diF-phenyl 2-methylsulfonyl-1-imidazolyl 801 CH 2 OCH 3 phenyl 2- (aminosulfonyl) phenyl 802 CH 2 OCH 3 phenyl 2- (methylaminosulfonyl) phenyl 803 CH 2 OCH 3 phenyl 1-pyrrolidinocarbonyl 804 CH 2 OCH 3 phenyl 2- (methylsulfonyl) phenyl 805 CH 2 OCH 3 phenyl 4-morpholino 806 CH 2 OCH 3 phenyl 2- ( 1 ' -CF3 -tetrazol-2-yl) phenyl 807 CH 2 OCH 3 phenyl 4-morpholinocarbonyl 808 CH 2 OCH 3 phenyl 2-methyl-1-imidazolyl 809 CH 2 OCH 3 phenyl 5-methyl-1-imidazolyl 810 CH 2 OCH 3 phenyl 2-methylsulfonyl-1-imidazolyl 811 CH 2 OCH 3 2-pyridyl 2- (aminosulfonyl) phenyl 812 CH 2 OCH 3 2-pyridyl 2- (methylaminosulfonyl ) phenyl 813 CH 2 OCH 3 2-pyridyl 1-pyrrolidinocarbonyl 814 CH 2 OCH 3 2-pyridyl 2- (methylsulfonyl) phenyl 815 CH 2 OCH 3 2-pyridyl 4-morpholino 816 CH 2 OCH 3 2-pyridyl 2-(l'-CF3-tetrazol-2-yl)phenyl 817 CH 2 OCH 3 ?-pyridyl 4-morpholinocarbonyl 818 CH 2 OCH 3 2 -pyridyl 2-methyl-l-imidazolyl 819 CH 2 OCH 3 2-pyridyl 5-methyl-1-imidazolyl 820 CH 2 OCH 3 2-pyridyl 2-methylsulfonyl-1-imidazolyl 821 CH 2 OCH 3 3-pyridyl 2- (aminosulfonyl)phenyl 822 CH 2 OCH 3 3-pyridyl 2- (methylaminosulfonyl) phenyl 823 CH 2 OCH 3 3-pyridyl 1-pyrrolidinocarbonyl 824 CH 2 OCH 3 3-pyridyl 2- (methylsulfonyl) phenyl 825 CH 2 OCH 3 3-pyridyl 4-morpho1ino 826 CH 2 OCH 3 3-pyridyl 2- (1' -CF3-tetrazol-2-yl) phenyl 827 CH 2 OCH 3 3-pyridyl 4-morpholinocarbonyl 828 CH 2 OCH 3 3-pyridyl 2-methyl-1-imidazolyl 829 CH 2 OCH 3 3-pyridyl 5-methyl-1-imidazolyl 830 CH 2 OCH 3 3-pyridyl 2-methylsulfonyl-1-imidazolyl 831 CH 2 OCH 3 2-pyrimidyl 2- (aminosulfonyl)phenyl 832 CH 2 OCH 3 2-pyrimidyl 2- (methylaminosulfonyl ) phenyl 833 CH 2 OCH 3 2-pyrimidyl 1-pyrrolidinocarbonyl 834 CH 2 OCH 3 2-pyrimidyl 2- (methylsulfonyl) phenyl 835 CH 2 OCH 3 2-pyrimidyl 4-morpholino 836 CH 2 OCH 3 2 -pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 837 CH 2 OCH 3 2-pyrimidyl 4-morpholinocarbonyl 838 CH 2 OCH 3 2-pyrimidyl 2-methyl-l-imidazolyl 839 CH 2 OCH 3 2-pyrimidyl 5-methyl-1-imidazolyl 840 CH 2 OCH 3 2-pyrimidyl 2-methylsulfonyl-1-imidazolyl 841 CH 2 OCH 3 5-pyrimidyl 2- (aminosulfonyl) phenyl 842 CH 2 OCH 3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 843 CH 2 OCH 3 5-pyrimidyl 1-pyrro1idinocarbonyl 844 CH 2 OCH 3 5-pyrimidyl 2- (methylsulfonyl) phenyl 845 CH 2 OCH 3 5-pyrimidyl 4-morpholino 846 CH 2 OCH 3 5-pyrimidyl 2- { 1 ' -CF3-tetrazol-2-yl) phenyl 847 CH 2 OCH 3 5-pyrimidyl 4-morpholinocarbonyl 848 CH 2 OCH 3 5-pyrimidyl 2-methyl-1-imidazolyl 849 CH 2 OCH 3 5-pyrimidyl 5-methyl-1-imidazolyl 850 CH 2 OCH 3 5-pyrimidyl 2-methylsulfonyl-1-imidazolyl 851 CH 2 OCH 3 2-Cl-phenyl 2- (aminosulfonyl)phenyl 852 CH 2 OCH 3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 853 CH 2 OCH 3 2-Cl-phenyl 1-pyrro1idinocarbonyl 854 CH 2 OCH 3 2-Cl-phenyl 2- (methylsulfonyl)phenyl 855 CH 2 OCH 3 2-Cl-phenyl 4-morpholino 856 CH 2 OCH 3 2-Cl-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl 857 CH 2 OCH 2-Cl-phenyl 4-morpholinocarbonyl 858 CH 2 OCH 3 2-Cl-phenyl 2-methyl-1-imidazolyl 859 CH 2 OCH 3 2-Cl-phenyl 5-methyl-1-imidazolyl 860 CH 2 OCH 3 2-Cl-phenyl 2-methylsulfonyl-1-imidazolyl 861 CH 2 OCH 3 2-F-phenyl 2- (aminosulfonyl) phenyl 862 CH 2 OCH 3 2-F-phenyl 2- (methylaminosulfonyl)phenyl 863 CH 2 OCH 3 2-F-phenyl 1-pyrrolidinocarbonyl 864 CH 2 OCH 3 2-F-phenyl 2- (methylsulfonyl) phenyl 865 CH 2 OCH 3 2-F-phenyl 4-morpholino 866 CH 2 OCH 3 2-F-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 867 CH 2 OCH 3 2-F-phenyl 4-morpholinocarbonyl 868 CH 2 OCH 3 2-F-phenyl 2-methyl-l-imidazolyl 869 CH 2 OCH 3 2-F-phenyl 5-methyl-1-imidazolyl 870 CH 2 OCH 3 2-F-phenyl 2-methylsulfonyl-1-imidazolyl 871 CH 2 OCH 3 2, 6-diF-phenyl 2- (aminosulfonyl) phenyl 872 CH 2 OCH 3 2 , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl 873 CH 2 OCH 3 2 , 6-diF-phenyl 1-pyrrolidinocarbonyl 874 CH 2 OCH 3 2 , 6-diF-phenyl 2- (methylsulfonyl) phenyl 875 CH 2 OCH 3 2, 6-diF-phenyl 4-morpholino 876 CH 2 OCH 3 2 , 6-diF-phenyl 2- ( 1 ' -CF3 -tetrazol-2-yl) phenyl 877 CH 2 OCH 3 2 , 6-diF-phenyl 4-morpho1inocarbonyl 878 CH 2 OCH 3 2 , 6-diF-phenyl 2-methyl-1-imidazolyl 879 CH 2 OCH 3 2 , 6-diF-phenyl 5-methyl-1-imidazolyl 880 CH 2 OCH 3 2, 6-diF-phenyl 2-methylsulfonyl-1-imidazolyl 881 CONH 2 phenyl 2- (aminosulfonyl) phenyl 882 CO H 2 phenyl 2- (methylaminosulfonyl)phenyl 883 CO H 2 phenyl 1-pyrrolidinocarbonyl 884 CO H 2 phenyl 2- (methylsulfonyl) phenyl 885 CONH 2 phenyl 4-morpholino 886 CO H 2 phenyl 2- (1 ' -CF3 -tetrazol-2-yl) phenyl 887 CONH 2 phenyl 4-morpholinocarbonyl 888 CONH 2 phenyl 2-methyl-1-imidazolyl 889 CONH 2 phenyl 5-methyl-1-imidazolyl 890 CONH 2 phenyl 2-methylsulfonyl-1-imidazolyl 891 CONH 2 2-pyridyl 2- (aminosulfonyl) phenyl 892 CONH 2 2-pyridyl 2- (methylaminosulfonyl) phenyl 893 CONH 2 2-pyridyl 1 -pyr rol idinocarbonyl 894 CONH 2 2-pyridyl 2 - (methylsulfonyl ) phenyl 895 CO H 2 2-pyridyl 4 -morpholino 896 CONH 2 2-pyridyl 2 - ( 1 ' -CF3 -tetrazol-2 -yl ) phenyl 897 CO H 2 2-pyridyl 4-morpholinocarbonyl 898 CO H 2 2-pyridyl 2-methyl-1-imidazolyl 899 CONH 2 2-pyridyl 5-methyl-1-imidazolyl 900 CONH 2 2-pyridyl 2-methylsulfonyl-1-imidazolyl 901 CO H 2 3-pyridyl 2- (aminosulfonyl) phenyl 902 CONH 2 3-pyridyl 2- (methylaminosulfonyl) phenyl 903 CONH 2 3 -pyridyl 1-pyrrolidinocarbonyl 904 CO H 2 3-pyridyl 2- (methylsulfonyl) phenyl 905 CONH 2 3-pyridyl 4-morpholino 906 CO H 2 3-pyridyl 2- (l'-CF3-tetrazol-2-yl) phenyl 907 CONH 2 3-pyridyl 4-morpholinocarbonyl 908 CONH 2 3-pyridyl 2-methyl-1-imidazolyl 909 CONH 2 3-pyridyl 5-methyl-l-imidazolyl 910 CONH 2 3 -pyridyl 2-methylsulfonyl-1-imidazolyl 911 CONH 2 2-pyrimidyl 2- (aminosulfonyl) phenyl 912 CONH 2 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 913 CONH 2 2-pyrimidyl 1-pyrrolidinocarbonyl 914 CONH 2 2-pyrimidyl 2- (methylsulfonyl) phenyl 915 CO H 2 2-pyrimidyl 4-morpho1ino 916 CONH 2 2-pyrimidyl 2- (l'-CF3-tetrazol-2-yl) phenyl 917 CO H 2-pyrimidyl 4-morpholinocarbonyl 918 CONH2 2-pyrimidyl 2-methyl-1-imidazolyl 919 CONH 2 2-pyrimidyl 5-methyl-1-imidazolyl 920 CO H 2 2-pyrimidyl 2-methylsulfonyl-1-imidazolyl 921 CONH 2 5-pyrimidyl 2- ( minosulfonyl) phenyl 922 CO H 2 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 923 CONH 2 5-pyrimidyl 1-pyrrolidinocarbonyl 924 CO H 2 5-pyrimidyl 2- (methylsulfonyl) phenyl 925 CO H 2 5-pyrimidyl 4-morpholino 926 CONH 2 5-pyrimidyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl 927 CONH 2 5-pyrimidyl 4-morpho1inocarbony1 928 CONH 2 5-pyrimidyl 2-methyl-1-imidazolyl 929 CONH 5-pyrimidyl 5-methyl-l-imidazolyl 930 CONH 2 5-pyrimidyl 2-methylsulfonyl-1-imidazolyl 931 CONH 2-Cl-phenyl 2- (aminosulfonyl) phenyl 932 CONH 2 2-Cl-phenyl 2- (methylaminosulfonyl)phenyl 933 CONH 2 2-Cl-phenyl 1-pyrrolidinocarbonyl 934 CONH 2 2-Cl-phenyl 2- (methylsulfonyl) phenyl 935 CO H 2 2-Cl-phenyl 4-morpholino 936 CONH2 2-Cl-phenyl 2-(l'-CF3-tetrazol-2-yl)phenyl 937 CONH 2 2-Cl-phenyl 4-morpholinocarbonyl 938 CONH 2 2-Cl-phenyl 2-methyl-1-imidazolyl 939 CONH 2 2-Cl-phenyl 5-methyl-1-imidazolyl 940 CONH 2-Cl-phenyl 2-methylsulfony1-1-imidazolyl 941 CO H 2 2-F-phenyl 2- (aminosulfonyl) phenyl 942 CONH 2 2-F-phenyl 2- (methylaminosulfonyl) phenyl 943 CONH 2 2-F-phenyl 1-pyrrolidinocarbonyl 944 CONH 2 2-F-phenyl 2- (methylsulfonyl) phenyl 945 CONH 2 2 -F-phenyl 4-morpholino 946 CO H 2 2 -F-phenyl 2- ( 1 ' -CF3 -tetrazol-2-yl) phenyl 947 CONH 2 2 -F-phenyl 4-morpholinocarbonyl 948 CONH 2 2 -F-phenyl 2-methyl-1-imidazolyl 949 CO H 2 -F-phenyl 5-methyl-1-imidazolyl 950 CO H 2 2 -F-phenyl 2-methylsulfonyl-1-imidazolyl 951 CONH 2 2, 6-diF-phenyl 2- (aminosulfonyl) phenyl 952 CO H 2 2, 6-diF-phenyl 2- (methylaminosulfonyl) phenyl 953 CONH 2 2, 6 -diF -phenyl 1-pyrrolidinocarbonyl 954 CO H 2 2, 6 -diF -phenyl 2- (methylsulfonyl) phenyl 955 CONH 2 2, 6-diF-phenyl 4-morpholino 956 CONH 2 2, 6-diF-phenyl 2- (1' -CF3-tetrazol-2-yl) phenyl 957 CO H 2 2, 6-diF-phenyl 4-morpholinocarbonyl 958 CO H 2 2, 6 -diF -phenyl 2-methyl-1-imidazolyl 959 CONH 2 2, 6-diF-phenyl 5-methyl-1-imidazolyl 960 CONH 2 2, 6-diF-phenyl 2-methylsulfonyl-1-imidazolyl Table 3 hh ij tt uu w ww X* yy zz aaa bbb ooo PPP qqq rrr sss_ ttt uuu vw www XXX yyy zzz aaaa bbbb A phenyl 2- (aminosulfonyl)phenyl phenyl 2- (methylaminosulfonyl)phenyl phenyl 1-pyrrolidinocarbonyl phenyl 2- (methylsulfonyl)phenyl phenyl 4-morpholino phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl phenyl 4-morpholinocarbonyl phenyl 2-methyl-1-imidazolyl phenyl 5-methyl-l-imidazolyl phenyl 2-methylsulfonyl-1-imidazolyl 2-pyridyl 2- (aminosulfony1)phenyl 2-pyridyl 2- (methylaminosulfonyl)phenyl 2-pyridyl 1-pyrrolidinocarbonyl 2-pyridyl 2- (methylsulfonyl)phenyl 2-pyridyl 4-morpholino 2-pyridyl 2- (l'-CF3-tetrazol-2-yl) phenyl 2-pyridyl 4-morpholinocarbonyl 2-pyridyl 2-methyl-l-imidazolyl 2-pyridyl 5-methyl-l-imidazolyl 2-pyridyl 2-methylsulfonyl-1-imidazolyl 3-pyridyl 2- (aminosulfonyl)phenyl 3-pyridyl 2- (methylaminosulfonyl)phenyl 3-pyridyl 1-pyrrolidinocarbonyl 3-pyridyl 2- (methylsulfonyl)phenyl 3-pyridyl 4-morpho1ino 3-pyridyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 3-pyridyl 4-morpholinocarbonyl 3-pyridyl 2-methyl-l-imidazolyl 3 -pyridyl 5-methyl-1-imidazolyl 3 -pyridyl 2-methylsulfonyl-1-imidazolyl 2-py imidyl 2- (aminosulfonyl) phenyl 2-pyrimidyl 2- (methylaminosulfonyl ) phenyl 2-pyrimidyl 1-pyrrolidinocarbonyl 2-pyrimidyl 2- (methylsulfonyl) phenyl 2-pyrimidyl 4-morpholino 2-pyrimidyl 2- (l'-CF3-tetrazol-2-yl) phenyl 2-pyrimidyl 4-morpholinocarbonyl 2-pyrimidyl 2-methyl-1-imidazolyl 2-pyrimidyl 5-methyl-l-imidazolyl 2-pyrimidyl 2-methylsulfonyl-1-imidazolyl 5-pyrimidyl 2- (aminosulfonyl) phenyl 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 5-pyrimidyl 1-pyrrolidinocarbonyl 5-pyrimidyl 2- (methylsulfonyl) phenyl 5-pyrimidyl 4-morpholino 5-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 5-pyrimidyl 4-morpholinocarbonyl 5-pyrimidyl 2-methyl-1-imidazolyl 5-pyrimidyl 5-methyl-1-imidazolyl 5-pyrimidyl 2-methylsulfonyl-1-imidazolyl 2-Cl-phenyl 2- (aminosulfonyl)phenyl 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 2-Cl-phenyl 1-pyrrolidinocarbonyl 2-Cl-phenyl 2- (methylsulfonyl)phenyl 2-Cl-phenyl 4-morpholino 2-Cl-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 2-Cl-phenyl 4-morpholinocarbonyl 2-Cl-phenyl 2-methyl-1-imidazolyl 2-Cl-phenyl 5-methyl-1-imidazolyl 2-Cl-phenyl 2-methylsulfonyl-1-imidazolyl 2-F-phenyl 2- (aminosulfonyl) phenyl 2-F-phenyl 2- (methylaminosulfonyl) phenyl 2-F-phenyl 1-pyrrolidinocarbonyl 2-F-phenyl 2- (methylsulfonyl) phenyl 2-F-phenyl 4-morpholino 2-F-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl 2-F-phenyl 4-morpholinocarbonyl 2-F-phenyl 2-methyl-1-imidazolyl 2-F-phenyl 5-methyl-l-imidazolyl 2-F-phenyl 2-methylsulfonyl-1-imidazolyl 2 , 6-diF-phenyl 2- (aminosulfonyl) phenyl 2 , 6-diF-phenyl 2- (methylaminosulfonyl) henyl 2 , 6-diF-phenyl 1-pyrrolidinocarbonyl 2 , 6-diF-phenyl 2- (methylsulfonyl) phenyl 2 , 6-diF-phenyl 4-morpholino 2,6-diF-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 2,6-diF-phenyl 4-morpholinocarbonyl 2 , 6-diF-phenyl 2-methyl-l-imidazolyl 2 , 6-diF-phenyl 5-methyl-1-imidazolyl 2 , 6-diF-phenyl 2-methylsulfonyl-1-imidazolyl Table 4 hh zz aaa bbb w ggg hhh Ex -1t R la A B 1 CH3 phenyl 2- (.aminosulfonyl ) phenyl 2 CH 3 phenyl 2- (methylaminosulfonyl) phenyl 3 CH 3 phenyl 1-pyrrolidinocarbonyl 4 CH 3 phenyl 2- (methylsulfonyl) phenyl 5 CH 3 phenyl 4-morpholino 6 CH 3 phenyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl 7 7 C CHH3 3 pphheennyyll 4-morpholinocarbonyl 8 CH 3 phenyl 2-methyl-l-imidazolyl 9 CH 3 phenyl 5-methyl-l-imidazolyl 10 CH3 phenyl 2-methylsulfonyl-1-imidazolyl 11 CH 3 2-pyridyl 2- (aminosulfonyl) phenyl 1 122 C CHH3 3 2 2--ppyyrriiddyyll 2- (methylaminosulfonyl) phenyl 13 CH3 2-pyridyl 1-pyrrolidinocarbonyl 14 CH 3 2-pyridyl 2- (methylsulfonyl) phenyl 15 CH3 2-pyridyl 4-morpholino 16 CH 3 2-pyridyl 2- (1' -CF3-tetrazol-2-yl) phenyl 1 177 C CHH 33 2 2--ppyyrriiddyyll 4-morpholinocarbonyl 18 CH 3 2-pyridyl 2-methyl-l-imidazolyl 19 CH3 2-pyridyl 5-methyl-l-imidazolyl 20 CH 3 2-pyridyl 2-methylsulfonyl-1-imidazolyl 21 CH3 3-pyridyl 2- (aminosulfonyl)phenyl 2 222 C CHH33 3 3--ppyyrriiddyyll 2- (methylaminosulfonyl) phenyl 23 CH3 3-pyridyl 1-pyrrolidinocarbonyl 24 CH3 3-pyridyl 2- (methylsulfonyl) phenyl 25 CH3 3-pyridyl 4-morpholino 26 CH3 3-pyridyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl 2 277 C CHH33 3 3--ppyyrriiddyyll 4-morpholinocarbonyl 28 CH3 3-pyridyl 2-methyl-1-imidazolyl 29 CH 3 3-pyridyl 5-methyl-1-imidazolyl 30 CH 3 3-pyridyl 2-methylsulfonyl-1-imidazolyl 31 CH3 2-pyrimidyl 2- (aminosulfonyl)phenyl 3 322 C CHH3 3 2 2--ppyyrriimmiiddyyll 2- (methylaminosulfonyl) phenyl 33 CH3 2-pyrimidyl 1-pyrrolidinocarbonyl CH 3 2 -pyrimidyl 2- (methylsulfonyl) phenyl CH3 2 -pyrimidyl 4-morpholino CH3 2 -pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl CH3 2 -pyrimidyl 4-morpholinocarbonyl CH 3 2 -pyrimidyl 2-methyl-1-imidazolyl CH 3 2-pyrimidyl 5-methyl-1-imidazolyl CH 3 2-pyrimidyl 2-methylsulfonyl-1-imidazolyl CH 3 5-pyrimidyl 2- (aminosulfonyl) phenyl CH 3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl CH 3 5-pyrimidyl 1-pyrrolidinocarbonyl CH 3 5-pyrimidyl 2- (methylsulfonyl) phenyl CH 3 5-pyrimidyl 4-morpho1ino CH 3 5-pyrimidyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl CH 3 5-pyrimidyl 4-morpholinocarbonyl CH 3 5-pyrimidyl 2-methyl-1-imidazolyl CH3 5-pyrimidyl 5-methyl-1-imidazolyl CH 3 5-pyrimidyl 2-methylsulfonyl-1-imidazolyl CH 3 2-Cl-phenyl 2- (aminosulfonyl) phenyl CH 3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl CH 3 2-Cl-phenyl 1-pyrrolidinocarbonyl CH 3 2-Cl-phenyl 2- (methylsulfonyl) phenyl CH 3 2-Cl-phenyl 4-morpho1ino CH 3 2-Cl-phenyl 2- ( 1 ' -CF3 -tetrazol-2-yl ) phenyl CH 3 2-Cl-phenyl 4-morpholinocarbonyl CH 3 2-Cl-phenyl 2-methyl-1-imidazolyl CH 3 2-Cl-phenyl 5-methyl-1-imidazolyl CH 3 2-Cl-phenyl 2-methylsulfonyl-1-imidazolyl CH 3 2-F-phenyl 2- (aminosulfonyl) phenyl CH 3 2-F-phenyl 2- (methylaminosulfonyl)phenyl CH 3 2-F-phenyl 1-pyrrolidinocarbonyl CH 3 2-F-phenyl 2- (methylsulfonyl) phenyl CH 3 2-F-phenyl 4-morpholino CH 3 2-F-phenyl 2- (1' -CF3-tetrazol-2-yl) phenyl CH 3 2-F-phenyl 4-morpholinocarbonyl CH 3 2-F-phenyl 2-methyl-1-imidazolyl CH 3 2-F-phenyl 5-methyl-l-imidazolyl CH 3 2-F-phenyl 2-methylsulfonyl-1-imidazolyl CH 3 2,6-diF-phenyl 2- (aminosulfonyl) phenyl CH 3 2 , 6-diF-phenyl 2- (methylaminosulfonyl) henyl CH3 2 , 6-diF-phenyl 1-pyrrolidinocarbonyl CH 3 2,6-diF-phenyl 2- (methylsulfonyl) phenyl CH 3 2,6-diF-phenyl 4-morpholino CH3 2,6-diF-phenyl 2- (1 ' -CF3 -tetrazol-2-yl) phenyl CH 3 2,6-diF-phenyl 4-morpholinocarbonyl CH 3 2,6-diF-phenyl 2-methyl-1-imidazolyl CH 3 2 , 6-diF-phenyl 5-methyl-l-imidazoly1 CH 3 2 , 6-diF-phenyl 2-methylsulfonyl-1-imidazolyl CH 2 CH 3 phenyl 2- (aminosulfonyl) phenyl CH 2 CH 3 phenyl 2- (methylaminosulfonyl)phenyl CH 2 CH 3 phenyl 1-pyrrolidinocarbonyl CH 2 CH 3 phenyl 2- (methylsulfonyl) phenyl CH 2 CH 3 phenyl 4-morpholino 86 CH 2 CH 3 phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 87 CH 2 CH 3 phenyl 4-morpholinocarbonyl 88 CH 2 CH 3 phenyl 2-methyl-1-imidazolyl 89 CH2CH3 phenyl 5-methyl-l-imidazolyl 90 CH 2 CH 3 phenyl 2-methylsulfonyl-1-imidazolyl 91 CH 2 CH 3 2-pyridyl 2- (.aminosulfonyl) phenyl 92 CH 2 CH 3 2-pyridyl 2- (methylaminosulfonyl)phenyl 93 CH 2 CH 3 2-pyridyl 1-pyrrolidinocarbonyl 94 CH 2 CH 3 2-pyridyl 2- (methylsulfonyl) phenyl 95 CH 2 CH 3 2-pyridyl 4-morpholino 96 CH 2 CH 3 2-pyridyl 2- (1 ' -CF3- etrazol-2-yl) phenyl 97 CH 2 CH 3 2-pyridyl 4-morpholinocarbonyl 98 CH 2 CH 3 2-pyridyl 2-methyl-1-imidazolyl 99 CH 2 CH 3 2-pyridyl 5-methyl-l-imidazolyl 100 CH 2 CH 3 2-pyridyl 2-methylsulfonyl-1-imidazolyl 101 CH 2 CH3 3-pyridyl 2- (aminosulfonyl)phenyl 102 CH 2 CH 3 3-pyridyl 2- (methylaminosulfonyl) phenyl 103 CH 2 CH 3 3-pyridyl 1-pyrrolidinocarbonyl 104 CH 2 CH3 3-pyridyl 2- (methylsulfonyl) phenyl 105 CH 2 CH 3 3-pyridyl 4-morpholino 106 CH 2 CH 3 3-pyridyl 2- (l'-CF3-tetrazol-2-yl) phenyl 107 CH 2 CH 3 3-pyridyl 4-morpholinocarbonyl 108 CH 2 CH 3 3-pyridyl 2-methyl-l-imidazolyl 109 CH 2 CH 3 3-pyridyl 5-methyl-l-imidazolyl 110 CH 2 CH 3 3-pyridyl 2-methylsulfonyl-1-imidazolyl 111 CH 2 CH 3 2-pyrimidyl 2- (aminosulfonyl) phenyl 112 CH 2 CH 3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 113 CH 2 CH 3 2-pyrimidyl 1-pyrrolidinocarbonyl 114 CH 2 CH 3 2-pyrimidyl 2- (methylsulfonyl) phenyl 115 CH 2 CH 3 2-pyrimidyl 4-morpholino 116 CH 2 CH 3 2-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 117 CH 2 CH 3 2-pyrimidyl 4-morpholinocarbonyl 118 CH 2 CH 3 2-pyrimidyl 2-methyl-l-imidazolyl 119 CH 2 CH 3 2-pyrimidyl 5-methyl-l-imidazolyl 120 CH 2 CH 3 2-pyrimidyl 2-methylsulfonyl-1-imidazolyl 121 CH 2 CH 3 5-pyrimidyl 2- (aminosulfonyl) phenyl 122 CH 2 CH 3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 123 CH 2 CH 3 5-pyrimidyl 1-pyrrolidinocarbonyl 124 CH 2 CH 3 5-pyrimidyl 2- (methylsulfonyl) phenyl 125 CH 2 CH3 5-pyrimidyl 4-morpholino 126 CH 2 CH 3 5-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 127 CH 2 CH 3 5-pyrimidyl 4-morpholinocarbonyl 128 CH 2 CH3 5-pyrimidyl 2-methyl-l-imidazolyl 129 CH 2 CH 3 5-pyrimidyl 5-methyl-l-imidazolyl 130 CH 2 CH 3 5-pyrimidyl 2-methylsulfonyl-1-imidazolyl 131 CH 2 CH 3 2-Cl-phenyl 2- (aminosulfonyl) phenyl 132 CH 2 CH 3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 133 CH 2 CH 3 2-Cl-phenyl 1-pyrrolidinocarbonyl 134 CH 2 CH 3 2-Cl-phenyl 2- (methylsulfonyl) phenyl 135 CH 2 CH 3 2-Cl-phenyl 4-morpholino 136 CH 2 CH 3 2-Cl-phenyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl 137 CH 2 CH 3 2-Cl-phenyl 4-morpholinocarbonyl 138 CH 2 CH 3 2-Cl-phenyl 2-methyl-1-imidazolyl 139 CH 2 CH 3 2-Cl-phenyl 5-methyl-1-imidazolyl 140 CH 2 CH 3 2-Cl-phenyl 2-methylsulfonyl-1-imidazolyl 141 CH 2 CH 3 2-F-phenyl 2- (aminosulfonyl) phenyl 142 CH 2 CH 3 2-F-phenyl 2- (methylaminosulfonyl) phenyl 143 CH 2 CH 3 2-F-phenyl 1-pyrro1idinocarbony1 144 CH 2 CH 3 2-F-phenyl 2- (methylsulfonyl) phenyl 145 CH 2 CH 3 2-F-phenyl 4-morpholino 146 CH 2 CH 3 2-F-phenyl 2- (1' -CF3-tetrazol-2-yl) phenyl 147 CH 2 CH 3 2-F-phenyl 4-morpholinocarbonyl 148 CH 2 CH 3 2-F-phenyl 2-methyl-1-imidazolyl 149 CH 2 CH 3 2-F-phenyl 5-methyl-l-imidazolyl 150 CH 2 CH 3 2-F-phenyl 2-methylsulfonyl-1-imidazolyl 151 CH 2 CH 3 2 , 6-diF-phenyl 2- (aminosulfonyl)phenyl 152 CH 2 CH 3 2 , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl 153 CH 2 CH 3 2 , 6-diF-phenyl 1-pyrro1idinocarbonyl 154 CH 2 CH 3 2 , 6-diF-phenyl 2- (methylsulfonyl) phenyl 155 CH 2 CH 3 2 , 6-diF-phenyl 4-morpholino 156 CH 2 CH 3 2 , 6-diF-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl 157 CH 2 CH 3 2 , 6-diF-phenyl 4-morpholinocarbonyl 158 CH 2 CH 3 2 , 6-diF-phenyl 2-methyl-1-imidazolyl 159 CH 2 CH 3 2 , 6-diF-phenyl 5-methyl-1-imidazolyl 160 CH 2 CH 3 2 , 6-diF-phenyl 2-methylsulfonyl-1-imidazolyl 161 CF 3 phenyl 2- (aminosulfonyl)phenyl 162 CF3 phenyl 2- (methylaminosulfonyl) phenyl 163 CF3 phenyl 1-pyrro1idinocarbonyl 164 CF 3 phenyl 2- (methylsulfonyl) phenyl 165 CF 3 phenyl 4-morpho1ino 166 CF 3 phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 167 CF 3 phenyl 4-morpholinocarbonyl 168 CF 3 phenyl 2-methyl-1-imidazolyl 169 CF 3 phenyl 5-methyl-1-imidazolyl 170 CF 3 phenyl 2-methylsulfonyl-1-imidazolyl 171 CF3 2-pyridyl 2- (aminosulfonyl) phenyl 172 CF 3 2-pyridyl 2- (methylaminosulfonyl)phenyl 173 CF3 2-pyridyl 1-pyrrolidinocarbonyl 174 CF 3 2-pyridyl 2- (methylsulfonyl) phenyl 175 CF3 2-pyridyl 4-morpholino 176 CF3 2-pyridyl 2-(l'-CF3-tetrazol-2-yl)phenyl 177 CF 3 2-pyridyl 4-morpholinocarbonyl 178 CF3 2-pyridyl 2-methyl-1-imidazolyl 179 CF3 2-pyridyl 5-methyl-1-imidazolyl 180 CF3 2-pyridyl 2-methylsulfonyl-1-imidazolyl 181 CF3 3-pyridyl 2- (aminosulfonyl)phenyl 182 CF 3 3-pyridyl 2- (methylaminosulfonyl)phenyl 183 CF3 3-pyridyl 1-pyrrolidinocarbonyl 184 CF 3 3-pyridyl 2- (methylsulfonyl) phenyl 185 CF 3 3-pyridyl 4-morpho1ino 186 CF 3 3-pyridyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 187 CF 3 3-pyridyl 4-morpholinocarbonyl 188 CF 3 3-pyridyl 2-methyl-l-imidazolyl 189 CF 3 3-pyridyl 5-methyl-l-imidazolyl 190 CF 3 3-pyridyl 2-methylsulfonyl-1-imidazolyl 191 CF 3 2-pyrimidyl 2- (aminosulfonyl) phenyl 192 CF 3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 193 CF 3 2-pyrimidyl 1-pyrrolidinocarbonyl 194 CF 3 2-pyrimidyl 2- (methylsulfonyl ) phenyl 195 CF 3 2-pyrimidyl 4-morpholino 196 CF 3 2-pyrimidyl 2- (l'-CF3-tetrazol-2-yl) phenyl 197 CF 3 2-pyrimidyl 4-morpholinocarbonyl 198 CF 3 2-pyrimidyl 2-methyl-l-imidazolyl 199 CF 3 2-pyrimidyl 5-methyl-l-imidazolyl 200 CF 3 2-pyrimidyl 2-methylsulfony1-1-imidazoly1 201 CF 3 5-pyrimidyl 2- (aminosulfonyl)phenyl 202 CF 3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 203 CF 3 5-pyrimidyl 1-pyrrolidinocarbonyl 204 CF 3 5-pyrimidyl 2- (methylsulfonyl) phenyl 205 CF 3 5-pyrimidyl 4-morpholino 206 CF 3 5-pyrimidyl 2- ( 1 ' -CF3 -tetrazol-2-yl ) phenyl 207 CF 3 5-pyrimidyl 4-morpholinocarbonyl 208 CF 3 5-pyrimidyl 2-methyl-l-imidazolyl 209 CF 3 5-pyrimidyl 5-methyl-l-imidazolyl 210 CF 3 5-pyrimidyl 2-methylsulfonyl-1-imidazolyl 211 CF 3 2-Cl-phenyl 2- (aminosulfonyl ) phenyl 212 CF 3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 213 CF 3 2-Cl-phenyl 1-pyrrolidinocarbonyl 214 CF 3 2-Cl-phenyl 2- (methylsulfonyl) phenyl 215 CF 3 2-Cl-phenyl 4-morpholino 216 CF 3 2-Cl-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 217 CF 3 2-Cl-phenyl 4-morpholinocarbonyl 218 CF 3 2-Cl-phenyl 2-methyl-l-imidazolyl 219 CF 3 2-Cl-phenyl 5-methyl-1-imidazolyl 220 CF 3 2-Cl-phenyl 2-methylsulfonyl-1-imidazolyl 221 CF 3 2-F-phenyl 2- (aminosulfonyl)phenyl 222 CF 3 2-F-phenyl 2- (methylaminosulfonyl) phenyl 223 CF 3 2-F-phenyl 1-pyrrolidinocarbonyl 224 CF 3 2-F-phenyl 2- (methylsulfonyl) phenyl 225 CF 3 2-F-phenyl 4-morpholino 226 CF 3 2-F-phenyl 2-(l'-CF3-tetrazol-2-yl)phenyl 227 CF 3 2-F-phenyl 4-morpholinocarbonyl 228 CF 3 2-F-phenyl 2-methyl-l-imidazolyl 229 CF 3 2-F-phenyl 5-methyl-l-imidazolyl 230 CF 3 2-F-phenyl 2-methylsulfonyl-1-imidazolyl 231 CF 3 2, 6-diF-phenyl 2- (aminosulfonyl)phenyl 232 CF 3 2 , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl 233 CF 3 2 , 6-diF-phenyl 1-pyrrolidinocarbonyl 234 CF 3 2, 6-diF-phenyl 2- (methylsulfonyl) phenyl 235 CF 3 2, 6-diF-phenyl 4-morpho1ino 236 CF 3 2, 6-diF-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 237 CF 3 2, 6-diF-phenyl 4-morpholinocarbonyl 238 CF 3 2 , 6-diF-phenyl 2-methyl-l-imidazolyl 239 CF 3 2, 6-diF-phenyl 5-methyl-1-imidazolyl 240 CF 3 2, 6-diF-phenyl 2-methylsulfonyl-1-imidazolyl 241 SCH 3 phenyl 2- (aminosulfonyl) phenyl 242 SCH 3 phenyl 2- (methylaminosulfonyl ) phenyl 243 SCH 3 phenyl 1-pyrrolidinocarbonyl 244 SCH 3 phenyl 2- (methylsulfonyl) phenyl 245 SCH 3 phenyl 4-morpholino 246 SCH 3 phenyl 2-(l'-CF3-tetrazol-2-yl)phenyl 247 SCH 3 phenyl 4-morpholinocarbonyl 248 SCH 3 phenyl 2-methyl-1-imidazolyl 249 SCH 3 phenyl 5-methyl-1-imidazolyl 250 SCH 3 phenyl 2-methylsulfonyl-1-imidazolyl 251 SCH 3 2-pyridyl 2- (aminosulfonyl) phenyl 252 SCH 3 2-pyridyl 2- (methylaminosulfonyl) phenyl 253 SCH 3 2-pyridyl 1-pyrrolidinocarbonyl 254 SCH 3 2-pyridyl 2- (methylsulfonyl) phenyl 255 SCH 3 2-pyridyl 4-morpholino 256 SCH 3 2-pyridyl 2-(l'-CF3-tetrazol-2-yl)phenyl 257 SCH 3 2-pyridyl 4-morpholinocarbonyl 258 SCH 3 2-pyridyl 2-methyl-l-imidazolyl 259 SCH 3 2-pyridyl 5-methyl-l-imidazolyl 260 SCH 3 2-pyridyl 2-methylsulfonyl-1-imidazolyl 261 SCH 3 3-pyridyl 2- (aminosulfonyl) phenyl 262 SCH 3 3-pyridyl 2- (methylaminosulfonyl) phenyl 263 SCH 3 3-pyridyl 1-pyrrolidinocarbonyl 264 SCH 3 3-pyridyl 2- (methylsulfonyl) phenyl 265 SCH 3 3-pyridyl 4-morpho1ino 266 SCH 3 3-pyridyl 2- ( 1 ' -CF3-tetrazol-2-yl ) phenyl 267 SCH 3 3-pyridyl 4-morpholinocarbonyl 268 SCH 3 3-pyridyl 2-methyl-l-imidazolyl 269 SCH 3 3-pyridyl 5-methyl-l-imidazolyl 270 SCH 3 3-pyridyl 2-methylsulfonyl-1-imidazolyl 271 SCH 3 2-pyrimidyl 2- (aminosulfonyl)phenyl 272 SCH 3 2-pyrimidyl 2- (methylaminosulfonyl)phenyl 273 SCH 3 2-pyrimidyl 1-pyrrolidinocarbonyl 274 SCH 3 2-pyrimidyl 2- (methylsulfonyl)phenyl 275 SCH 3 2-pyrimidyl 4-morpholino 276 SCH 3 2-pyrimidyl 2- (l'-CF3-tetrazol-2-yl) phenyl 277 SCH 3 2-pyrimidyl 4-morpholinocarbonyl 278 SCH 3 2-pyrimidyl 2-methyl-1-imidazolyl 279 SCH 3 2-pyrimidyl 5-methyl-l-imidazolyl 280 SCH 3 2-pyrimidyl 2-methylsulfonyl-1-imidazolyl 281 SCH 3 5-pyrimidyl 2- (aminosulfonyl) phenyl 282 SCH 3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 283 SCH 3 5-pyrimidyl 1-pyrrolidinocarbonyl 284 SCH 3 5-pyrimidyl 2- (methylsulfonyl)phenyl 285 SCH 3 5-pyrimidyl 4-morpholino 286 SCH 3 5-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 287 SCH 3 5-pyrimidyl 4-morpholinocarbonyl 288 SCH 3 5-pyrimidyl 2-methyl-l-imidazolyl 289 SCH 3 5-pyrimidyl 5-methyl-1-imidazolyl 290 SCH 3 5-pyrimidyl 2-methylsulfonyl-1-imidazolyl 291 SCH 3 2-Cl-phenyl 2- (aminosulfonyl)phenyl 292 SCH 3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 293 SCH 3 2-Cl-phenyl 1-pyrrolidinocarbonyl 294 SCH 3 2-Cl-phenyl 2- (methylsulfonyl) phenyl 295 SCH 3 2-Cl-phenyl 4-morpholino 296 SCH 3 2-Cl-phenyl 2- ( 1 ' -CF3 -tetrazol-2-yl ) phenyl 297 SCH 3 2-Cl-phenyl 4-morpholinocarbonyl 298 SCH 3 2-Cl-phenyl 2-methyl-l-imidazolyl 299 SCH 3 2-Cl-phenyl 5-methyl-l-imidazolyl 300 SCH 3 2-Cl-phenyl 2-methylsulfonyl-1-imidazolyl 301 SCH 3 2-F-phenyl 2- (aminosulfonyl)phenyl 302 SCH 3 2-F-phenyl 2- (methylaminosulfonyl) phenyl 303 SCH 3 2-F-phenyl 1-pyrrolidinocarbonyl 304 SCH 3 2-F-phenyl 2- (methylsulfonyl) phenyl 305 SCH 3 2-F-phenyl 4-morpholino 306 SCH 3 2-F-phenyl 2-(l'-CF3-tetrazol-2-yl)phenyl 307 SCH 3 2-F-phenyl 4-morpholinocarbonyl 308 SCH 3 2-F-phenyl 2-methyl-l-imidazolyl 309 SCH 3 2-F-phenyl 5-methyl-l-imidazolyl 310 SCH 3 2-F-phenyl 2-methylsulfonyl-1-imidazolyl 311 SCH 3 2,6-diF-phenyl 2- (aminosulfonyl) phenyl 312 SCH3 2,6-diF-phenyl 2- (methylaminosulfonyl)phenyl 313 SCH 3 2,6-diF-phenyl 1-pyrrolidinocarbonyl 314 SCH 3 2,6-diF-phenyl 2- (methylsulfonyl) phenyl 315 SCH 3 2,6-diF-phenyl 4-morpholino 316 SCH 3 2,6-diF-phenyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl 317 SCH 3 2, 6-diF-phenyl 4-morpholinocarbonyl 318 SCH 3 2,6-diF-phenyl 2-methyl-1-imidazolyl 319 SCH 3 2,6-diF-phenyl 5-methyl-l-imidazolyl 320 SCH 3 2,6-diF-phenyl 2-methylsulfonyl-1-imidazolyl 321 SOCH 3 phenyl 2- (aminosulfonyl)phenyl 322 SOCH 3 phenyl 2- (methylaminosulfonyl) phenyl 323 SOCH 3 phenyl 1-pyrrolidinocarbonyl 324 SOCH 3 phenyl 2- (methylsulfonyl)phenyl 325 SOCH 3 phenyl 4-morpholino 326 SOCH 3 phenyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl 327 SOCH 3 phenyl 4-morpholinocarbonyl 328 SOCH 3 phenyl 2-methyl-l-imidazolyl 329 SOCH 3 phenyl 5-methyl-l-imidazolyl 330 SOCH 3 phenyl 2-methylsulfonyl-1-imidazolyl 331 SOCH 3 2-pyridyl 2- (aminosulfonyl) phenyl 332 SOCH3 2-pyridyl 2- (methylaminosulfonyl ) phenyl 333 SOCH3 2-pyridyl 1-pyrrolidinocarbonyl 334 SOCH 3 2-pyridyl 2- (methylsulfonyl) phenyl 335 SOCH 3 2-pyridyl 4-morpholino 336 SOCH 3 2-pyridyl 2- (l'-CF3-tetrazol-2-yl) phenyl 337 SOCH 3 2-pyridyl 4-morpholinocarbonyl 338 SOCH 3 2-pyridyl 2-methyl-l-imidazolyl 339 SOCH 3 2-pyridyl 5-methyl-l-imidazolyl 340 SOCH 3 2-pyridyl 2-methylsulfonyl-1-imidazolyl 341 SOCH 3 3-pyridyl 2- (aminosulfony1) phenyl 342 SOCH 3 3-pyridyl 2- (methylaminosulfonyl) phenyl 343 SOCH 3 3-pyridyl 1-pyrrolidinocarbonyl 344 SOCH 3 3-pyridyl 2- (methylsulfonyl) phenyl 345 SOCH 3 3-pyridyl 4-morpholino 346 SOCH 3 3-pyridyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl 347 SOCH 3 3 -pyridyl 4-morpholinocarbonyl 348 SOCH 3 3-pyridyl 2-methyl-1-imidazolyl 349 SOCH 3 3-pyridyl 5-methyl-1-imidazolyl 350 SOCH 3 3-pyridyl 2-methylsulfonyl-1-imidazolyl 351 SOCH 3 2-pyrimidyl 2- ( . aminosulfonyl ) phenyl 352 SOCH 3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 353 SOCH 3 2-pyrimidyl 1-pyrrolidinocarbonyl 354 SOCH 3 2-pyrimidyl 2- (methylsulfonyl) phenyl 355 SOCH 3 2-pyrimidyl 4-morpholino 356 SOCH 3 2-pyrimidyl 2- (l'-CF3-tetrazol-2-yl) phenyl 357 SOCH 3 2-pyrimidyl 4-morpholinocarbonyl 358 SOCH 3 2-pyrimidyl 2-methyl-1-imidazolyl 359 SOCH 3 2-pyrimidyl 5-methyl-l-imidazolyl 360 SOCH 3 2-pyrimidyl 2-methylsulfonyl-1-imidazolyl 361 SOCH 3 5-pyrimidyl 2- (aminosulfonyl) phenyl 362 SOCH 3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 363 SOCH 3 5-pyrimidyl 1-pyrrolidinocarbonyl 364 SOCH 3 5-pyrimidyl 2- (methylsulfonyl) phenyl 365 SOCH 3 5-pyrimidyl 4-morpholino 366 SOCH 3 5-pyrimidyl 2-(l'-CF3-tetrazol-2-yl)phenyl 367 SOCH 3 5-pyrimidyl 4-morpholinocarbonyl 368 SOCH 3 5-pyrimidyl 2-methyl-l-imidazolyl 369 SOCH 3 5-pyrimidyl 5-methyl-l-imidazolyl 370 SOCH 3 5-pyrimidyl 2-methylsulfonyl-1-imidazolyl 371 SOCH 3 2-Cl-phenyl 2- (aminosulfonyl)phenyl 372 SOCH 3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 373 SOCH 3 2-Cl-phenyl 1-pyrrolidinocarbonyl 374 SOCH 3 2-Cl-phenyl 2- (methylsulfonyl) phenyl 375 SOCH3 2-Cl-phenyl 4-morpholino 376 SOCH 3 2-Cl-phenyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl 377 SOCH 3 2-Cl-phenyl 4-morpholinocarbonyl 378 SOCH 3 2-Cl-phenyl 2-methy1-1-imidazolyl 379 SOCH 3 2-Cl-phenyl 5-methyl-l-imidazoly1 380 SOCH 3 2-Cl-phenyl 2-methylsulfonyl-1-imidazolyl 381 SOCH 3 2-F-phenyl 2- (aminosulfonyl) phenyl 382 SOCH 3 2-F-phenyl 2- (methylaminosulfonyl) phenyl 383 SOCH3 2-F-phenyl 1-pyrro1idinocarbony1 384 SOCH3 2-F-phenyl 2- (methylsulfonyl) phenyl 385 SOCH3 2-F-phenyl 4-morpholino 386 SOCH3 2-F-phenyl 2-(l'-CF3-tetrazol-2-yl)phenyl 387 SOCH 3 2-F-phenyl 4-morpholinocarbonyl 388 SOCH3 2-F-phenyl 2-methy1-1-imidazolyl 389 SOCH3 2-F-phenyl 5-methyl-1-imidazolyl 390 SOCH 3 2-F-phenyl 2-methylsulfonyl-1-imidazolyl 391 SOCH3 2,6-diF-phenyl 2- (aminosulfony1) phenyl 392 SOCH3 2,6-diF-phenyl 2- (methylaminosulfonyl) phenyl 393 SOCH 3 2,6-diF-phenyl 1-pyrrolidinocarbonyl 394 SOCH3 2, 6-diF-phenyl 2- (methylsulfonyl) phenyl 395 SOCH3 2,6-diF-phenyl 4-morpholino 396 SOCH3 2,6-diF-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 397 SOCH 3 2,6-diF-phenyl 4-morpholinocarbonyl 398 SOCH 2, 6-diF-phe 2-methyl-1-imidazolyl 399 SOCH 3 2, 6-diF-phe 5-methyl-1-imidazolyl 400 SOCH 3 2, 6-diF-phe 2-methylsulfonyl-1-imidazolyl 401 SO 2 CH 3 phenyl 2- (aminosulfonyl) phenyl 402 SO 2 CH 3 phenyl 2- (methylaminosulfonyl) phenyl 403 S0 2 CH 3 phenyl 1-pyrrolidinocarbonyl 404 SO 2 CH 3 phenyl 2- (methylsulfonyl ) phenyl 405 SO 2 CH 3 phenyl 4-morpholino 406 SO 2 CH 3 phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl 407 SO 2 CH 3 phenyl 4-morpholinocarbonyl 408 S0 2 CH 3 phenyl 2-methyl-l-imidazolyl 409 SO 2 CH 3 phenyl 5-methyl-1-imidazolyl 410 SO 2 CH 3 phenyl 2-methylsulfonyl-1-imidazolyl 411 S0 2 CH 3 2-pyridyl 2- (aminosulfonyl)phenyl 412 S0 2 CH 3 2-pyridyl 2- (methylaminosulfonyl) phenyl 413 SO 2 CH 3 2-pyridyl 1-pyrrolidinocarbonyl 414 SO 2 CH 3 2-pyridyl 2- (methylsulfonyl ) phenyl 415 SO 2 CH 3 2-pyridyl 4-morpholino 416 SO 2 CH 3 2-pyridyl 2- (l'-CF3-tetrazol-2-yl) phenyl 417 SO 2 CH 3 2-pyridyl 4-morpholinocarbonyl 418 SO 2 CH 3 2-pyridyl 2-methyl-l-imidazolyl 419 SO 2 CH 3 2-pyridyl 5-methyl-1-imidazolyl 420 S0 2 CH 3 2-pyridyl 2-methylsulfonyl-1-imidazolyl 421 SO 2 CH 3 3-pyridyl 2- (aminosulfonyl) phenyl 422 SO 2 CH 3 3-pyridyl 2- (methylaminosulfonyl) phenyl 423 SO 2 CH3 3-pyridyl 1-pyrrolidinocarbonyl 424 SO 2 CH 3 3-pyridyl 2- (methylsulfonyl) phenyl 425 SO 2 CH 3 3-pyridyl 4-morpholino 426 SO 2 CH 3 3-pyridyl 2- ( 1 ' -CF3-tetrazol-2-yl ) phenyl 427 S0 2 CH 3 3-pyridyl 4-morpholinocarbonyl 428 SO 2 CH 3 3-pyridyl 2-methyl-1-imidazolyl 429 S0 2 CH 3 3-pyridyl 5-methyl-l-imidazolyl 430 SO 2 CH 3 3-pyridyl 2-methylsulfonyl-1-imidazolyl 431 SO 2 CH 3 2-pyrimidyl 2- (aminosulfonyl) phenyl 432 SO 2 CH 3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 433 S0 2 CH 3 2-pyrimidyl 1-pyrrolidinocarbonyl 434 SO 2 CH 3 2-pyrimidyl 2- (methylsulfonyl)phenyl 435 SO2CH 3 2-pyrimidyl 4-morpholino 436 SO2CH 3 2-pyrimidyl 2- ( 1 ' -CF3 -tetrazol-2-yl) phenyl 437 SO 2 CH 3 2-pyrimidyl 4-morpholinocarbonyl 438 SO 2 CH 3 2-pyrimidyl 2-methyl-1-imidazolyl 439 S0 2 CH 3 2-pyrimidyl 5-methyl-l-imidazolyl 440 SO2CH3 2-pyrimidyl 2-methylsulfonyl-1-imidazolyl 441 SO 2 CH 3 5-pyrimidyl 2- (aminosulfonyl) phenyl 442 SO 2 CH 3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 443 SO2CH 3 5-pyrimidyl 1-pyrrolidinocarbonyl 444 SO2CH3 5-pyrimidyl 2- (methylsulfonyl) phenyl 445 S0 2 CH 3 5-pyrimidyl 4-morpholino 446 SO 2 CH3 5-pyrimidyl 2- ( 1 ' -CF3 -tetrazol-2-yl ) phenyl 447 SO2CH3 5-pyrimidyl 4-morpholinocarbonyl 448 SO 2 CH 3 5-pyrimidyl 2-methyl-l-imidazolyl 449 SO 2 CH 3 5-pyrimidyl 5-methyl-l-imidazolyl 450 S0 2 CH 3 5-pyrimidyl 2-methylsulfonyl-1-imidazolyl 451 SO 2 CH 3 2-Cl-phenyl 2- (aminosulfonyl) phenyl 452 SO 2 CH 3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 453 SO 2 CH 3 2-Cl-phenyl 1-pyrrolidinocarbonyl 454 SO 2 CH 3 2-Cl-phenyl 2- (methylsulfonyl)phenyl 455 SO 2 CH 3 2-Cl-phenyl 4-morpholino 456 SO 2 CH 3 2-Cl-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 457 SO 2 CH 3 2 -Cl-phenyl 4-morpholinocarbonyl 458 S0 2 CH 3 2-Cl-phenyl 2-methyl-1-imidazolyl 459 SO 2 CH 3 2-Cl-phenyl 5-methyl-1-imidazolyl 460 SO 2 CH 3 2-Cl-phenyl 2-methylsulfonyl-1-imidazolyl 461 SO 2 CH 3 2-F-phenyl 2- (aminosulfonyl ) phenyl 462 SO 2 CH 3 2-F-phenyl 2- (methylaminosulfonyl) phenyl 463 SO 2 CH 3 2-F-phenyl 1-pyrrolidinocarbonyl 464 SO 2 CH 3 2-F-phenyl 2- (methylsulfonyl) phenyl 465 SO 2 CH 3 2-F-phenyl 4-morpholino 466 SO 2 CH 3 2-F-phenyl 2-(l'-CF3-tetrazol-2-yl)phenyl 467 SO 2 CH 3 2-F-phenyl 4-morpho1inocarbony1 468 SO 2 CH 3 2-F-phenyl 2-methyl-1-imidazolyl 469 SO 2 CH 3 2-F-phenyl 5-methyl-1-imidazolyl 470 SO 2 CH 3 2-F-phenyl 2-methylsulfonyl-1-imidazolyl 471 SO 2 CH 3 2 , 6-diF-phenyl 2- (aminosulfonyl) phenyl 472 SO 2 CH 3 2 , 6-diF-phenyl 2- (methylaminosulfonyl)phenyl 473 SO 2 CH 3 2 , 6-diF-phenyl 1-pyrrolidinocarbonyl 474 SO 2 CH 3 2 , 6-diF-phenyl 2- (methylsulfonyl) phenyl 475 S0 2 CH 3 2 , 6-diF-phenyl 4-morpholino 476 S0 2 CH 3 2 , 6-diF-phenyl 2-(l'-CF3-tetrazol-2-yl)phenyl 477 SO 2 CH 3 2 , 6-diF-phenyl 4-morpholinocarbonyl 478 SO 2 CH 3 2 , 6-diF-phenyl 2-methyl-l-imidazolyl 479 SO 2 CH 3 2, 6-diF-phenyl 5-methyl-l-imidazolyl 480 SO 2 CH 3 2 , 6-diF-phenyl 2-methylsulfonyl-1-imidazolyl 481 CH 2 H phenyl 2- (aminosulfonyl ) phenyl -SO 2 CH 3 482 CH 2 H phenyl 2- (methylaminosulfonyl) phenyl -SO 2 CH 3 483 CH 2 H phenyl 1-pyrrolidinocarbonyl -SO 2 CH 3 484 CH 2 NH phenyl 2- (methylsulfonyl) phenyl -SO2CH3 485 CH 2 NH phenyl 4-morpholino -SO2CH3 486 CH 2 NH phenyl 2- ( 1 ' -CF3 -tetrazol-2-yl) phenyl -SO 2 CH3 487 CH 2 NH phenyl 4-morpholinocarbonyl -SO 2 CH 3 488 CH 2 NH phenyl 2-methyl-1-imidazolyl -SO 2 CH 3 489 CH 2 NH phenyl 5-methyl-1-imidazolyl -SO 2 CH 3 490 CH 2 NH phenyl 2-methylsulfonyl-1-imidazolyl -SO 2 CH 3 491 CH 2 NH 2-pyridyl 2- (aminosulfonyl) phenyl -S0 2 CH 3 492 CH 2 NH 2-pyridyl 2- (methylaminosulfonyl) phenyl -SO 2 CH 3 493 CHNH 2-pyridyl 1-pyrrolidinocarbonyl -SO 2 CH 3 494 CH 2 H 2-pyridyl 2- (methylsulfonyl ) phenyl -SO 2 CH 3 495 CH 2 H 2-pyridyl 4-morpho1ino -SO 2 CH 3 496 CH 2 NH 2-pyridyl 2- ( 1 ' -CF3 -tetrazol-2-yl ) phenyl -SO 2 CH 3 497 CH 2 NH 2-pyridyl 4-morpholinocarbonyl -SO 2 CH 3 498 CH 2 NH 2-pyridyl 2-methyl-1-imidazolyl -SO 2 CH 3 499 CH 2 NH 2-pyridyl 5-methyl-1-imidazolyl 500 CH 2 NH 2-pyridyl 2-methylsulfonyl-1-imidazolyl -SO 2 CH 3 501 CHNH 3-pyridyl 2- (aminosulfonyl) phenyl -SO 2 CH 3 502 CH 2 H 3-pyridyl 2- (methylaminosulfonyl) phenyl -SO 2 CH 3 503 CH 2 NH 3-pyridyl 1-pyrrolidinocarbonyl -SO 2 CH 3 504 CH 2 NH 3-pyridyl 2- (methylsulfonyl) phenyl -SO 2 CH 3 505 CH 2 NH 3-pyridyl 4-morpholino -SO 2 CH 3 506 CH 2 H 3-pyridyl 2- (1 ' -CF3 -tetrazol-2-yl ) phenyl -SO 2 CH 3 507 CH 2 H 3-pyridyl 4-morpho1inocarbony1 -SO 2 CH 3 508 CH 2 H 3-pyridyl 2-methyl-1-imidazolyl -SO 2 CH 3 509 CH 2 NH 3-pyridyl 5-methyl-1-imidazolyl -SO 2 CH 3 510 CH 2 NH 3-pyridyl 2-methylsulfonyl-1-imidazolyl -SO 2 CH 3 511 CH 2 NH 2-pyrimidyl 2- (aminosulfonyl) phenyl -SO 2 CH3 512 CH 2 NH 2-pyrimidyl 2- (methylaminosulfonyl) phenyl -SO 2 CH3 513 CH 2 NH 2-pyrimidyl 1-pyrrolidinocarbonyl -SO 2 CH3 514 CH 2 NH 2-pyrimidyl 2- (methylsulfonyl ) phenyl -SO 2 CH 3 515 CH 2 NH 2-pyrimidyl 4-morpholino -SO2CH3 516 CH 2 NH 2-pyrimidyl 2- ( 1 ' -CF3 -tetrazol-2-yl ) phenyl -SO 2 CH 3 517 CH 2 NH 2-pyrimidyl 4-morpho1inocarbony1 -SO 2 CH 3 518 CH 2 NH 2-pyrimidyl 2-methyl-1-imidazolyl -S0 2 CH 3 519 CH 2 H 2-pyrimidyl 5-methyl-1-imidazolyl -SO 2 CH 3 520 CH 2 H 2-pyrimidyl 2-methylsulfonyl-1-imidazolyl -SO 2 CH 3 521 CHNH 5-pyrimidyl 2- (aminosulfonyl) phenyl -SO 2 CH 3 522 CH 2 H 5-pyrimidyl 2- (methylaminosulfonyl) phenyl -SO 2 CH 3 523 CH 2 NH 5-pyrimidyl 1-pyrrolidinocarbonyl -SO 2 CH3 524 CH 2 NH 5-pyrimidyl 2- (methylsulfonyl) phenyl -SO 2 CH 3 525 CH 2 H 5-pyrimidyl 4-morpholino -SO 2 CH 3 526 CH 2 H 5-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl -S0 2 CH 3 527 CHNH 5-pyrimidyl 4-morpholinocarbonyl -SO 2 CH 3 528 CH 2 H 5-pyrimidyl 2-methyl-l-imidazolyl -SO 2 CH 3 529 CH 2 H 5-pyrimidyl 5-methyl-1-imidazolyl -SO 2 CH 3 530 CH 2 H 5-pyrimidyl 2-methylsulfonyl-1-imidazolyl -SO 2 CH 3 531 CH 2 NH 2-Cl-phenyl 2- (aminosulfonyl )phenyl -SO 2 CH 3 532 CH 2 NH 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl -SO 2 CH 3 533 CH 2 NH 2-Cl-phenyl 1-pyrro1idinocarbonyl -SO 2 CH 3 534 CH 2 NH 2-Cl-phenyl 2- (methylsulfonyl) phenyl -SO 2 CH 3 535 CH 2 H 2-Cl-phenyl 4-morpholino -SO2CH 3 536 CH 2 NH 2-Cl-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl -SO 2 CH 3 537 CH 2 NH 2-Cl-phenyl 4-morpholinocarbonyl -SO2CH3 538 CH 2 H 2-Cl-phenyl 2-methyl-l-imidazolyl -SO2CH 3 539 CH 2 NH 2-Cl-phenyl 5-methyl-l-imidazolyl -SO 2 CH3 540 CH 2 NH 2-Cl-phenyl 2-methylsulfonyl-1-imidazolyl -SO 2 CH 3 541 CH 2 NH 2-F-phenyl 2- (aminosulfonyl) phenyl -SO 2 CH3 542 CH 2 H 2-F-phenyl 2- (methylaminosulfonyl) phenyl -SO2CH3 543 CH 2 NH 2-F-phenyl 1-pyrrolidinocarbonyl -SO 2 CH 3 544 CH 2 NH 2-F-phenyl 2 - (methylsulfonyl ) phenyl -S0 2 CH 3 545 CH 2 NH 2-F-phenyl 4-morpholino -SO 2 CH 3 546 CH 2 NH 2-F-phenyl 2-(l'-CF3-tetrazol-2-yl)phenyl -SO 2 CH 3 547 CH 2 NH 2-F-phenyl 4-morpholinocarbonyl -SO 2 CH 3 548 CH 2 H 2-F-phenyl 2-methyl-1-imidazolyl -SO2CH3 549 CH 2 H 2-F-phenyl 5-methyl-1-imidazolyl -S0 2 CH 3 550 CH 2 NH 2-F-phenyl 2-methylsulfonyl-1-imidazolyl -SO 2 CH 3 551 CH 2 NH 2, 6-diF-phenyl 2- (aminosulfonyl) phenyl -SO 2 CH 3 552 CH 2 NH 2, 6-diF-phenyl 2- (methylaminosulfonyl) phenyl -SO 2 CH 3 553 CH 2 NH 2, 6-diF-phenyl 1-pyrro1idinocarbonyl -SO 2 CH 3 554 CH 2 NH 2, 6-diF-phenyl 2- (methylsulfonyl) phenyl -SO 2 CH 3 555 CH 2 H 2, 6-diF-phenyl 4-morpholino -SO 2 CH 3 556 CH 2 NH 2, 6-diF-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl -SO 2 CH 3 557 CH 2 NH 2, 6-diF-phenyl 4-morpholinocarbonyl -SO 2 CH 3 558 CH 2 H 2, 6-diF-phenyl 2-methyl-1-imidazolyl -SO 2 CH 3 559 CH 2 H 2,6-diF-phenyl 5-methyl-1-imidazolyl -SO 2 CH 3 560 CH 2 NH 2, 6-diF-phenyl 2-methylsulfonyl-1-imidazolyl -SO 2 CH 3 561 Cl phenyl 2- (aminosulfonyl) phenyl 562 Cl phenyl 2- (methylaminosulfonyl) phenyl 563 Cl phenyl 1-pyrrolidinocarbonyl 564 Cl phenyl 2- (methylsulfonyl) phenyl 565 Cl phenyl 4-morpholino 566 Cl phenyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl 567 Cl phenyl 4-morpholinocarbonyl 568 Cl phenyl 2-methyl-1-imidazolyl 569 Cl phenyl 5-methyl-1-imidazolyl 570 Cl phenyl 2-methylsulfonyl-1-imidazolyl 571 Cl 2-pyridyl 2- (aminosulfonyl)phenyl 572 Cl 2-pyridyl 2- (methylaminosulfonyl) phenyl 573 Cl 2-pyridyl 1-pyrrolidinocarbonyl 574 Cl 2-pyridyl 2- (methylsulfonyl) phenyl 575 Cl 2-pyridyl 4-morpho1ino 576 Cl 2-pyridyl 2- ( 1 ' -CF3 -tetrazol-2-yl) phenyl 577 Cl 2-pyridyl 4-morpholinocarbonyl 578 Cl 2-pyridyl 2-methyl-1-imidazolyl 579 Cl 2-pyridyl 5-methyl-1-imidazolyl 580 Cl 2-pyridyl 2-methylsulfonyl-1-imidazolyl 581 Cl 3-pyridyl 2- (aminosulfonyl) phenyl 582 Cl 3-pyridyl 2- (methylaminosulfonyl) phenyl 583 Cl 3-pyridyl 1-pyrrolidinocarbonyl 584 Cl 3-pyridyl 2- (methylsulfonyl) phenyl 585 Cl 3-pyridyl 4-morpholino 586 Cl 3-pyridyl 2- (l'-CF3-tetrazol-2-yl) phenyl 587 Cl 3-pyridyl 4-morpholinocarbonyl 588 Cl -pyridyl 2-methyl-1-imidazolyl 589 Cl 3-pyridyl 5-methyl-1-imidazolyl 590 Cl 3-pyridyl 2-methylsulfonyl-1-imidazolyl 591 Cl 2-pyrimidyl 2- (aminosulfonyl ) phenyl 592 Cl 2-pyrimidyl 2- (methylaminosulfonyl ) phenyl 593 Cl 2-pyrimidyl 1-pyrrolidinocarbonyl 594 Cl 2-pyrimidyl 2- (methylsulfonyl) phenyl 595 Cl 2-pyrimidyl 4-morpholino 596 Cl 2-pyrimidyl 2- ( 1 ' -CF3-tetrazol-2-yl ) phenyl 597 Cl 2-pyrimidyl 4-morpholinocarbonyl 598 Cl 2-pyrimidyl 2-methyl-1-imidazolyl 599 Cl 2-pyrimidyl 5-methyl-l-imidazolyl 600 Cl 2-pyrimidyl 2-methylsulfonyl-1-imidazolyl 601 Cl 5-pyrimidyl 2- (aminosulfonyl) phenyl 602 Cl 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 603 Cl 5-pyrimidyl 1-pyrrolidinocarbonyl 604 Cl 5-pyrimidyl 2- (methylsulfonyl ) phenyl 605 Cl 5-pyrimidyl 4-morpholino 606 Cl 5-pyrimidyl 2- (l'-CF3-tetrazol-2-yl) phenyl 607 Cl 5-pyrimidyl 4-morpholinocarbonyl 608 Cl 5-pyrimidyl 2-methyl-1-imidazolyl 609 Cl 5-pyrimidyl 5-methyl-l-imidazolyl 610 Cl 5-pyrimidyl 2-methylsulfonyl-1-imidazolyl 611 Cl 2-Cl-phenyl 2- (aminosulfonyl) phenyl 612 Cl 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 613 Cl 2-Cl-phenyl 1-pyrrolidinocarbonyl 614 Cl 2-Cl-phenyl 2- (methylsulfonyl) phenyl 615 Cl 2-Cl-phenyl 4-morpholino 616 Cl 2-Cl-phenyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl 617 Cl 2-Cl-phenyl 4-morpholinocarbonyl 618 Cl 2-Cl-phenyl 2-methyl-l-imidazolyl 619 Cl 2-Cl-phenyl 5-methyl-l-imidazolyl 620 Cl 2-Cl-phenyl 2-methylsulfonyl-1-imidazolyl 621 Cl 2-F-phenyl 2- (aminosulfonyl) phenyl 622 Cl 2-F-phenyl 2- (methylaminosulfonyl) phenyl 623 Cl 2-F-phenyl 1-pyrrolidinocarbonyl 624 Cl 2-F-phenyl 2- (methylsulfonyl) phenyl 625 Cl 2-F-phenyl 4-morpholino 626 Cl 2-F-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 627 Cl 2-F-phenyl 4-morpholinocarbonyl 628 Cl 2-F-phenyl 2-methyl-l-imidazolyl 629 Cl 2-F-phenyl 5-methyl-l-imidazolyl 630 Cl 2-F-phenyl 2-methylsulfonyl-1-imidazolyl 631 Cl 2 , 6-diF-phenyl 2- (aminosulfonyl) phenyl 632 Cl 2, 6-diF-phenyl 2- (methylaminosulfonyl) phenyl 633 Cl 2,6-diF-phenyl 1-pyrrolidinocarbonyl 634 Cl 2, 6-diF-phenyl 2- (methylsulfonyl) phenyl 635 Cl 2, 6-diF-phenyl 4-morpholino 636 Cl 2 , 6-diF-phenyl 2- ( 1 ' -CF3 -tetrazol-2-yl ) phenyl 637 Cl 2 , 6-diF-phenyl 4-morpholinocarbonyl 638 Cl 2 , 6-diF-phenyl 2-methyl-1-imidazolyl 639 Cl 2 , 6-diF-phenyl 5-methyl-1-imidazolyl 640 Cl 2 , 6-diF-phenyl 2-methylsulfonyl-1-imidazolyl 641 F phenyl 2- (aminosulfonyl) phenyl 642 F phenyl 2- (methylaminosulfonyl) phenyl 643 F phenyl 1-pyrrolidinocarbonyl 644 F phenyl 2- (methylsulfonyl) phenyl 645 F phenyl 4-morpholino 646 F phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 647 F phenyl 4-morpholinocarbonyl 648 F phenyl 2-methyl-1-imidazolyl 649 F phenyl 5-methyl-1-imidazolyl 650 F phenyl 2-methylsulfonyl-1-imidazolyl 651 F 2-pyridyl 2- (aminosulfonyl) phenyl 652 F 2-pyridyl 2- (methylaminosulfonyl) phenyl 653 F 2-pyridyl 1-pyrrolidinocarbonyl 654 F 2-pyridyl 2- (methylsulfonyl) phenyl 655 F 2-pyridyl 4-morpholino 656 F 2-pyridyl 2- (l'-CF3-tetrazol-2-yl) phenyl 657 F 2-pyridyl 4-morpholinocarbonyl 658 F 2-pyridyl 2-methyl-1-imidazolyl 659 F 2-pyridyl 5-methyl-l-imidazolyl 660 F 2-pyridyl 2-methylsulfonyl-1-imidazolyl 661 F 3-pyridyl 2- (aminosulfonyl) phenyl 662 F 3-pyridyl 2- (methylaminosulfonyl) phenyl 663 F 3-pyridyl 1-pyrrolidinocarbonyl 664 F 3-pyridyl 2- (methylsulfonyl) phenyl 665 F 3-pyridyl 4-morpholino 666 F 3-pyridyl 2- (1' -CF3-tetrazol-2-yl) phenyl 667 F 3-pyridyl 4-morpholinocarbonyl 668 F 3-pyridyl 2-methyl-1-imidazolyl 669 F 3-pyridyl 5-methyl-1-imidazolyl 670 F 3-pyridyl 2-methylsulfonyl-1-imidazolyl 671 F 2-pyrimidyl 2- (aminosulfonyl) phenyl 672 F 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 673 F 2-pyrimidyl 1-pyrrolidinocarbonyl 674 F 2-pyrimidyl 2- (methylsulfonyl) phenyl 675 F 2-pyrimidyl 4-morpholino 676 F 2-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl 677 F 2-pyrimidyl 4-morpho1inocarbonyl 678 F 2-pyrimidyl 2-methyl-l-imidazolyl 679 F 2-pyrimidyl 5-methyl-1-imidazolyl 680 F 2-pyrimidyl 2-methylsulfonyl-1-imidazolyl 681 F 5-pyrimidyl 2- (aminosulfonyl)phenyl 682 F 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 683 F 5-pyrimidyl 1-pyrroiidinocarbonyl 684 F 5-pyrimidyl 2- (methylsulfonyl) phenyl 685 F 5-pyrimidyl 4-morpholino 686 F 5-pyrimidyl 2- ( 1 ' -CF3 -tetrazol-2-yl ) phenyl 687 F 5-pyrimidyl 4-morpholinocarbonyl 688 F 5-pyrimidyl 2-methyl-1-imidazolyl 689 F 5-pyrimidyl 5-methyl-1-imidazolyl 690 F 5-pyrimidyl 2-methylsulfonyl-1-imidazolyl 691 F 2-Cl-phenyl 2- (aminosulfonyl ) phenyl 692 F 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 693 F 2-Cl-phenyl 1-pyrrolidinocarbonyl 694 F 2-Cl-phenyl 2- (methylsulfonyl) phenyl 695 F 2-Cl-phenyl 4-morpholino 696 F 2-Cl-phenyl 2- (1 ' -CF3 -tetrazol-2-yl ) phenyl 697 F 2-Cl-phenyl 4-morpho1inocarbonyl 698 F 2-Cl-phenyl 2-methyl-1-imidazolyl 699 F 2-Cl-phenyl 5-methyl-l-imidazolyl 700 F 2-Cl-phenyl 2-methylsulfonyl-1-imidazolyl 701 F 2-F-phenyl 2- (aminosulfonyl) phenyl 702 F 2-F-phenyl 2- (methylaminosulfonyl) phenyl 703 F 2-F-phenyl 1-pyrrolidinocarbonyl 704 F 2-F-phenyl 2- (methylsulfonyl ) phenyl 705 F 2-F-phenyl 4-morpholino 706 F 2-F-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl 707 F 2-F-phenyl 4-morpholinocarbonyl 708 F 2-F-phenyl 2-methyl-1-imidazolyl 709 F 2-F-phenyl 5-methyl-l-imidazolyl 710 F 2-F-phenyl 2-methylsulfonyl-1-imidazolyl 711 F 2, 6-diF-phenyl 2- (aminosulfonyl) phenyl 712 F 2 , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl 713 F 2, 6-diF-phenyl 1-pyrrolidinocarbonyl 714 F 2 , 6-diF-phenyl 2- (methylsulfonyl) phenyl 715 F 2, 6-diF-phenyl 4-morpholino 716 F 2 , 6-diF-phenyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl 717 F 2 , 6-diF-phenyl 4-morpholinocarbonyl 718 F 2 , 6-diF-phenyl 2-methyl-l-imidazolyl 719 F 2 , 6-diF-phenyl 5-methyl-l-imidazolyl 720 F 2 , 6-diF-phenyl 2-methylsulfonyl-1-imidazolyl 721 CO 2 CH 3 phenyl 2- (aminosulfonyl) phenyl 722 CO 2 CH 3 phenyl 2- (methylaminosulfonyl) phenyl 723 CO 2 CH 3 phenyl 1-pyrrolidinocarbonyl 724 CO 2 CH 3 phenyl 2- (methylsulfonyl) phenyl 725 CO 2 CH 3 phenyl 4-morpholino 726 CO 2 CH 3 phenyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl 727 CO 2 CH 3 phenyl 4-morpholinocarbonyl 728 CO 2 CH 3 phenyl 2-methyl-1-imidazolyl 729 CO 2 CH 3 phenyl 5-methyl-1-imidazolyl 730 CO 2 CH 3 phenyl 2-methylsulfonyl-1-imidazolyl 731 CO 2 CH3 2-pyridyl 2- (aminosulfonyl)phenyl 732 CO 2 CH 3 2-pyridyl 2- (methylaminosulfonyl) phenyl 733 CO 2 CH 3 2-pyridyl 1-pyrro1idinocarbonyl 734 CO 2 CH3 2-pyridyl 2- (methylsulfonyl) phenyl 735 CO2CH 3 2-pyridyl 4-morpho1ino 736 CO 2 CH3 2-pyridyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl 737 CO 2 CH 3 2-pyridyl 4-morpholinocarbonyl 738 CO 2 CH3 2-pyridyl 2-methyl-l-imidazolyl 739 CO 2 CH3 2-pyridyl 5-methyl-l-imidazolyl 740 CO 2 CH 3 2-pyridyl 2-methylsulfonyl-1-imidazolyl 741 CO 2 CH 3 3-pyridyl 2- (aminosulfonyl )phenyl 742 CO 2 CH 3 3-pyridyl 2- (methylaminosulfonyl) phenyl 743 CO2CH3 3-pyridyl 1-pyrrolidinocarbonyl 744 CO 2 CH 3 3-pyridyl 2- (methylsulfonyl) phenyl 745 CO 2 CH 3 3-pyridyl 4-morpho1ino 746 C0 CH 3 3-pyridyl 2 - ( l ' -CF3 -tetrazol-2 -yl ) phenyl 747 CO 2 CH 3 3-pyridyl 4-morpholinocarbonyl 748 CO 2 CH 3 3-pyridyl 2-methyl-1-imidazolyl 749 CO 2 CH 3 3-pyridyl 5-methyl-1-imidazolyl 750 CO 2 CH 3 3-pyridyl 2-methylsulfonyl-1-imidazolyl 751 CO 2 CH 3 2-pyrimidyl 2- (aminosulfonyl) phenyl 752 CO 2 CH 3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 753 CO 2 CH 3 2-pyrimidyl 1-pyrrolidinocarbonyl 754 CO2CH 3 2-pyrimidyl 2- (methylsulfonyl) phenyl 755 CO 2 CH 3 2-pyrimidyl 4-morpholino 756 CO 2 CH 3 2-pyrimidyl 2- ( 1 ' -CF3 -tetrazol-2-yl) phenyl 757 CO 2 CH 3 2-pyrimidyl 4-morpholinocarbonyl 758 CO 2 CH 3 2-pyrimidyl 2-methyl-1-imidazolyl 759 CO 2 CH 3 2-pyrimidyl 5-methyl-1-imidazolyl 760 CO 2 CH 3 2-pyrimidyl 2-methylsulfonyl-1-imidazolyl 761 CO 2 CH 3 5-pyrimidyl 2- (aminosulfonyl) phenyl 762 CO 2 CH 3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 763 CO 2 CH 3 5-pyrimidyl 1-pyrrolidinocarbonyl 764 CO 2 CH 3 5-pyrimidyl 2- (methylsulfonyl) phenyl 765 CO 2 CH 3 5-pyrimidyl 4-morpholino 766 CO 2 CH 3 5-pyrimidyl 2- (l'-CF3-tetrazol-2-yl) phenyl 767 CO 2 CH 3 5-pyrimidyl 4-morpho1inocarbony1 768 CO 2 CH 3 5-pyrimidyl 2-methyl-1-imidazolyl 769 CO 2 CH 3 5-pyrimidyl 5-methyl-1-imidazolyl 770 CO 2 CH 3 5-pyrimidyl 2-methylsulfonyl-1-imidazolyl 771 CO 2 CH 3 2-Cl-phenyl 2- (aminosulfony1) phenyl 772 CO 2 CH 3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 773 CO 2 CH 3 2-Cl-phenyl 1-pyrrolidinocarbonyl 774 CO 2 CH 3 2-Cl-phenyl 2- (methylsulfonyl) phenyl 775 C0 2 CH 3 2-Cl-phenyl 4-morpholino 776 CO 2 CH 3 2-Cl-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl 777 CO 2 CH3 2-Cl-phenyl 4-morpholinocarbonyl 778 CO 2 CH 3 2-Cl-phenyl 2-methyl-1-imidazolyl 779 CO 2 CH 3 2-Cl-phenyl 5-methyl-1-imidazolyl 780 CO 2 CH 3 2-Cl-phenyl 2-methylsulfonyl-1-imidazolyl 781 CO 2 CH 3 2-F-phenyl 2- (aminosulfonyl) phenyl 782 CO 2 CH3 2-F-phenyl 2- (methylaminosulfonyl) phenyl 783 CO 2 CH 3 2-F-phenyl 1-pyrrolidinocarbonyl 784 CO 2 CH3 2-F-phenyl 2- (methylsulfonyl) phenyl 785 CO 2 CH 3 2-F-phenyl 4-morpho1ino 786 CO 2 CH 3 2-F-phenyl 2- (1' -CF3-tetrazol-2-yl)phenyl 787 CO 2 CH 3 2-F-phenyl 4-morpholinocarbonyl 788 CO 2 CH3 2-F-phenyl 2-methyl-1-imidazolyl 789 CO 2 CH 3 2-F-phenyl 5-methyl-1-imidazolyl 790 CO 2 CH 3 2-F-phenyl 2-methylsulfonyl-1-imidazolyl 791 CO2CH 3 2, 6-diF-phenyl 2- (aminosulfonyl)phenyl 792 CO 2 CH 3 2, 6-diF-phenyl 2- (methylaminosulfonyl) phenyl 793 CO 2 CH 3 2,6-diF-phenyl 1-pyrrolidinocarbonyl 794 CO 2 CH 3 2, 6-diF-phenyl 2- (methylsulfonyl) phenyl 795 CO 2 CH 3 2,6-diF-phenyl 4-morpholino 796 CO 2 CH 3 2,6-diF-phenyl 2- ( 1 ' -CF3 -tetrazol-2-yl) phenyl 797 CO 2 CH 3 2, 6-diF-phenyl 4-morpholinocarbonyl 798 C0 2 CH 3 2 , 6-diF-phenyl 2-methyl-l-imidazolyl 799 CO 2 CH 3 2 , 6-diF-phenyl 5-methyl-1-imidazolyl 800 CO 2 CH 3 2 , 6-diF-phenyl 2-methylsulfonyl-1-imidazolyl 801 CH 2 OCH 3 phenyl 2- (aminosulfonyl) phenyl 802 CH 2 OCH 3 phenyl 2- (methylaminosulfonyl) phenyl 803 CH 2 OCH 3 phenyl 1-pyrrolidinocarbonyl 804 CH 2 OCH 3 phenyl 2- (methylsulfonyl) phenyl 805 CH 2 OCH 3 phenyl 4-morpholino 806 CH 2 OCH 3 phenyl 2- ( 1 ' -CF3-tetrazol-2-yl ) phenyl 807 CH 2 OCH 3 phenyl 4-morpholinocarbonyl 808 CH 2 OCH 3 phenyl 2-methyl-1-imidazolyl 809 CH 2 OCH 3 phenyl 5-methyl-1-imidazolyl 810 CH 2 OCH 3 phenyl 2-methylsulfonyl-1-imidazolyl 811 CH 2 OCH 3 2-pyridyl 2- (aminosulfonyl) phenyl 812 CH 2 OCH 3 2-pyridyl 2- (methylaminosulfonyl) phenyl 813 CH 2 OCH 3 2-pyridyl 1-pyrrolidinocarbonyl 814 CH 2 OCH 3 2-pyridyl 2- (methylsulfonyl) phenyl 815 CH 2 OCH 3 2-pyridyl 4-morpholino 816 CH 2 OCH 3 2-pyridyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl 817 CH 2 OCH 3 2-pyridyl 4-morpholinocarbonyl 818 CH 2 OCH 3 2-pyridyl 2-methyl-l-imidazolyl 819 CH 2 OCH 3 2-pyridyl 5-methyl-1-imidazolyl 820 CH 2 OCH 3 2-pyridyl 2-methylsulfonyl-1-imidazolyl 821 CH 2 OCH 3 3-pyridyl 2- (aminosulfonyl ) phenyl 822 CH 2 OCH 3 3-pyridyl 2- (methylaminosulfonyl) phenyl 823 CH 2 OCH 3 3-pyridyl 1-pyrrolidinocarbonyl 824 CH 2 OCH 3 3-pyridyl 2- (methylsulfonyl) phenyl 825 CH 2 OCH 3 3-pyridyl 4-morpholino 826 CH 2 OCH 3 3-pyridyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 827 CH 2 OCH 3 3-pyridyl 4-morpholinocarbonyl 828 CH 2 OCH 3 3-pyridyl 2-methyl-l-imidazolyl 829 CH 2 OCH 3 3-pyridyl 5-methyl-l-imidazolyl 830 CH 2 OCH 3 3-pyridyl 2-methylsulfonyl-1-imidazolyl 831 CH 2 OCH 3 2-pyrimidyl 2- (aminosulfonyl ) phenyl 832 CH 2 OCH 3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 833 CH 2 OCH 3 2-pyrimidyl 1-pyrrolidinocarbonyl 834 CH 2 OCH 3 2-pyrimidyl 2- (methylsulfonyl) phenyl 835 CH 2 OCH 3 2-pyrimidyl 4-morpholino 836 CH 2 OCH 3 2-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 837 CH 2 OCH 3 2-pyrimidyl 4-morpholinocarbonyl 838 CH 2 OCH 3 2-pyrimidyl 2-methyl-1-imidazolyl 839 CH 2 OCH 3 2-pyrimidyl 5-methyl-1-imidazolyl 840 CH 2 OCH 3 2-pyrimidyl 2-methylsulfonyl-1-imidazolyl 841 CH 2 OCH3 5-pyrimidyl 2- (aminosulfonyl) phenyl 842 CH 2 OCH 3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 843 CH 2 OCH 3 5-pyrimidyl 1-pyrro1idinocarbony1 844 CH 2 OCH 3 5-pyrimidyl 2- (methylsulfonyl) phenyl 845 CH 2 OCH 3 5-pyrimidyl 4-morpholino 846 CH 2 OCH 3 5-pyrimidyl 2- ( 1 ' -CF3 -tetrazol-2-yl) phenyl 847 CH 2 OCH3 5-pyrimidyl 4-morpholinocarbonyl 848 CH 2 OCH 3 5-pyrimidyl 2-methyl-l-imidazolyl 849 CH 2 OCH 3 5-pyrimidyl 5-methyl-l-imidazolyl 850 CH 2 OCH 3 5-pyrimidyl 2-methylsulfonyl-1-imidazolyl 851 CH 2 OCH 3 2-Cl-phenyl 2- (aminosulfonyl) phenyl 852 CH 2 OCH 3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 853 CH 2 OCH 3 2-Cl-phenyl 1-pyrrolidinocarbonyl 854 CH 2 OCH 3 2-Cl-phenyl 2- (methylsulfonyl) phenyl 855 CH 2 OCH 3 2-Cl-phenyl 4-morpholino 856 CH 2 OCH 3 2-Cl-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 857 CH 2 OCH3 2-Cl-phenyl 4-morpholinocarbonyl 858 CH 2 OCH 3 2-Cl-phenyl 2-methyl-l-imidazolyl 859 CH 2 OCH 3 2-Cl-phenyl 5-methyl-1-imidazolyl 860 CH 2 OCH 3 2-Cl-phenyl 2-methylsulfonyl-1-imidazolyl 861 CH 2 OCH 3 2-F-phenyl 2- (aminosulfonyl ) phenyl 862 CH 2 OCH 3 2-F-phenyl 2- (methylaminosulfonyl) phenyl 863 CH 2 OCH 3 2-F-phenyl 1-pyrrolidinocarbonyl 864 CH 2 OCH 3 2-F-phenyl 2- (methylsulfony1 ) phenyl 865 CH 2 OCH 3 2-F-phenyl 4-morpholino 866 CH 2 OCH 3 2-F-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 867 CH 2 OCH 3 2-F-phenyl 4-morpho1inocarbony1 868 CH 2 OCH 3 2-F-phenyl 2-methyl-l-imidazolyl 869 CH 2 OCH 3 2-F-phenyl 5-methyl-l-imidazolyl 870 CH 2 OCH 3 2-F-phenyl 2-methylsulfonyl-1-imidazolyl 871 CH 2 OCH 3 2 , 6-diF-phenyl 2- (aminosulfonyl ) phenyl 872 CH 2 OCH 3 2 , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl 873 CH 2 OCH 3 2 , 6-diF-phenyl 1-pyrro1idinocarbony1 874 CH 2 OCH 3 2 , 6-diF-phenyl 2- (methylsulfonyl) phenyl 875 CH 2 OCH 3 2 , 6-diF-phenyl 4-morpholino 876 CH 2 OCH 3 2 , 6-diF-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl 877 CH 2 OCH 3 2 , 6-diF-phenyl 4-morpholinocarbonyl 878 CH 2 OCH 3 2, 6-diF-phenyl 2-methyl-1-imidazolyl 879 CH 2 OCH 3 2 , 6-diF-phenyl 5-methyl-1-imidazolyl 880 CH 2 OCH 3 2 , 6-diF-phenyl 2-methylsulfonyl-1-imidazolyl 881 CO H 2 phenyl 2- (aminosulfonyl) phenyl 882 CONH 2 phenyl 2- (methylaminosulfonyl) phenyl 883 CONH 2 phenyl 1-pyrrolidinocarbonyl 884 CO H 2 phenyl 2- (methylsulfonyl) phenyl 885 CONH 2 phenyl 4-morpholino 886 CONH 2 phenyl 2- (1 ' -CF3-tetrazol-2-yl ) phenyl 887 CONH 2 phenyl 4-morpholinocarbonyl 888 CONH 2 phenyl 2-methyl-l-imidazolyl 889 CONH 2 phenyl 5-methyl-l-imidazolyl 890 CONH 2 phenyl 2-methylsulfonyl-1-imidazolyl 891 CONH 2 2-pyridyl 2- (aminosulfonyl) phenyl 892 CONH2 2-pyridyl 2- (methylaminosulfonyl) phenyl 893 CONH 2 2-pyridyl 1-pyrrolidinocarbonyl 894 CONH 2 2-pyridyl 2- (methylsulfonyl) phenyl 895 CONH 2 2-pyridyl 4-morpholino 896 CONH 2 2-pyridyl 2- (1 ' -CF3-tetrazol-2-yl ) phenyl 897 CONH 2 2-pyridyl 4-morpholinocarbonyl 898 CONH 2 2-pyridyl 2-methyl-1-imidazolyl 899 CONH2 2-pyridyl 5-methyl-1-imidazolyl 900 CO H 2 2-pyridyl 2-methylsulfonyl-1-imidazolyl 901 CO H2 3-pyridyl 2- (aminosulfonyl ) phenyl 902 CONH 2 3-pyridyl 2- (methylaminosulfonyl) phenyl 903 CONH 2 3 -pyridyl 1-pyrrolidinocarbonyl 904 CONH 3-pyridyl 2- (methylsulfonyl) phenyl 905 CONH 2 3-pyridyl 4-morpholino 906 CONH 2 3-pyridyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 907 CONH 2 3-pyridyl 4-morpholinocarbonyl 908 CONH2 3-pyridyl 2-methyl-1-imidazolyl 909 CONH 2 3-pyridyl 5-methyl-l-imidazolyl 910 CO H 2 3-pyridyl 2-methylsulfonyl-1-imidazolyl 911 CO H 2 2-pyrimidyl 2- (aminosulfonyl ) phenyl 912 CONH 2 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 913 CO H 2 2-pyrimidyl 1-pyrrolidinocarbonyl 914 CONH 2 2-pyrimidyl 2- (methylsulfonyl) phenyl 915 CONH 2 2-pyrimidyl 4-morpholino 916 CO H 2 2-pyrimidyl 2- (1 ' -CF3 -tetrazol-2-yl ) phenyl 917 CONH2 2-pyrimidyl 4-morpholinocarbonyl 918 CONH 2 2-pyrimidyl 2-methyl-l-imidazolyl 919 CO H 2 2-pyrimidyl 5-methyl-1-imidazolyl 920 CO H 2 2-pyrimidyl 2-methylsulfonyl-1-imidazolyl 921 CONH 2 5-pyrimidyl 2- (aminosulfonyl) phenyl 922 CONH 2 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 923 CONH 2 5-pyrimidyl 1-pyrro1idinocarbony1 924 CO H 2 5-pyrimidyl 2- (methylsulfonyl) phenyl 925 CO H 2 5-pyrimidyl 4-morpholino 926 CO H 2 5-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 927 CONH 2 5-pyrimidyl 4-morpho1inocarbony1 928 CO H 2 5-pyrimidyl 2-methyl-l-imidazolyl 929 CO H2 5-pyrimidyl 5-methyl-1-imidazolyl 930 CONH 2 5-pyrimidyl 2-methylsulfonyl-1-imidazolyl 931 CONH 2 2-Cl-phenyl 2- (aminosulfonyl) phenyl 932 CONH 2 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 933 CO H 2 2-Cl-phenyl 1-pyrrolidinocarbonyl 934 CONH 2 2-Cl-phenyl 2- (methylsulfonyl) phenyl 935 CO H 2 2-Cl-phenyl 4-morpholino 936 CONH 2 2-Cl-phenyl 2- ( 1 ' -CF3 -tetrazol-2-yl) phenyl 937 CO H 2 2-Cl-phenyl 4-morpholinocarbonyl 938 CONH 2 2-Cl-phenyl 2-methyl-l-imidazolyl 939 CONH 2 2-Cl-phenyl 5-methyl-l-imidazolyl 940 CONH 2 2-Cl-phenyl 2-methylsulfonyl-1-imidazolyl 941 CONH2 2-F-phenyl 2- (aminosulfonyl) phenyl 942 CONH 2 2-F-phenyl 2- (methylaminosulfonyl) phenyl 943 CO H 2 2-F-phenyl 1-pyrrolidinocarbonyl 944 CONH 2 2-F-phenyl 2- (methylsulfonyl) phenyl 945 CONH 2 2-F-phenyl 4-morpholino 946 CO H2 2-F-phenyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl 947 CO H2 2-F-phenyl 4-morpholinocarbonyl 948 CONH 2 2-F-phenyl 2-methyl-1-imidazolyl 949 CONH 2 2-F-phenyl 5-methyl-1-imidazolyl 950 CONH2 2-F-phenyl 2-methylsulfonyl-1-imidazolyl 951 CONH 2 2,6-diF-phenyl 2- (aminosulfonyl)phenyl 952 CO H2 2,6-diF-phenyl 2- (methylaminosulfonyl) phenyl 953 CO H 2 2,6-diF-phenyl 1-pyrrolidinocarbonyl 954 CONH 2 2, , 6-diF-phenyl 2- (methylsulfonyl) phenyl 955 CO H 2 2, , 6-diF-phenyl 4-morpho1ino 956 CONH 2 2, .6-diF-phenyl 2- (1' -CF3-tetrazol-2-yl) phenyl 957 CONH 2 2, , 6 -diF -phenyl 4-morpholinocarbonyl 958 CONH 2 2, , 6 -diF -phenyl 2-methyl-l-imidazolyl 959 CONH 2 2, .6-diF-phenyl 5-methyl-1-imidazolyl 960 CO H 2 2, .6-diF-phenyl 2-methylsulfonyl-1-imidazolyl Table 5 ee ff 99 hh zz aaa bbb ccc ddd eee fff ggg hhh Ex # A B I phenyl 2- (aminosulfonyl)phenyl 2 phenyl 2- (methylaminosulfonyl)phenyl 3 phenyl 1-pyrrolidinocarbonyl 4 phenyl 2- (methylsulfonyl) phenyl 5 phenyl 4-morpholino 6 phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl 7 phenyl 4-morpholinocarbonyl 8 phenyl 2-methyl-1-imidazolyl 9 phenyl 5-methyl-1-imidazolyl 10 phenyl 2-methylsulfonyl-1-imidazolyl II 2-pyridyl 2- (aminosulfonyl)phenyl 12 2-pyridyl 2- (methylaminosulfonyl)phenyl 13 2-pyridyl 1-pyrrolidinocarbonyl 14 2-pyridyl 2- (methylsulfonyl)phenyl 15 2-pyridyl 4-morpholino 16 2-pyridyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl 17 2-pyridyl 4-morpholinocarbonyl 18 2-pyridyl 2-methyl-l-imidazolyl 19 2-pyridyl 5-methyl-1-imidazolyl 20 2-pyridyl 2-methylsulfonyl-1-imidazolyl 21 3-pyridyl 2- ( minosulfonyl)phenyl 22 3-pyridyl 2- (methylaminosulfonyl)phenyl 23 3-pyridyl 1-pyrrolidinocarbonyl 24 3-pyridyl 2- (methylsulfonyl)phenyl 25 3-pyridyl 4-morpholino 26 3-pyridyl 2- (l'-CF3-tetrazol-2-yl) phenyl 27 3-pyridyl 4-morpholinocarbonyl 28 3-pyridyl 2-methyl-1-imidazolyl 29 3-pyridyl 5-methyl-1-imidazolyl 30 3-pyridyl 2-methylsulfonyl-1-imidazolyl 31 2-pyrimidyl 2- (aminosulfonyl)phenyl 32 2-pyrimidyl 2- (methylaminosulfonyl)phenyl 33 2-pyrimidyl 1-pyrrolidinocarbonyl 34 2-pyrimidyl 2- (methylsulfonyl)phenyl 35 2-pyrimidyl 4-morpholino 36 2-pyrimidyl 2-(l'-CF3-tetrazol-2-yl)phenyl 37 2-pyrimidyl 4-morpho1inocarbony1 2-pyrimidyl 2-methyl-1-imidazolyl 2-pyrimidyl 5-me hyl-1-imidazolyl 2-pyrimidyl 2-methylsulfonyl-1-imidazolyl 5-pyrimidyl 2- (aminosulfonyl) phenyl 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 5-pyrimidyl 1-pyrrolidinocarbonyl 5-pyrimidyl 2- (methylsulfonyl)phenyl 5-pyrimidyl 4-morpholino 5-pyrimidyl 2- ( 1 ' -CF3-tetrazol-2-yl ) phenyl 5-pyrimidyl 4-morpholinocarbonyl 5-pyrimidyl 2-methyl-l-imidazolyl 5-pyrimidyl 5-methyl-l-imidazolyl 5-pyrimidyl 2-methylsulfonyl-1-imidazolyl 2-Cl-phenyl 2- (aminosulfonyl) phenyl 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 2-Cl-phenyl 1-pyrrolidinocarbonyl 2-Cl-phenyl 2- (methylsulfonyl) phenyl 2-Cl-phenyl 4-morpholino 2-Cl-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 2-Cl-phenyl 4-morpholinocarbonyl 2-Cl-phenyl 2-methyl-1-imidazolyl 2-Cl-phenyl 5-methyl-1-imidazolyl 2-Cl-phenyl 2-methylsulfonyl-1-imidazolyl 2-F-phenyl 2- (aminosulfony1) phenyl 2-F-phenyl 2- (methylaminosulfonyl) phenyl 2-F-phenyl 1-pyrrolidinocarbonyl 2-F-phenyl 2- (methylsulfonyl)phenyl 2-F-phenyl 4-morpholino 2-F-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 2-F-phenyl 4-morpholinocarbonyl 2-F-phenyl 2-methyl-l-imidazolyl 2-F-phenyl 5-methyl-l-imidazolyl 2-F-phenyl 2-methylsulfonyl-1-imidazolyl 2 , 6-diF-phenyl 2- (aminosulfonyl) phenyl 2 , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl 2 , 6-diF-phenyl 1-pyrrolidinocarbonyl 2 , 6-diF-phenyl 2- (methylsulfonyl)phenyl 2 , 6-diF-phenyl 4-morpholino 2 , 6-diF-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 2 , 6-diF-phenyl 4-morpholinocarbonyl 2 , 6-diF-phenyl 2-methyl-l-imidazolyl 2, 6-diF-phenyl 5-methyl-1-imidazolyl 2 , 6-diF-phenyl 2-methylsulfony1-1-imidazolyl Utility The compounds of this invention are useful as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals. The term "thromboembolic disorders" as used herein includes arterial or venous cardiovascular or cerebrovascular thromboembolic disorders, including, for example, unstable angina, first or recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary and cerebral arterial thrombosis, cerebral embolism, kidney embolisms, and pulmonary embolisms. The anticoagulant effect of compounds of the present invention is believed to be due to inhibition of factor Xa or thrombin. The effectiveness of compounds of the present invention as inhibitors of factor Xa was determined using purified human factor Xa and synthetic substrate. The rate of factor Xa hydrolysis of chromogenic substrate S2222 (Kabi Pharmacia, Franklin, OH) was measured both in the absence and presence of compounds of the present invention. Hydrolysis of the substrate resulted in the release of pNA, which was monitored spectrophotometrically by measuring the increase in absorbance at 405 nM. A decrease in the rate of absorbance change at 405 nm in the presence of inhibitor is indicative of enzyme inhibition. The results of this assay are expressed as inhibitory constant, Ki. Factor Xa determinations were made in 0.10 M sodium phosphate buffer, pH 7.5, containing 0.20 M NaCl, and 0.5 % PEG 8000. The Michaelis constant, K , for substrate hydrolysis was determined at 25°C using the method of Lineweaver and Burk. Values of Ki were determined by allowing 0.2-0.5 nM human factor Xa (Enzyme Research Laboratories, South Bend, IN) to react with the substrate (0.20 ιri -1 mM) in the presence of inhibitor. Reactions were allowed to go for 30 minutes and the velocities (rate of absorbance change vs time) were measured in the time frame of 25-30 minutes. The following relationship was used to calculate Ki values : (v 0 -v s )/v s = I/(Ki (1 + S/K m )) where : v 0 is the velocity of the control in the absence of inhibitor; v s is the velocity in the presence of inhibitor; I is the concentration of inhibitor; Ki is the dissociation constant of the enzyme: inhibitor complex; S is the concentration of substrate; K m is the Michaelis constant. Using the methodology described above, a number of compounds of the present invention were found to exhibit a Ki of IO μM, thereby confirming the utility of the compounds of the present invention as effective Xa inhibitors. The antithrombotic effect of compounds of the present invention can be demonstrated in a rabbit arterio-venous (AV) shunt thrombosis model. In this model, rabbits weighing 2-3 kg anesthetized with a mixture of xylazine (10 mg/kg i.m.) and ketamine (50 mg/kg i.m.) are used. A saline-filled AV shunt device is connected between the femoral arterial and the femoral venous cannulae . The AV shunt device consists of a piece of 6-cm tygon tubing which contains a piece of silk thread. Blood will flow from the femoral artery via the AV- shunt into the femoral vein. The exposure of flowing blood to a silk thread will induce the formation of a significant thrombus. After forty minutes, the shunt is disconnected and the silk thread covered with thrombus is weighed. Test agents or vehicle will be given (i.v., i.p., s.c, or orally) prior to the opening of the AV shunt. The percentage inhibition of thrombus formation is determined for each treatment group. The ID50 values (dose which produces 50% inhibition of thrombus formation) are estimated by linear regression. The compounds of formula (I) may also be useful as inhibitors of serine proteases, notably human thrombin, plasma kallikrein and plas in. Because of their inhibitory action, these compounds are indicated for use in the prevention or treatment of physiological reactions, blood coagulation and inflammation, catalyzed by the aforesaid class of enzymes. Specifically, the compounds have utility as drugs for the treatment of diseases arising from elevated thrombin activity , such as myocardial infarction, and as reagents used as anticoagulants in the processing of blood to plasma for diagnostic and other commercial purposes . Some compounds of the present invention were shown to be direct acting inhibitors of the serine protease thrombin by their ability to inhibit the cleavage of small molecule substrates by thrombin in a purified system. In vi tro inhibition constants were determined by the method described by Kettner et al . in J. Biol . Chem . 265, 18289-18297 (1990), herein incorporated by reference. In these assays, thrombin- mediated hydrolysis of the chromogenic substrate S2238 (Helena Laboratories, Beaumont, TX) was monitored spectrophoto etrically. Addition of an inhibitor to the assay mixture results in decreased absorbance and is indicative of thrombin inhibition. Human thrombin (Enzyme Research Laboratories, Inc., South Bend, IN) at a concentration of 0.2 nM in 0.10 M sodium phosphate buffer, pH 7.5, 0.20 M NaCl, and 0.5% PEG 6000, was incubated with various substrate concentrations ranging from 0.20 to 0.02 mM. After 25 to 30 minutes of incubation, thrombin activity was assayed by monitoring the rate of increase in absorbance at 405 nm which arises owing to substrate hydrolysis. Inhibition constants were derived from reciprocal plots of the reaction velocity as a function of substrate concentration using the standard method of Lineweaver and Burk. Using the methodology described above, some compounds of this invention were evaluated and found to exhibit a Ki of less than 10 μ , thereby confirming the utility of the compounds of the present invention as effective thrombin inhibitors. The compounds of the present invention can be administered alone or in combination with one or more additional therapeutic agents . These include other anticoagulant or coagulation inhibitory agents, anti-platelet or platelet inhibitory agents, thrombin inhibitors, or thrombolytic or fibrinolytic agents . The compounds are administered to a mammal in a therapeutically effective amount. By "therapeutically effective amount" it is meant an amount of a compound of Formula I that, when administered alone or in combination with an additional therapeutic agent to a mammal, is effective to prevent or ameliorate the thromboembolic disease condition or the progression of the disease. By "administered in combination" or "combination therapy" it is meant that the compound of Formula I and one or more additional therapeutic agents are administered concurrently to the mammal being treated. When administered in combination each component may be administered at the same time or sequentially in any order at different points in time. Thus, each component may be administered separately but sufficiently closely in time so as to provide the desired therapeutic effect. Other anticoagulant agents (or coagulation inhibitory agents) that may be used in combination with the compounds of this invention include warfarin and heparin, as well as other factor Xa inhibitors such as those described in the publications identified above under Background of the Invention. The term anti-platelet agents (or platelet inhibitory agents) , as used herein, denotes agents that inhibit platelet function such as by inhibiting the aggregation, adhesion or granular secretion of platelets. Such agents include, but are not limited to, the various known non-steroidal anti- inflammatory drugs (NSAIDS) such as aspirin, ibuprofen, naproxen, sulindac, indomethacin, mefenamate, droxicam, diclofenac, sulfinpyrazone, and piroxicam, including pharmaceutically acceptable salts or prodrugs thereof. Of the NSAIDS, aspirin (acetylsalicyclic acid or ASA) , and piroxicam are preferred. Other suitable anti-platelet agents include ticlopidine, including pharmaceutically acceptable salts or prodrugs thereof. Ticlopidine is also a preferred compound since it is known to be gentle on the gastro-intestinal tract in use. Still other suitable platelet inhibitory agents include Ilb/IIIa antagonists, thromboxane-A2-receptor antagonists and thromboxane-A2-synthetase inhibitors, as well as pharmaceutically acceptable salts or prodrugs thereof . The term thrombin inhibitors (or anti-thrombin agents) , as used herein, denotes inhibitors of the serine protease thrombin. By inhibiting thrombin, various thrombin-mediated processes, such as thrombin-mediated platelet activation (that is, for example, the aggregation of platelets, and/or the granular secretion of plasminogen activator inhibitor-1 and/or serotonin) and/or fibrin formation are disrupted. A number of thrombin inhibitors are known to one of skill in the art and these inhibitors are contemplated to be used in combination with the present compounds. Such inhibitors include, but are not limited to, boroarginine derivatives, boropeptides, heparins, hirudin and argatroban, including pharmaceutically acceptable salts and prodrugs thereof. Boroarginine derivatives and boropeptides include N-acetyl and peptide derivatives of boronic acid, such as C-terminal a-aminoboronic acid derivatives of lysine, ornithine, arginine, homoarginine and corresponding isothiouronium analogs thereof . The term hirudin, as used herein, includes suitable derivatives or analogs of hirudin, referred to herein as hirulogs, such as disulfatohirudin. Boropeptide thrombin inhibitors include compounds described in Kettner et al., U.S. Patent No. 5,187,157 and European Patent Application Publication Number 293 881 A2, the disclosures of which are hereby incorporated herein by reference. Other suitable boroarginine derivatives and boropeptide thrombin inhibitors include those disclosed in PCT Application Publication Number 92/07869 and European Patent Application Publication Number 471,651 A2, the disclosures of which are hereby incorporated herein by reference. The term thrombolytics (or fibrinolytic) agents (or thrombolytics or fibrinolytics) , as used herein, denotes agents that lyse blood clots (thrombi).- Such agents include tissue plasminogen activator, anistreplase, urokinase or streptokinase, including pharmaceutically acceptable salts or prodrugs thereof. The term anistreplase, as used herein, refers to anisoylated plasminogen streptokinase activator complex, as described, for example, in European Patent Application No. 028,489, the disclosure of which is hereby incorporated herein by reference herein. The term urokinase, as used herein, is intended to denote both dual and single chain urokinase, the latter also being referred to herein as prourokinase . Administration of the compounds of Formula I of the invention in combination with such additional therapeutic agent, may afford an efficacy advantage over the compounds and agents alone, and may do so while permitting the use of lower doses of each. A lower dosage minimizes the potential of side effects, thereby providing an increased margin of safety. The compounds of the present invention are also useful as standard or reference compounds, for example as a -quality standard or control, in tests or assays involving the inhibition of factor Xa. Such compounds may be provided in a commercial kit, for example, for use in pharmaceutical research involving factor Xa. For example, a compound of the present invention could be used as a reference in an assay to compare its known activity to a compound with an unknown activity. This would ensure the experimenter that the assay was being performed properly and provide a basis for comparison, especially if the test compound was a derivative of the reference compound. When developing new assays or protocols, compounds according to the present invention could be used to test their effectiveness. The compounds of the present invention may also be used in diagnostic assays involving factor Xa. For example, the presence of factor Xa in an unknown sample could be determined by addition of chromogenic substrate S2222 to a series of solutions containing test sample and optionally one of the compounds of the present invention. If production of pNA is observed in the solutions containing test sample, but not in the presence of a compound of the present invention, then one would conclude factor Xa was present. Dosaσe and Formulation The compounds of this invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations) , pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. They may also be administered in intravenous (bolus or infusion) , intraperitoneal, subcutaneous, or intramuscular form, all using dosage forms well known to those of ordinary skill in the pharmaceutical arts. They can be administered alone, but generally will be administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice. The dosage regimen for the compounds of the present invention will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; the route of administration, the renal and hepatic function of the patient, and the effect desired. A physician or veterinarian can determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the thromboembolic disorder. By way of general guidance, the daily oral dosage of each active ingredient, when used for the indicated effects, will range between about 0.001 to 1000 mg/kg of body weight, preferably between about 0.01 to 100 mg/kg of body weight per day, and most preferably between about 1.0 to 20 mg/kg/day. Intravenously, the most preferred doses will range from about 1 to about 10 mg/kg/minute during a constant rate infusion. Compounds of this invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three, or four times daily. Compounds of this invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using transdermal skin patches. When administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen . The compounds are typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers (collectively referred to herein as pharmaceutical carriers) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices . For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl callulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like. The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles . Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines . Compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-pheno1 , polyhydroxyethylaspartamidephenol, or polyethyleneoxide- polylysine substituted with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans , polycyanoacylates, and crosslinked or amphipathic block copolymers of hydrogels . Dosage forms (pharmaceutical compositions) suitable for administration may contain from about 1 milligram to about 100 milligrams of active ingredient per dosage unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition. Gelatin capsules may contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours . Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract. Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance. In general, water, a suitable oil, saline, aqueous dextrose (glucose) , and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol . Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences-, Mack Publishing Company, a standard reference text in this field. Representative useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows: Capsules A large number of unit capsules can be prepared by filling standard two-piece hard gelatin capsules each with 100 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate. Soft Gelatin Capsules A mixture of active ingredient in a digestable oil such as soybean oil, cottonseed oil or olive oil may be prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient. The capsules should be washed and dried. Tablets Tablets may be prepared by conventional procedures so that the dosage unit is 100 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption. Iniectable A parenteral composition suitable for administration by injection may be prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol and water. The solution should be made isotonic with sodium chloride and sterilized. Suspension An aqueous suspension can be prepared for oral administration so that each 5 mL contain 100 mg of finely divided active ingredient, 200 mg of sodium carboxymethyl cellulose, 5 mg of sodium benzoate J 1.0 g of sorbitol solution, U.S. P., and 0.025 mL of vanillin. Where the compounds of this invention are combined with other anticoagulant agents, for example, a daily dosage may be about 0.1 to 100 milligrams of the compound of Formula I and about 1 to 7.5 milligrams of the second anticoagulant, per kilogram of patient body weight. For a tablet dosage form, the compounds of this invention generally may be present in an amount of about 5 to 10 milligrams per dosage unit, and the second anti-coagulant in an amount of about 1 to 5 milligrams per dosage unit. Where the compounds of Formula I are administered in combination with an anti-platelet agent, by way of general guidance, typically a daily dosage may be about 0.01 to 25 milligrams of the compound of Formula I and about 50 to 150 milligrams of the anti-platelet agent, preferably about 0.1 to 1 milligrams of the compound of Formula I and about 1 to 3 milligrams of antiplatelet agents, per kilogram of patient body weight . Where the compounds of Formula I are adminstered in combination with thrombolytic agent, typically a daily dosage may be about 0.1 to 1 milligrams of the compound of Formula I, per kilogram of patient body weight and, in the case of the thrombolytic agents, the usual dosage of the thrombolyic agent when administered alone may be reduced by about 70-80% when administered with a compound of Formula I. Where two or more of the foregoing second therapeutic agents are administered with the compound of Formula I, generally the amount of each component in a typical daily dosage and typical dosage form may be reduced relative to the usual dosage of the agent when administered alone, in view of the additive or synergistic effect of the therapeutic agents when administered in combination. Particularly when provided as a single dosage unit, the potential exists for a chemical interaction between the combined active ingredients. For this reason, when the compound of Formula I and a second therapeutic agent are combined in a single dosage unit they are formulated such that although the active ingredients are combined in a single dosage unit, the physical contact between the active ingredients is minimized (that is, reduced) . For example, one active ingredient may be enteric coated. By enteric coating one of the active ingredients, it is possible not only to minimize the contact between the combined active ingredients, but also, it is possible to control the release of one of these components in the gastrointestinal tract such that one of these components is not released in the stomach but rather is released in the intestines. One of the active ingredients may also be coated with a material which effects a sustained- release throughout the gastrointestinal tract and also serves to minimize physical contact between the combined active ingredients. Furthermore, the sustained-released component can be additionally enteric coated such that the release of this component occurs only in the intestine. Still another approach would involve the formulation of a combination product in which the one component is coated with a sustained and/or enteric release polymer, and the other component is also coated with a polymer such as a lowviscosity grade of hydroxypropyl methylcellulose (HPMC) or other appropriate materials as known in the art, in order to further separate the active components . The polymer coating serves to form an additional barrier to interaction with the other component. These as well as other ways of minimizing contact between the components of combination products of the present invention, whether administered in a single dosage form or administered in separate forms but at the same time by the same manner, will be readily apparent to those skilled in the art, once armed with the present disclosure. Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings . It is therefore to be understood that within the scope of the appended claims, the invention may be practiced otherwise that as specifically described herein.

Claims: WHAT IS CLAIMED IS ; 1 . A compound of formula I : I or a stereoisomer or pharmaceutically acceptable salt thereof, wherein; ring M contains, in addition to J, 0-3 N atoms, provided that if M contains 2 N atoms then R lb is not present and if M contains 3 N atoms then R la and R lb are not present; J is N or NH; D is selected from CN, C (=NR 8 ) NR 7 R 9 , NHC (=NR 8 ) NR 7 R 9 , NR 8 CH(=NR 7 ), C(0)NR 7 R 8 , and (CR 8 R 9 ) t NR 7 R 8 , provided that D is substituted ortho to G on E; E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, and piperidinyl substituted with 1-2 R; R is selected from H, Cl, F, Br, I, (CH2) t O R3 ' c l-4 alkyl, OCF 3 , CF 3 , C(0)NR 7 R 8 , and (CR 8 R 9 ) t NR 7 R 8 ; G is absent or is selected from NHCH 2 , OCH 2 , and SCH2, provided that when s is 0, then G is attached to a carbon atom on ring M; Z is selected from a C1- 4 alkylene, (CH2) r O(C H 2)r (CH 2 ) r NR 3 (CH2)r, (CH 2 ) r C (0) (CH 2 ) τ , (CH 2 ) r (O) 0 (CH 2 ) T , (CH 2 ) r OC(0) (CH 2 ) r , (CH 2 ) r C (0) NR 3 (CH 2 ) T . (CH 2 ) r NR 3 C(0) (CH 2 ) r , (CH 2 ) r OC (0) 0 (CH 2 ) τ , (CH 2 )rOC(0)NR 3 (CH 2 )r, (CH 2 ) r NR 3 C (O) 0 (CH 2 ) r , (CH 2 ) r NR 3 C(0)NR (CH 2 ) r , (CH 2 ) r S (0) p (CH 2 ) τ , (CH 2 )rS02NR 3 (CH 2 )r, (CH 2 ) r NR 3 S0 2 (CH 2 ) r . and (CH2) r R 3 Sθ 2 NR 3 (CH 2 ) r - provided that Z does not form a N- N, N-0, N-S, NCH 2 N, NCH 2 0, or NCH 2 S bond with ring M or group A; R la and R lb are independently absent or selected from -(CH 2 ) r -R 1 ', -CH=CH-R 1 ', NCH2R 1 ", OCH2R 1 ", SCH2R 1 ", NH ( CH 2 )2 ( CH 2 )tR 1' 0(CH 2 )2(CH 2 )tR 1' , and S ( CH 2 ) 2 ( CH 2 ) tR 1 ' • alternatively, R la and R lb , when attached to adjacent carbon atoms, together with the atoms to which they are attached form a 5-8 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R 4 and which contains from 0-2 heteroatoms selected from the group consisting of N, 0, and S; R 1 ' is selected from H, C 1 - 3 alkyl, F, Cl, Br, I, -CN, -CHO, (CF 2 )rCF 3 , (CH 2 ) r OR 2 , NR 2 R 2a , C(0)R 2c , OC(0)R 2 , (CF 2 ) r C0 2 R 2c , S(0) p R 2b , NR 2 (CH 2 ) r OR 2 , CH (=NR 2c )NR 2 R 2a , NR 2 C(0)R 2b , NR 2 C(0)NHR 2b , NR 2 C(0) 2 R 2a , OC (0) NR 2a R 2b , C(0)NR 2 R 2a , C(0)NR 2 (CH 2 ) r OR 2 , S0 2 NR 2 R 2a , NR 2 S0 2 R 2b , C 3 _ 6 carbocyclic residue substituted with 0-2 R 4 , and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4 ; R 1 " is selected from H, CH(CH 2 OR 2 ) 2 , C(0)R 2c , C(0)NR 2 R 2a , S(0)R 2b , S(0) 2 R 2b , and S0 2 NR 2 R 2a ; R 2 , at each occurrence, is selected from H, CF 3 , Cι_6 alkyl, benzyl, C3-6 carbocyclic residue substituted with 0-2 R b , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4b ; R a , at each occurrence, is selected from H, CF 3 , Cι_ 6 alkyl, benzyl, C3-- 6 carbocyclic residue substituted with 0-2 R 4b , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4b ; R 2b , at each occurrence, is selected from CF 3 , C 1 - 4 alkoxy, Cι_ 6 alkyl, benzyl, C 3 .. 6 carbocyclic residue substituted with 0-2 R 4b , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4b ; R 2c , at each occurrence, is selected from CF 3 , OH, C 1 - 4 alkoxy, C1-6 alkyl, benzyl, C 3 .- 6 carbocyclic residue substituted with 0-2 R b , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4b ; alternatively, R 2 and R 2a combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R 4b which contains from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S; alternatively, R 2 and R 2a , together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R 4b and containing from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S; R 3 , at each occurrence, is selected from H, C 1 - 4 alkyl, and phenyl; R 3a , at each occurrence, is selected from H, Cχ_ 4 alkyl, and phenyl ; R 3b , at each occurrence, is selected from H, C 1 - 4 alkyl, and phenyl ; R 3c , at each occurrence, is selected from C 1 - 4 alkyl, and phenyl ; A is selected from: C3-10 carbocyclic residue substituted with 0-2 R 4 , and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4 ; B is selected from: X-Y, NR 2 R 2a , C(=NR 2 )NR 2 R 2a , NR 2 C (=NR 2 )NR 2 R 2a , C3-10 carbocyclic residue substituted with 0-2 R 4a , and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R a ; X is selected from Cι_ alkylene, -CR 2 (CR 2 R 2b ) (CH 2 ) t - , -C(O)-, -C(=NR lβ )-, -CR 2 (NRl"R2)-, _CR2(OR 2 )-, -CR 2 (SR 2 )-, -C(0)CR 2 R 2a -, -CR 2 R 2 C(0), -S(0) p -, -S (0) p CR 2 R 2a -, -CR 2 R 2a S(0) p -, -S(0) 2 NR 2 -, -NR 2 S(0) 2 -. -NR 2 S (0) 2 CR 2 R 2a - , -CR 2 R 2a S(0) 2 NR 2 -, -NR 2 S(0) 2 NR 2 -, -C(0)NR 2 -, -NR 2 C(0)-, -C(0)NR 2 CR 2 R 2a -, -NR 2 C(0)CR 2 R 2a -, -CR 2 R 2a C (0)NR 2 -, -CR 2 R 2a NR 2 C(0)-, -NR 2 C(0)0-, -OC(0)NR 2 -, -NR 2 C (0)NR 2 - , -NR 2 -, -NR 2 CR 2 R 2a -, -CR 2 R 2a NR 2 -, O, -CR 2 R 2a 0-, and -0CR 2 R 2a -; Y is selected from: (CH 2 ) r NR 2 R 2a , provided that X-Y do not form a N-N, O-N, or S-N bond, C3-10 carbocyclic residue substituted with 0-2 R 4a , and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R a ; R 4 , at each occurrence, is selected from H, =0, (CH 2 ) r OR 2 , F, Cl, Br, I, Cι_ 4 alkyl, -CN, N0 2 , (CH 2 ) r NR 2 R 2a , (CH 2 )rC(0)R 2c , NR 2 C(0)R 2b , C(0)NR 2 R 2a , NR 2 C (0)NR 2 R 2a , CH(=NR 2 )NR 2 R 2 , CH(=NS(0) 2 R 5 )NR 2 R 2a , NHC (=NR 2 ) NR 2 R 2a , C(0)NHC(=NR 2 )NR 2 R 2a , S0 2 NR 2 R 2a , NR 2 S0 2 NR 2 R 2a , NR 2 S0 2 -Cι_ alkyl, NR 2 S0 2 R 5 , S(0) p R 5 , (CF 2 ) r CF 3 , NCH 2 R 1 ", OCH2R 1" , SCH2R 1" , N ( CH 2 ) 2 ( CH 2 )tR 1' 0 ( CH 2 ) 2 ( CH 2 ) tR 1' , and S ( CH 2 ) 2 ( CH 2 ) tR 1' , alternatively, one R 4 is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S; R 4a , at each occurrence, is selected from H, =0, (CH 2 ) r OR 2 , (CH 2 ) r -F, (CH 2 ) r -Br, (CH 2 ) r -Cl, Cl, Br, F, I, C 1 - 4 alkyl, -CN, N0 2 , (CH 2 ) r NR 2 R 2a , (CH 2 ) r C(0)R 2c , NR 2 C(0)R 2b , C(0)NR 2 R 2a , C(0)NH(CH 2 ) 2 NR 2 R 2a , NR 2 C (0) NR 2 R 2a , CH(=NR 2 )NR 2 R 2a , NHC(=NR 2 )NR 2 R 2a , S0 2 NR 2 R 2a , NR 2 S0 2 NR 2 R 2a , NR 2 S0 2 -Cι_4 alkyl, C (0)NHS0 2 -Cι_ 4 alkyl, NR 2 S0 2 R 5 , S(0) p R 5 , and (CF 2 )rCF 3 ; alternatively, one R 4a is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-1 R 5 ; R 4b , at each occurrence, is selected from H, =0, (CH 2 ) r OR 3 , F, Cl, Br, I, Cι_ 4 alkyl, -CN, N0 2 , (CH 2 ) r NR 3 R 3 , (CH 2 ) r C(0)R 3 , (CH 2 ) r C(0)OR 3c , NR 3 C(0)R 3a , C(0)NR 3 R 3a , NR 3 C(0)NR 3 R 3a , CH (=NR 3 )NR 3 R 3a , NR 3 C (=NR 3 ) NR 3 R 3a , S0 2 NR 3 R 3a , NR 3 S0 2 NR 3 R 3a , NR 3 S0 2 -Cι_ alkyl, NR 3 S0 2 CF 3 , NR 3 S0 2 -phenyl , S(0) p CF 3 , S(0) p -Cι-4 alkyl, S (0) p -phenyl, and (CF 2 )rCF 3 ; R 5 , at each occurrence, is selected from CF 3 , Cχ-6 alkyl, phenyl substituted with 0-2 R 6 , and benzyl substituted with 0-2 R 6 ; R 6 , at each occurrence, is selected from H, OH, (CH 2 ) r OR 2 , halo, Cι_4 alkyl, CN, N0 2 , (CH 2 ) r R 2 R 2a , (CH 2 ) r C (0)R 2b , NR 2 C(0)R 2b , NR 2 C(0)NR 2 R 2a , CH(=NH)NH 2 , NHC(=NH)NH 2 , S0 2 NR 2 R 2a , NR 2 S0 2 NR 2 R 2a , and NR 2 S0 2 Cι_ 4 alkyl; R 7 , at each occurrence, is selected from H, OH, Cis alkyl, Cι- 6 alkylcarbonyl , Cι_ 6 alkoxy, Cι_ 4 alkoxycarbonyl, (CH 2 ) n -phenyl, Cβ-i aryloxy, C δ -io aryloxycarbonyl , C6_ιo arylmethylcarbonyl, Cχ_ 4 alkylcarbonyloxy Cι_ 4 alkoxycarbonyl, Cβ-io arylcarbόnyloxy C 1 - 4 alkoxycarbonyl, Cχ_ 6 alkylaminocarbonyl , phenylaminocarbonyl , and phenyl Cχ- 4 alkoxycarbonyl; R 8 , at each occurrence, is selected from H, C 1 - 6 alkyl and (CH 2 ) π -phenyl; alternatively, R 7 and R 8 combine to form a 5 or 6 membered saturated, ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S; R 9 , at each occurrence, is selected from H, Cis alkyl and (CH 2 ) n -phenyl; n, at each occurrence, is selected from 0, 1, 2, and 3; m, at each occurrence, is selected from 0, 1, and 2; p, at each occurrence, is selected from 0, 1, and 2; r, at each occurrence, is selected from 0, 1, 2, and 3; s, at each occurrence, is selected from 0, 1, and 2; and, t, at each occurrence, is selected from 0, 1, 2, and 3; provided that D-E-G- (CH 2 ) s - and -Z-A-B are not both benzamidines . 2. A compound according to Claim 1, wherein the compound is of formulae Ia-Ih: Id le If wherein, groups D-E- and -Z-A-B are attached to adjacent atoms on the ring; R is selected from H, Cl, F, Br, I, (CH 2 ) t OR 3 , C 1 - 4 alkyl, OCF 3 , CF 3 , C(0)NR 7 R 8 , and (CR 8 R 9 ) t NR 7 R 8 ; Z is selected from a CH 2 0, 0CH 2 , CH 2 NH, NHCH 2 , C(0), CH 2 C(0), C(0)CH 2 , NHC(O), C(0)NH, CH 2 S(0) 2 , S(0) 2 {CH 2 ), S0 2 NH, and NHSO 2 , provided that Z does not form a N-N, N-O, NCH 2 N, or NCH 2 O bond with ring M or group A; A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4 ; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1,2, 3-oxadiazolyl, 1,2, 4-oxadiazolyl, 1,2, 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2, 3-thiadiazolyl, 1,2, 4-thiadiazolyl, 1,2, 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2, 3-triazolyl, 1,2,4-triazolyl, 1, 2 , 5-triazolyl, 1, 3 , 4-triazolyl, benzofuranyl, benzothiofuranyl, indolyl, benzimidazolyl, benzoxazolyl benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl; B is selected from: Y, X-γ, NR 2 R 2a , C (=NR 2 )NR 2 R 2a , and NR 2 C (=NR 2 ) NR 2 R 2a ; X is selected from Cι_ alkylene, -C(O)-, -C(=NR)-, -CR 2 (NR 2 R 2a )-, -C(0)CR 2 R 2a -, -CR 2 R 2a C(0), -C(0)NR 2 -, -NR 2 C(0)-, -C(0)NR 2 CR 2 R 2a -, -NR 2 C (0) CR 2 R 2a -, -CR 2 R 2a C(0)NR 2 -, -CR 2 R 2a NR 2 C(0)-, -NR 2 C (O)NR 2 - , -NR 2 -, -NR 2 CR 2 R 2a -, -CR 2 R a NR 2 -, 0, -CR 2 R 2a O-, and -OCR 2 R 2a -; Y is NR 2 R 2a , provided that X-Y do not form a N-N or O-N bond; alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4a ; cylcopropyl, cyclopentyl, cyclohexyl, phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1 , 2 , 3-oxadiazolyl , 1,2, 4-oxadiazolyl, 1,2, 5-oxadiazolyl, 1, 3, 4-oxadiazolyl, 1,2,3 -thiadiazolyl , 1,2, 4-thiadiazolyl , 1,2, 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2, 3-triazolyl, 1,2,4-triazolyl, 1, 2 , 5-triazolyl, 1, 3 , 4-triazolyl, benzofuranyl, benzothiofuranyl, indolyl, benzimidazolyl, benzoxazolyl , benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl ; alternatively, Y is selected from the following bicyclic heteroaryl ring systems : K is selected from 0, S, NH, and N. 3. A compound according to Claim 2 , wherein the compound is of formulae Ila-IIf: wherein; Z is selected from a C(O), CH 2 C(0), C(0)CH 2 , NHC(O), C(0)NH, C(0)N(CH 3 ) , CH 2 S(0) 2 . S(0) 2 (CH 2 ), S0 2 NH, and NHS0 2 , provided that Z does not form a N-N or NCH 2 N bond with ring M or group A. 4. A compound according to Claim 3, wherein; E is phenyl substituted with R or 2-pyridyl substituted with R; D is selected from NH 2 , NHCH 3 , CH 2 NH 2 , CH 2 NHCH 3 , CH(CH 3 )NH 2 , and C(CH 3 ) 2 NH 2 , provided that D is substituted ortho to ring M on E; .and, R is selected from H, OCH 3 , Cl, and F. 5. A compound according to Claim 4, wherein; D-E is selected from 2-aminophenyl, 2-methylaminophenyl, 2- aminomethylphenyl, 4-methoxy-2-.aminophenyl, 4-methoxy-2- (methylamino) phenyl, 4-methoxy-2-aminomethylphenyl, 4- methoxy-2- (methylaminomethyl) phenyl , 4-methoxy-2- (1- aminoethyl ) phenyl , 4-methoxy-2- (2-amino-2-propyl) phenyl , 4-Cl-2-aminophenyl, 4-C1-2- (methylamino) phenyl, 4-C1-2- aminomethylphenyl, 4-C1-2- (methylaminomethyl) phenyl, 4- Cl-2-(l-aminoethyl) phenyl, 4-C1-2- (2-amino-2- propyl) phenyl , 4-F-2-aminophenyl, 4-F-2- (methylamino) phenyl, 4-F-2-aminomethylphenyl, 4-F-2- (methylaminomethyl ) phenyl , 4-F-2- ( 1-aminoethyl) phenyl , and 4-F-2- (2-amino-2-propyl) phenyl . 6. A compound according to Claim 3, wherein; Z is C(0)CH 2 and CONH, provided that Z does not form a N-N bond with group A; A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R 4 ; and, B is selected from X-Y, phenyl, pyrrolidino, morpholino, 1,2, 3-triazolyl, and imidazolyl, and is substituted with 0-1 R a ; R 4 , at each occurrence, is selected from OH, (CH 2 ) r OR 2 , halo, Cι- 4 alkyl, (CH 2 ) r NR 2 R 2a , and (CF 2 ) r CF 3 ; Ra i s selected from Cι_ 4 alkyl, CF 3 , S(p) p R 5 , S0 2 NR 2 R 2 , and l-CF3-tetrazol-2-yl; R 5 , at each occurrence, is selected from CF 3 , Cι_ 6 alkyl, phenyl, and benzyl; X is CH 2 or C(O); and, Y is selected from pyrrolidino and morpholino. 7. A compound according to Claim 6, wherein; A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F- phenyl, 2-methylphenyl, 2-aminophenyl, and 2- methoxyphenyl; and, B is selected from the group: 2-CF3-phenyl, 2- (aminosulfonyl) phenyl, 2- (methylaminosulfonyl) phenyl, 2- (dimethylaminosulfonyl) phenyl, 1-pyrrolidinocarbonyl, 2- (methylsulfonyl) phenyl, 4-morpholino, 2- (1' -CF3~tetrazol- 2-yl) phenyl, 4-morpholinocarbonyl, 2-methyl-l-imidazolyl, 5-methyl-l-imidazolyl, 2-methylsulfonyl-1-imidazolyl and, 5-methyl-l, 2, 3-triazolyl. 8. A compound according to Claim 3, wherein; E is phenyl substituted with R or 2-pyridyl substituted with R; D is selected from NH 2 , NHCH 3 , CH 2 NH 2 , CH 2 NHCH 3 , CH(CH 3 )NH 2 , and C(CH 3 ) 2 NH2, provided that D is substituted ortho to ring M on E; and, R is selected from H, OCH 3 , Cl, and F; Z is C(0)CH2 and CONH, provided that Z does not form a N-N bond with group A; A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R 4 ; and, B is selected from X-Y, phenyl, pyrrolidino, morpholino, 1, 2, 3 -triazolyl, and imidazolyl, and is substituted with 0-1 R 4a ; R 4 , at each occurrence, is selected from OH, (CH2) r ° 2 ' halo, Cι_4 alkyl, (CH 2 ) r NR 2 R 2a , and (CF 2 ) r CF 3 ; R 4a i s selected from Cι_ 4 alkyl, CF 3 , S(0) p R 5 , Sθ 2 NR 2 R 2a , and l-CF 3 -tetrazol-2-yl; R 5 , at each occurrence, is selected from CF 3 , Cι_ 6 alkyl, phenyl, and benzyl; X is CH 2 or C(O); and, Y is selected from pyrrolidino and morpholino. 9. A compound according to Claim 8, wherein; D-E is selected from 2-aminophenyl, 2-methylaminophenyl, 2- aminomethylphenyl , 4-methoxy-2-aminophenyl, 4-methoxy-2- (methylamino) phenyl, 4-methoxy-2-aminomethylphenyl, 4- methoxy-2- (methylaminomethyl) phenyl, 4-methoxy-2- (1- aminoethyl) phenyl , 4-methoxy-2- (2-amino-2-propyl ) phenyl , 4-Cl-2-aminophenyl, 4-C1-2- (methylamino)phenyl, 4-C1-2- aminomethylphenyl , 4-Cl-2- (methylaminomethyl) phenyl , 4- Cl-2-(l-aminoethyl) phenyl, 4-C1-2- (2-amino-2- propyl) phenyl , 4-F-2-aminophenyl, 4-F-2- (methylamino) phenyl, 4-F-2-aminomethylphenyl, 4-F-2- (methylaminomethyl) phenyl, 4-F-2- (1-aminoethyl) phenyl, and 4-F-2- (2-amino-2-propyl) phenyl; A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F- phenyl, 2-methylphenyl , 2-aminophenyl, and 2- methoxyphenyl ; and, B is selected from the group: 2-CF3-phenyl , 2- (aminosulfonyl) phenyl, 2- (methylaminosulfonyl) phenyl, 2- (dimethylaminosulfonyl) phenyl, 1-pyrrolidinocarbonyl, 2- (methylsulfonyl) phenyl, 4-morpholino, 2- (1 ' -CF3-tetrazol- 2-yl) phenyl, 4-morpholinocarbonyl, 2-methyl-l-imidazolyl, 5-methyl-l-imidazolyl, 2-methylsulfonyl-1-imidazolyl and, 5-methyl-l, 2, 3-triazolyl. 10. A compound according to Claim 9, wherein the compound is of formula Ila. 11. A compound according to Claim 9, wherein the compound is of formula lib. 12. A compound according to Claim 9 , wherein the compound is of formula lie . 13. A compound according to Claim 9 , wherein the compound is of formula lid. 14. A compound according to Claim 9, wherein the compound is of formula lie. 15. A compound according to Claim 9, wherein the compound is of formula Ilf. 16. A compound according to Claim 3, wherein; D is selected from -CN, C (=NR 8 ) NR 7 R 9 , C(0)NR 7 R 8 , NR 7 R 8 , and CH 2 NR 7 R 8 , provided that D is substituted ortho to ring M on E; E is phenyl substituted with R or pyridyl substituted with R; R is selected from H, Cl , F, OR 3 , CH 3 , CH 2 CH 3 , OCF 3 , CF 3 , NR 7 R 8 , and CH 2 NR 7 R 8 ; Z is selected from C(0), CH 2 C(0), C(0)CH 2 , NHC(O), and C(0)NH, provided that Z does not form a N-N bond with ring M or group A; R la and R lb are independently absent or selected from -(CH 2 ) r -R 1' / NCH2R 1" , OCH2R 1 ", SCH2R 1" , N(CH 2 ) 2 ( CH 2 ) t R 1' , 0(CH 2 )2(CH 2 ) t R 1 \ and S (CH 2 ) 2 (CH 2 ) tR 1' * or combined to form a 5-8 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R 4 and which contains from 0-2 heteroatoms selected from the group consisting of N, 0, and S; R 1 ', at each occurrence, is selected from H, C 1 - 3 alkyl, halo, (CF 2 )rCF 3 , OR 2 , NR 2 R 2a , C(0)R 2c , (CF 2 ) r C0 2 R 2c , S(0) p R 2b , NR 2 (CH 2 ) r OR 2 , NR 2 C(0)R 2b , NR 2 C(0) 2 R 2b , C(0)NR 2 R 2a , S0 2 NR 2 R 2a , and NR 2 S0 2 R 2b ; A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4 ; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, and imidazolyl; B is selected from: Y, X-Y, NR 2 R 2a , C (=NR 2 )NR 2 R 2a , and NR 2 C(=NR 2 )NR 2 R 2 ; X is selected from CH 2 , -CR 2 (CR 2 R 2b ) (CH 2 ) t -> -C(O)-, -C(=NR)-, -CH(NR 2 R 2a )-, -C(0)NR 2 -, -NR 2 C(0)-, -NR 2 C (O)NR 2 -, -NR 2 -, and O; Y is NR 2 R 2a , provided that X-Y do not form a N-N or O-N bond; alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4a ; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2, 3-oxadiazolyl, 1,2, 4-oxadiazolyl, 1, 2, 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2, 3 -thiadiazolyl , 1,2, 4-thiadiazolyl , 1,2, 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2, 3-triazolyl, 1,2,4-triazolyl, 1, 2, 5-triazolyl, and 1, 3, 4-triazolyl; R 4 , at each occurrence, is selected from =0, OH, Cl, F, Cι_ 4 alkyl, (CH 2 ) r NR 2 R 2a , (CH 2 ) r C (0) R 2b , NR 2 C(0)R 2b , C(0)NR 2 R 2a , CH(=NH)NH 2 , NHC(=NH)NH 2 , S0 2 NR 2 R 2a , NR 2 S0 2 -Cι_ alkyl, NR 2 S0 2 R 5 , S(0) p R 5 , and (CF 2 ) r CF 3 ; R 4a , at each occurrence, is selected from =0, OH, Cl, F, Cι_ 4 alkyl, (CH 2 ) r NR 2 R 2a , (CH 2 ) r C (0) R 2b , NR 2 C(0)R 2b , C(0)NR 2 R 2a , CH(=NH)NH 2 , NHC(=NH)NH 2 , S0 2 NR 2 R 2a , NR 2 S0 2 -Cι_ 4 alkyl, NR 2 S0 2 R 5 , S(0) p R 5 , (CF 2 ) r CF 3 , and l-CF 3 -tetrazol-2-yl; R 5 , at each occurrence, is selected from CF 3 , C 1 - 6 alkyl, phenyl substituted with 0-2 R 6 , and benzyl substituted with 0-2 R 6 ; R 6 , at each occurrence, is selected from H, =0, OH, OR 2 , Cl, F, CH 3 , CN, N0 2 , (CH 2 ) r NR 2 R 2a , (CH 2 ) r C (0) R 2b , NR 2 C(0)R 2b , CH(=NH)NH 2 , NHC(=NH)NH 2 , and S0 2 NR 2 R 2a ; R 7 , at each occurrence, is selected from H, OH, C 3 .- 6 alkyl, C 1 - 6 alkylcarbonyl , Cι_ 6 alkoxy, Cι_4 alkoxycarbonyl, benzyl, Cs-10 aryloxy, C δ -io aryloxycarbonyl , Cβ-io arylmethylcarbonyl , C 1 - 4 alkylcarbonyloxy C 1 - 4 alkoxycarbonyl, C 6 _ιo arylcarbonyloxy Cι_ 4 alkoxycarbonyl, Cι- 6 alkylaminocarbonyl , phenylaminocarbonyl , and phenyl Cι_4 alkoxycarbonyl; R 8 , at each occurrence, is selected from H, Cι_ 6 alkyl and benzyl; and alternatively, R 7 and R 8 combine to form a morpholino group; and, R 9 , at each occurrence, is selected from H, Cι_ 6 alkyl and benzyl . 17. A compound according to Claim 16, wherein; E is phenyl substituted with R or 2-pyridyl substituted with R; R is selected from H, Cl, F, OCH 3 , CH 3 , OCF 3 , CF 3 , NH 2 , and CH 2 NH 2 ; Z is selected from a C(0)CH 2 and C(0)NH, provided that Z does not form a N-N bond with group A; R la is selected from H, CH 3 , CH 2 CH 3 , Cl, F, CF 3 , OCH 3 , NR 2 R 2a , S(0) p R 2b , CH 2 S(0) p R 2b , CH 2 NR 2 S(0) p R 2b , C(0)R 2c , CH 2 C(0)R 2c , C(0)NR 2 R 2a , and S0 2 NR 2 R 2a ; R lb is selected from H, CH 3 , CH 2 CH 3 , Cl, F, CF 3 , OCH / NR 2 R 2a , S(0) p R 2b , CH 2 S(0) p R 2b , CH 2 NR 2 S (0) p R 2b , C(0)R 2c , CH 2 C(0)R 2c , C(0)NR 2 R 2a , and S0 2 NR 2 R 2a ; A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4 ; phenyl, pyridyl, pyrimidyl, furanyl, thiophenyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, and imidazolyl; B is selected from: Y and X-Y; X is selected from CH 2 , -CR 2 (CR 2 R 2b ) -, -C(O)-, -C(=NR)-, -CH(NR 2 R 2a )-, -C(0)NR 2 -, -NR 2 C(0)-, -NR 2 C (O)NR 2 - , -NR 2 -, and 0; Y is NR 2 R 2a , provided that X-Y do not form a N-N or O-N bond; alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4a ; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2, 3-oxadiazolyl, 1,2, 4-oxadiazolyl, 1, 2, 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2, 3-thiadiazolyl, 1, 2, 4-thiadiazolyl, 1,2, 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2, 3-triazolyl, 1,2, 4-triazolyl, 1, 2, 5-triazolyl, and 1, 3 , 4-triazolyl; R 2 , at each occurrence, is selected from H, CF 3 , CH 3 , benzyl, and phenyl; R 2a , at each occurrence, is selected from H, CF 3 , CH 3 , benzyl, and phenyl; R 2b , at each occurrence, is selected from CF 3 , OCH 3 , CH 3 , benzyl, and phenyl; R 2c , at each occurrence, is selected from CF3, OH, OCH 3 , CH , benzyl, and phenyl; alternatively, R 2 and R 2a combine to form a 5 or 6 membered saturated, partially unsaturated, or unsaturated ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S; R 3 , at each occurrence, is selected from H, CH 3 , CH 2 CH 3 , and phenyl ; R 3a , at each occurrence, is selected from H, CH 3 , CH 2 CH 3 , and phenyl ; R 4 , at each occurrence, is selected from OH, Cl, F, CH 3 , CH 2 CH 3 , NR 2 R 2a , CH 2 NR 2 R 2a , C(0)R 2b , NR 2 C(0)R 2b , C(0)NR 2 R 2a , and CF3; R 4 , at each occurrence, is selected from OH, Cl, F, CH 3 , CH 2 CH 3 , NR 2 R 2a , CH 2 NR 2 R 2a , C(0)R 2b , C(0)NR 2 R 2a , S0 2 NR 2 R 2a , S(0) P R 5 , CF 3 , and l-CF 3 -tetrazol-2-yl; R 5 , at each occurrence, is selected from CF 3 , Cι_ 6 alkyl, phenyl substituted with 0-2 R 6 , and benzyl substituted with 1 R 6 ; R 6 , at each occurrence, is selected from H, OH, OCH 3 , Cl, F, CH 3 , CN, N0 2 , NR 2 R 2a , CH 2 NR 2 R 2a , and S0 2 NR 2 R 2a ; R 7 , at each occurrence, is selected from H and C 1 -- 3 alkyl; R 8 , at each occurrence, is selected from H, CH 3 , and benzyl; R 9 , at each occurrence, is selected from H, CH 3 , and benzyl; and, t, at each occurrence, is selected from 0 and 1. 18. A compound according to Claim ,17, wherein; D is selected from NR 7 R 8 , and CH 2 R 7 R 8 , provided that D is substituted ortho to ring M on E; R l is absent or is selected from H, CH 3 , CHCH 3 , Cl, F, CF 3 , OCH 3 , NR 2 R 2a , S(0) p R 2b , C(0)NR 2 R 2a , CH 2 S(0) p R 2b , CH 2 NR 2 S(0) p R 2b , C(0)R 2c , CH 2 C(0)R 2c , and S0 2 NR 2 R 2a ; R lb is absent or is selected from H ' , CH 3 , CH 2 CH 3 , Cl, F, CF 3 , OCH 3 , NRR 2 , S(0) p R 2b , C(0)NR 2 R 2a , CH 2 S(0) p R 2b , CH 2 NR 2 S(0) p R 2b , C(0)R 2b , CH 2 C(0)R 2b , and S0 2 NR 2 R 2a ; A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4 ; phenyl, pyridyl, and pyrimidyl; B is selected from: Y and X-Y; X is selected from -C(O)- and 0; Y is NR 2 R 2a , provided that X-Y do not form a O-N bond; alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4a ; phenyl, piperazinyl, pyridyl, pyrimidyl, morpholinyl , pyrrolidinyl , imidazolyl , and 1,2,3- triazolyl ; R 2 , at each occurrence, is selected from H, CF3, CH3, benzyl, and phenyl; R 2a , at each occurrence, is selected from H, CF 3 , CH 3 , benzyl, and phenyl; R 2b , at each occurrence, is selected from CF 3 , OCH3, CH3, benzyl, and phenyl; R 2c , at each occurrence, is selected from CF 3 , OH, OCH3, CH3, benzyl, and phenyl; alternatively, R 2 and R 2a combine to form a ring system selected from pyrrolidinyl, piperazinyl and morpholino; R 4 , at each occurrence, is selected from Cl, F, CH 3 , NR 2 R 2a , and CF 3 ; R 4a , at each occurrence, is selected from Cl, F, CH 3 , S0 2 NR 2 R 2a , S(0) p R 5 , and CF 3 ; R 5 , at each occurrence, is selected from CF 3 and CH 3 ; R 7 , at each occurrence, is selected from H, CH 3 , and CH 2 CH 3 ; and, R 8 , at each occurrence, is selected from H and CH 3 . 19. A compound according to Claim 1, wherein the compound is selected from: 3-Methyl-1- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2 ' -sulfamido- [1,1'] -biphen-4-yl) ) carboxyamide; 3-Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -IH-pyrazole-5- (N- (2 ' -sulfamido- [1,1'] -biphen-4-yl) ) carboxyamide; 3-Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2 ' -sulfamido- [1, 1 ' ] -biphen-4- yl) ) carboxyamide; 3-Methyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2 ' -sulfamido- [1, 1 ' ] -biphen-4- yl) ) carboxyamide; 3-Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (2 ' -sulfamido- [1,1'] -biphen-4-yl) ) carboxyamide; 3-Trifluoromethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (2 ' -sulfamido- [1, 1 ' ] -biphen-4- y1) ) carboxy.amide; 3-Methyl-1- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2 ' -methylsulfonyl- [1,1'] -biphen-4-yl) ) carboxyamide; 3-Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2 ' -methylsulfonyl- [1,1*] -biphen-4-yl) ) carboxyamide; -Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) ) carboxyamide; -Methyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) ) carboxyamide; -Ethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (2 ' -methylsulfonyl- [1,1'] -biphen-4-yl) ) carboxyamide; -Trifluoromethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (2 ' -methylsulfonyl- [1, 1 ' ] -biphen-4- yl) ) carboxyamide; -Methyl-1- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1,1' ] -biphen-4-yl) ) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (3- fluoro-2 ' -sulfamido- [1, 1' ] -biphen-4-yl) ) carboxyamide; -Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1,1'] -biphen-4- yl) ) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1,1'] -biphen-4- y1) ) carboxyamide; -Ethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (3-fluoro-2 ' -sulfamido- [1,1'] -biphen-4- yl) ) carboxyamide; -Trifluoromethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1, 1 ' ] -biphen-4- yl) ) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1, 1 ' ] -biphen-4- yl) ) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (3- fluoro-2 ' -methylsulfonyl- [1,1' ] -biphen-4- yl) ) carboxyamide; -Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) ) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) ) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (3-fluoro-2 ' -methylsulfonyl- [1, 1 ' ] -biphen-4- yl) ) carboxyamide; -Trifluoromethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1']- biphen-4-yl) ) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- (1-pyrrolidinocarbonyl)phenyl) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- (1-pyrrolidinocarbonyl) phenyl) carboxyamide; -Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (4- (1- pyrrolidinocarbonyl)phenyl) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (4- (1- pyrrolidinocarbonyl)phenyl) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (4- (1-pyrrolidinocarbonyl)phenyl) carboxyamide;; -Trifluoromethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (4- (1- pyrrolidinocarbonyl)phenyl) carboxyamide; -Methyl-1- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2-fluoro-4- (1-pyrrolidinocarbonyl)phenyl) carboxyamide; -Ethyl-1- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2- fluoro-4- (1-pyrrolidinocarbonyl)phenyl) carboxyamide; -Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2-fluoro-4- (1- pyrro1idinocarbonyl)phenyl) carboxyamide; -Methyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2-fluoro-4- (1- pyrrolidinocarbonyl)phenyl) carboxy-amide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (2-fluoro-4- (1-pyrrolidinocarbonyl) carboxyamide; -Trifluoromethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (2-fluoro-4- (1- pyrrolidinocarbonyl)phenyl) carboxy-amide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- ( (2-sulfamido)phenyl)pyridin-2-yl)carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -IH-pyrazole-5- (N- (5- ( (2-sulfamido)phenyl)pyridin-2-yl) carboxyamide; -Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-sulfamido)phenyl)pyridin-2- yl) carboxy-amide; -Methyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-sulfamido)phenyl)pyridin-2- yl) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (5-( (2-sulfamido) phenyl)pyridin-2-yl) carboxyamide; -Trifluoromethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5-(N-(5-( (2-sulfamido)phenyl)pyridin-2- yl) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- ( (2-methylsulphonyl)phenyl)pyridin-2-yl) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- (2-methylsulphonyl)phenyl)pyridin-2-yl) carboxyamide; -Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-methylsulphonyl)phenyl)pyridin-2- yl) carboxyamide; -Methyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-methylsulphonyl)phenyl)pyridin-2- yl) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (5- ( (2-methylsulphonyl)phenyl)pyridin-2- yl) carboxyamide; -Trifluoromethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) - IH-pyrazole-5- (N- (5- ( (2-methylsulphonyl)phenyl)pyridin-2- yl) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- ( (2-sulfamido)phenyl)pyrimidin-2-yl) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- ( (2-sulfamido)phenyl)pyrimidin-2-yl) carboxyamide; -Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-sulfamido)phenyl)pyrimidin-2- yl) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -IH- pyrazole-5- (N- (5- ( (2-sulfamido)phenyl)pyrimidin-2- yl) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5-(N-(5-( (2-sulfamido)phenyl)pyrimidin-2-yl) carboxyamide; -Trifluoromethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) - IH-pyrazole-5- (N- (5- ( (2-sulfamido)phenyl)pyrimidin-2- yl) carboxyamide; -Methyl-1- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- ( (2-methylsulphonyl)phenyl)pyrimidin-2- yl) carboxyamide; -Ethyl-1- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- (2-methylsulphonyl)phenyl)pyrimidin-2-yl) carboxyamide; -Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-methylsulphonyl)phenyl)pyrimidin-2- yl) carboxy-amide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-methylsulphonyl)phenyl)pyrimidin-2- yl) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (5- ( (2-methylsulphonyl)phenyl)pyrimidin-2- yl) carboxyamide; -Trifluoromethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (5- ( (2-methylsulphonyl)phenyl)pyrimidin- 2-yl) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- ( (2-methyl) imidazo-1-yl)phenyl) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- ( (2-methyl) imidazo-1-yl)phenyl) carboxyamide; -Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (4- ( (2-methyl) imidazo-1- yl)phenyl) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (4- ( (2-methyl) imidazo-1- yl)phenyl) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (4- ( (2-methyl) imidazo-1-yl)phenyl) carboxyamide; -Trifluoromethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) - IH-pyrazole-5- (N- (4- ( (2-methyl) imidazo-1- yl)phenyl) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- ( (5-methyl) imidazo-1-yl) phenyl) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- ( (5-methyl) imidazo-1-yl)phenyl) carboxyamide; -Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (4- ( (5-methyl) imidazo-1- y1)phenyl) carboxyamide; -Methyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (4- ( (5-methyl) imidazo-1- yl) henyl) carboxyamide; -Ethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (4- ( (5-methyl) imidazo-1-yl) phenyl) carboxyamide; -Trifluoromethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (4- ( (5-methyl) imidazo-1- yl) phenyl) carboxyamide; -Methyl-1- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2-fluoro-4- ( (2-methyl) imidazo-1-yl)phenyl) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2- fluoro-4- ( (2-methyl) imidazo-1-yl)phenyl) carboxyamide,• 3-Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2-fluoro-4- ( (2-methyl) imidazo-1- y1)phenyl) carboxyamide; 3-Methyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2-fluoro-4- ( (2-methyl) imidazo-1- yl) henyl) carboxyamide; 3-Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (2-fluoro-4- ( (2-methyl) imidazo-1- yl)phenyl) carboxyamide; 3-Trifluoromethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (2-fluoro-4- ( (2-methyl) imidazo-1- yl)phenyl) carboxyamide; 3-Methyl-1- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2-fluoro-4- ( (5-methyl) imidazo-1-yl)phenyl) carboxyamide; 3-Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2- fluoro-4- ( (5-methyl) imidazo-1-yl)phenyl) carboxyamide; 3-Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2-fluoro-4- ( (5-methyl) imidazo-1- yl) henyl) carboxyamide; 3-Methyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2-fluoro-4- ( (5-methyl) imidazo-1- yl)phenyl) carboxyamide; 3-Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (2-fluoro-4- ( (5-methyl) imidazo-1- y1)phenyl) carboxyamide; and, 3-Trifluoromethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) - IH-pyrazole-5- (N- (2-fluoro-4- ( (5-methyl) imidazo-1- yl)phenyl) carboxyamide; and pharmaceutically acceptable salts thereof. 20. A compound according to Claim 1, wherein the compound is selected from: 3-Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2 '-sulfamido- [1,1'] -biphen-4-yl) ) carboxyamide; 5-Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-3- (N- (2 ' -sulfamido- [1, 1' ] -biphen-4-yl) ) carboxyamide; 3-Methyl-l- (2-N,N-dimethylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2 ' -N-methylsulfamido- [1, 1' ] -biphen-4- yl) ) carboxyamide; 3-Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1,1] -biphen-4- yl) ) carboxyamide; 3-Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1] -biphen-4- yl) ) carboxyamide; 3-Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2 ' -methylsulfonyl- [1,1] -biphen-4- yl) ) carboxyamide; 3-Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2 ' -sulfamido- [1,1] -biphen-4- yl) ) carboxyamide; 3-Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (4-N- pyrrolidinocarbonyl)phenyl) carboxyamide; N-Benzylsulfonyl-4- (3-trifluoromethyl-l- (2-aminomethyl-4- methoxyphenyl) -lH-pyrazole-5-carboxyamido)piperidine; 3-Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5-(N- (5- (2 ' -sulfonamido)phenyl)pyrid-2- yl) carboxyamide; 3-Trifluoromethyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- (pyrid-2-yl) )pyrid-2-yl) carboxyamide; N-Benzyl-4- (3-trifluoromethyl-l- (2-aminomethyl-4- methoxyphenyl) -lH-pyrazole-5-carboxyamido)piperidine; N-Phenylsulfonyl-4- (3-trifluoromethyl-l- (2-aminomethyl-4- methoxyphenyl) -lH-pyrazole-5-carboxyamido)piperidine; 3-Trifluoromethyl-1- (2-aminomethyl-4-chlorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) ) carboxyamide; -Trifluoromethyl-l- (2-aminomethyl-4-chlorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1,1'] -biphen-4- yl) ) carboxyamide; -Trifluoromethyl-l- (2-aminomethyl-5-chlorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) ) carboxyamide; -Trifluoromethyl-l- (2-aminomethyl-4-chlorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1,1' ] -biphen-4- yl) ) carboxyamide; 3-Trifluoromethyl-l- (2-aminomethyl-4-fluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 * -methylsulfonyl- [1,1*] -biphen- 4-yl) ) carboxyamide; 3-Trifluoromethyl-l- (2-aminomethyl-4-fluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1,1'] -biphen-4- yl) ) carboxyamide; 3-Trifluoromethyl-l- (2-aminomethyl-5-fluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) ) carboxyamide; 3-Trifluoromethyl-l- (2-aminomethyl-5-fluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 * -sulfamido- [1, 1 ' ] -biphen-4- yl) ) carboxyamide; 3-Trifluoromethyl-l- (2-aminomethyl-4, 5-difluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) ) carboxyamide; 3-Trifluoromethyl-l- (2-aminomethyl-4, 5-difluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1, 1 * ] -biphen-4- yl) ) carboxyamide; 3.-Trifluoromethyl-l- (2-aminomethyl-3-fluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) ) carboxyamide; 3-Trifluoromethyl-l- (2-aminomethyl-3-fluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1, 1 ' ] -biphen-4- yl) ) carboxyamide; 3-Trifluoromethyl-l- (2-aminomethyl-4-fluorophenyl) -1H- pyrazole-5- (N- (4- (2-methylsulfonyl- [1, 1 ' ] -biphen-4- yl) ) carboxyamide; 3-Trifluoromethyl-l- (2-aminomethyl-4-fluorophenyl) -1H- pyrazole-5- (N- (4- (2-sulfamido- [1, 1 ' ] -biphen-4- yl) ) carboxyamide; 3-Trifluoromethyl-l- (2-aminomethyl-4-fluorophenyl) -1H- pyrazole-5-(N-(4-(N-( (N'- methylsulfonyl) iminoly) pyrrolidino) )phenyl) carboxyamide; -Trifluoromethyl-l- (2- (N-glycyl) aminomethyl-4-methoxyphenyl) • lH-pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1']- biphen-4-yl) ) carboxyamide; -Trifluoromethyl-l- (2- (N-phenylacetyl) aminomethyl-4- methoxyphenyl) -lH-pyrazole-5- (TSF- (3-fluoro-2 ' - methylsulfonyl- [1, 1 ' ] -biphen-4-yl) ) carboxyamide; - (Trifluoromethyl) -1- (2- (aminomethyl) phenyl) -lH-pyrazole-5- (N- (2 ' -methylsulfonyl- [1, 1 ' ] -biphen-4-yl) ) carboxyamide; -Trifluoromethyl-l- (2- (aminomethyl)phenyl) -lH-pyrazole-5- (N- (2 * -aminosulfonyl- [1,1'] -biphen-4-yl) ) carboxyamide; -Trifluoromethyl-l- (2- (aminomethyl)phenyl) -lH-pyrazole-5- (N- (3-fluoro-2 * -aminosulfonyl- [1,1'] -biphen-4- yl) ) carboxyamide; -Trifluoromethyl-l- (2- (aminomethyl)phenyl) -IH-pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) ) carboxyamide; -Trifluoromethyl-l- (2- (N- (glycyl) aminomethyl) phenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1, 1 ' ] -biphen- 4-yl) ) carboxyamide; -Trifluoromethyl-l- (2- ( (N- (N- methylglycyl)aminomethyl)phenyl) -lH-pyrazole-5- (N- (3- fluoro-2 * -methylsulfonyl- [1, 1 * ] -biphen-4- yl) ) carboxyamide; -Trifluoromethyl-l- (2-carboxamidophenyl) -lH-pyrazole-5- (N- (3- fluoro-2 ' -methylsulfonyl- [1, 1 ' ] -biphen-4- yl) ) carboxy-amide; -Trifluoromethyl-l- (2-cyanophenyl) -lH-pyrazole-5- (N- (3- fluoro-2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) ) carboxyamide; - (2 ' -Aminomethylphenyl) -5- [ [ (2 ' -methylsulfonyl) -3-fluoro- [1,1*] -biphen-4-yl] aminocarbonyl] -tetrazole; - (2 * -Aminomethylphenyl) -5- [ (2 * -aminosulfonyl- [1, 1 * ] -biphen-4- yl) aminocarbonyl] -tetrazole; - [2- (Aminomethyl)phenyl] -3-thiomethoxy-5- [ (2-fluoro) - (2 ' - methylsulfonyl- [1,1'] -biphen-4-yl) aminocarbonyl]pyrazole; - [2- (Aminomethyl)phenyl] -3-methysulfonyl-5- [ (2-fluoro) - (2 * - methylsulfonyl- [1,1'] -biphen-4-yl) aminocarbonyl]pyrazole; - [2- (Aminomethyl)phenyl] -5- [ (2-fluoro) - (2 ' -methylsulfonyl- [1,1'] -biphen-4-yl) aminocarbonyl] triazole;

Inventors: BOSTROM LORI L, GALEMMO ROBERT A JR, PINTO DONALD J P, ROSSI KAREN ANITA, BOSTROM, LORI, L., GALEMMO, ROBERT, A., JR., PINTO, DONALD, J., P., ROSSI, KAREN, ANITA
Applicants: DU PONT PHARM CO, DU PONT PHARMACEUTICALS COMPANY
Application year: 1998
Main classification: C07D231
IPC codes: A61K31, A61P7, C07D231, C07D249, C07D257, C07D401, C07D403